{"PMC7524545": [["The COVID-19 pandemic has led to high rates of unemployment across advanced economies.1 The burdens associated with unemployment, however, have not hit all households equally.", [["The COVID", "TEST", 0, 9], ["advanced", "OBSERVATION_MODIFIER", 67, 75], ["economies", "OBSERVATION", 76, 85]]], ["Families with children and unemployed parents have reported especially high rates of hardship, with potential long-term consequences for child wellbeing and development.", [["children", "ORGANISM", 14, 22], ["children", "SPECIES", 14, 22]]], ["The increase of parental unemployment in the USA necessitates greater attention towards these potential consequences.", [["increase", "OBSERVATION_MODIFIER", 4, 12]]]], "8d5fa7f790faf615bd5015600c02e5c869fc3108": [["a b s t r a c tThe aim of this study was to report two cases of Clostridium perfringens type A and Clostridium difficile coinfection in adult dogs.", [["Clostridium perfringens type A", "DISEASE", 64, 94], ["Clostridium difficile coinfection", "DISEASE", 99, 132], ["Clostridium perfringens type A", "ORGANISM", 64, 94], ["Clostridium difficile", "ORGANISM", 99, 120], ["dogs", "ORGANISM", 142, 146], ["Clostridium perfringens", "SPECIES", 64, 87], ["Clostridium difficile", "SPECIES", 99, 120], ["dogs", "SPECIES", 142, 146], ["Clostridium perfringens type A", "SPECIES", 64, 94], ["Clostridium difficile", "SPECIES", 99, 120], ["this study", "TEST", 26, 36], ["Clostridium perfringens", "PROBLEM", 64, 87], ["Clostridium difficile coinfection", "PROBLEM", 99, 132], ["Clostridium", "OBSERVATION", 64, 75], ["Clostridium difficile", "OBSERVATION", 99, 120]]], ["Both animals were positive for A/B toxin.", [["animals", "ORGANISM", 5, 12], ["A/B toxin", "GENE_OR_GENE_PRODUCT", 31, 40], ["B toxin", "PROTEIN", 33, 40], ["A/B toxin", "PROBLEM", 31, 40]]], ["Toxigenic C. difficile and C. perfringens type A positive for NetE and NetF-encoding genes were isolated.", [["C. difficile", "DISEASE", 10, 22], ["Toxigenic", "ORGANISM", 0, 9], ["C. difficile", "ORGANISM", 10, 22], ["C. perfringens type A", "ORGANISM", 27, 48], ["NetE", "GENE_OR_GENE_PRODUCT", 62, 66], ["NetF", "GENE_OR_GENE_PRODUCT", 71, 75], ["NetE and NetF-encoding genes", "DNA", 62, 90], ["C. difficile", "SPECIES", 10, 22], ["C. perfringens", "SPECIES", 27, 41], ["C. difficile", "SPECIES", 10, 22], ["C. perfringens type A", "SPECIES", 27, 48], ["Toxigenic C. difficile", "PROBLEM", 0, 22], ["C. perfringens type", "TEST", 27, 46], ["NetE", "TEST", 62, 66], ["NetF", "TEST", 71, 75], ["encoding genes", "PROBLEM", 76, 90], ["difficile", "OBSERVATION", 13, 22], ["perfringens type", "OBSERVATION_MODIFIER", 30, 46]]], ["This report reinforces the necessity of studying a possible synergism of C. difficile and C. perfringens in enteric disorders.a b s t r a c t\u00a9 2016 Elsevier Ltd.", [["C. difficile", "DISEASE", 73, 85], ["C. perfringens", "DISEASE", 90, 104], ["enteric disorders", "DISEASE", 108, 125], ["C. difficile", "ORGANISM", 73, 85], ["C. perfringens", "ORGANISM", 90, 104], ["C. difficile", "SPECIES", 73, 85], ["C. perfringens", "SPECIES", 90, 104], ["C. difficile", "SPECIES", 73, 85], ["C. perfringens", "SPECIES", 90, 104], ["C. difficile", "PROBLEM", 73, 85], ["C. perfringens", "PROBLEM", 90, 104], ["enteric disorders", "PROBLEM", 108, 125], ["difficile", "OBSERVATION", 76, 85]]], ["All rights reserved.a b s t r a c tClostridium perfringens type A and Clostridium difficile are commonly described as enteropathogens in dogs.", [["Clostridium difficile", "DISEASE", 70, 91], ["tClostridium perfringens type A", "ORGANISM", 34, 65], ["Clostridium difficile", "ORGANISM", 70, 91], ["dogs", "ORGANISM", 137, 141], ["tClostridium perfringens", "SPECIES", 34, 58], ["Clostridium difficile", "SPECIES", 70, 91], ["dogs", "SPECIES", 137, 141], ["tClostridium perfringens type A", "SPECIES", 34, 65], ["Clostridium difficile", "SPECIES", 70, 91], ["a b s", "TEST", 20, 25], ["a c tClostridium perfringens", "PROBLEM", 30, 58], ["Clostridium difficile", "PROBLEM", 70, 91], ["Clostridium difficile", "OBSERVATION", 70, 91]]], ["However, the role of both agents remains incompletely characterized, and diagnoses of these infections are still a challenge.", [["infections", "DISEASE", 92, 102], ["these infections", "PROBLEM", 86, 102], ["incompletely characterized", "OBSERVATION_MODIFIER", 41, 67], ["infections", "OBSERVATION", 92, 102]]], ["Regarding C. perfringens type A, the high prevalence of enterotoxin-encoding gene cpe in diarrheic dogs led to a suspicion that this additional virulence factor was responsible for the pathogenesis of canine C. perfringensassociated diarrhea.", [["diarrhea", "DISEASE", 233, 241], ["C. perfringens type A", "ORGANISM", 10, 31], ["enterotoxin-encoding gene cpe", "GENE_OR_GENE_PRODUCT", 56, 85], ["diarrheic dogs", "ORGANISM", 89, 103], ["canine", "ORGANISM", 201, 207], ["enterotoxin-encoding gene cpe", "DNA", 56, 85], ["virulence factor", "PROTEIN", 144, 160], ["C. perfringens", "SPECIES", 10, 24], ["dogs", "SPECIES", 99, 103], ["C. perfringensassociated", "SPECIES", 208, 232], ["C. perfringens type A", "SPECIES", 10, 31], ["canine", "SPECIES", 201, 207], ["C. perfringens", "PROBLEM", 10, 24], ["enterotoxin", "TREATMENT", 56, 67], ["encoding gene cpe", "PROBLEM", 68, 85], ["diarrheic dogs", "PROBLEM", 89, 103], ["this additional virulence factor", "PROBLEM", 128, 160], ["canine C. perfringensassociated diarrhea", "PROBLEM", 201, 241], ["perfringens type", "OBSERVATION_MODIFIER", 13, 29]]], ["However, several studies have failed to confirm this hypothesis [11] .", [["several studies", "TEST", 9, 24], ["this hypothesis", "PROBLEM", 48, 63]]], ["Recently, three pore-forming toxins (NetE, NetF and NetG) that are always present in C. perfringens type A cpe \u00fe strains were described in association with fatal canine hemorrhagic gastroenteritis [2] .", [["pore", "ANATOMY", 16, 20], ["canine hemorrhagic gastroenteritis", "DISEASE", 162, 196], ["NetE", "GENE_OR_GENE_PRODUCT", 37, 41], ["NetF", "GENE_OR_GENE_PRODUCT", 43, 47], ["NetG", "GENE_OR_GENE_PRODUCT", 52, 56], ["C. perfringens type A cpe \u00fe", "ORGANISM", 85, 112], ["pore-forming toxins", "PROTEIN", 16, 35], ["NetE", "PROTEIN", 37, 41], ["NetF", "PROTEIN", 43, 47], ["NetG", "PROTEIN", 52, 56], ["C. perfringens", "SPECIES", 85, 99], ["C. perfringens", "SPECIES", 85, 99], ["A cpe \u00fe strains", "PROBLEM", 105, 120], ["fatal canine hemorrhagic gastroenteritis", "PROBLEM", 156, 196], ["hemorrhagic", "OBSERVATION_MODIFIER", 169, 180], ["gastroenteritis", "OBSERVATION", 181, 196]]], ["Until now, the study by Gohari was the only study in the literature on this topic.", [["the study", "TEST", 11, 20]]], ["Thus, the predisposing factors and occurrence of this disease remain unclear.a b s t r a c tThe role of C. difficile in canine diarrhea is also incompletely characterized.", [["C. difficile", "DISEASE", 104, 116], ["diarrhea", "DISEASE", 127, 135], ["C. difficile", "ORGANISM", 104, 116], ["canine", "ORGANISM", 120, 126], ["C. difficile", "SPECIES", 104, 116], ["canine", "SPECIES", 120, 126], ["C. difficile", "SPECIES", 104, 116], ["canine", "SPECIES", 120, 126], ["the predisposing factors", "PROBLEM", 6, 30], ["this disease", "PROBLEM", 49, 61], ["C. difficile in canine diarrhea", "PROBLEM", 104, 135], ["difficile", "OBSERVATION", 107, 116], ["canine diarrhea", "OBSERVATION", 120, 135], ["incompletely characterized", "OBSERVATION_MODIFIER", 144, 170]]], ["Nonetheless, there are reports of chronic and acute diarrhea caused by A/B toxins of C. difficile.", [["diarrhea", "DISEASE", 52, 60], ["C. difficile", "DISEASE", 85, 97], ["A/B toxins", "ORGANISM", 71, 81], ["C. difficile", "ORGANISM", 85, 97], ["C. difficile", "SPECIES", 85, 97], ["C. difficile", "SPECIES", 85, 97], ["chronic and acute diarrhea", "PROBLEM", 34, 60], ["A/B toxins", "PROBLEM", 71, 81], ["C. difficile", "PROBLEM", 85, 97], ["chronic", "OBSERVATION_MODIFIER", 34, 41], ["acute", "OBSERVATION_MODIFIER", 46, 51], ["diarrhea", "OBSERVATION", 52, 60], ["difficile", "OBSERVATION", 88, 97]]], ["However, it remains unclear whether C. difficile is the primary or secondary agent that causes diarrhea in dogs [7, 17] .", [["C. difficile", "DISEASE", 36, 48], ["diarrhea", "DISEASE", 95, 103], ["C. difficile", "ORGANISM", 36, 48], ["C. difficile", "SPECIES", 36, 48], ["dogs", "SPECIES", 107, 111], ["C. difficile", "SPECIES", 36, 48], ["C. difficile", "PROBLEM", 36, 48], ["secondary agent", "PROBLEM", 67, 82], ["diarrhea in dogs", "PROBLEM", 95, 111], ["difficile", "OBSERVATION", 39, 48]]], ["In addition, several studies showed a high similarity between C. difficile isolates from humans and animals, suggesting a possible zoonotic transmission [3] .a b s t r a c tDespite the known importance of both enteropathogens, there are no descriptions of co-infection of these two Clostridium species in dogs.", [["C. difficile", "DISEASE", 62, 74], ["C. difficile isolates", "ORGANISM", 62, 83], ["humans", "ORGANISM", 89, 95], ["Clostridium species", "ORGANISM", 282, 301], ["dogs", "ORGANISM", 305, 309], ["C. difficile", "SPECIES", 62, 74], ["humans", "SPECIES", 89, 95], ["dogs", "SPECIES", 305, 309], ["C. difficile", "SPECIES", 62, 74], ["humans", "SPECIES", 89, 95], ["several studies", "TEST", 13, 28], ["a high similarity", "PROBLEM", 36, 53], ["C. difficile isolates", "PROBLEM", 62, 83], ["both enteropathogens", "PROBLEM", 205, 225], ["co-infection", "PROBLEM", 256, 268], ["these two Clostridium species in dogs", "PROBLEM", 272, 309], ["enteropathogens", "OBSERVATION", 210, 225], ["no descriptions of", "UNCERTAINTY", 237, 255], ["co-infection", "OBSERVATION", 256, 268]]], ["Thus, the aim of this study was to report two cases of C. perfringens and C. difficile co-infection in adult dogs.a b s t r a c tAn 18-month-old male German Shepherd (dog 1) was presented to the Veterinary Hospital of Federal University of Minas Gerais (Belo Horizonte city, Brazil) with a history of bloody diarrhea for two days.", [["C. perfringens", "DISEASE", 55, 69], ["C. difficile co-infection", "DISEASE", 74, 99], ["bloody diarrhea", "DISEASE", 301, 316], ["C. perfringens", "ORGANISM", 55, 69], ["C. difficile", "ORGANISM", 74, 86], ["dogs", "ORGANISM", 109, 113], ["dog", "ORGANISM", 167, 170], ["C. perfringens", "SPECIES", 55, 69], ["C. difficile", "SPECIES", 74, 86], ["dogs", "SPECIES", 109, 113], ["dog", "SPECIES", 167, 170], ["C. perfringens", "SPECIES", 55, 69], ["C. difficile", "SPECIES", 74, 86], ["this study", "TEST", 17, 27], ["C. perfringens", "PROBLEM", 55, 69], ["C. difficile co-infection", "PROBLEM", 74, 99], ["bloody diarrhea", "PROBLEM", 301, 316], ["difficile", "OBSERVATION_MODIFIER", 77, 86], ["co-infection", "OBSERVATION", 87, 99]]], ["The dog was fed a regular commercial diet, had no history of other diseases in the past few months and was up-to-date on vaccinations and deworming.", [["dog", "ORGANISM", 4, 7], ["dog", "SPECIES", 4, 7], ["other diseases", "PROBLEM", 61, 75], ["vaccinations", "TREATMENT", 121, 133], ["diseases", "OBSERVATION", 67, 75]]], ["During the clinical examination, a stool sample was collected directly from the rectum for a differential diagnosis of the most common enteropathogens in dogs.", [["stool sample", "ANATOMY", 35, 47], ["rectum", "ANATOMY", 80, 86], ["rectum", "ORGAN", 80, 86], ["dogs", "ORGANISM", 154, 158], ["dogs", "SPECIES", 154, 158], ["the clinical examination", "TEST", 7, 31], ["a stool sample", "TEST", 33, 47], ["rectum", "ANATOMY", 80, 86], ["most common", "OBSERVATION_MODIFIER", 123, 134]]], ["The animal was treated with trimethoprim/sulfadiazine, omeprazole and fluid therapy.", [["trimethoprim/sulfadiazine", "CHEMICAL", 28, 53], ["omeprazole", "CHEMICAL", 55, 65], ["trimethoprim", "CHEMICAL", 28, 40], ["sulfadiazine", "CHEMICAL", 41, 53], ["omeprazole", "CHEMICAL", 55, 65], ["trimethoprim", "SIMPLE_CHEMICAL", 28, 40], ["sulfadiazine", "SIMPLE_CHEMICAL", 41, 53], ["omeprazole", "SIMPLE_CHEMICAL", 55, 65], ["fluid", "ORGANISM_SUBSTANCE", 70, 75], ["trimethoprim", "TREATMENT", 28, 40], ["sulfadiazine", "TREATMENT", 41, 53], ["omeprazole", "TREATMENT", 55, 65], ["fluid therapy", "TREATMENT", 70, 83], ["fluid therapy", "OBSERVATION", 70, 83]]], ["On the second day after admission, there was no blood in the feces, but the animal was still diarrheic.", [["blood", "ANATOMY", 48, 53], ["feces", "ANATOMY", 61, 66], ["diarrheic", "DISEASE", 93, 102], ["blood", "ORGANISM_SUBSTANCE", 48, 53], ["feces", "ORGANISM_SUBSTANCE", 61, 66], ["blood in the feces", "PROBLEM", 48, 66], ["diarrheic", "PROBLEM", 93, 102], ["no", "UNCERTAINTY", 45, 47], ["feces", "ANATOMY", 61, 66], ["diarrheic", "OBSERVATION", 93, 102]]], ["The consistency of the fecal material gradually returned to solid with a normal odor.", [["fecal material", "ANATOMY", 23, 37], ["fecal material", "MULTI-TISSUE_STRUCTURE", 23, 37], ["the fecal material", "PROBLEM", 19, 37], ["consistency", "OBSERVATION_MODIFIER", 4, 15], ["fecal material", "OBSERVATION", 23, 37], ["normal", "OBSERVATION_MODIFIER", 73, 79], ["odor", "OBSERVATION", 80, 84]]], ["The animal was discharged from the Veterinary Hospital five days after admission.a b s t r a c tThe second dog (dog 2) was a 12-year-old, mixed breed female.", [["dog", "ORGANISM", 107, 110], ["dog", "SPECIES", 107, 110]]], ["Similar to dog 1, this animal was also fed a regular commercial diet, had no history of other diseases and was up-to-date on vaccinations and deworming.", [["dog", "ORGANISM", 11, 14], ["animal", "ORGANISM", 23, 29], ["dog", "SPECIES", 11, 14], ["other diseases", "PROBLEM", 88, 102], ["vaccinations", "TREATMENT", 125, 137], ["diseases", "OBSERVATION", 94, 102]]], ["The owner reported a history of bloody diarrhea for two days.", [["diarrhea", "DISEASE", 39, 47], ["bloody diarrhea", "PROBLEM", 32, 47]]], ["During the clinical examination, the animal was apathetic and severely dehydrated.", [["animal", "ORGANISM", 37, 43], ["the clinical examination", "TEST", 7, 31], ["apathetic", "PROBLEM", 48, 57], ["severely dehydrated", "PROBLEM", 62, 81], ["severely", "OBSERVATION_MODIFIER", 62, 70], ["dehydrated", "OBSERVATION", 71, 81]]], ["The dog died a few minutes after admission while receiving fluid therapy.", [["dog", "ORGANISM", 4, 7], ["fluid", "ORGANISM_SUBSTANCE", 59, 64], ["dog", "SPECIES", 4, 7], ["fluid therapy", "TREATMENT", 59, 72]]], ["During the post mortem examination, the intestinal contents from the small intestine were collected.", [["intestinal", "ANATOMY", 40, 50], ["small intestine", "ANATOMY", 69, 84], ["intestinal", "ORGAN", 40, 50], ["small intestine", "ORGAN", 69, 84], ["the post mortem examination", "TEST", 7, 34], ["intestinal", "ANATOMY", 40, 50], ["small intestine", "ANATOMY", 69, 84]]], ["Fragments of this organ were sampled in 10% neutral-buffered formalin.", [["organ", "ANATOMY", 18, 23], ["formalin", "CHEMICAL", 61, 69], ["formalin", "CHEMICAL", 61, 69], ["organ", "ORGAN", 18, 23], ["formalin", "SIMPLE_CHEMICAL", 61, 69], ["organ", "ANATOMY", 18, 23]]], ["After fixation, specimens were routinely processed for histopathology, sectioned to 4 mm and stained with hematoxylin and eosin.a b s t r a c tThe stool sample of dog 1 and the intestinal contents of dog 2 were submitted to the following laboratory exams: rotavirus detection by polyacrylamide gel electrophoresis followed by silver staining [4] ; parvovirus, rotavirus, coronavirus and Giardia lamblia detection by a chromatographic immunoassay (Ecodiagnostica, Brazil); isolation and genotyping of C. difficile [15] and C. perfringens [2, 12, 19] ; C. perfringens enterotoxin detection by an enzyme-linked immunosorbent assay (EIA) kit (RIDASCREEN \u00ae C. perfringens Enterotoxin -R-Biopharm, Germany); C. difficile A/B toxin detection by ELISA (C. difficile Tox A/B II -Techlab Inc., USA); culture for Salmonella spp. in Hektoen Enteric Agar and XLT4 agar (Biobr as \u00ae , Prodimol Biotechnology); isolation of Escherichia coli in MacConkey agar (Biobr as \u00ae , Prodimol Biotechnology), followed by a previously described PCR method [8] to investigate the following virulence factor genes: eae, stx1, stx2, ehxA, aggR, ipaH, eltA, etlB, est, and stap.a b s t r a c tBoth dogs had positive C. perfringens and C. difficile isolations and A/B toxins detection.", [["specimens", "ANATOMY", 16, 25], ["stool sample", "ANATOMY", 147, 159], ["intestinal", "ANATOMY", 177, 187], ["polyacrylamide gel", "CHEMICAL", 279, 297], ["silver", "CHEMICAL", 326, 332], ["Giardia lamblia", "DISEASE", 387, 402], ["C. difficile", "DISEASE", 500, 512], ["hematoxylin", "CHEMICAL", 106, 117], ["eosin", "CHEMICAL", 122, 127], ["polyacrylamide", "CHEMICAL", 279, 293], ["silver", "CHEMICAL", 326, 332], ["hematoxylin", "SIMPLE_CHEMICAL", 106, 117], ["dog", "ORGANISM", 163, 166], ["intestinal", "ORGAN", 177, 187], ["dog", "ORGANISM", 200, 203], ["rotavirus", "ORGANISM", 256, 265], ["silver", "SIMPLE_CHEMICAL", 326, 332], ["parvovirus", "ORGANISM", 348, 358], ["rotavirus", "ORGANISM", 360, 369], ["coronavirus", "ORGANISM", 371, 382], ["Giardia lamblia", "ORGANISM", 387, 402], ["C. difficile [15]", "ORGANISM", 500, 517], ["C. perfringens", "ORGANISM", 522, 536], ["C. perfringens", "ORGANISM", 551, 565], ["enterotoxin", "ORGANISM", 566, 577], ["C. difficile A/B toxin", "ORGANISM", 702, 724], ["Salmonella spp.", "ORGANISM", 802, 817], ["Escherichia coli", "ORGANISM", 908, 924], ["eae", "GENE_OR_GENE_PRODUCT", 1085, 1088], ["stx1", "GENE_OR_GENE_PRODUCT", 1090, 1094], ["stx2", "GENE_OR_GENE_PRODUCT", 1096, 1100], ["ehxA", "GENE_OR_GENE_PRODUCT", 1102, 1106], ["aggR", "GENE_OR_GENE_PRODUCT", 1108, 1112], ["ipaH", "GENE_OR_GENE_PRODUCT", 1114, 1118], ["eltA", "GENE_OR_GENE_PRODUCT", 1120, 1124], ["etlB", "GENE_OR_GENE_PRODUCT", 1126, 1130], ["C. perfringens", "ORGANISM", 1184, 1198], ["C. difficile", "ORGANISM", 1203, 1215], ["A/B toxins", "ORGANISM", 1231, 1241], ["virulence factor genes", "DNA", 1061, 1083], ["eae", "DNA", 1085, 1088], ["stx1", "DNA", 1090, 1094], ["stx2", "DNA", 1096, 1100], ["ehxA", "DNA", 1102, 1106], ["aggR", "DNA", 1108, 1112], ["ipaH", "DNA", 1114, 1118], ["eltA", "DNA", 1120, 1124], ["etlB", "DNA", 1126, 1130], ["est", "DNA", 1132, 1135], ["stap", "DNA", 1141, 1145], ["dog", "SPECIES", 163, 166], ["dog", "SPECIES", 200, 203], ["rotavirus", "SPECIES", 360, 369], ["coronavirus", "SPECIES", 371, 382], ["Giardia lamblia", "SPECIES", 387, 402], ["C. difficile", "SPECIES", 500, 512], ["C. perfringens", "SPECIES", 522, 536], ["C. perfringens enterotoxin", "SPECIES", 551, 577], ["C. perfringens", "SPECIES", 652, 666], ["C. difficile", "SPECIES", 702, 714], ["C. difficile", "SPECIES", 745, 757], ["Salmonella spp.", "SPECIES", 802, 817], ["Escherichia coli", "SPECIES", 908, 924], ["dogs", "SPECIES", 1166, 1170], ["C. perfringens", "SPECIES", 1184, 1198], ["C. difficile", "SPECIES", 1203, 1215], ["rotavirus", "SPECIES", 256, 265], ["rotavirus", "SPECIES", 360, 369], ["Giardia lamblia", "SPECIES", 387, 402], ["C. difficile", "SPECIES", 500, 512], ["C. perfringens", "SPECIES", 522, 536], ["C. perfringens", "SPECIES", 551, 565], ["C. perfringens Enterotoxin -R-Biopharm", "SPECIES", 652, 690], ["C. difficile", "SPECIES", 702, 714], ["C. difficile", "SPECIES", 745, 757], ["Salmonella spp.", "SPECIES", 802, 817], ["Escherichia coli", "SPECIES", 908, 924], ["C. perfringens", "SPECIES", 1184, 1198], ["C. difficile", "SPECIES", 1203, 1215], ["fixation", "TREATMENT", 6, 14], ["specimens", "TEST", 16, 25], ["histopathology", "TEST", 55, 69], ["hematoxylin", "TEST", 106, 117], ["eosin", "TEST", 122, 127], ["The stool sample", "TEST", 143, 159], ["laboratory exams", "TEST", 238, 254], ["rotavirus detection", "PROBLEM", 256, 275], ["polyacrylamide gel electrophoresis", "TEST", 279, 313], ["silver staining", "TEST", 326, 341], ["parvovirus", "PROBLEM", 348, 358], ["rotavirus", "PROBLEM", 360, 369], ["coronavirus", "PROBLEM", 371, 382], ["Giardia lamblia detection", "PROBLEM", 387, 412], ["a chromatographic immunoassay", "TEST", 416, 445], ["isolation", "TREATMENT", 472, 481], ["C. difficile", "PROBLEM", 500, 512], ["C. perfringens", "PROBLEM", 522, 536], ["C. perfringens enterotoxin detection", "TEST", 551, 587], ["an enzyme", "TEST", 591, 600], ["immunosorbent assay", "TEST", 608, 627], ["EIA", "TEST", 629, 632], ["kit", "TEST", 634, 637], ["RIDASCREEN", "TEST", 639, 649], ["perfringens", "TEST", 655, 666], ["Enterotoxin", "TEST", 667, 678], ["C. difficile", "PROBLEM", 702, 714], ["A/B toxin detection", "TEST", 715, 734], ["ELISA", "TEST", 738, 743], ["C. difficile Tox", "TEST", 745, 761], ["culture", "TEST", 790, 797], ["Salmonella spp.", "PROBLEM", 802, 817], ["Enteric Agar", "TREATMENT", 829, 841], ["Escherichia coli", "PROBLEM", 908, 924], ["eae", "PROBLEM", 1085, 1088], ["stx1", "PROBLEM", 1090, 1094], ["stx2", "PROBLEM", 1096, 1100], ["ehxA", "PROBLEM", 1102, 1106], ["ipaH", "PROBLEM", 1114, 1118], ["tBoth dogs", "PROBLEM", 1160, 1170], ["positive C. perfringens", "PROBLEM", 1175, 1198], ["C. difficile isolations", "PROBLEM", 1203, 1226], ["A/B toxins detection", "TEST", 1231, 1251], ["intestinal", "ANATOMY", 177, 187], ["Escherichia coli", "OBSERVATION", 908, 924], ["ipaH", "ANATOMY", 1114, 1118], ["C. perfringens", "OBSERVATION", 1184, 1198], ["difficile isolations", "OBSERVATION", 1206, 1226]]], ["However, they were negative for C. perfringens enterotoxin by the EIA.", [["C. perfringens", "ORGANISM", 32, 46], ["enterotoxin", "GENE_OR_GENE_PRODUCT", 47, 58], ["C. perfringens enterotoxin", "PROTEIN", 32, 58], ["C. perfringens", "SPECIES", 32, 46], ["C. perfringens", "SPECIES", 32, 46], ["C. perfringens enterotoxin", "PROBLEM", 32, 58], ["the EIA", "TEST", 62, 69]]], ["E. coli was also isolated, but all strains were negative for virulence factors by PCR.", [["E. coli", "ORGANISM", 0, 7], ["virulence factors", "PROTEIN", 61, 78], ["E. coli", "SPECIES", 0, 7], ["E. coli", "SPECIES", 0, 7], ["E. coli", "PROBLEM", 0, 7], ["all strains", "TEST", 31, 42], ["virulence factors", "PROBLEM", 61, 78], ["PCR", "TEST", 82, 85], ["coli", "OBSERVATION", 3, 7]]], ["All other exams were negative.", [["All other exams", "TEST", 0, 15], ["negative", "OBSERVATION", 21, 29]]], ["Therefore, the involvement of Giardia spp., Salmonella spp., rotavirus, coronavirus and parvovirus was ruled out.a b s t r a c tC. perfringens strains were genotyped as type A and positive for cpe, netE and netF in both cases.", [["rotavirus, coronavirus and parvovirus", "DISEASE", 61, 98], ["Giardia spp.", "ORGANISM", 30, 42], ["Salmonella spp.", "ORGANISM", 44, 59], ["rotavirus", "ORGANISM", 61, 70], ["coronavirus", "ORGANISM", 72, 83], ["parvovirus", "ORGANISM", 88, 98], ["perfringens", "ORGANISM", 131, 142], ["cpe", "GENE_OR_GENE_PRODUCT", 193, 196], ["netE", "GENE_OR_GENE_PRODUCT", 198, 202], ["netF", "GENE_OR_GENE_PRODUCT", 207, 211], ["cpe", "PROTEIN", 193, 196], ["netE", "PROTEIN", 198, 202], ["netF", "PROTEIN", 207, 211], ["Giardia spp.", "SPECIES", 30, 42], ["Salmonella spp.", "SPECIES", 44, 59], ["rotavirus, coronavirus", "SPECIES", 61, 83], ["perfringens", "SPECIES", 131, 142], ["Giardia spp.", "SPECIES", 30, 42], ["Salmonella spp.", "SPECIES", 44, 59], ["perfringens", "SPECIES", 131, 142], ["Giardia spp.", "PROBLEM", 30, 42], ["Salmonella spp.", "PROBLEM", 44, 59], ["rotavirus", "PROBLEM", 61, 70], ["coronavirus", "PROBLEM", 72, 83], ["parvovirus", "PROBLEM", 88, 98], ["perfringens strains", "PROBLEM", 131, 150], ["cpe", "PROBLEM", 193, 196], ["netE", "TEST", 198, 202], ["Giardia spp.", "OBSERVATION", 30, 42]]], ["Interestingly, the C. perfringens isolate from dog 1 was also positive for netG.", [["C. perfringens", "ORGANISM", 19, 33], ["dog 1", "ORGANISM", 47, 52], ["netG", "GENE_OR_GENE_PRODUCT", 75, 79], ["netG", "PROTEIN", 75, 79], ["C. perfringens", "SPECIES", 19, 33], ["dog", "SPECIES", 47, 50], ["C. perfringens", "SPECIES", 19, 33], ["dog 1", "SPECIES", 47, 52], ["the C. perfringens isolate", "TEST", 15, 41], ["netG", "PROBLEM", 75, 79]]], ["Both C. difficile isolates were positive for toxin A-and toxin B-encoding genes (tcdA and tcdB) but negative for binary toxin gene (cdtB).", [["C. difficile", "DISEASE", 5, 17], ["C. difficile isolates", "ORGANISM", 5, 26], ["toxin A", "GENE_OR_GENE_PRODUCT", 45, 52], ["toxin B", "GENE_OR_GENE_PRODUCT", 57, 64], ["tcdA", "GENE_OR_GENE_PRODUCT", 81, 85], ["tcdB", "GENE_OR_GENE_PRODUCT", 90, 94], ["binary toxin gene", "GENE_OR_GENE_PRODUCT", 113, 130], ["cdtB", "GENE_OR_GENE_PRODUCT", 132, 136], ["toxin A-and toxin B-encoding genes", "DNA", 45, 79], ["tcdA", "DNA", 81, 85], ["tcdB", "DNA", 90, 94], ["binary toxin gene", "DNA", 113, 130], ["cdtB", "DNA", 132, 136], ["C. difficile", "SPECIES", 5, 17], ["C. difficile", "SPECIES", 5, 17], ["Both C. difficile isolates", "TEST", 0, 26], ["toxin A", "TEST", 45, 52], ["toxin B", "TEST", 57, 64], ["tcdA", "TEST", 81, 85], ["tcdB", "TEST", 90, 94], ["binary toxin gene (cdtB", "PROBLEM", 113, 136]]], ["PCR ribotyping was conducted as previously described [5] .", [["PCR ribotyping", "TEST", 0, 14]]], ["Both strains were identified as 014/020.", [["strains", "OBSERVATION_MODIFIER", 5, 12]]], ["Table 1 summarizes the laboratory findings from both dogs.a b s t r a c tDuring the post mortem examination of dog 2, the small intestine was distended by a hemorrhagic fluid and gas content, with markedly reddish serosa (congestion).", [["small intestine", "ANATOMY", 122, 137], ["hemorrhagic fluid", "ANATOMY", 157, 174], ["reddish serosa", "ANATOMY", 206, 220], ["hemorrhagic", "DISEASE", 157, 168], ["dogs", "ORGANISM", 53, 57], ["dog", "ORGANISM", 111, 114], ["small intestine", "ORGAN", 122, 137], ["fluid", "ORGANISM_SUBSTANCE", 169, 174], ["serosa", "MULTI-TISSUE_STRUCTURE", 214, 220], ["dogs", "SPECIES", 53, 57], ["the post mortem examination", "TEST", 80, 107], ["distended", "PROBLEM", 142, 151], ["a hemorrhagic fluid and gas content", "PROBLEM", 155, 190], ["markedly reddish serosa (congestion", "PROBLEM", 197, 232], ["small intestine", "ANATOMY", 122, 137], ["distended", "OBSERVATION", 142, 151], ["hemorrhagic", "OBSERVATION_MODIFIER", 157, 168], ["fluid", "OBSERVATION", 169, 174], ["gas content", "OBSERVATION", 179, 190], ["markedly", "OBSERVATION_MODIFIER", 197, 205], ["reddish", "OBSERVATION_MODIFIER", 206, 213], ["serosa", "OBSERVATION_MODIFIER", 214, 220], ["congestion", "OBSERVATION", 222, 232]]], ["The mucosal surface was diffusely red and covered with reddish and viscous material.", [["mucosal surface", "ANATOMY", 4, 19], ["mucosal surface", "ORGANISM_SUBSTANCE", 4, 19], ["diffusely red", "PROBLEM", 24, 37], ["reddish and viscous material", "PROBLEM", 55, 83], ["mucosal", "ANATOMY", 4, 11], ["surface", "OBSERVATION_MODIFIER", 12, 19], ["diffusely", "OBSERVATION_MODIFIER", 24, 33], ["red", "OBSERVATION", 34, 37], ["reddish", "OBSERVATION_MODIFIER", 55, 62], ["viscous material", "OBSERVATION_MODIFIER", 67, 83]]], ["The microscopic evaluation was limited by autolysis of the organ.", [["organ", "ANATOMY", 59, 64], ["organ", "ORGAN", 59, 64], ["The microscopic evaluation", "TEST", 0, 26], ["autolysis of the organ", "PROBLEM", 42, 64], ["organ", "ANATOMY", 59, 64]]], ["However, evidence of necrosis of the villi and hemorrhage in the lamina propria and intestinal lumen were observed.", [["villi", "ANATOMY", 37, 42], ["lamina propria", "ANATOMY", 65, 79], ["intestinal lumen", "ANATOMY", 84, 100], ["necrosis", "DISEASE", 21, 29], ["hemorrhage", "DISEASE", 47, 57], ["villi", "MULTI-TISSUE_STRUCTURE", 37, 42], ["lamina propria", "TISSUE", 65, 79], ["intestinal lumen", "MULTI-TISSUE_STRUCTURE", 84, 100], ["necrosis of the villi", "PROBLEM", 21, 42], ["hemorrhage in the lamina propria", "PROBLEM", 47, 79], ["intestinal lumen", "TREATMENT", 84, 100], ["evidence of", "UNCERTAINTY", 9, 20], ["necrosis", "OBSERVATION", 21, 29], ["villi", "ANATOMY", 37, 42], ["hemorrhage", "OBSERVATION", 47, 57], ["lamina", "ANATOMY_MODIFIER", 65, 71], ["propria", "ANATOMY_MODIFIER", 72, 79], ["intestinal lumen", "ANATOMY", 84, 100]]], ["Numerous Gram positive rods were attached to the luminal surface of the denuded villi (Fig. 1) .", [["luminal surface", "ANATOMY", 49, 64], ["villi", "ANATOMY", 80, 85], ["luminal", "CHEMICAL", 49, 56], ["Gram", "GENE_OR_GENE_PRODUCT", 9, 13], ["luminal surface", "CELLULAR_COMPONENT", 49, 64], ["villi", "MULTI-TISSUE_STRUCTURE", 80, 85], ["Numerous Gram positive rods", "PROBLEM", 0, 27], ["Gram", "OBSERVATION_MODIFIER", 9, 13], ["positive rods", "OBSERVATION", 14, 27], ["luminal", "ANATOMY_MODIFIER", 49, 56], ["surface", "ANATOMY_MODIFIER", 57, 64], ["denuded villi", "ANATOMY", 72, 85]]], ["The lamina propria and submucosa were mildly expanded by edema, and the blood vessels of the submucosa were markedly congested.a b s t r a c tTo clarify whether dog 1 was permanently colonized by a C. perfringens cpe \u00fe netE \u00fe netF \u00fe netG \u00fe strain, a new stool sample was collected approximately eight months after the diarrhea episode.", [["lamina propria", "ANATOMY", 4, 18], ["submucosa", "ANATOMY", 23, 32], ["edema", "ANATOMY", 57, 62], ["blood vessels", "ANATOMY", 72, 85], ["submucosa", "ANATOMY", 93, 102], ["stool sample", "ANATOMY", 254, 266], ["edema", "DISEASE", 57, 62], ["diarrhea", "DISEASE", 318, 326], ["lamina propria", "TISSUE", 4, 18], ["submucosa", "MULTI-TISSUE_STRUCTURE", 23, 32], ["edema", "PATHOLOGICAL_FORMATION", 57, 62], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 72, 85], ["submucosa", "MULTI-TISSUE_STRUCTURE", 93, 102], ["dog", "ORGANISM", 161, 164], ["C. perfringens", "ORGANISM", 198, 212], ["cpe", "ORGANISM", 213, 216], ["netE", "GENE_OR_GENE_PRODUCT", 219, 223], ["netF", "GENE_OR_GENE_PRODUCT", 226, 230], ["netG \u00fe", "GENE_OR_GENE_PRODUCT", 233, 239], ["netF", "PROTEIN", 226, 230], ["C. perfringens", "SPECIES", 198, 212], ["C. perfringens", "SPECIES", 198, 212], ["mildly expanded", "PROBLEM", 38, 53], ["edema", "PROBLEM", 57, 62], ["markedly congested", "PROBLEM", 108, 126], ["netG \u00fe strain", "PROBLEM", 233, 246], ["a new stool sample", "TEST", 248, 266], ["the diarrhea episode", "PROBLEM", 314, 334], ["lamina", "ANATOMY_MODIFIER", 4, 10], ["propria", "ANATOMY_MODIFIER", 11, 18], ["submucosa", "ANATOMY", 23, 32], ["mildly", "OBSERVATION_MODIFIER", 38, 44], ["expanded", "OBSERVATION", 45, 53], ["edema", "OBSERVATION", 57, 62], ["blood vessels", "ANATOMY", 72, 85], ["submucosa", "ANATOMY", 93, 102], ["markedly", "OBSERVATION_MODIFIER", 108, 116], ["congested", "OBSERVATION", 117, 126]]], ["This second stool sample was positive for C. perfringens type A, but the isolated strain was negative for cpe, netE, netF and netG.a b s t r a c tGohari et al. [2] described an association of these three new C. perfringens pore forming toxins (NetE, NetF and NetG) in fatal cases of canine hemorrhagic diarrhea.", [["stool sample", "ANATOMY", 12, 24], ["canine hemorrhagic diarrhea", "DISEASE", 283, 310], ["C. perfringens type A", "ORGANISM", 42, 63], ["cpe", "GENE_OR_GENE_PRODUCT", 106, 109], ["netE", "GENE_OR_GENE_PRODUCT", 111, 115], ["netF", "GENE_OR_GENE_PRODUCT", 117, 121], ["C. perfringens", "ORGANISM", 208, 222], ["NetE", "SIMPLE_CHEMICAL", 244, 248], ["NetF", "GENE_OR_GENE_PRODUCT", 250, 254], ["NetG", "GENE_OR_GENE_PRODUCT", 259, 263], ["canine", "ORGANISM", 283, 289], ["cpe", "PROTEIN", 106, 109], ["netE", "PROTEIN", 111, 115], ["netF", "PROTEIN", 117, 121], ["netG", "PROTEIN", 126, 130], ["C. perfringens pore forming toxins", "PROTEIN", 208, 242], ["NetE", "PROTEIN", 244, 248], ["NetF", "PROTEIN", 250, 254], ["NetG", "PROTEIN", 259, 263], ["C. perfringens", "SPECIES", 42, 56], ["C. perfringens", "SPECIES", 208, 222], ["canine", "SPECIES", 283, 289], ["C. perfringens type A", "SPECIES", 42, 63], ["C. perfringens", "SPECIES", 208, 222], ["canine", "SPECIES", 283, 289], ["This second stool sample", "TEST", 0, 24], ["C. perfringens type A", "PROBLEM", 42, 63], ["the isolated strain", "TEST", 69, 88], ["cpe", "PROBLEM", 106, 109], ["netE", "TEST", 111, 115], ["netF", "TEST", 117, 121], ["netG", "TEST", 126, 130], ["canine hemorrhagic diarrhea", "PROBLEM", 283, 310], ["hemorrhagic", "OBSERVATION_MODIFIER", 290, 301], ["diarrhea", "OBSERVATION", 302, 310]]], ["Both dogs in the present report presented at a Veterinary Hospital with bloody diarrhea, but dog 1 recovered completely after a 3-day treatment.", [["bloody diarrhea", "DISEASE", 72, 87], ["dogs", "ORGANISM", 5, 9], ["dogs", "SPECIES", 5, 9], ["bloody diarrhea", "PROBLEM", 72, 87], ["a 3-day treatment", "TREATMENT", 126, 143], ["dogs", "OBSERVATION", 5, 9]]], ["Despite the bloody diarrhea, this animal was clinically healthy and not severely dehydrated during the clinical examination.", [["diarrhea", "DISEASE", 19, 27], ["the bloody diarrhea", "PROBLEM", 8, 27], ["severely dehydrated", "PROBLEM", 72, 91], ["the clinical examination", "TEST", 99, 123], ["bloody", "OBSERVATION_MODIFIER", 12, 18], ["diarrhea", "OBSERVATION", 19, 27]]], ["In contrast to the previous report by [2] ; our findings suggest that a C. perfringens infection might be involved in less dramatic cases of hemorrhagic enteritis.a b s t r a c tIn contrast, the acute clinical evolution experienced by dog 2 and the post mortem findings corroborate the observations described in acute canine C. perfringens type A-associated diarrhea [7, 9, 17] .", [["C. perfringens infection", "DISEASE", 72, 96], ["hemorrhagic enteritis", "DISEASE", 141, 162], ["C. perfringens type A-associated diarrhea", "DISEASE", 325, 366], ["C. perfringens", "ORGANISM", 72, 86], ["canine", "ORGANISM", 318, 324], ["C. perfringens type A-associated diarrhea", "ORGANISM", 325, 366], ["C. perfringens", "SPECIES", 72, 86], ["C. perfringens", "SPECIES", 325, 339], ["C. perfringens", "SPECIES", 72, 86], ["C. perfringens type A-associated diarrhea", "SPECIES", 325, 366], ["a C. perfringens infection", "PROBLEM", 70, 96], ["hemorrhagic enteritis", "PROBLEM", 141, 162], ["a c tIn contrast", "TREATMENT", 173, 189], ["the post mortem findings", "TEST", 245, 269], ["acute canine C. perfringens type A-associated diarrhea", "PROBLEM", 312, 366], ["hemorrhagic", "OBSERVATION_MODIFIER", 141, 152], ["enteritis", "OBSERVATION", 153, 162], ["acute", "OBSERVATION_MODIFIER", 195, 200]]], ["This is only the second study on C. perfringens netE positivity in dogs.", [["C. perfringens", "ORGANISM", 33, 47], ["netE", "GENE_OR_GENE_PRODUCT", 48, 52], ["dogs", "ORGANISM", 67, 71], ["C. perfringens", "SPECIES", 33, 47], ["dogs", "SPECIES", 67, 71], ["C. perfringens", "SPECIES", 33, 47], ["the second study", "TEST", 13, 29]]], ["Some studies suggest that changes in feed is an important predisposing factor to trigger a C. perfringens type A infection in dogs and other species [7, 11] .", [["C. perfringens type A infection", "DISEASE", 91, 122], ["C. perfringens type A", "ORGANISM", 91, 112], ["dogs", "ORGANISM", 126, 130], ["C. perfringens", "SPECIES", 91, 105], ["dogs", "SPECIES", 126, 130], ["C. perfringens type A", "SPECIES", 91, 112], ["Some studies", "TEST", 0, 12], ["changes in feed", "PROBLEM", 26, 41], ["a C. perfringens type A infection in dogs", "PROBLEM", 89, 130], ["infection", "OBSERVATION", 113, 122]]], ["According to the owners, both dogs in the present case report were only fed a commercial diet.", [["dogs", "ORGANISM", 30, 34], ["dogs", "SPECIES", 30, 34]]], ["The absence of a known diet alteration or any other relevant predisposing factor corroborates the only study available thus far on C. perfringens netE positivity in dogs [2] and highlights the need for additional studies on this matter.a b s t r a c tBoth dogs were also positive for A/B toxins, and toxigenic strains were isolated, which suggested the involvement of C. difficile.", [["C. difficile", "DISEASE", 368, 380], ["C. perfringens", "ORGANISM", 131, 145], ["netE", "ORGANISM", 146, 150], ["dogs", "ORGANISM", 165, 169], ["dogs", "ORGANISM", 256, 260], ["A/B", "GENE_OR_GENE_PRODUCT", 284, 287], ["C. difficile", "ORGANISM", 368, 380], ["C. perfringens", "SPECIES", 131, 145], ["dogs", "SPECIES", 165, 169], ["C. difficile", "SPECIES", 368, 380], ["C. perfringens", "SPECIES", 131, 145], ["C. difficile", "SPECIES", 368, 380], ["a known diet alteration", "PROBLEM", 15, 38], ["additional studies", "TEST", 202, 220], ["a b s t r a c tBoth dogs", "TEST", 236, 260], ["A/B toxins", "PROBLEM", 284, 294], ["toxigenic strains", "PROBLEM", 300, 317], ["C. difficile", "PROBLEM", 368, 380], ["C. difficile", "OBSERVATION", 368, 380]]], ["Both strains were identified with PCR as ribotype 014/020, which is recognized as one of the most common causes of C. difficile infection (CDI) in the European community.", [["C. difficile infection", "DISEASE", 115, 137], ["CDI", "DISEASE", 139, 142], ["C. difficile", "ORGANISM", 115, 127], ["C. difficile", "SPECIES", 115, 127], ["C. difficile", "SPECIES", 115, 127], ["Both strains", "PROBLEM", 0, 12], ["PCR", "TEST", 34, 37], ["ribotype", "TEST", 41, 49], ["C. difficile infection", "PROBLEM", 115, 137], ["strains", "OBSERVATION", 5, 12], ["C.", "OBSERVATION_MODIFIER", 115, 117], ["difficile", "OBSERVATION_MODIFIER", 118, 127], ["infection", "OBSERVATION", 128, 137]]], ["It also has been previously described in dogs in several countries [6, 18] .", [["dogs", "ORGANISM", 41, 45], ["dogs", "SPECIES", 41, 45]]], ["In Brazil, ribotype 014/ 020 was previously reported in several animal species, including domestic and wild animals, and also in humans with confirmed CDI [1, 10, 13, 14] .a b s t r a c tC. perfringens infection in adult dogs is commonly linked to food or environmental changes, but no marked changes were reported by the owners in both cases described here.", [["ribotype 014/ 020", "CHEMICAL", 11, 28], ["CDI", "DISEASE", 151, 154], ["perfringens infection", "DISEASE", 190, 211], ["humans", "ORGANISM", 129, 135], ["perfringens", "ORGANISM", 190, 201], ["dogs", "ORGANISM", 221, 225], ["humans", "SPECIES", 129, 135], ["perfringens", "SPECIES", 190, 201], ["dogs", "SPECIES", 221, 225], ["ribotype 014/ 020", "SPECIES", 11, 28], ["humans", "SPECIES", 129, 135], ["perfringens", "SPECIES", 190, 201], ["perfringens infection", "PROBLEM", 190, 211], ["infection", "OBSERVATION", 202, 211]]], ["Specifically for C. difficile, antibiotic therapy is well known as the most common predisposing factor for CDI.", [["C. difficile", "DISEASE", 17, 29], ["CDI", "DISEASE", 107, 110], ["C. difficile", "ORGANISM", 17, 29], ["C. difficile", "SPECIES", 17, 29], ["C. difficile", "SPECIES", 17, 29], ["C. difficile", "PROBLEM", 17, 29], ["antibiotic therapy", "TREATMENT", 31, 49], ["CDI", "PROBLEM", 107, 110], ["difficile", "OBSERVATION", 20, 29], ["CDI", "OBSERVATION", 107, 110]]], ["However, in the present report, neither dog received any antibiotics before being sampled [16] . described five cases of C. perfringens type C and C. difficile co-infection in foals.", [["C. perfringens type C", "DISEASE", 121, 142], ["C. difficile co-infection", "DISEASE", 147, 172], ["dog", "ORGANISM", 40, 43], ["C. perfringens type C", "ORGANISM", 121, 142], ["C. difficile", "ORGANISM", 147, 159], ["foals", "ORGANISM", 176, 181], ["C. perfringens", "SPECIES", 121, 135], ["C. difficile", "SPECIES", 147, 159], ["foals", "SPECIES", 176, 181], ["C. perfringens type C", "SPECIES", 121, 142], ["C. difficile", "SPECIES", 147, 159], ["any antibiotics", "TREATMENT", 53, 68], ["C. perfringens type C", "PROBLEM", 121, 142], ["C. difficile co-infection in foals", "PROBLEM", 147, 181], ["C. perfringens", "OBSERVATION_MODIFIER", 121, 135], ["difficile", "OBSERVATION_MODIFIER", 150, 159], ["co-infection", "OBSERVATION", 160, 172]]], ["Similar to the two cases described here, none of the affected foals were on antibiotic therapy.", [["foals", "ORGANISM", 62, 67], ["the affected foals", "PROBLEM", 49, 67], ["antibiotic therapy", "TREATMENT", 76, 94]]], ["In light of this, the authors suggested that the C. perfringens infection may have acted as a predisposing factor for C. difficile or vice versa.", [["C. perfringens infection", "DISEASE", 49, 73], ["C. difficile", "DISEASE", 118, 130], ["C. perfringens", "ORGANISM", 49, 63], ["C. difficile", "ORGANISM", 118, 130], ["C. perfringens", "SPECIES", 49, 63], ["C. difficile", "SPECIES", 118, 130], ["C. perfringens", "SPECIES", 49, 63], ["C. difficile", "SPECIES", 118, 130], ["the C. perfringens infection", "PROBLEM", 45, 73], ["C. difficile", "PROBLEM", 118, 130]]], ["Anyway, Together, these two reports reinforce the need to study a possible synergism of 12 years cpe \u00fe netE \u00fe netF \u00fe e A \u00fe B \u00fe CDT -014/020 \u00fe Death a Both C. perfringens isolates were also negative for netB, tpeL and cpb2.", [["C. perfringens", "ORGANISM", 155, 169], ["netB", "GENE_OR_GENE_PRODUCT", 202, 206], ["tpeL", "GENE_OR_GENE_PRODUCT", 208, 212], ["cpb2", "GENE_OR_GENE_PRODUCT", 217, 221], ["netF", "PROTEIN", 110, 114], ["netB", "PROTEIN", 202, 206], ["tpeL", "PROTEIN", 208, 212], ["cpb2", "PROTEIN", 217, 221], ["C. perfringens", "SPECIES", 155, 169], ["C. perfringens", "SPECIES", 155, 169], ["CDT", "TEST", 127, 130], ["Death", "PROBLEM", 142, 147], ["a Both C. perfringens isolates", "TEST", 148, 178], ["netB", "TEST", 202, 206]]], ["C. perfringens and C. difficile in enteric disorders.", [["C. difficile", "DISEASE", 19, 31], ["enteric disorders", "DISEASE", 35, 52], ["C. perfringens", "ORGANISM", 0, 14], ["C. difficile", "ORGANISM", 19, 31], ["C. perfringens", "SPECIES", 0, 14], ["C. difficile", "SPECIES", 19, 31], ["C. perfringens", "SPECIES", 0, 14], ["C. difficile", "SPECIES", 19, 31], ["C. perfringens", "PROBLEM", 0, 14], ["C. difficile in enteric disorders", "PROBLEM", 19, 52], ["perfringens", "OBSERVATION", 3, 14], ["C.", "OBSERVATION_MODIFIER", 19, 21], ["difficile", "OBSERVATION_MODIFIER", 22, 31], ["enteric disorders", "OBSERVATION", 35, 52]]]], "a54c5264dc9b37bbb9a6549cf7fc9a96564c9d6d": [["IntroductionThe standard incidence of nasopharyngeal carcinoma (NPC) worldwide is 1.2 per 100,000 (1.7 per 100,000 men and 0.7 per 100,000 women) and is especially high among the Chinese population [1] .", [["nasopharyngeal carcinoma", "ANATOMY", 38, 62], ["NPC", "ANATOMY", 64, 67], ["nasopharyngeal carcinoma", "DISEASE", 38, 62], ["NPC", "DISEASE", 64, 67], ["nasopharyngeal carcinoma", "CANCER", 38, 62], ["NPC", "CANCER", 64, 67], ["women", "ORGANISM", 139, 144], ["men", "SPECIES", 115, 118], ["women", "SPECIES", 139, 144], ["nasopharyngeal carcinoma", "PROBLEM", 38, 62], ["nasopharyngeal", "ANATOMY", 38, 52], ["carcinoma", "OBSERVATION", 53, 62]]], ["The peak age of NPC incidence is 50-60 years [2] .", [["NPC", "ANATOMY", 16, 19], ["NPC", "DISEASE", 16, 19], ["NPC", "CANCER", 16, 19], ["NPC incidence", "PROBLEM", 16, 29]]], ["The most important risk factors for NPC are genetic predisposition, Epstein-Barr viral infection, and dietary and environmental factors [3] .", [["NPC", "ANATOMY", 36, 39], ["NPC", "DISEASE", 36, 39], ["Epstein-Barr viral infection", "DISEASE", 68, 96], ["NPC", "CANCER", 36, 39], ["Epstein-Barr viral", "ORGANISM", 68, 86], ["NPC", "PROBLEM", 36, 39], ["genetic predisposition", "PROBLEM", 44, 66], ["Barr viral infection", "PROBLEM", 76, 96], ["Barr viral infection", "OBSERVATION", 76, 96]]], ["NPC is a prevalent disease in Taiwan [4] .", [["NPC", "ANATOMY", 0, 3], ["NPC", "DISEASE", 0, 3], ["NPC", "CANCER", 0, 3]]], ["Radiotherapy or radiotherapy combined with chemotherapy is the mainstay of treatment [4] ; however, severe side effects, such as sensorineural hearing loss, mucositis, dry mouth, and dietary problems, as well as the limitations of conventional treatments have led to the widespread application of complementary and/or alternative medicines.", [["sensorineural hearing loss", "DISEASE", 129, 155], ["mucositis", "DISEASE", 157, 166], ["dry mouth", "DISEASE", 168, 177], ["Radiotherapy", "TREATMENT", 0, 12], ["radiotherapy", "TREATMENT", 16, 28], ["chemotherapy", "TREATMENT", 43, 55], ["treatment", "TREATMENT", 75, 84], ["severe side effects", "PROBLEM", 100, 119], ["sensorineural hearing loss", "PROBLEM", 129, 155], ["mucositis", "PROBLEM", 157, 166], ["dry mouth", "PROBLEM", 168, 177], ["dietary problems", "PROBLEM", 183, 199], ["conventional treatments", "TREATMENT", 231, 254], ["alternative medicines", "TREATMENT", 318, 339], ["severe", "OBSERVATION_MODIFIER", 100, 106], ["side effects", "OBSERVATION_MODIFIER", 107, 119], ["sensorineural hearing loss", "OBSERVATION", 129, 155], ["mucositis", "OBSERVATION", 157, 166], ["mouth", "ANATOMY", 172, 177]]], ["Furthermore, the local recurrence rate of NPC after initial radiotherapy is approximately 10%.", [["NPC", "ANATOMY", 42, 45], ["NPC", "DISEASE", 42, 45], ["NPC", "CANCER", 42, 45], ["the local recurrence rate of NPC", "PROBLEM", 13, 45], ["initial radiotherapy", "TREATMENT", 52, 72], ["local", "OBSERVATION_MODIFIER", 17, 22], ["recurrence", "OBSERVATION_MODIFIER", 23, 33]]], ["Re-irradiating the same field may cause potentially serious side effects and complications.", [["serious side effects and complications", "PROBLEM", 52, 90]]], ["The treatment of recurrent NPC remains a challenging clinical problem [5, 6] .", [["NPC", "ANATOMY", 27, 30], ["NPC", "DISEASE", 27, 30], ["NPC", "CANCER", 27, 30], ["recurrent NPC", "PROBLEM", 17, 30], ["recurrent", "OBSERVATION_MODIFIER", 17, 26], ["NPC", "OBSERVATION", 27, 30]]], ["Therefore, it is necessary to identify new therapeutic methods for NPC and recurrent NPC.IntroductionThe renin-angiotensin system (RAS) is an endocrine system that plays a central role in cardiovascular and renal physiology by regulating blood pressure and sodium balance [7] .", [["NPC", "ANATOMY", 67, 70], ["NPC", "ANATOMY", 85, 88], ["endocrine system", "ANATOMY", 142, 158], ["cardiovascular", "ANATOMY", 188, 202], ["renal", "ANATOMY", 207, 212], ["blood", "ANATOMY", 238, 243], ["NPC", "DISEASE", 67, 70], ["NPC", "DISEASE", 85, 88], ["sodium", "CHEMICAL", 257, 263], ["sodium", "CHEMICAL", 257, 263], ["NPC", "CANCER", 67, 70], ["NPC", "CANCER", 85, 88], ["renin-angiotensin system", "GENE_OR_GENE_PRODUCT", 105, 129], ["RAS", "GENE_OR_GENE_PRODUCT", 131, 134], ["cardiovascular", "ANATOMICAL_SYSTEM", 188, 202], ["renal", "ORGAN", 207, 212], ["blood", "ORGANISM_SUBSTANCE", 238, 243], ["sodium", "SIMPLE_CHEMICAL", 257, 263], ["NPC", "PROBLEM", 67, 70], ["recurrent NPC", "PROBLEM", 75, 88], ["The renin-angiotensin system", "TREATMENT", 101, 129], ["blood pressure", "TEST", 238, 252], ["sodium balance", "TEST", 257, 271], ["recurrent", "OBSERVATION_MODIFIER", 75, 84], ["NPC", "OBSERVATION", 85, 88], ["renal", "ANATOMY", 207, 212]]], ["One member of the Balternative RAS axis^is the angiotensin-(1-7) [Ang-(1-7)] peptide, which is generated by subsequent cleavage of angiotensin II by angiotensin-converting enzyme 2.", [["angiotensin-(1-7)", "CHEMICAL", 47, 64], ["Ang-(1-7)", "CHEMICAL", 66, 75], ["angiotensin II", "CHEMICAL", 131, 145], ["angiotensin", "CHEMICAL", 149, 160], ["angiotensin-(1-7", "GENE_OR_GENE_PRODUCT", 47, 63], ["Ang-(1-7)] peptide", "SIMPLE_CHEMICAL", 66, 84], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 131, 145], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 149, 180], ["angiotensin II", "PROTEIN", 131, 145], ["angiotensin-converting enzyme 2", "PROTEIN", 149, 180], ["the angiotensin", "TEST", 43, 58], ["Ang", "TEST", 66, 69], ["angiotensin II", "TREATMENT", 131, 145], ["angiotensin-converting enzyme", "TREATMENT", 149, 178]]], ["Ang-(1-7) binds to G protein-coupled receptors, namely, the Mas receptor (MasR), which activates distinct signaling pathways that lead to cellular effects [8] .", [["cellular", "ANATOMY", 138, 146], ["Ang-(1-7)", "CHEMICAL", 0, 9], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 0, 8], ["G protein-coupled receptors", "GENE_OR_GENE_PRODUCT", 19, 46], ["Mas receptor", "GENE_OR_GENE_PRODUCT", 60, 72], ["MasR", "GENE_OR_GENE_PRODUCT", 74, 78], ["cellular", "CELL", 138, 146], ["G protein-coupled receptors", "PROTEIN", 19, 46], ["Mas receptor", "PROTEIN", 60, 72], ["MasR", "PROTEIN", 74, 78], ["Ang", "TEST", 0, 3]]], ["In cancer, Ang-(1-7) is an anti-proliferative and anti-angiogenic molecule that mediates its effects by binding to MasR [9, 10] .", [["cancer", "ANATOMY", 3, 9], ["cancer", "DISEASE", 3, 9], ["Ang-(1-7", "CHEMICAL", 11, 19], ["cancer", "CANCER", 3, 9], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 11, 19], ["MasR", "GENE_OR_GENE_PRODUCT", 115, 119], ["MasR", "PROTEIN", 115, 119], ["cancer", "PROBLEM", 3, 9], ["Ang", "TEST", 11, 14], ["an anti-proliferative and anti-angiogenic molecule", "PROBLEM", 24, 74], ["cancer", "OBSERVATION", 3, 9], ["anti-angiogenic molecule", "OBSERVATION", 50, 74]]], ["In vitro studies on lung cancer cells have confirmed the antiproliferative function of Ang-(1-7) via MasR.", [["lung cancer cells", "ANATOMY", 20, 37], ["lung cancer", "DISEASE", 20, 31], ["Ang-(1-7", "CHEMICAL", 87, 95], ["lung cancer cells", "CELL", 20, 37], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 87, 95], ["MasR", "GENE_OR_GENE_PRODUCT", 101, 105], ["lung cancer cells", "CELL_TYPE", 20, 37], ["MasR", "PROTEIN", 101, 105], ["vitro studies", "TEST", 3, 16], ["lung cancer cells", "PROBLEM", 20, 37], ["Ang", "TEST", 87, 90], ["lung", "ANATOMY", 20, 24], ["cancer", "OBSERVATION", 25, 31]]], ["Ang-(1-7) inhibits cell migration and invasion by inactivating the PI3K/Akt, p38 and JNK signaling pathways [11, 12] .", [["cell", "ANATOMY", 19, 23], ["Ang-(1-7)", "CHEMICAL", 0, 9], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 0, 8], ["cell", "CELL", 19, 23], ["PI3K", "GENE_OR_GENE_PRODUCT", 67, 71], ["Akt", "GENE_OR_GENE_PRODUCT", 72, 75], ["p38", "GENE_OR_GENE_PRODUCT", 77, 80], ["JNK", "GENE_OR_GENE_PRODUCT", 85, 88], ["PI3K", "PROTEIN", 67, 71], ["Akt", "PROTEIN", 72, 75], ["p38", "PROTEIN", 77, 80], ["JNK", "PROTEIN", 85, 88], ["Ang", "TEST", 0, 3], ["inhibits cell migration", "PROBLEM", 10, 33], ["invasion", "PROBLEM", 38, 46], ["the PI3K", "TEST", 63, 71], ["Akt", "TEST", 72, 75], ["p38", "TEST", 77, 80], ["JNK signaling pathways", "TEST", 85, 107], ["cell migration", "OBSERVATION", 19, 33]]], ["In vivo studies have indicated that administration of Ang-(1-7) reduces lung and prostate tumor xenografts [13, 14] , as well as prostate cancer metastasis [15] .", [["lung", "ANATOMY", 72, 76], ["prostate tumor xenografts", "ANATOMY", 81, 106], ["prostate cancer", "ANATOMY", 129, 144], ["Ang-(1-7)", "CHEMICAL", 54, 63], ["lung and prostate tumor", "DISEASE", 72, 95], ["prostate cancer metastasis", "DISEASE", 129, 155], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 54, 62], ["lung", "ORGAN", 72, 76], ["prostate tumor xenografts", "CANCER", 81, 106], ["prostate cancer", "CANCER", 129, 144], ["vivo studies", "TEST", 3, 15], ["Ang-(1-7) reduces lung and prostate tumor xenografts", "TREATMENT", 54, 106], ["prostate cancer metastasis", "PROBLEM", 129, 155], ["lung", "ANATOMY", 72, 76], ["prostate", "ANATOMY", 81, 89], ["tumor", "OBSERVATION", 90, 95], ["prostate", "ANATOMY", 129, 137], ["cancer", "OBSERVATION", 138, 144]]], ["Furthermore, a recent report showed that Ang-(1-7) downregulated the AT1 receptor (AT1R) mRNA level, upregulated AT2 receptor and MasR mRNA levels and p38-MAPK phosphorylation, and suppressed communication between H22 hepatocellular carcinoma and endothelial cells, which may provide a novel and promising approach for the treatment of hepatocellular carcinoma [16] .", [["H22 hepatocellular carcinoma", "ANATOMY", 214, 242], ["endothelial cells", "ANATOMY", 247, 264], ["hepatocellular carcinoma", "ANATOMY", 336, 360], ["Ang-(1-7", "CHEMICAL", 41, 49], ["hepatocellular carcinoma", "DISEASE", 218, 242], ["hepatocellular carcinoma", "DISEASE", 336, 360], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 41, 49], ["AT1 receptor", "GENE_OR_GENE_PRODUCT", 69, 81], ["AT1R", "GENE_OR_GENE_PRODUCT", 83, 87], ["AT2 receptor", "GENE_OR_GENE_PRODUCT", 113, 125], ["MasR", "GENE_OR_GENE_PRODUCT", 130, 134], ["p38-MAPK", "GENE_OR_GENE_PRODUCT", 151, 159], ["H22 hepatocellular carcinoma", "CELL", 214, 242], ["endothelial cells", "CELL", 247, 264], ["hepatocellular carcinoma", "CANCER", 336, 360], ["AT1 receptor (AT1R) mRNA", "RNA", 69, 93], ["AT2 receptor", "PROTEIN", 113, 125], ["p38", "PROTEIN", 151, 154], ["MAPK", "PROTEIN", 155, 159], ["endothelial cells", "CELL_TYPE", 247, 264], ["Ang", "TEST", 41, 44], ["the AT1 receptor", "TEST", 65, 81], ["mRNA level", "TEST", 89, 99], ["AT2 receptor", "TEST", 113, 125], ["MasR mRNA levels", "TEST", 130, 146], ["p38", "TEST", 151, 154], ["MAPK phosphorylation", "TEST", 155, 175], ["H22 hepatocellular carcinoma", "PROBLEM", 214, 242], ["endothelial cells", "PROBLEM", 247, 264], ["hepatocellular carcinoma", "PROBLEM", 336, 360], ["H22", "ANATOMY", 214, 217], ["hepatocellular carcinoma", "OBSERVATION", 218, 242], ["endothelial cells", "OBSERVATION", 247, 264], ["hepatocellular", "ANATOMY", 336, 350], ["carcinoma", "OBSERVATION", 351, 360]]], ["As noted above, Ang-(1-7) may promote tumor cell death by regulating the stoichiometry of the receptors and subsequently altering their signaling.", [["tumor cell", "ANATOMY", 38, 48], ["Ang-(1-7)", "CHEMICAL", 16, 25], ["tumor", "DISEASE", 38, 43], ["death", "DISEASE", 49, 54], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 16, 24], ["tumor cell", "CELL", 38, 48], ["Ang", "TEST", 16, 19], ["tumor cell death", "PROBLEM", 38, 54], ["tumor cell death", "OBSERVATION", 38, 54]]], ["Moreover, autophagy (type II programmed cell death) is a major intracellular pathway via the degradation and recycling of proteins, ribosomes and organelles [17] .", [["cell", "ANATOMY", 40, 44], ["intracellular", "ANATOMY", 63, 76], ["ribosomes", "ANATOMY", 132, 141], ["organelles", "ANATOMY", 146, 156], ["cell", "CELL", 40, 44], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 63, 76], ["ribosomes", "CELLULAR_COMPONENT", 132, 141], ["organelles", "CELLULAR_COMPONENT", 146, 156], ["ribosomes", "PROTEIN", 132, 141], ["autophagy (type II programmed cell death", "PROBLEM", 10, 50]]], ["Autophagy as a novel cancer therapy is an effective approach used to alleviate treatment resistance in apoptosis-defective tumor cells [18] .", [["cancer", "ANATOMY", 21, 27], ["tumor cells", "ANATOMY", 123, 134], ["cancer", "DISEASE", 21, 27], ["tumor", "DISEASE", 123, 128], ["cancer", "CANCER", 21, 27], ["tumor cells", "CELL", 123, 134], ["defective tumor cells", "CELL_TYPE", 113, 134], ["Autophagy", "TREATMENT", 0, 9], ["a novel cancer therapy", "TREATMENT", 13, 35], ["an effective approach", "TREATMENT", 39, 60], ["treatment resistance", "TREATMENT", 79, 99], ["defective tumor cells", "PROBLEM", 113, 134], ["cancer", "OBSERVATION", 21, 27], ["defective", "OBSERVATION_MODIFIER", 113, 122], ["tumor cells", "OBSERVATION", 123, 134]]], ["Ang-(1-7) acts as a tumor suppressor, making it a promising therapeutic target.IntroductionIn a study on Ang-(1-7) in NPC, Pei et al. indicated that Ang-(1-7) inhibits the proliferation of human NPC cells and reduces human nasopharyngeal xenograft growth and tumor angiogenesis [19] .", [["tumor", "ANATOMY", 20, 25], ["NPC", "ANATOMY", 118, 121], ["NPC cells", "ANATOMY", 195, 204], ["nasopharyngeal xenograft", "ANATOMY", 223, 247], ["tumor", "ANATOMY", 259, 264], ["Ang-(1-7)", "CHEMICAL", 0, 9], ["tumor", "DISEASE", 20, 25], ["Ang-(1-7", "CHEMICAL", 105, 113], ["Ang-(1-7", "CHEMICAL", 149, 157], ["tumor", "DISEASE", 259, 264], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 0, 8], ["tumor", "CANCER", 20, 25], ["NPC", "CANCER", 118, 121], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 149, 157], ["human", "ORGANISM", 189, 194], ["NPC cells", "CELL", 195, 204], ["human", "ORGANISM", 217, 222], ["nasopharyngeal xenograft", "CANCER", 223, 247], ["tumor", "CANCER", 259, 264], ["human NPC cells", "CELL_TYPE", 189, 204], ["human", "SPECIES", 189, 194], ["human", "SPECIES", 217, 222], ["human", "SPECIES", 189, 194], ["human", "SPECIES", 217, 222], ["Ang", "TEST", 0, 3], ["a tumor suppressor", "TREATMENT", 18, 36], ["a study", "TEST", 94, 101], ["Ang", "TEST", 105, 108], ["Ang", "TEST", 149, 152], ["human NPC cells", "TREATMENT", 189, 204], ["human nasopharyngeal xenograft growth", "PROBLEM", 217, 254], ["tumor angiogenesis", "PROBLEM", 259, 277], ["tumor", "OBSERVATION", 20, 25], ["NPC", "ANATOMY", 118, 121], ["nasopharyngeal xenograft", "OBSERVATION", 223, 247], ["tumor", "OBSERVATION", 259, 264]]], ["These results suggest that Ang-(1-7) could serve as a novel anti-angiogenic treatment and potential target gene for NPC therapy.", [["NPC", "ANATOMY", 116, 119], ["Ang-(1-7)", "CHEMICAL", 27, 36], ["NPC", "DISEASE", 116, 119], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 27, 35], ["NPC", "CANCER", 116, 119], ["Ang", "TEST", 27, 30], ["a novel anti-angiogenic treatment", "TREATMENT", 52, 85], ["NPC therapy", "TREATMENT", 116, 127]]], ["However, the effects of Ang-(1-7) on autophagic activity in NPC remain unclear.", [["NPC", "ANATOMY", 60, 63], ["Ang-(1-7)", "CHEMICAL", 24, 33], ["NPC", "DISEASE", 60, 63], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 24, 32], ["NPC", "CANCER", 60, 63], ["Ang", "TEST", 24, 27], ["NPC", "PROBLEM", 60, 63], ["activity", "OBSERVATION_MODIFIER", 48, 56], ["NPC", "ANATOMY", 60, 63]]], ["In the present study, we investigated the regulatory mechanisms of Ang-(1-7) on NPC cells in vitro and two NPC tumor xenograft models (pre-and post-treatment) in vivo.", [["NPC cells", "ANATOMY", 80, 89], ["NPC tumor xenograft", "ANATOMY", 107, 126], ["Ang-(1-7", "CHEMICAL", 67, 75], ["tumor", "DISEASE", 111, 116], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 67, 75], ["NPC cells", "CELL", 80, 89], ["NPC tumor xenograft", "CANCER", 107, 126], ["NPC cells", "CELL_LINE", 80, 89], ["the present study", "TEST", 3, 20], ["Ang", "TEST", 67, 70], ["NPC cells", "TREATMENT", 80, 89], ["vitro", "TREATMENT", 93, 98], ["two NPC tumor xenograft models", "TREATMENT", 103, 133], ["post-treatment)", "TREATMENT", 143, 158], ["NPC", "ANATOMY", 107, 110], ["tumor xenograft", "OBSERVATION", 111, 126]]], ["Our data suggest that Ang-(1-7) is a potential novel therapeutic agent for NPC because it exerts autophagic activity.MaterialsDulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), phosphate-buffered saline (PBS), sodium pyruvate, trypsin, and antibiotics were purchased from Gibco, BRL (Grand Island, NY, USA).", [["NPC", "ANATOMY", 75, 78], ["fetal bovine serum", "ANATOMY", 169, 187], ["FBS", "ANATOMY", 189, 192], ["Ang-(1-7", "CHEMICAL", 22, 30], ["NPC", "DISEASE", 75, 78], ["phosphate", "CHEMICAL", 195, 204], ["sodium pyruvate", "CHEMICAL", 228, 243], ["phosphate", "CHEMICAL", 195, 204], ["sodium pyruvate", "CHEMICAL", 228, 243], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 22, 30], ["NPC", "CANCER", 75, 78], ["bovine", "ORGANISM", 175, 181], ["serum", "ORGANISM_SUBSTANCE", 182, 187], ["FBS", "ORGANISM_SUBSTANCE", 189, 192], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 195, 220], ["PBS", "SIMPLE_CHEMICAL", 222, 225], ["sodium pyruvate", "SIMPLE_CHEMICAL", 228, 243], ["trypsin", "SIMPLE_CHEMICAL", 245, 252], ["bovine", "SPECIES", 175, 181], ["bovine", "SPECIES", 175, 181], ["Our data", "TEST", 0, 8], ["Ang", "TEST", 22, 25], ["novel therapeutic agent", "TREATMENT", 47, 70], ["NPC", "PROBLEM", 75, 78], ["Materials", "TEST", 117, 126], ["Eagle's medium (DMEM", "TEST", 146, 166], ["fetal bovine serum", "TEST", 169, 187], ["FBS", "TEST", 189, 192], ["phosphate", "TEST", 195, 204], ["sodium pyruvate", "TEST", 228, 243], ["trypsin", "TEST", 245, 252], ["antibiotics", "TREATMENT", 258, 269], ["autophagic activity", "OBSERVATION", 97, 116]]], ["3-(4,5-Dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT), dimethyl sulfoxide (DMSO), and the MasR antagonist A779 were purchased from Sigma-Aldrich (St. Louis, MO, USA).", [["3-(4,5-Dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide", "CHEMICAL", 0, 59], ["MTT", "CHEMICAL", 61, 64], ["dimethyl sulfoxide", "CHEMICAL", 67, 85], ["DMSO", "CHEMICAL", 87, 91], ["A779", "CHEMICAL", 118, 122], ["3-(4,5-Dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide", "CHEMICAL", 0, 59], ["MTT", "CHEMICAL", 61, 64], ["dimethyl sulfoxide", "CHEMICAL", 67, 85], ["DMSO", "CHEMICAL", 87, 91], ["A779", "CHEMICAL", 118, 122], ["3-(4,5-Dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide", "SIMPLE_CHEMICAL", 0, 59], ["MTT", "SIMPLE_CHEMICAL", 61, 64], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 67, 85], ["DMSO", "SIMPLE_CHEMICAL", 87, 91], ["A779", "SIMPLE_CHEMICAL", 118, 122], ["Sigma-Aldrich", "ORGANISM", 143, 156], ["St. Louis", "ORGANISM", 158, 167], ["Dimethylthiazol-2yl)", "TREATMENT", 7, 27], ["diphenyltetrazolium bromide", "TREATMENT", 32, 59], ["dimethyl sulfoxide (DMSO)", "TREATMENT", 67, 92], ["the MasR antagonist", "TREATMENT", 98, 117]]], ["Matrigel (Basement Membrane Matrix) was purchased from BD Biosciences (Franklin Lakes, NJ, USA).", [["Matrigel (Basement Membrane Matrix", "TREATMENT", 0, 34]]], ["The specific inhibitor 3-methyladenine (3-MA) was purchased from Merck Millipore (Merck KGaA, Darmstadt, Germany).", [["3-methyladenine", "CHEMICAL", 23, 38], ["3-MA", "CHEMICAL", 40, 44], ["3-methyladenine", "CHEMICAL", 23, 38], ["3-MA", "CHEMICAL", 40, 44], ["3-methyladenine", "SIMPLE_CHEMICAL", 23, 38], ["3-MA", "SIMPLE_CHEMICAL", 40, 44], ["The specific inhibitor", "TREATMENT", 0, 22], ["methyladenine", "TREATMENT", 25, 38]]], ["All reagents and compounds were of analytical grade. with 10% FBS, 100 kU/L penicillin and 100 mg/L streptomycin) at 37\u00b0C and 5% CO 2 in a humidified atmosphere.Cell proliferation assayCells were seeded in a 96-well culture plate at 5000 cells/well.", [["FBS", "ANATOMY", 62, 65], ["Cell", "ANATOMY", 161, 165], ["cells", "ANATOMY", 238, 243], ["penicillin", "CHEMICAL", 76, 86], ["streptomycin", "CHEMICAL", 100, 112], ["penicillin", "CHEMICAL", 76, 86], ["streptomycin", "CHEMICAL", 100, 112], ["CO 2", "CHEMICAL", 129, 133], ["FBS", "ORGANISM_SUBSTANCE", 62, 65], ["penicillin", "SIMPLE_CHEMICAL", 76, 86], ["streptomycin", "SIMPLE_CHEMICAL", 100, 112], ["Cell", "CELL", 161, 165], ["assayCells", "CELL", 180, 190], ["cells", "CELL", 238, 243], ["5000 cells", "CELL_LINE", 233, 243], ["All reagents", "TREATMENT", 0, 12], ["10% FBS", "TREATMENT", 58, 65], ["penicillin", "TREATMENT", 76, 86], ["streptomycin", "TREATMENT", 100, 112], ["a humidified atmosphere", "TREATMENT", 137, 160], ["Cell proliferation assayCells", "PROBLEM", 161, 190]]], ["MTT (1 mg/ml) was added to each well for at least 4 h.", [["MTT", "CHEMICAL", 0, 3], ["MTT", "CHEMICAL", 0, 3], ["MTT", "SIMPLE_CHEMICAL", 0, 3]]], ["The reaction was stopped by the addition of DMSO, and optical density was measured at 570 nm on a multi-well plate reader.Wound healing assayThe cell density was adjusted to 2.5 \u00d7 10 5 /ml.", [["Wound", "ANATOMY", 122, 127], ["cell", "ANATOMY", 145, 149], ["DMSO", "CHEMICAL", 44, 48], ["DMSO", "CHEMICAL", 44, 48], ["DMSO", "SIMPLE_CHEMICAL", 44, 48], ["Wound", "PATHOLOGICAL_FORMATION", 122, 127], ["cell", "CELL", 145, 149], ["The reaction", "PROBLEM", 0, 12], ["DMSO", "TREATMENT", 44, 48], ["a multi-well plate reader", "TREATMENT", 96, 121], ["Wound healing assay", "PROBLEM", 122, 141], ["The cell density", "TREATMENT", 141, 157], ["healing", "OBSERVATION", 128, 135], ["cell density", "OBSERVATION", 145, 157]]], ["Cells were seeded in 35-mm culture dishes with silicon inserts consisting of two chambers separated by a 500-\u03bcm wall (ibidi GmbH, Munich, Germany).", [["Cells", "ANATOMY", 0, 5], ["silicon", "CHEMICAL", 47, 54], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5], ["35-mm culture dishes", "TREATMENT", 21, 41], ["silicon inserts", "TREATMENT", 47, 62]]], ["After overnight incubation at 5% CO 2 at 37\u00b0C for 24 h, the silicon inserts were removed.", [["CO", "CHEMICAL", 33, 35], ["silicon", "CHEMICAL", 60, 67], ["the silicon inserts", "TREATMENT", 56, 75], ["silicon inserts", "OBSERVATION", 60, 75]]], ["Cells were treated with Ang-(1-7) and A779 and incubated for 0, 24, 48 or 72 h.", [["Cells", "ANATOMY", 0, 5], ["Ang-(1-7)", "CHEMICAL", 24, 33], ["Cells", "CELL", 0, 5], ["A779", "CELL", 38, 42], ["Ang", "TEST", 24, 27]]], ["Wound healing was observed by 200\u00d7 phase-contrast microscopy (Olympus CKX41, Tokyo, Japan) in three independent experiments.", [["Wound", "ANATOMY", 0, 5], ["Wound", "PATHOLOGICAL_FORMATION", 0, 5], ["Wound healing", "PROBLEM", 0, 13], ["healing", "OBSERVATION", 6, 13]]], ["Images evaluated using Image-Pro Plus 6.0 software (Media Cybernetics, Rockville, MD, USA) were used to calculate the mean \u00b1 standard deviation.", [["Images", "TEST", 0, 6], ["Image", "TEST", 23, 28], ["standard deviation", "OBSERVATION", 125, 143]]], ["Cell migration is expressed as wound closure, and each group was compared with the control group (0 h).Transwell invasion assayThe cell density was adjusted to 2.5 \u00d7 10 5 /ml.", [["Cell", "ANATOMY", 0, 4], ["wound", "ANATOMY", 31, 36], ["cell", "ANATOMY", 131, 135], ["Cell", "CELL", 0, 4], ["wound", "PATHOLOGICAL_FORMATION", 31, 36], ["cell", "CELL", 131, 135], ["Cell migration", "TREATMENT", 0, 14], ["wound closure", "TREATMENT", 31, 44], ["Transwell invasion assay", "TEST", 103, 127], ["The cell density", "TREATMENT", 127, 143], ["wound closure", "OBSERVATION", 31, 44], ["invasion", "OBSERVATION", 113, 121], ["cell density", "OBSERVATION", 131, 143]]], ["Cells were seeded in the upper chamber of a 24-well Transwell chamber (Corning Life Sciences, Corning, NY, USA) with 50 \u03bcl Matrigel\u2122 (BD Biosciences).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5], ["upper", "ANATOMY_MODIFIER", 25, 30], ["chamber", "ANATOMY_MODIFIER", 31, 38]]], ["Complete medium (750 \u03bcl) was added to the lower chamber.", [["medium", "OBSERVATION_MODIFIER", 9, 15], ["lower", "ANATOMY_MODIFIER", 42, 47], ["chamber", "ANATOMY_MODIFIER", 48, 55]]], ["The plate was incubated at 37\u00b0C for 18-24 h.", [["The plate", "TREATMENT", 0, 9], ["plate", "OBSERVATION_MODIFIER", 4, 9]]], ["Cells were fixed with 3.7% paraformaldehyde for 2 min and permeabilized with 100% methanol for 20 min at room temperature.", [["Cells", "ANATOMY", 0, 5], ["methanol", "CHEMICAL", 82, 90], ["paraformaldehyde", "CHEMICAL", 27, 43], ["methanol", "CHEMICAL", 82, 90], ["Cells", "CELL", 0, 5], ["paraformaldehyde", "SIMPLE_CHEMICAL", 27, 43], ["methanol", "SIMPLE_CHEMICAL", 82, 90], ["Cells", "TEST", 0, 5], ["3.7% paraformaldehyde", "TREATMENT", 22, 43], ["100% methanol", "TREATMENT", 77, 90]]], ["Cells were then stained with 0.1% crystal violet solution for 20 min and washed twice with PBS.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["0.1% crystal violet solution", "TREATMENT", 29, 57], ["PBS", "TREATMENT", 91, 94]]], ["Non-invasive cells were removed with a cotton swab.", [["cells", "ANATOMY", 13, 18], ["cells", "CELL", 13, 18], ["cotton", "SPECIES", 39, 45], ["Non-invasive cells", "PROBLEM", 0, 18], ["a cotton swab", "TEST", 37, 50]]], ["Cell numbers were counted using phase-contrast microscopy, and the mean value was used as the number of invasive cells.", [["Cell", "ANATOMY", 0, 4], ["invasive cells", "ANATOMY", 104, 118], ["Cell", "CELL", 0, 4], ["cells", "CELL", 113, 118], ["invasive cells", "CELL_TYPE", 104, 118], ["Cell numbers", "TEST", 0, 12], ["phase-contrast microscopy", "TEST", 32, 57], ["the mean value", "TEST", 63, 77], ["invasive cells", "OBSERVATION", 104, 118]]], ["Images measured using Image-Pro Plus 6.0 software were used to calculate the mean \u00b1 standard deviation.", [["Images", "TEST", 0, 6], ["Image", "TEST", 22, 27], ["standard deviation", "OBSERVATION", 84, 102]]], ["Invasion suppression rate = [(penetration cell number in the control group \u2212 penetration cell number in the treated group)/penetration cell number in the control group] \u00d7 100%.Small-interfering RNA (siRNA) transfectionPlasmids expressing siRNA specifically targeting Bcl-2 or control siRNA (no silencing) were designed and synthesized (Stealth RNAi, Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) to knockdown the expression of Bcl-2.Small-interfering RNA (siRNA) transfectionConfluent cells were cultured in serum-free DMEM for 24 h before transfection, which was conducted in 24-well plates using 50 nM siRNAs and Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol.", [["cell", "ANATOMY", 42, 46], ["cell", "ANATOMY", 89, 93], ["cell", "ANATOMY", 135, 139], ["Confluent cells", "ANATOMY", 485, 500], ["serum", "ANATOMY", 518, 523], ["cell", "CELL", 42, 46], ["cell", "CELL", 89, 93], ["cell", "CELL", 135, 139], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 267, 272], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 437, 442], ["Confluent cells", "CELL", 485, 500], ["serum", "ORGANISM_SUBSTANCE", 518, 523], ["Bcl-2", "DNA", 267, 272], ["Bcl-2", "PROTEIN", 437, 442], ["Invasion suppression rate", "PROBLEM", 0, 25], ["penetration cell number", "TREATMENT", 30, 53], ["the control group \u2212 penetration cell number", "TREATMENT", 57, 100], ["Small-interfering RNA", "PROBLEM", 176, 197], ["(siRNA) transfectionPlasmids", "TREATMENT", 198, 226], ["Bcl", "TEST", 267, 270], ["Bcl", "TEST", 437, 440], ["Small-interfering RNA (siRNA) transfectionConfluent cells", "PROBLEM", 443, 500], ["serum", "TEST", 518, 523], ["transfection", "TEST", 550, 562], ["50 nM siRNAs", "TREATMENT", 608, 620], ["Lipofectamine", "TREATMENT", 625, 638], ["the manufacturer's protocol", "TREATMENT", 689, 716], ["interfering RNA", "OBSERVATION", 182, 197], ["Bcl", "ANATOMY", 437, 440], ["interfering RNA", "OBSERVATION", 449, 464], ["Confluent", "OBSERVATION_MODIFIER", 485, 494]]], ["After 48-72 h of siRNA incubation, cells were harvested for further analyses.", [["cells", "ANATOMY", 35, 40], ["cells", "CELL", 35, 40], ["siRNA incubation", "TREATMENT", 17, 33], ["cells", "TREATMENT", 35, 40], ["further analyses", "TEST", 60, 76]]], ["Bcl-2 knockdown was confirmed by Western blotting.In vivo tumor xenograft mouse modelsMale nude mice (5-7 weeks old) were maintained according to the Institutional Animal Care and Use Committee (IACUC) of the Animal Experimentation in Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.", [["tumor xenograft", "ANATOMY", 58, 73], ["tumor", "DISEASE", 58, 63], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 0, 5], ["tumor xenograft", "CANCER", 58, 73], ["mouse", "ORGANISM", 74, 79], ["Male nude mice", "ORGANISM", 86, 100], ["Bcl-2", "PROTEIN", 0, 5], ["mouse", "SPECIES", 74, 79], ["mice", "SPECIES", 96, 100], ["mouse", "SPECIES", 74, 79], ["mice", "SPECIES", 96, 100], ["Bcl", "TEST", 0, 3], ["vivo tumor xenograft mouse models", "TREATMENT", 53, 86], ["tumor xenograft", "OBSERVATION", 58, 73]]], ["Two treatment models were established.", [["Two treatment models", "TREATMENT", 0, 20]]], ["In the first model (post-treatment group), NPC-TW-01 cells (1 \u00d7 10 7 in 0.1 ml PBS) were injected into the right upper back of each mouse.", [["NPC-TW-01 cells", "ANATOMY", 43, 58], ["right upper back", "ANATOMY", 107, 123], ["NPC-TW-01 cells", "CELL", 43, 58], ["upper back", "ORGANISM_SUBDIVISION", 113, 123], ["mouse", "ORGANISM", 132, 137], ["NPC-TW-01 cells", "CELL_LINE", 43, 58], ["mouse", "SPECIES", 132, 137], ["mouse", "SPECIES", 132, 137], ["post-treatment group)", "TREATMENT", 20, 41], ["NPC-TW-01 cells", "TREATMENT", 43, 58], ["right", "ANATOMY_MODIFIER", 107, 112], ["upper", "ANATOMY_MODIFIER", 113, 118], ["each mouse", "ANATOMY_MODIFIER", 127, 137]]], ["When the tumors grew to 50 mm 3 in size, the mice were randomly divided into four treatment groups: mock group (equal volume saline), low-dose Ang-(1-7) (0.2 \u03bcg/kg), high-dose Ang-(1-7) (1 \u03bcg/kg), or Ang-(1-7) (1 \u03bcg/kg) + A779 (1 \u03bcg/kg).", [["tumors", "ANATOMY", 9, 15], ["tumors", "DISEASE", 9, 15], ["Ang-(1-7)", "CHEMICAL", 143, 152], ["Ang-(1-7)", "CHEMICAL", 176, 185], ["Ang-(1-7)", "CHEMICAL", 200, 209], ["A779", "CHEMICAL", 222, 226], ["A779", "CHEMICAL", 222, 226], ["tumors", "CANCER", 9, 15], ["mice", "ORGANISM", 45, 49], ["saline", "SIMPLE_CHEMICAL", 125, 131], ["Ang-(1-7)", "SIMPLE_CHEMICAL", 143, 152], ["Ang-(1-7)", "SIMPLE_CHEMICAL", 176, 185], ["Ang-(1-7)", "SIMPLE_CHEMICAL", 200, 209], ["A779", "SIMPLE_CHEMICAL", 222, 226], ["mice", "SPECIES", 45, 49], ["mice", "SPECIES", 45, 49], ["the tumors", "PROBLEM", 5, 15], ["mock group (equal volume saline", "TREATMENT", 100, 131], ["low-dose Ang", "TREATMENT", 134, 146], ["high-dose Ang", "TREATMENT", 166, 179], ["tumors", "OBSERVATION", 9, 15], ["50 mm", "OBSERVATION_MODIFIER", 24, 29], ["size", "OBSERVATION_MODIFIER", 35, 39]]], ["All drugs were subcutaneously injected once each day.", [["subcutaneously", "ANATOMY", 15, 29], ["All drugs", "TREATMENT", 0, 9]]], ["In the second model (pre-treatment group), mice were randomly divided into five groups: mock group, low-dose Ang-(1-7) (0.2 \u03bcg/kg), high-dose Ang-(1-7) (1 \u03bcg/kg), Ang-(1-7) (1 \u03bcg/kg) + A779 (1 \u03bcg/kg), or Ang-(1-7) (1 \u03bcg/kg) + 3-MA (5 \u03bcg/kg).", [["Ang-(1-7)", "CHEMICAL", 109, 118], ["Ang-(1-7)", "CHEMICAL", 142, 151], ["Ang-(1-7)", "CHEMICAL", 163, 172], ["A779", "CHEMICAL", 185, 189], ["Ang-(1-7)", "CHEMICAL", 204, 213], ["3-MA", "CHEMICAL", 226, 230], ["A779", "CHEMICAL", 185, 189], ["3-MA", "CHEMICAL", 226, 230], ["mice", "ORGANISM", 43, 47], ["Ang-(1-7", "SIMPLE_CHEMICAL", 109, 117], ["Ang-(1-7)", "SIMPLE_CHEMICAL", 142, 151], ["Ang-(1-7)", "SIMPLE_CHEMICAL", 163, 172], ["A779", "SIMPLE_CHEMICAL", 185, 189], ["Ang-(1-7)", "SIMPLE_CHEMICAL", 204, 213], ["3-MA", "SIMPLE_CHEMICAL", 226, 230], ["mice", "SPECIES", 43, 47], ["mice", "SPECIES", 43, 47], ["low-dose Ang", "TREATMENT", 100, 112], ["high-dose Ang", "TREATMENT", 132, 145]]], ["Cells were pre-treated for 2 weeks, and NPC-TW-01 cells were subcutaneously inoculated into the back of each mouse.", [["Cells", "ANATOMY", 0, 5], ["NPC-TW-01 cells", "ANATOMY", 40, 55], ["back", "ANATOMY", 96, 100], ["Cells", "CELL", 0, 5], ["NPC-TW-01 cells", "CELL", 40, 55], ["back", "ORGANISM_SUBDIVISION", 96, 100], ["mouse", "ORGANISM", 109, 114], ["NPC-TW-01 cells", "CELL_LINE", 40, 55], ["mouse", "SPECIES", 109, 114], ["mouse", "SPECIES", 109, 114], ["Cells", "TEST", 0, 5], ["NPC-TW-01 cells", "TREATMENT", 40, 55]]], ["Drug treatment was continued once a day for 4 weeks.", [["Drug", "SIMPLE_CHEMICAL", 0, 4], ["Drug treatment", "TREATMENT", 0, 14]]], ["After 6 weeks, all mice were euthanized, and the tumors were collected for subsequent experiments.", [["tumors", "ANATOMY", 49, 55], ["tumors", "DISEASE", 49, 55], ["mice", "ORGANISM", 19, 23], ["tumors", "CANCER", 49, 55], ["mice", "SPECIES", 19, 23], ["mice", "SPECIES", 19, 23], ["the tumors", "PROBLEM", 45, 55], ["tumors", "OBSERVATION", 49, 55]]], ["The methods used in the animal experiments were performed in accordance with relevant guidelines.", [["The methods", "TREATMENT", 0, 11]]], ["All animal studies were approved by the IACUC of Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan (IACUC approval number 2016121913).Immunohistochemistry and immunofluorescence stainingTumor sections (4 \u03bcm) were prepared on slide glasses, and sectioned slides were deparaffinized in xylene and gradually hydrated using an alcohol gradient from 100 to 70%.", [["Tumor sections", "ANATOMY", 194, 208], ["xylene", "CHEMICAL", 292, 298], ["alcohol", "CHEMICAL", 331, 338], ["xylene", "CHEMICAL", 292, 298], ["alcohol", "CHEMICAL", 331, 338], ["Tumor sections", "CANCER", 194, 208], ["xylene", "SIMPLE_CHEMICAL", 292, 298], ["alcohol", "SIMPLE_CHEMICAL", 331, 338], ["All animal studies", "TEST", 0, 18], ["Immunohistochemistry", "TEST", 142, 162], ["immunofluorescence staining", "TEST", 167, 194], ["Tumor sections", "TEST", 194, 208], ["slide glasses", "TREATMENT", 233, 246], ["sectioned slides", "TEST", 252, 268], ["xylene", "TREATMENT", 292, 298], ["an alcohol gradient", "TREATMENT", 328, 347], ["Tumor", "OBSERVATION", 194, 199]]], ["After washing with PBS, slides were warmed in a microwave with citrate buffer following incubation in 3% H 2 O 2 .", [["citrate", "CHEMICAL", 63, 70], ["citrate", "CHEMICAL", 63, 70], ["H 2 O 2", "CHEMICAL", 105, 112], ["citrate", "SIMPLE_CHEMICAL", 63, 70], ["PBS", "TREATMENT", 19, 22], ["slides", "TEST", 24, 30], ["a microwave with citrate buffer", "TREATMENT", 46, 77]]], ["Sections were then incubated with 5% bovine serum albumin in PBS to block nonspecific binding.", [["serum", "ANATOMY", 44, 49], ["bovine", "ORGANISM", 37, 43], ["serum", "ORGANISM_SUBSTANCE", 44, 49], ["albumin", "GENE_OR_GENE_PRODUCT", 50, 57], ["PBS", "SIMPLE_CHEMICAL", 61, 64], ["bovine", "SPECIES", 37, 43], ["bovine", "SPECIES", 37, 43], ["5% bovine serum albumin in PBS", "TREATMENT", 34, 64], ["block nonspecific binding", "PROBLEM", 68, 93], ["nonspecific binding", "OBSERVATION", 74, 93]]], ["Ki67 (1:100, ab15580; Abcam, Cambridge, UK) and microtubule-associated protein 1A/1Blight chain 3 (LC3-II) (1:200, L7543; Sigma-Aldrich) antibodies were added to the slides and incubated overnight at 4\u00b0C. Sections were then incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies for 1 h at room temperature.", [["microtubule", "ANATOMY", 48, 59], ["Ki67", "GENE_OR_GENE_PRODUCT", 0, 4], ["Abcam", "GENE_OR_GENE_PRODUCT", 22, 27], ["UK", "GENE_OR_GENE_PRODUCT", 40, 42], ["microtubule-associated protein 1A", "GENE_OR_GENE_PRODUCT", 48, 81], ["1Blight chain 3", "GENE_OR_GENE_PRODUCT", 82, 97], ["LC3-II", "GENE_OR_GENE_PRODUCT", 99, 105], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 122, 135], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 239, 261], ["HRP", "SIMPLE_CHEMICAL", 263, 266], ["Ki67 (1:100, ab15580; Abcam, Cambridge, UK) and microtubule-associated protein 1A/1Blight chain 3 (LC3-II) (1:200, L7543; Sigma-Aldrich) antibodies", "PROTEIN", 0, 147], ["horseradish peroxidase (HRP)-conjugated secondary antibodies", "PROTEIN", 239, 299], ["horseradish", "SPECIES", 239, 250], ["Ki67", "TEST", 0, 4], ["Abcam", "TEST", 22, 27], ["microtubule", "TEST", 48, 59], ["protein 1A", "TEST", 71, 81], ["1Blight chain", "TEST", 82, 95], ["LC3", "TEST", 99, 102], ["horseradish peroxidase", "TEST", 239, 261], ["conjugated secondary antibodies", "PROBLEM", 268, 299]]], ["After washing, the sections were incubated with DAB substrate.", [["sections", "ANATOMY", 19, 27], ["DAB", "CHEMICAL", 48, 51], ["DAB", "SIMPLE_CHEMICAL", 48, 51], ["the sections", "TEST", 15, 27]]], ["Finally, hematoxylin staining was performed after mounting the slides using Permount mounting medium (Sigma-Aldrich).", [["hematoxylin", "CHEMICAL", 9, 20], ["hematoxylin", "SIMPLE_CHEMICAL", 9, 20], ["hematoxylin staining", "TEST", 9, 29]]], ["Cell proliferation was detected also by immunofluorescence staining using an antibody against Ki67 (1:100, ab15580; Abcam) for 2 h.", [["Cell", "ANATOMY", 0, 4], ["Cell", "CELL", 0, 4], ["Ki67", "GENE_OR_GENE_PRODUCT", 94, 98], ["Abcam", "GENE_OR_GENE_PRODUCT", 116, 121], ["Ki67", "PROTEIN", 94, 98], ["Abcam", "PROTEIN", 116, 121], ["Cell proliferation", "PROBLEM", 0, 18], ["immunofluorescence staining", "TEST", 40, 67], ["an antibody", "TEST", 74, 85], ["Ki67", "TEST", 94, 98], ["ab", "TEST", 107, 109], ["Abcam", "TEST", 116, 121]]], ["Next, tissue sections were incubated with Alexa Fluor-labeled secondary antibodies (1:500) for 20 min at 37\u00b0C and washed with PBS.", [["tissue sections", "ANATOMY", 6, 21], ["Alexa Fluor", "CHEMICAL", 42, 53], ["tissue sections", "CANCER", 6, 21], ["Alexa Fluor", "SIMPLE_CHEMICAL", 42, 53], ["Alexa Fluor-labeled secondary antibodies", "PROTEIN", 42, 82], ["tissue sections", "TEST", 6, 21], ["Alexa Fluor", "TEST", 42, 53], ["PBS", "TREATMENT", 126, 129]]], ["The coverslips were mounted in Prolong Gold anti-fade reagent with 4\u2032,6-diamidino-2-phenylindole (DAPI; Invitrogen) for 10 min at room temperature and examined by fluorescence microscopy (Olympus CKX41 and U-RFLT 50).Western blot analysisProteins were extracted from frozen tissue samples by homogenization of the tissues in radioimmunoprecipitation assay (RIPA) lysis buffer.", [["tissue samples", "ANATOMY", 274, 288], ["tissues", "ANATOMY", 314, 321], ["4\u2032,6-diamidino-2-phenylindole", "CHEMICAL", 67, 96], ["DAPI", "CHEMICAL", 98, 102], ["4\u2032,6-diamidino-2-phenylindole", "CHEMICAL", 67, 96], ["DAPI", "CHEMICAL", 98, 102], ["4\u2032,6-diamidino-2-phenylindole", "SIMPLE_CHEMICAL", 67, 96], ["DAPI", "SIMPLE_CHEMICAL", 98, 102], ["Invitrogen", "SIMPLE_CHEMICAL", 104, 114], ["tissue samples", "TISSUE", 274, 288], ["tissues", "TISSUE", 314, 321], ["Prolong Gold anti-fade reagent", "TREATMENT", 31, 61], ["diamidino", "TREATMENT", 72, 81], ["phenylindole (DAPI", "TREATMENT", 84, 102], ["Invitrogen", "TREATMENT", 104, 114], ["fluorescence microscopy", "TEST", 163, 186], ["Olympus CKX41", "TEST", 188, 201], ["U", "TEST", 206, 207], ["RFLT", "TEST", 208, 212], ["blot analysis", "TEST", 225, 238], ["frozen tissue samples", "TEST", 267, 288], ["radioimmunoprecipitation assay", "TEST", 325, 355], ["RIPA) lysis buffer", "TREATMENT", 357, 375], ["frozen tissue", "OBSERVATION_MODIFIER", 267, 280], ["tissues", "ANATOMY", 314, 321]]], ["Proteins were also extracted from NPC cells by lysing the cells in RIPA buffer and collecting the supernatant.", [["NPC cells", "ANATOMY", 34, 43], ["cells", "ANATOMY", 58, 63], ["supernatant", "ANATOMY", 98, 109], ["NPC cells", "CELL", 34, 43], ["cells", "CELL", 58, 63], ["NPC cells", "CELL_LINE", 34, 43], ["NPC cells", "TREATMENT", 34, 43], ["RIPA buffer", "TREATMENT", 67, 78], ["NPC cells", "OBSERVATION", 34, 43]]], ["The protein concentration was estimated using the BCA Protein Assay Kit (Thermo, Waltham, MA, USA).", [["The protein concentration", "TEST", 0, 25]]], ["Immunoblotting was performed according to standard procedures.", [["Immunoblotting", "TEST", 0, 14]]], ["The antibodies used included polyclonal antibodiesStatistical analysisData are presented as means \u00b1 standard deviation.", [["antibodies", "PROTEIN", 4, 14], ["polyclonal antibodies", "PROTEIN", 29, 50], ["The antibodies", "TEST", 0, 14], ["polyclonal antibodies", "TREATMENT", 29, 50]]], ["Statistical comparisons between two groups were performed using unpaired Student's t tests.", [["unpaired Student's t tests", "TEST", 64, 90]]], ["Differences among groups were tested by one-way ANOVA analysis of variance with Bonferroni's multiple comparison tests.", [["Bonferroni's multiple comparison tests", "TEST", 80, 118]]], ["Moreover, data in cell migration and invasion assays were analyzed by two-way ANOVA analysis of variance with Bonferroni's multiple comparison tests.", [["cell", "ANATOMY", 18, 22], ["cell", "CELL", 18, 22], ["data in cell migration", "TEST", 10, 32], ["invasion assays", "TEST", 37, 52], ["Bonferroni's multiple comparison tests", "TEST", 110, 148]]], ["In all cases, differences were considered statistically significant at p < 0.05.Ang-(1-7) inhibits NPC proliferation in vitroCell proliferation was measured by MTT assay (Fig. 1) .", [["NPC", "ANATOMY", 99, 102], ["Cell", "ANATOMY", 125, 129], ["Ang-(1-7)", "CHEMICAL", 80, 89], ["MTT", "CHEMICAL", 160, 163], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 80, 88], ["NPC", "CANCER", 99, 102], ["Cell", "CELL", 125, 129], ["NPC", "PROTEIN", 99, 102], ["Ang", "TEST", 80, 83], ["NPC proliferation", "PROBLEM", 99, 116], ["Cell proliferation", "PROBLEM", 125, 143], ["MTT assay", "TEST", 160, 169], ["NPC", "ANATOMY", 99, 102], ["proliferation", "OBSERVATION", 103, 116]]], ["The anti-proliferative effects of Ang-(1-7) on NPC in vitro were investigated by treating NPC-TW01 cells with a range of doses [0-1.0 \u03bcM] of Ang-(1-7) for 24-72 h.", [["NPC", "ANATOMY", 47, 50], ["NPC-TW01 cells", "ANATOMY", 90, 104], ["Ang-(1-7)", "CHEMICAL", 34, 43], ["Ang-(1-7", "CHEMICAL", 141, 149], ["Ang-(1-7", "SIMPLE_CHEMICAL", 34, 42], ["NPC", "CANCER", 47, 50], ["NPC-TW01 cells", "CELL", 90, 104], ["NPC-TW01 cells", "CELL_LINE", 90, 104], ["Ang", "TEST", 34, 37], ["NPC in vitro", "TREATMENT", 47, 59], ["NPC-TW01 cells", "TREATMENT", 90, 104], ["Ang", "TEST", 141, 144], ["anti-proliferative", "OBSERVATION_MODIFIER", 4, 22]]], ["Cell viability decreased with increasing concentrations of Ang-(1-7), with a 50% inhibitory concentration of 0.51 \u03bcM at 72 h (Fig. 1a) .", [["Cell", "ANATOMY", 0, 4], ["Ang-(1-7", "CHEMICAL", 59, 67], ["Cell", "CELL", 0, 4], ["1-7", "SIMPLE_CHEMICAL", 64, 67], ["Cell viability", "TEST", 0, 14], ["Ang", "TEST", 59, 62], ["viability", "OBSERVATION_MODIFIER", 5, 14], ["decreased", "OBSERVATION_MODIFIER", 15, 24], ["increasing", "OBSERVATION_MODIFIER", 30, 40], ["concentrations", "OBSERVATION_MODIFIER", 41, 55]]], ["These effects were reversed by coadministration with the MasR antagonist A779 (0.1 and 1.0 \u03bcM) at 72 h (Fig. 1b) .Ang-(1-7) inhibits NPC cell migration and invasion in vitroTo determine whether Ang-(1-7) suppresses NPC-TW01 cell migration, a wound healing assay was performed.", [["NPC cell", "ANATOMY", 133, 141], ["NPC-TW01 cell", "ANATOMY", 215, 228], ["wound", "ANATOMY", 242, 247], ["A779", "CHEMICAL", 73, 77], ["Ang-(1-7)", "CHEMICAL", 114, 123], ["Ang-(1-7", "CHEMICAL", 194, 202], ["A779", "CHEMICAL", 73, 77], ["A779", "SIMPLE_CHEMICAL", 73, 77], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 114, 122], ["NPC cell", "CELL", 133, 141], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 194, 202], ["NPC-TW01 cell", "CELL", 215, 228], ["wound", "PATHOLOGICAL_FORMATION", 242, 247], ["TW01 cell", "CELL_LINE", 219, 228], ["the MasR antagonist", "TREATMENT", 53, 72], ["Ang", "TEST", 114, 117], ["NPC cell migration", "TREATMENT", 133, 151], ["invasion in vitroTo", "TREATMENT", 156, 175], ["Ang", "TEST", 194, 197], ["NPC", "PROBLEM", 215, 218], ["TW01 cell migration", "TREATMENT", 219, 238], ["a wound healing assay", "TEST", 240, 261], ["NPC cell migration", "OBSERVATION", 133, 151], ["wound", "ANATOMY", 242, 247]]], ["Scratch wounds were almost the same width in each experimental group at 0 h.", [["wounds", "ANATOMY", 8, 14], ["wounds", "PATHOLOGICAL_FORMATION", 8, 14], ["Scratch wounds", "PROBLEM", 0, 14], ["wounds", "OBSERVATION", 8, 14]]], ["Healing and cell migration rate were not significantly reduced in the Ang-(1-7) (0.2 \u03bcM) treatment group at 24-72 h (Fig. 2a, b) .", [["cell", "ANATOMY", 12, 16], ["Ang-(1-7)", "CHEMICAL", 70, 79], ["cell", "CELL", 12, 16], ["1-7)", "SIMPLE_CHEMICAL", 75, 79], ["Healing and cell migration rate", "TEST", 0, 31], ["the Ang", "TEST", 66, 73], ["cell migration", "OBSERVATION", 12, 26], ["significantly", "OBSERVATION_MODIFIER", 41, 54], ["reduced", "OBSERVATION_MODIFIER", 55, 62]]], ["However, the percentage of wound closure was significantly lower (p < 0.01) in the group Ang-(1-7) plus A779 or A779 alone than in the group treated with Ang-(1-7) alone at 48 and 72 h (Fig. 2a, b) .", [["wound", "ANATOMY", 27, 32], ["A779", "ANATOMY", 112, 116], ["Ang-(1-7)", "CHEMICAL", 89, 98], ["A779", "CHEMICAL", 104, 108], ["A779", "CHEMICAL", 112, 116], ["Ang-(1-7)", "CHEMICAL", 154, 163], ["wound", "PATHOLOGICAL_FORMATION", 27, 32], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 89, 97], ["A779", "SIMPLE_CHEMICAL", 104, 108], ["A779", "SIMPLE_CHEMICAL", 112, 116], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 154, 162], ["wound closure", "TREATMENT", 27, 40], ["Ang", "TEST", 154, 157], ["percentage", "OBSERVATION_MODIFIER", 13, 23], ["wound closure", "OBSERVATION", 27, 40], ["significantly", "OBSERVATION_MODIFIER", 45, 58], ["lower", "OBSERVATION_MODIFIER", 59, 64]]], ["To determine whether Ang-(1-7) inhibits NPC-TW01 cells, cell invasion was analyzed by a transwell matrigel invasion assay.", [["NPC-TW01 cells", "ANATOMY", 40, 54], ["cell", "ANATOMY", 56, 60], ["matrigel", "ANATOMY", 98, 106], ["Ang-(1-7)", "CHEMICAL", 21, 30], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 21, 29], ["NPC-TW01 cells", "CELL", 40, 54], ["cell", "CELL", 56, 60], ["NPC", "PROTEIN", 40, 43], ["TW01 cells", "CELL_LINE", 44, 54], ["Ang", "TEST", 21, 24], ["NPC-TW01 cells", "TREATMENT", 40, 54], ["cell invasion", "PROBLEM", 56, 69], ["a transwell matrigel invasion assay", "TEST", 86, 121], ["cell invasion", "OBSERVATION", 56, 69], ["transwell matrigel invasion", "OBSERVATION", 88, 115]]], ["Cell invasion in the group treated Ang-(1-7) alone was significantly lower (p < 0.01) than in the control group; and lower (p < 0.01 or p < 0.05) than in the group treated with Ang-(1-7) plus A779 or in the group treated with A779 alone at 24~72 h.", [["Cell", "ANATOMY", 0, 4], ["Ang-(1-7)", "CHEMICAL", 35, 44], ["Ang-(1-7)", "CHEMICAL", 177, 186], ["A779", "CHEMICAL", 192, 196], ["A779", "CHEMICAL", 226, 230], ["A779", "CHEMICAL", 226, 230], ["Cell", "CELL", 0, 4], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 35, 43], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 177, 185], ["A779", "SIMPLE_CHEMICAL", 192, 196], ["A779", "SIMPLE_CHEMICAL", 226, 230], ["Cell invasion", "PROBLEM", 0, 13], ["Ang", "TEST", 35, 38], ["Ang", "TEST", 177, 180], ["invasion", "OBSERVATION", 5, 13], ["lower", "ANATOMY_MODIFIER", 117, 122]]], ["Moreover, the ratio with control of transwell cell in Ang-(1-7) alone group was 0.52 (\u00b1 0.14), 0.40 (\u00b1 0.09), and 0.47(\u00b1 0.11) at 24 h, 48 h, and 72 h, respectively, significantly lower than Ang-(1-7) plus A779 group or A779 alone group (Fig. 2c, d) .", [["transwell cell", "ANATOMY", 36, 50], ["A779", "ANATOMY", 220, 224], ["Ang-(1-7)", "CHEMICAL", 54, 63], ["Ang-(1-7)", "CHEMICAL", 191, 200], ["A779", "CHEMICAL", 220, 224], ["transwell cell", "CELL", 36, 50], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 54, 62], ["1-7", "SIMPLE_CHEMICAL", 196, 199], ["A779", "SIMPLE_CHEMICAL", 206, 210], ["A779", "SIMPLE_CHEMICAL", 220, 224], ["transwell cell", "CELL_LINE", 36, 50], ["the ratio", "TEST", 10, 19], ["transwell cell", "TEST", 36, 50], ["Ang", "TEST", 54, 57], ["Ang", "TEST", 191, 194], ["transwell cell", "OBSERVATION", 36, 50]]], ["Taken together, these results suggest that Ang-(1-7) inhibits cell migration and invasion in NPC-TW01 cells.Ang-(1-7) inhibits NPC cell migration and invasion in vitroAng-(1-7) induces Beclin-1/Bcl-2 signaling to activate NPC cell autophagy by upregulating LC3-II expression and downregulating PI3K/Akt/mTOR and p-p38 signaling in vitro To investigate the signaling pathways involved in autophagy induction in Ang-(1-7)-treated NPC-TW01 cells, Beclin-1 and Bcl-2 protein levels were examined by Western blot.", [["cell", "ANATOMY", 62, 66], ["NPC-TW01 cells", "ANATOMY", 93, 107], ["NPC cell", "ANATOMY", 127, 135], ["NPC cell", "ANATOMY", 222, 230], ["NPC-TW01 cells", "ANATOMY", 428, 442], ["Ang-(1-7", "CHEMICAL", 43, 51], ["Ang-(1-7)", "CHEMICAL", 108, 117], ["vitroAng-(1-7", "CHEMICAL", 162, 175], ["Ang-(1-7)", "CHEMICAL", 410, 419], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 43, 51], ["cell", "CELL", 62, 66], ["NPC-TW01 cells", "CELL", 93, 107], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 108, 116], ["NPC cell", "CELL", 127, 135], ["vitroAng-(1-7", "GENE_OR_GENE_PRODUCT", 162, 175], ["Beclin-1", "GENE_OR_GENE_PRODUCT", 185, 193], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 194, 199], ["NPC cell", "CELL", 222, 230], ["LC3-II", "GENE_OR_GENE_PRODUCT", 257, 263], ["PI3K", "GENE_OR_GENE_PRODUCT", 294, 298], ["Akt", "GENE_OR_GENE_PRODUCT", 299, 302], ["mTOR", "GENE_OR_GENE_PRODUCT", 303, 307], ["p-p38", "GENE_OR_GENE_PRODUCT", 312, 317], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 410, 418], ["NPC-TW01 cells", "CELL", 428, 442], ["Beclin-1", "GENE_OR_GENE_PRODUCT", 444, 452], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 457, 462], ["NPC-TW01 cells", "CELL_LINE", 93, 107], ["Beclin", "PROTEIN", 185, 191], ["Bcl-2", "PROTEIN", 194, 199], ["LC3", "PROTEIN", 257, 260], ["PI3K", "PROTEIN", 294, 298], ["Akt", "PROTEIN", 299, 302], ["mTOR", "PROTEIN", 303, 307], ["p38", "PROTEIN", 314, 317], ["Ang-(1-7)-treated NPC-TW01 cells", "CELL_LINE", 410, 442], ["Beclin-1", "PROTEIN", 444, 452], ["Bcl-2", "PROTEIN", 457, 462], ["Ang", "TEST", 43, 46], ["inhibits cell migration", "PROBLEM", 53, 76], ["invasion in NPC", "PROBLEM", 81, 96], ["Ang", "TEST", 108, 111], ["NPC cell migration", "TREATMENT", 127, 145], ["invasion in vitroAng", "TEST", 150, 170], ["Beclin", "TEST", 185, 191], ["Bcl", "TEST", 194, 197], ["NPC cell autophagy", "TEST", 222, 240], ["LC3", "TEST", 257, 260], ["downregulating PI3K", "TEST", 279, 298], ["Akt", "TEST", 299, 302], ["mTOR", "TEST", 303, 307], ["p", "TEST", 312, 313], ["the signaling pathways", "PROBLEM", 352, 374], ["autophagy induction", "TREATMENT", 387, 406], ["Ang", "TEST", 410, 413], ["NPC", "TEST", 428, 431], ["Beclin", "TEST", 444, 450], ["Bcl", "TEST", 457, 460], ["protein levels", "TEST", 463, 477], ["cell migration", "OBSERVATION", 62, 76], ["invasion", "OBSERVATION_MODIFIER", 81, 89], ["NPC", "ANATOMY", 93, 96], ["NPC", "ANATOMY", 127, 130], ["cell migration", "OBSERVATION", 131, 145], ["invasion", "OBSERVATION_MODIFIER", 150, 158]]], ["Beclin-1 was upregulated at 24 h and 72 h, whereas Bcl-2 protein levels were lower at 72 h, in 0.2 \u03bcM Ang-(1-7)-treated cells relative to the control cells (0 \u03bcM) (Fig. 3a, b) .", [["cells", "ANATOMY", 120, 125], ["cells", "ANATOMY", 150, 155], ["Ang-(1-7)", "CHEMICAL", 102, 111], ["Beclin-1", "GENE_OR_GENE_PRODUCT", 0, 8], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 51, 56], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 102, 110], ["cells", "CELL", 120, 125], ["cells", "CELL", 150, 155], ["Beclin-1", "PROTEIN", 0, 8], ["Bcl-2", "PROTEIN", 51, 56], ["control cells", "CELL_TYPE", 142, 155], ["Beclin", "TEST", 0, 6], ["Bcl", "TEST", 51, 54], ["protein levels", "TEST", 57, 71], ["Ang", "TEST", 102, 105], ["the control cells", "TEST", 138, 155]]], ["We also knocked down Bcl-2 to examine the interaction between Beclin-1 and Bcl-2, which is believed to play a regulatory role in autophagy. siRNA-mediated knockdown of Bcl-2 was performed to assess whether Bcl-2 modulates Beclin-1 and LC3-II expression under Ang-(1-7) exposure.", [["Ang-(1-7)", "CHEMICAL", 259, 268], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 21, 26], ["Beclin-1", "GENE_OR_GENE_PRODUCT", 62, 70], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 75, 80], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 168, 173], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 206, 211], ["Beclin-1", "GENE_OR_GENE_PRODUCT", 222, 230], ["LC3-II", "GENE_OR_GENE_PRODUCT", 235, 241], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 259, 267], ["Bcl-2", "PROTEIN", 21, 26], ["Beclin-1", "PROTEIN", 62, 70], ["Bcl-2", "PROTEIN", 75, 80], ["Bcl-2", "PROTEIN", 168, 173], ["Bcl-2", "PROTEIN", 206, 211], ["Beclin", "PROTEIN", 222, 228], ["LC3", "PROTEIN", 235, 238], ["Bcl", "TEST", 21, 24], ["Beclin", "TEST", 62, 68], ["siRNA", "TEST", 140, 145], ["Bcl", "TEST", 168, 171], ["Bcl", "TEST", 206, 209], ["Beclin", "TEST", 222, 228], ["LC3", "TEST", 235, 238], ["Ang", "TEST", 259, 262]]], ["Bcl-2 knockdown was confirmed by Western blotting.", [["Bcl-2", "GENE_OR_GENE_PRODUCT", 0, 5], ["Bcl-2", "PROTEIN", 0, 5], ["Bcl", "TEST", 0, 3]]], ["The levels of Beclin-1 and LC3-II were increased significantly in cells treated with 0.2 \u03bcM Ang-(1-7) and Bcl-2 siRNA (Fig. 3e, f) .", [["cells", "ANATOMY", 66, 71], ["Ang", "CHEMICAL", 92, 95], ["Beclin-1", "GENE_OR_GENE_PRODUCT", 14, 22], ["LC3-II", "GENE_OR_GENE_PRODUCT", 27, 33], ["cells", "CELL", 66, 71], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 92, 100], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 106, 111], ["Beclin-1", "PROTEIN", 14, 22], ["LC3-II", "PROTEIN", 27, 33], ["The levels", "TEST", 0, 10], ["Beclin", "TEST", 14, 20], ["LC3", "TEST", 27, 30], ["Ang", "TEST", 92, 95], ["Bcl", "TEST", 106, 109], ["increased", "OBSERVATION_MODIFIER", 39, 48], ["significantly", "OBSERVATION_MODIFIER", 49, 62]]], ["These findings suggest that Ang-(1-7) activates autophagy in NPC-TW01 cells by modulating the Beclin-1/Bcl-2 complex.", [["NPC-TW01 cells", "ANATOMY", 61, 75], ["Ang-(1-7)", "CHEMICAL", 28, 37], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 28, 36], ["NPC-TW01 cells", "CELL", 61, 75], ["Beclin-1", "GENE_OR_GENE_PRODUCT", 94, 102], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 103, 108], ["NPC-TW01 cells", "CELL_LINE", 61, 75], ["Beclin-1", "PROTEIN", 94, 102], ["Bcl-2 complex", "PROTEIN", 103, 116], ["Ang", "TEST", 28, 31], ["NPC", "TEST", 61, 64], ["the Beclin", "TEST", 90, 100], ["NPC", "ANATOMY", 61, 64]]], ["In addition, Western blot analysis indicated that the ratio of LC3-II to LC3-I was significantly higher following treatment with 0.2 \u03bcM Ang-(1-7) compared with the controls at 24 h and 72 h, and LC3-II expression was lower in the Ang-(1-7) plus A779 coadministration and A779 alone groups than in the Ang-(1-7) alone group at 72 h (Fig. 3a, b) .", [["A779", "ANATOMY", 245, 249], ["Ang-(1-7", "CHEMICAL", 136, 144], ["Ang-(1-7)", "CHEMICAL", 230, 239], ["A779", "CHEMICAL", 245, 249], ["A779", "CHEMICAL", 271, 275], ["Ang-(1-7)", "CHEMICAL", 301, 310], ["LC3-II", "GENE_OR_GENE_PRODUCT", 63, 69], ["LC3-I", "GENE_OR_GENE_PRODUCT", 73, 78], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 136, 144], ["LC3-II", "GENE_OR_GENE_PRODUCT", 195, 201], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 230, 238], ["A779", "SIMPLE_CHEMICAL", 245, 249], ["A779", "SIMPLE_CHEMICAL", 271, 275], ["1-7", "SIMPLE_CHEMICAL", 306, 309], ["LC3-II", "PROTEIN", 63, 69], ["LC3-I", "PROTEIN", 73, 78], ["LC3", "PROTEIN", 195, 198], ["Western blot analysis", "TEST", 13, 34], ["the ratio", "TEST", 50, 59], ["LC3", "TEST", 63, 66], ["LC3", "TEST", 73, 76], ["treatment", "TREATMENT", 114, 123], ["Ang", "TEST", 136, 139], ["LC3", "TEST", 195, 198], ["the Ang", "TEST", 226, 233], ["A779 coadministration", "TREATMENT", 245, 266], ["the Ang", "TEST", 297, 304], ["lower", "OBSERVATION_MODIFIER", 217, 222], ["Ang", "ANATOMY", 230, 233]]], ["In reverse, p62 expression was lower in the 0.2 \u03bcM Ang-(1-7)-treated cultures than in the controls at 24 h and 72 h, and the level of p62 in the Ang-(1-7) plus A779 coadministration and A779 alone groups was higher than in the Ang-(1-7) alone group at 72 h (Fig. 3a, b) .", [["cultures", "ANATOMY", 69, 77], ["A779", "ANATOMY", 160, 164], ["Ang-(1-7)", "CHEMICAL", 51, 60], ["Ang-(1-7)", "CHEMICAL", 145, 154], ["A779", "CHEMICAL", 160, 164], ["A779", "CHEMICAL", 186, 190], ["Ang-(1-7)", "CHEMICAL", 227, 236], ["p62", "GENE_OR_GENE_PRODUCT", 12, 15], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 51, 59], ["p62", "GENE_OR_GENE_PRODUCT", 134, 137], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 145, 153], ["A779", "SIMPLE_CHEMICAL", 160, 164], ["A779", "SIMPLE_CHEMICAL", 186, 190], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 227, 235], ["p62", "PROTEIN", 12, 15], ["Ang-(1-7)-treated cultures", "CELL_LINE", 51, 77], ["p62", "PROTEIN", 134, 137], ["p62 expression", "TEST", 12, 26], ["Ang", "TEST", 51, 54], ["cultures", "TEST", 69, 77], ["the level", "TEST", 121, 130], ["the Ang", "TEST", 141, 148], ["the Ang", "TEST", 223, 230], ["lower", "OBSERVATION_MODIFIER", 31, 36]]], ["Taken together, these data suggest that autophagy is activated in NPC-TW01 cells after prolonged Ang-(1-7) treatment.", [["NPC-TW01 cells", "ANATOMY", 66, 80], ["Ang-(1-7)", "CHEMICAL", 97, 106], ["NPC-TW01 cells", "CELL", 66, 80], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 97, 105], ["NPC-TW01 cells", "CELL_LINE", 66, 80], ["these data", "TEST", 16, 26], ["autophagy", "PROBLEM", 40, 49], ["prolonged Ang", "TREATMENT", 87, 100], ["treatment", "TREATMENT", 107, 116]]], ["We also investigated whether the effects of Ang-(1-7) on NPC-TW01 cells are mediated by phosphorylation of proteins involved in this pathway.", [["NPC-TW01 cells", "ANATOMY", 57, 71], ["Ang-(1-7)", "CHEMICAL", 44, 53], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 44, 52], ["NPC-TW01 cells", "CELL", 57, 71], ["NPC", "CELL_TYPE", 57, 60], ["TW01 cells", "CELL_LINE", 61, 71], ["Ang", "TEST", 44, 47], ["NPC-TW01 cells", "TREATMENT", 57, 71]]], ["The phosphorylation of PI3K and S6 ribosomal protein was significantly inhibited by Ang-(1-7) treatment at 24 h and 72 h.", [["Ang-(1-7)", "CHEMICAL", 84, 93], ["PI3K", "GENE_OR_GENE_PRODUCT", 23, 27], ["S6", "GENE_OR_GENE_PRODUCT", 32, 34], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 84, 92], ["PI3K", "PROTEIN", 23, 27], ["S6 ribosomal protein", "PROTEIN", 32, 52], ["The phosphorylation of PI3K", "TEST", 0, 27], ["S6 ribosomal protein", "TEST", 32, 52], ["Ang", "TEST", 84, 87]]], ["The ratios of p-AKT/AKT and p-p38/p38 were significantly decreased following Ang-(1-7) treatment at 72 h, and Ang-(1-7) also reduced p-mTOR expression, suggesting that Ang-(1-7) inhibits the PI3K/Akt/mTOR pathway.", [["Ang-(1-7)", "CHEMICAL", 77, 86], ["Ang-(1-7", "CHEMICAL", 110, 118], ["Ang-(1-7", "CHEMICAL", 168, 176], ["AKT", "GENE_OR_GENE_PRODUCT", 16, 19], ["AKT", "GENE_OR_GENE_PRODUCT", 20, 23], ["p-p38", "GENE_OR_GENE_PRODUCT", 28, 33], ["p38", "GENE_OR_GENE_PRODUCT", 34, 37], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 77, 85], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 110, 118], ["p-mTOR", "GENE_OR_GENE_PRODUCT", 133, 139], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 168, 176], ["PI3K", "GENE_OR_GENE_PRODUCT", 191, 195], ["Akt", "GENE_OR_GENE_PRODUCT", 196, 199], ["mTOR", "GENE_OR_GENE_PRODUCT", 200, 204], ["p", "PROTEIN", 14, 15], ["AKT", "PROTEIN", 16, 19], ["AKT", "PROTEIN", 20, 23], ["p38", "PROTEIN", 30, 33], ["p38", "PROTEIN", 34, 37], ["p-mTOR", "PROTEIN", 133, 139], ["PI3K", "PROTEIN", 191, 195], ["Akt", "PROTEIN", 196, 199], ["mTOR", "PROTEIN", 200, 204], ["The ratios", "TEST", 0, 10], ["p", "TEST", 14, 15], ["AKT", "TEST", 20, 23], ["p-p38/p38", "TEST", 28, 37], ["Ang", "TEST", 77, 80], ["treatment", "TREATMENT", 87, 96], ["Ang", "TEST", 110, 113], ["reduced p-mTOR expression", "PROBLEM", 125, 150], ["Ang", "TEST", 168, 171], ["the PI3K", "TEST", 187, 195], ["Akt/mTOR pathway", "TREATMENT", 196, 212], ["p-mTOR expression", "OBSERVATION", 133, 150]]], ["Additionally, p38 phosphorylation was affected by Ang-(1-7) treatment at 72 h.", [["Ang-(1-7)", "CHEMICAL", 50, 59], ["p38", "GENE_OR_GENE_PRODUCT", 14, 17], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 50, 58], ["p38", "PROTEIN", 14, 17], ["p38 phosphorylation", "TEST", 14, 33], ["Ang", "TEST", 50, 53], ["treatment", "TREATMENT", 60, 69]]], ["However, the results showed that A779 have an ineffective action for members of the PI3K/Akt/ mTOR pathway (Fig. 3c, d) .", [["A779", "CHEMICAL", 33, 37], ["A779", "CHEMICAL", 33, 37], ["A779", "SIMPLE_CHEMICAL", 33, 37], ["PI3K", "GENE_OR_GENE_PRODUCT", 84, 88], ["Akt", "GENE_OR_GENE_PRODUCT", 89, 92], ["mTOR", "GENE_OR_GENE_PRODUCT", 94, 98], ["PI3K", "PROTEIN", 84, 88], ["Akt", "PROTEIN", 89, 92], ["mTOR", "PROTEIN", 94, 98], ["the PI3K", "TREATMENT", 80, 88], ["Akt/ mTOR pathway", "TREATMENT", 89, 106]]], ["Therefore, we designed two mouse models (pre-and post-treatment) to investigate whether Ang-(1-7) induces autophagy in vivo.Ang-(1-7) inhibits tumor growth in vivo, but not via autophagy, post-treatmentTumor size was decreased only in the 1 \u03bcg/kg Ang-(1-7) posttreatment group (667.7 \u00b1 101.7 mm 3 ) compared with the mock group (1601.6 \u00b1 223.4 mm 3 ).", [["tumor", "ANATOMY", 143, 148], ["Tumor", "ANATOMY", 202, 207], ["Ang-(1-7)", "CHEMICAL", 88, 97], ["Ang-(1-7)", "CHEMICAL", 124, 133], ["tumor", "DISEASE", 143, 148], ["Ang", "CHEMICAL", 247, 250], ["mouse", "ORGANISM", 27, 32], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 88, 96], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 124, 132], ["tumor", "CANCER", 143, 148], ["Tumor", "CANCER", 202, 207], ["mouse", "SPECIES", 27, 32], ["mouse", "SPECIES", 27, 32], ["post-treatment", "TREATMENT", 49, 63], ["Ang", "TEST", 88, 91], ["Ang", "TEST", 124, 127], ["tumor growth in vivo", "PROBLEM", 143, 163], ["post-treatment", "TREATMENT", 188, 202], ["Tumor size", "TEST", 202, 212], ["Ang", "TEST", 247, 250], ["posttreatment group", "TEST", 257, 276], ["tumor", "OBSERVATION", 143, 148], ["size", "OBSERVATION_MODIFIER", 208, 212], ["decreased", "OBSERVATION_MODIFIER", 217, 226]]], ["In contrast, tumor volume was increased in the 1 \u03bcg/kg Ang-(1-7) + A779 Ang-(1-7) post-treatment group (2186.1 \u00b1 521.6 mm 3 ) (Fig. 4a, b) .", [["tumor", "ANATOMY", 13, 18], ["tumor", "DISEASE", 13, 18], ["Ang-(1-7)", "CHEMICAL", 55, 64], ["Ang-(1-7", "CHEMICAL", 72, 80], ["tumor", "CANCER", 13, 18], ["tumor volume", "TEST", 13, 25], ["Ang", "TEST", 55, 58], ["Ang", "TEST", 72, 75], ["tumor", "OBSERVATION", 13, 18], ["volume", "OBSERVATION_MODIFIER", 19, 25], ["increased", "OBSERVATION_MODIFIER", 30, 39]]], ["To examine protein markers of autophagy in vivo, Bcl-2 protein expression was examined by Western blotting.", [["Bcl-2", "GENE_OR_GENE_PRODUCT", 49, 54], ["Bcl-2", "PROTEIN", 49, 54], ["protein markers", "TEST", 11, 26], ["autophagy", "TEST", 30, 39], ["Bcl", "TEST", 49, 52]]], ["Bcl-2 expression was higher in the 1 \u03bcg/kg Ang-(1-7) + A779 Ang-(1-7) post-treatment group than in the mock group.", [["Ang-(1-7)", "CHEMICAL", 43, 52], ["Ang-(1-7)", "CHEMICAL", 60, 69], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 0, 5], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 43, 51], ["Bcl-2", "PROTEIN", 0, 5], ["Bcl", "TEST", 0, 3], ["Ang", "TEST", 43, 46], ["Ang", "TEST", 60, 63], ["2 expression", "OBSERVATION_MODIFIER", 4, 16], ["higher", "OBSERVATION_MODIFIER", 21, 27]]], ["However, no significant differences were observed in other autophagyassociated proteins, including class III PI3K, Beclin-1, LC3, and p62 (Fig. 4c, d) .Pre-treatment with Ang-(1-7) induces autophagy in vivoAng-(1-7) pre-treatment (0.2 and 1 \u03bcg/kg; tumor size 59.2 \u00b1 47.2 and 805.7 \u00b1 107.8 mm 3 , respectively) significantly reduced the tumor size compared with the mock group (1458.4 \u00b1 213.9 mm 3 ), and this effect was reversed by A779 coadministration (1826.1 \u00b1 570.8 mm 3 ) (Fig. 5a, b) .", [["tumor", "ANATOMY", 248, 253], ["tumor", "ANATOMY", 336, 341], ["Ang-(1-7)", "CHEMICAL", 171, 180], ["vivoAng-(1-7)", "CHEMICAL", 202, 215], ["tumor", "DISEASE", 248, 253], ["tumor", "DISEASE", 336, 341], ["A779", "CHEMICAL", 432, 436], ["A779", "CHEMICAL", 432, 436], ["class III PI3K", "GENE_OR_GENE_PRODUCT", 99, 113], ["Beclin-1", "GENE_OR_GENE_PRODUCT", 115, 123], ["LC3", "GENE_OR_GENE_PRODUCT", 125, 128], ["p62", "GENE_OR_GENE_PRODUCT", 134, 137], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 171, 179], ["vivoAng-(1-7", "SIMPLE_CHEMICAL", 202, 214], ["tumor", "CANCER", 248, 253], ["tumor", "CANCER", 336, 341], ["A779", "SIMPLE_CHEMICAL", 432, 436], ["autophagyassociated proteins", "PROTEIN", 59, 87], ["class III PI3K", "PROTEIN", 99, 113], ["Beclin-1", "PROTEIN", 115, 123], ["LC3", "PROTEIN", 125, 128], ["p62", "PROTEIN", 134, 137], ["Fig. 4c, d)", "PROTEIN", 139, 150], ["significant differences", "PROBLEM", 12, 35], ["Beclin", "TEST", 115, 121], ["LC3", "TEST", 125, 128], ["p62", "TEST", 134, 137], ["Ang", "TEST", 171, 174], ["tumor size", "TEST", 248, 258], ["the tumor size", "PROBLEM", 332, 346], ["no", "UNCERTAINTY", 9, 11], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["tumor", "OBSERVATION", 336, 341], ["size", "OBSERVATION_MODIFIER", 342, 346]]], ["The protein levels of class III PI3K and LC3-II (in the 1 \u03bcg/kg Ang-(1-7) pre-treatment group) and Beclin-1 (in the 0.2 or 1 \u03bcg/kg Ang-(1-7) pre-treatment group) were increased relative to those in the mock group, whereas the expression of Bcl-2 and p62 was decreased in both Ang-(1-7) pre-treatment groups (Fig. 5c, d) .", [["Ang-(1-7)", "CHEMICAL", 64, 73], ["Ang-(1-7)", "CHEMICAL", 131, 140], ["Ang-(1-7)", "CHEMICAL", 276, 285], ["class III PI3K", "GENE_OR_GENE_PRODUCT", 22, 36], ["LC3-II", "GENE_OR_GENE_PRODUCT", 41, 47], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 64, 72], ["Beclin-1", "GENE_OR_GENE_PRODUCT", 99, 107], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 131, 139], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 240, 245], ["p62", "GENE_OR_GENE_PRODUCT", 250, 253], ["class III PI3K", "PROTEIN", 22, 36], ["LC3-II", "PROTEIN", 41, 47], ["Beclin-1", "PROTEIN", 99, 107], ["Bcl-2", "PROTEIN", 240, 245], ["p62", "PROTEIN", 250, 253], ["The protein levels", "TEST", 0, 18], ["PI3K", "TEST", 32, 36], ["LC3", "TEST", 41, 44], ["Ang", "TEST", 64, 67], ["Beclin", "TEST", 99, 105], ["Ang", "TEST", 131, 134], ["Bcl", "TEST", 240, 243], ["p62", "TEST", 250, 253], ["Ang", "TEST", 276, 279], ["decreased", "OBSERVATION_MODIFIER", 258, 267]]], ["The effect of all protein levels was reversed in the Ang-(1-7) pretreatment group following pre-treatment with Ang-(1-7) + A779 (Fig. 5c, d) .", [["Ang-(1-7)", "CHEMICAL", 53, 62], ["Ang-(1-7)", "CHEMICAL", 111, 120], ["1-7)", "SIMPLE_CHEMICAL", 58, 62], ["Ang-(1-7", "SIMPLE_CHEMICAL", 111, 119], ["all protein levels", "TEST", 14, 32], ["Ang", "TEST", 111, 114]]], ["Moreover, to identify cell proliferation and autophagy, Ki67 and LC3-II expression was assessed by immunofluorescence staining and immunohistochemistry.", [["cell", "ANATOMY", 22, 26], ["cell", "CELL", 22, 26], ["Ki67", "GENE_OR_GENE_PRODUCT", 56, 60], ["LC3-II", "GENE_OR_GENE_PRODUCT", 65, 71], ["Ki67", "PROTEIN", 56, 60], ["LC3", "PROTEIN", 65, 68], ["cell proliferation", "TEST", 22, 40], ["autophagy", "TEST", 45, 54], ["Ki67", "TEST", 56, 60], ["LC3", "TEST", 65, 68], ["immunofluorescence staining", "TEST", 99, 126], ["immunohistochemistry", "TEST", 131, 151], ["cell proliferation", "OBSERVATION", 22, 40]]], ["The intensity of Ki67 expression (green fluorescence) was weaker in the Ang-(1-7) and Ang-(1-7) + 5 \u03bcg/kg 3-MA pre-treatment groups than in the mock and Ang-(1-7) + A779 pre-treatment groups according to both immunofluorescence staining (Fig. 5e: left panel) and immunohistochemistry (Fig. 5e: middle panel) .", [["Ang-(1-7)", "CHEMICAL", 72, 81], ["Ang-(1-7", "CHEMICAL", 86, 94], ["3-MA", "CHEMICAL", 106, 110], ["Ang-(1-7)", "CHEMICAL", 153, 162], ["3-MA", "CHEMICAL", 106, 110], ["Ki67", "GENE_OR_GENE_PRODUCT", 17, 21], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 72, 80], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 86, 94], ["3-MA", "SIMPLE_CHEMICAL", 106, 110], ["Ang-(1-7", "SIMPLE_CHEMICAL", 153, 161], ["Ki67", "PROTEIN", 17, 21], ["Ki67 expression", "TEST", 17, 32], ["green fluorescence", "TEST", 34, 52], ["the Ang", "TEST", 68, 75], ["Ang", "TEST", 86, 89], ["Ang", "TEST", 153, 156], ["A779 pre-treatment groups", "TREATMENT", 165, 190], ["both immunofluorescence staining", "TEST", 204, 236], ["left panel", "TEST", 247, 257], ["immunohistochemistry", "TEST", 263, 283], ["middle panel", "TEST", 294, 306], ["Ki67 expression", "OBSERVATION", 17, 32], ["Ang", "ANATOMY", 72, 75]]], ["LC3-II staining was more intense in the Ang-(1-7) and Ang-(1-7) + 3-MA pre-treatment groups compared with the mock and Ang-(1-7) + A779 pre-treatment groups.", [["Ang-(1-7)", "CHEMICAL", 40, 49], ["Ang-(1-7)", "CHEMICAL", 54, 63], ["3-MA", "CHEMICAL", 66, 70], ["Ang-(1-7)", "CHEMICAL", 119, 128], ["3-MA", "CHEMICAL", 66, 70], ["LC3-II", "GENE_OR_GENE_PRODUCT", 0, 6], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 40, 48], ["Ang-(1-7", "SIMPLE_CHEMICAL", 54, 62], ["3-MA", "SIMPLE_CHEMICAL", 66, 70], ["Ang-(1-7", "SIMPLE_CHEMICAL", 119, 127], ["LC3", "PROTEIN", 0, 3], ["LC3-II staining", "TEST", 0, 15], ["the Ang", "TEST", 36, 43], ["Ang", "TEST", 54, 57], ["the mock", "TEST", 106, 114], ["Ang", "TEST", 119, 122], ["II staining", "OBSERVATION_MODIFIER", 4, 15], ["more", "OBSERVATION_MODIFIER", 20, 24], ["intense", "OBSERVATION_MODIFIER", 25, 32], ["Ang", "ANATOMY", 40, 43]]], ["Therefore, these results suggest that pre-treatment with Ang-(1-7) may induce autophagy in vivo.Pre-treatment with Ang-(1-7) downregulates phosphorylation of PI3K/Akt/mTOR pathway effectors in vivoThe PI3K/Akt/mTOR pathway plays an important role in regulating cell death, including apoptosis and autophagy.", [["cell", "ANATOMY", 261, 265], ["Ang-(1-7)", "CHEMICAL", 57, 66], ["Ang-(1-7", "CHEMICAL", 115, 123], ["death", "DISEASE", 266, 271], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 57, 65], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 115, 123], ["PI3K", "GENE_OR_GENE_PRODUCT", 158, 162], ["Akt", "GENE_OR_GENE_PRODUCT", 163, 166], ["mTOR", "GENE_OR_GENE_PRODUCT", 167, 171], ["PI3K", "GENE_OR_GENE_PRODUCT", 201, 205], ["Akt", "GENE_OR_GENE_PRODUCT", 206, 209], ["mTOR", "GENE_OR_GENE_PRODUCT", 210, 214], ["cell", "CELL", 261, 265], ["PI3K", "PROTEIN", 158, 162], ["Akt", "PROTEIN", 163, 166], ["mTOR", "PROTEIN", 167, 171], ["PI3K", "PROTEIN", 201, 205], ["Akt", "PROTEIN", 206, 209], ["mTOR", "PROTEIN", 210, 214], ["Ang", "TEST", 57, 60], ["Ang", "TEST", 115, 118], ["phosphorylation of PI3K", "TREATMENT", 139, 162], ["Akt/mTOR pathway effectors", "TREATMENT", 163, 189], ["Akt/mTOR pathway", "TREATMENT", 206, 222], ["apoptosis", "PROBLEM", 283, 292], ["autophagy", "PROBLEM", 297, 306], ["cell death", "OBSERVATION", 261, 271]]], ["This effect was reversed in the Ang-(1-7) + A779 pre-treatment group.", [["A779", "ANATOMY", 44, 48], ["Ang-(1-7)", "CHEMICAL", 32, 41], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 32, 40], ["Ang-(1-7) + A779 pre-treatment group", "CELL_LINE", 32, 68]]], ["Ang-(1-7) pre-treatment also reduced PI3K expression, suggesting that Ang-(1-7) pre-treatment may inhibit the PI3K/Akt/mTOR pathway.", [["Ang-(1-7)", "CHEMICAL", 0, 9], ["Ang-(1-7)", "CHEMICAL", 70, 79], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 0, 8], ["PI3K", "GENE_OR_GENE_PRODUCT", 37, 41], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 70, 78], ["PI3K", "GENE_OR_GENE_PRODUCT", 110, 114], ["Akt", "GENE_OR_GENE_PRODUCT", 115, 118], ["mTOR", "GENE_OR_GENE_PRODUCT", 119, 123], ["PI3K", "PROTEIN", 37, 41], ["PI3K", "PROTEIN", 110, 114], ["Akt", "PROTEIN", 115, 118], ["mTOR", "PROTEIN", 119, 123], ["Ang", "TEST", 0, 3], ["reduced PI3K expression", "PROBLEM", 29, 52], ["Ang", "TEST", 70, 73], ["the PI3K", "TEST", 106, 114], ["Akt/mTOR pathway", "TREATMENT", 115, 131], ["PI3K expression", "OBSERVATION", 37, 52]]], ["However, p38 phosphorylation was not affected (Fig. 6a, b) .DiscussionA wealth of evidence indicates that Ang-(1-7) plays an important role in cancer pathogenesis.", [["cancer", "ANATOMY", 143, 149], ["Ang-(1-7", "CHEMICAL", 106, 114], ["cancer", "DISEASE", 143, 149], ["p38", "GENE_OR_GENE_PRODUCT", 9, 12], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 106, 114], ["cancer", "CANCER", 143, 149], ["p38", "PROTEIN", 9, 12], ["p38 phosphorylation", "TEST", 9, 28], ["Ang", "TEST", 106, 109], ["cancer pathogenesis", "PROBLEM", 143, 162], ["cancer", "OBSERVATION", 143, 149]]], ["Ang-(1-7) has been identified in a variety of tumors, including lung carcinoma [11] [12] [13] 20] , prostate cancer [14, 15] , breast cancer [21, 22] , and hepatocellular carcinoma [16] .", [["tumors", "ANATOMY", 46, 52], ["lung carcinoma", "ANATOMY", 64, 78], ["prostate cancer", "ANATOMY", 100, 115], ["breast cancer", "ANATOMY", 127, 140], ["hepatocellular carcinoma", "ANATOMY", 156, 180], ["Ang-(1-7)", "CHEMICAL", 0, 9], ["tumors", "DISEASE", 46, 52], ["lung carcinoma", "DISEASE", 64, 78], ["prostate cancer", "DISEASE", 100, 115], ["breast cancer", "DISEASE", 127, 140], ["hepatocellular carcinoma", "DISEASE", 156, 180], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 0, 8], ["tumors", "CANCER", 46, 52], ["lung carcinoma", "CANCER", 64, 78], ["prostate cancer", "CANCER", 100, 115], ["breast cancer", "CANCER", 127, 140], ["hepatocellular carcinoma", "CANCER", 156, 180], ["Ang", "TEST", 0, 3], ["a variety of tumors", "PROBLEM", 33, 52], ["lung carcinoma", "PROBLEM", 64, 78], ["prostate cancer", "PROBLEM", 100, 115], ["breast cancer", "PROBLEM", 127, 140], ["hepatocellular carcinoma", "PROBLEM", 156, 180], ["tumors", "OBSERVATION", 46, 52], ["lung", "ANATOMY", 64, 68], ["carcinoma", "OBSERVATION", 69, 78], ["prostate", "ANATOMY", 100, 108], ["cancer", "OBSERVATION", 109, 115], ["breast", "ANATOMY", 127, 133], ["cancer", "OBSERVATION", 134, 140], ["hepatocellular", "ANATOMY", 156, 170], ["carcinoma", "OBSERVATION", 171, 180]]], ["Only few studies have demonstrated a regulatory function of the RAS in NPC.", [["NPC", "ANATOMY", 71, 74], ["NPC", "DISEASE", 71, 74], ["RAS", "GENE_OR_GENE_PRODUCT", 64, 67], ["NPC", "CANCER", 71, 74], ["RAS", "PROTEIN", 64, 67], ["NPC", "PROTEIN", 71, 74], ["few studies", "TEST", 5, 16], ["NPC", "ANATOMY", 71, 74]]], ["Wang et al. indicated that AT1R plays a significant role not only in the cell proliferation and invasion, but also in radiation resistance, of NPC cells [23] .", [["cell", "ANATOMY", 73, 77], ["NPC cells", "ANATOMY", 143, 152], ["AT1R", "GENE_OR_GENE_PRODUCT", 27, 31], ["cell", "CELL", 73, 77], ["NPC cells", "CELL", 143, 152], ["AT1R", "PROTEIN", 27, 31], ["NPC cells", "CELL_LINE", 143, 152], ["invasion", "PROBLEM", 96, 104], ["NPC cells", "PROBLEM", 143, 152], ["significant", "OBSERVATION_MODIFIER", 40, 51], ["cell proliferation", "OBSERVATION", 73, 91], ["invasion", "OBSERVATION", 96, 104], ["radiation resistance", "OBSERVATION", 118, 138]]], ["No association was found between angiotensin-converting enzyme 2 polymorphisms and the risk of NPC [24] .", [["NPC", "ANATOMY", 95, 98], ["angiotensin", "CHEMICAL", 33, 44], ["NPC", "DISEASE", 95, 98], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 33, 64], ["NPC", "CANCER", 95, 98], ["angiotensin-converting enzyme 2", "PROTEIN", 33, 64], ["angiotensin", "TREATMENT", 33, 44], ["NPC", "PROBLEM", 95, 98]]], ["However, the effects of the RAS on autophagy-associated pathways in NPC remain questionable.", [["NPC", "ANATOMY", 68, 71], ["NPC", "DISEASE", 68, 71], ["RAS", "GENE_OR_GENE_PRODUCT", 28, 31], ["NPC", "CANCER", 68, 71], ["RAS", "PROTEIN", 28, 31], ["NPC", "PROBLEM", 68, 71]]], ["Therefore were 2.5-fold higher than that of the AT2 receptor (Fig. S1 ).DiscussionWe also examined MasR expression in the Ang-(1-7)/MasR axis in the NPC-TW01 cell and human nasopharyngeal xenografts, which revealed that Ang-(1-7) upregulated MasR expression in vitro and in vivo (Fig. S2) .", [["NPC-TW01 cell", "ANATOMY", 149, 162], ["nasopharyngeal xenografts", "ANATOMY", 173, 198], ["Ang", "CHEMICAL", 122, 125], ["Ang-(1-7", "CHEMICAL", 220, 228], ["AT2 receptor", "GENE_OR_GENE_PRODUCT", 48, 60], ["S1", "GENE_OR_GENE_PRODUCT", 67, 69], ["MasR", "GENE_OR_GENE_PRODUCT", 99, 103], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 122, 130], ["MasR", "GENE_OR_GENE_PRODUCT", 132, 136], ["NPC-TW01 cell", "CELL", 149, 162], ["human", "ORGANISM", 167, 172], ["nasopharyngeal xenografts", "CANCER", 173, 198], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 220, 228], ["MasR", "GENE_OR_GENE_PRODUCT", 242, 246], ["AT2 receptor", "PROTEIN", 48, 60], ["S1", "PROTEIN", 67, 69], ["MasR", "PROTEIN", 99, 103], ["MasR", "PROTEIN", 132, 136], ["NPC", "CELL_LINE", 149, 152], ["TW01 cell", "CELL_LINE", 153, 162], ["MasR", "PROTEIN", 242, 246], ["S2", "PROTEIN", 285, 287], ["human", "SPECIES", 167, 172], ["human", "SPECIES", 167, 172], ["the Ang", "TEST", 118, 125], ["TW01 cell", "TREATMENT", 153, 162], ["human nasopharyngeal xenografts", "TREATMENT", 167, 198], ["Ang", "TEST", 220, 223], ["NPC", "ANATOMY", 149, 152], ["nasopharyngeal", "ANATOMY", 173, 187]]], ["Second, we revealed that Ang-(1-7) at low concentrations (0.04, 0.2 and 1 \u03bcM) inhibited cell viability, migration, and invasion in NPC-TW01 cells (Figs.", [["cell", "ANATOMY", 88, 92], ["NPC-TW01 cells", "ANATOMY", 131, 145], ["Ang-(1-7)", "CHEMICAL", 25, 34], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 25, 33], ["cell", "CELL", 88, 92], ["NPC-TW01 cells", "CELL", 131, 145], ["NPC-TW01 cells", "CELL_LINE", 131, 145], ["Ang", "TEST", 25, 28], ["cell viability", "TEST", 88, 102], ["migration", "TEST", 104, 113], ["invasion in NPC", "PROBLEM", 119, 134], ["Ang", "OBSERVATION", 25, 28], ["cell viability", "OBSERVATION", 88, 102], ["migration", "OBSERVATION_MODIFIER", 104, 113], ["invasion", "OBSERVATION_MODIFIER", 119, 127], ["NPC", "ANATOMY", 131, 134]]], ["These results are consistent with a previous study, which reported that Ang-(1-7) upregulated the mRNA level of MasR.", [["Ang-(1-7", "CHEMICAL", 72, 80], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 72, 80], ["MasR", "GENE_OR_GENE_PRODUCT", 112, 116], ["MasR", "PROTEIN", 112, 116], ["a previous study", "TEST", 34, 50], ["Ang", "TEST", 72, 75], ["consistent with", "UNCERTAINTY", 18, 33], ["MasR", "ANATOMY", 112, 116]]], ["Moreover, treatment with 0.5 \u03bcM Ang-(1-7) significantly decreased H22 murine hepatocellular carcinoma cell proliferation and cell-endothelial cell communication and induced caspase-3 activity [16] .", [["H22 murine hepatocellular carcinoma cell", "ANATOMY", 66, 106], ["cell", "ANATOMY", 125, 129], ["endothelial cell", "ANATOMY", 130, 146], ["Ang-(1-7)", "CHEMICAL", 32, 41], ["carcinoma", "DISEASE", 92, 101], ["1-7", "SIMPLE_CHEMICAL", 37, 40], ["H22", "CELL", 66, 69], ["murine", "ORGANISM", 70, 76], ["hepatocellular carcinoma cell", "CELL", 77, 106], ["cell", "CELL", 125, 129], ["endothelial cell", "CELL", 130, 146], ["caspase-3", "GENE_OR_GENE_PRODUCT", 173, 182], ["H22 murine hepatocellular carcinoma cell", "CELL_LINE", 66, 106], ["caspase-3", "PROTEIN", 173, 182], ["murine", "SPECIES", 70, 76], ["treatment", "TREATMENT", 10, 19], ["0.5 \u03bcM Ang", "TREATMENT", 25, 35], ["H22 murine hepatocellular carcinoma cell proliferation", "TREATMENT", 66, 120], ["cell-endothelial cell communication", "TREATMENT", 125, 160], ["induced caspase", "TREATMENT", 165, 180], ["hepatocellular", "ANATOMY", 77, 91], ["carcinoma cell proliferation", "OBSERVATION", 92, 120], ["endothelial cell", "OBSERVATION", 130, 146]]], ["Ang-(1-7) inhibited the migration and invasion of A549 human lung adenocarcinoma cells following treatment with Ang-(1-7) in a dose-dependent manner [12] .", [["A549", "ANATOMY", 50, 54], ["lung adenocarcinoma cells", "ANATOMY", 61, 86], ["Ang-(1-7)", "CHEMICAL", 0, 9], ["lung adenocarcinoma", "DISEASE", 61, 80], ["Ang-(1-7", "CHEMICAL", 112, 120], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 0, 8], ["A549", "CELL", 50, 54], ["human", "ORGANISM", 55, 60], ["lung adenocarcinoma cells", "CELL", 61, 86], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 112, 120], ["A549 human lung adenocarcinoma cells", "CELL_LINE", 50, 86], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 55, 60], ["Ang", "TEST", 0, 3], ["the migration", "PROBLEM", 20, 33], ["invasion of A549 human lung adenocarcinoma cells", "TREATMENT", 38, 86], ["Ang", "TREATMENT", 112, 115], ["migration", "OBSERVATION_MODIFIER", 24, 33], ["invasion", "OBSERVATION_MODIFIER", 38, 46], ["A549 human", "OBSERVATION", 50, 60], ["lung", "ANATOMY", 61, 65], ["adenocarcinoma cells", "OBSERVATION", 66, 86]]], ["Beclin-1 and LC3-II are important members involved in autophagy of mammalian cells [25] .", [["cells", "ANATOMY", 77, 82], ["Beclin-1", "GENE_OR_GENE_PRODUCT", 0, 8], ["LC3-II", "GENE_OR_GENE_PRODUCT", 13, 19], ["mammalian cells", "CELL", 67, 82], ["Beclin-1", "PROTEIN", 0, 8], ["LC3-II", "PROTEIN", 13, 19], ["mammalian cells", "CELL_TYPE", 67, 82], ["Beclin", "TEST", 0, 6]]], ["Therefore, we analyzed the expression of these proteins by Western blot analysis in NPC-TW01 cells.", [["NPC-TW01 cells", "ANATOMY", 84, 98], ["NPC-TW01 cells", "CELL", 84, 98], ["NPC-TW01 cells", "CELL_LINE", 84, 98], ["Western blot analysis", "TEST", 59, 80]]], ["Treatment with 0.2 \u03bcM Ang-(1-7) for 24 h was significantly upregulated the levels of Beclin-1 and LC3-II and downregulated that of p62.DiscussionWe also examined the expression of the apoptosis-associated proteins pro-caspase-3, pro-caspase-8, and pro-caspase-9.", [["Ang-(1-7)", "CHEMICAL", 22, 31], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 22, 30], ["Beclin-1", "GENE_OR_GENE_PRODUCT", 85, 93], ["LC3-II", "GENE_OR_GENE_PRODUCT", 98, 104], ["p62", "GENE_OR_GENE_PRODUCT", 131, 134], ["pro-caspase-3", "GENE_OR_GENE_PRODUCT", 214, 227], ["pro-caspase-8", "GENE_OR_GENE_PRODUCT", 229, 242], ["pro-caspase-9", "GENE_OR_GENE_PRODUCT", 248, 261], ["Beclin-1", "PROTEIN", 85, 93], ["LC3-II", "PROTEIN", 98, 104], ["p62", "PROTEIN", 131, 134], ["apoptosis-associated proteins", "PROTEIN", 184, 213], ["pro-caspase-3", "PROTEIN", 214, 227], ["pro-caspase-8", "PROTEIN", 229, 242], ["pro-caspase-9", "PROTEIN", 248, 261], ["Treatment", "TREATMENT", 0, 9], ["0.2 \u03bcM Ang", "TREATMENT", 15, 25], ["Beclin", "TEST", 85, 91], ["the apoptosis", "PROBLEM", 180, 193], ["proteins pro-caspase", "TREATMENT", 205, 225], ["pro-caspase", "TEST", 229, 240], ["pro-caspase", "TEST", 248, 259]]], ["Our data indicate that 2.5 and 5 \u03bcM Ang-(1-7) induced a decrease in pro-caspase-3 and -9 expression, respectively, in NPC-TW01 cells.", [["NPC-TW01 cells", "ANATOMY", 118, 132], ["Ang-(1-7", "CHEMICAL", 36, 44], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 36, 44], ["pro-caspase-3", "GENE_OR_GENE_PRODUCT", 68, 81], ["-9", "GENE_OR_GENE_PRODUCT", 86, 88], ["NPC-TW01 cells", "CELL", 118, 132], ["NPC-TW01 cells", "CELL_LINE", 118, 132], ["Our data", "TEST", 0, 8], ["Ang", "TEST", 36, 39], ["a decrease in pro-caspase", "PROBLEM", 54, 79], ["decrease", "OBSERVATION_MODIFIER", 56, 64], ["NPC", "ANATOMY", 118, 121]]], ["However, pro-caspase-8 expression was not affected (Fig. S3 ).", [["pro-caspase-8", "GENE_OR_GENE_PRODUCT", 9, 22], ["pro-caspase-8", "PROTEIN", 9, 22], ["pro-caspase", "TEST", 9, 20]]], ["In addition, the Bcl-2 inhibitor activates the autophagic pathway through the blocking interaction of Bcl-2/ Beclin1 and upregulating Beclin-1 [26] .", [["Bcl-2", "GENE_OR_GENE_PRODUCT", 17, 22], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 102, 107], ["Beclin1", "GENE_OR_GENE_PRODUCT", 109, 116], ["Beclin-1", "GENE_OR_GENE_PRODUCT", 134, 142], ["Bcl-2", "PROTEIN", 17, 22], ["Bcl-2", "PROTEIN", 102, 107], ["Beclin1", "PROTEIN", 109, 116], ["Beclin", "PROTEIN", 134, 140], ["the Bcl", "TEST", 13, 20], ["Bcl", "TEST", 102, 105], ["Beclin", "TEST", 134, 140]]], ["Therefore, by examining the interaction between Bcl-2 and Beclin-1 identified by Bcl-2 siRNA transfection experiments, we found that 0.2 \u03bcM Ang-(1-7) caused autophagosome formation because of the increase in LC3-ll levels and induced autophagy via activation of the Beclin-1/Bcl-2 signaling pathway (Fig. 3e) .", [["autophagosome", "ANATOMY", 157, 170], ["Ang-(1-7)", "CHEMICAL", 140, 149], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 48, 53], ["Beclin-1", "GENE_OR_GENE_PRODUCT", 58, 66], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 81, 86], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 140, 148], ["autophagosome", "CELLULAR_COMPONENT", 157, 170], ["LC3-ll", "GENE_OR_GENE_PRODUCT", 208, 214], ["Beclin-1", "GENE_OR_GENE_PRODUCT", 266, 274], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 275, 280], ["Bcl-2", "PROTEIN", 48, 53], ["Beclin-1", "PROTEIN", 58, 66], ["LC3", "PROTEIN", 208, 211], ["Beclin-1", "PROTEIN", 266, 274], ["Bcl-2", "PROTEIN", 275, 280], ["Bcl", "TEST", 48, 51], ["Beclin", "TEST", 58, 64], ["Bcl", "TEST", 81, 84], ["Ang", "TEST", 140, 143], ["autophagosome formation", "PROBLEM", 157, 180], ["the increase in LC3-ll levels", "PROBLEM", 192, 221], ["the Beclin", "TEST", 262, 272], ["Bcl", "TEST", 275, 278], ["autophagosome formation", "OBSERVATION", 157, 180], ["increase", "OBSERVATION_MODIFIER", 196, 204]]], ["However, concentrations of Ang-(1-7) greater than 2.5 \u03bcM triggered NPC-TW01 cell apoptosis due to decreased pro-caspase-3 and -9 expression, confirming that Ang-(1-7) stimulates NPC cell autophagy at lower concentrations.", [["NPC-TW01 cell", "ANATOMY", 67, 80], ["NPC cell", "ANATOMY", 178, 186], ["Ang-(1-7", "CHEMICAL", 27, 35], ["Ang-(1-7", "CHEMICAL", 157, 165], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 27, 35], ["NPC-TW01 cell", "CELL", 67, 80], ["pro-caspase-3", "GENE_OR_GENE_PRODUCT", 108, 121], ["-9", "GENE_OR_GENE_PRODUCT", 126, 128], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 157, 165], ["NPC cell", "CELL", 178, 186], ["Ang", "TEST", 27, 30], ["NPC", "PROBLEM", 67, 70], ["TW01 cell apoptosis", "PROBLEM", 71, 90], ["decreased pro-caspase", "PROBLEM", 98, 119], ["Ang", "TEST", 157, 160], ["stimulates NPC cell autophagy", "TREATMENT", 167, 196], ["lower concentrations", "OBSERVATION_MODIFIER", 200, 220]]], ["As a downstream effector of Akt, mTOR suppresses autophagy [27, 28] .", [["Akt", "GENE_OR_GENE_PRODUCT", 28, 31], ["mTOR", "GENE_OR_GENE_PRODUCT", 33, 37], ["Akt", "PROTEIN", 28, 31], ["mTOR", "PROTEIN", 33, 37]]], ["Ang-(1-7), a peptide with anti-inflammatory properties, plays an important role in the regulation of the tumor microenvironment, and inactivation of the PI3K/Akt and p38 MAPK pathways may be responsible for the inhibitory effects of Ang-(1-7) [12] .", [["tumor", "ANATOMY", 105, 110], ["Ang-(1-7)", "CHEMICAL", 0, 9], ["tumor", "DISEASE", 105, 110], ["Ang-(1-7)", "CHEMICAL", 233, 242], ["Ang-(1-7)", "CHEMICAL", 233, 242], ["Ang-(1-7", "SIMPLE_CHEMICAL", 0, 8], ["tumor", "CANCER", 105, 110], ["PI3K", "GENE_OR_GENE_PRODUCT", 153, 157], ["Akt", "GENE_OR_GENE_PRODUCT", 158, 161], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 166, 174], ["PI3K", "PROTEIN", 153, 157], ["Akt", "PROTEIN", 158, 161], ["MAPK", "PROTEIN", 170, 174], ["Ang", "TEST", 0, 3], ["a peptide with anti-inflammatory properties", "TREATMENT", 11, 54], ["the PI3K", "TEST", 149, 157], ["p38 MAPK pathways", "TEST", 166, 183], ["anti-inflammatory properties", "OBSERVATION", 26, 54], ["tumor", "OBSERVATION", 105, 110]]], ["In the present study, we investigated whether the effects of Ang-(1-7) in NPC-TW01 cells are mediated by these pathways by examining phosphorylation of the involved proteins.", [["NPC-TW01 cells", "ANATOMY", 74, 88], ["Ang-(1-7)", "CHEMICAL", 61, 70], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 61, 69], ["NPC-TW01 cells", "CELL", 74, 88], ["NPC-TW01 cells", "CELL_LINE", 74, 88], ["the present study", "TEST", 3, 20], ["Ang", "TEST", 61, 64], ["NPC-TW01 cells", "TREATMENT", 74, 88]]], ["The phosphorylation of PI3K, Akt, p-GSK3-\u03b2, and mTOR was inhibited by Ang-(1-7) treatment.", [["Ang-(1-7)", "CHEMICAL", 70, 79], ["PI3K", "GENE_OR_GENE_PRODUCT", 23, 27], ["Akt", "GENE_OR_GENE_PRODUCT", 29, 32], ["p-GSK3-\u03b2", "GENE_OR_GENE_PRODUCT", 34, 42], ["mTOR", "GENE_OR_GENE_PRODUCT", 48, 52], ["Ang-(1-7", "SIMPLE_CHEMICAL", 70, 78], ["PI3K", "PROTEIN", 23, 27], ["Akt", "PROTEIN", 29, 32], ["GSK3", "PROTEIN", 36, 40], ["\u03b2", "PROTEIN", 41, 42], ["mTOR", "PROTEIN", 48, 52], ["The phosphorylation", "TEST", 0, 19], ["PI3K", "TEST", 23, 27], ["Akt", "TEST", 29, 32], ["GSK3", "TEST", 36, 40], ["Ang", "TEST", 70, 73], ["treatment", "TREATMENT", 80, 89]]], ["Ang-(1-7) also reduced p38 phosphorylation, suggesting that Ang-(1-7) blocks the phosphorylation of proteins involved in the PI3K/Akt/mTOR and p38 pathways (Fig. 3c, d) .DiscussionThe mechanism of Ang-(1-7)-induced cell autophagy remains unclear.", [["cell", "ANATOMY", 215, 219], ["Ang-(1-7)", "CHEMICAL", 0, 9], ["Ang-(1-7", "CHEMICAL", 60, 68], ["Ang-(1-7)", "CHEMICAL", 197, 206], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 0, 8], ["p38", "GENE_OR_GENE_PRODUCT", 23, 26], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 60, 68], ["PI3K", "GENE_OR_GENE_PRODUCT", 125, 129], ["Akt", "GENE_OR_GENE_PRODUCT", 130, 133], ["mTOR", "GENE_OR_GENE_PRODUCT", 134, 138], ["p38", "GENE_OR_GENE_PRODUCT", 143, 146], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 197, 205], ["cell", "CELL", 215, 219], ["p38", "PROTEIN", 23, 26], ["PI3K", "PROTEIN", 125, 129], ["Akt", "PROTEIN", 130, 133], ["mTOR", "PROTEIN", 134, 138], ["p38", "PROTEIN", 143, 146], ["Ang", "TEST", 0, 3], ["reduced p38 phosphorylation", "PROBLEM", 15, 42], ["Ang", "TEST", 60, 63], ["the phosphorylation of proteins", "TEST", 77, 108], ["the PI3K", "TEST", 121, 129], ["p38 pathways", "TEST", 143, 155], ["Ang", "TEST", 197, 200], ["induced cell autophagy", "PROBLEM", 207, 229], ["cell autophagy", "OBSERVATION", 215, 229]]], ["In the brain, Ang-(1-7) may help prevent hypertension-induced excessive autophagic activation [29] .", [["brain", "ANATOMY", 7, 12], ["Ang-(1-7)", "CHEMICAL", 14, 23], ["hypertension", "DISEASE", 41, 53], ["brain", "ORGAN", 7, 12], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 14, 22], ["Ang", "TEST", 14, 17], ["hypertension", "PROBLEM", 41, 53], ["excessive autophagic activation", "PROBLEM", 62, 93], ["brain", "ANATOMY", 7, 12], ["Ang", "ANATOMY", 14, 17], ["hypertension", "OBSERVATION", 41, 53], ["excessive", "OBSERVATION_MODIFIER", 62, 71], ["autophagic activation", "OBSERVATION", 72, 93]]], ["In the heart, MasR mediates cardioprotection of Ang-(1-7) against angiotensin II-induced cardiomyocyte autophagy and cardiac remodeling by inhibiting oxidative stress [30] .", [["heart", "ANATOMY", 7, 12], ["cardiomyocyte", "ANATOMY", 89, 102], ["cardiac", "ANATOMY", 117, 124], ["Ang-(1-7)", "CHEMICAL", 48, 57], ["angiotensin II", "CHEMICAL", 66, 80], ["heart", "ORGAN", 7, 12], ["MasR", "GENE_OR_GENE_PRODUCT", 14, 18], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 48, 56], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 66, 80], ["cardiomyocyte", "CELL", 89, 102], ["cardiac", "ORGAN", 117, 124], ["MasR", "PROTEIN", 14, 18], ["Ang", "TEST", 48, 51], ["angiotensin II", "PROBLEM", 66, 80], ["cardiomyocyte autophagy", "PROBLEM", 89, 112], ["cardiac remodeling", "PROBLEM", 117, 135], ["inhibiting oxidative stress", "PROBLEM", 139, 166], ["heart", "ANATOMY", 7, 12], ["cardiomyocyte", "ANATOMY", 89, 102], ["autophagy", "OBSERVATION", 103, 112], ["cardiac", "ANATOMY", 117, 124]]], ["Ang-(1-7) induced time-dependent upregulation in autophagic activity via LC3-II and Beclin-1 in serum-starved human aortic endothelial cells [31] .", [["autophagic", "ANATOMY", 49, 59], ["serum", "ANATOMY", 96, 101], ["aortic endothelial cells", "ANATOMY", 116, 140], ["Ang-(1-7)", "CHEMICAL", 0, 9], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 0, 8], ["LC3-II", "GENE_OR_GENE_PRODUCT", 73, 79], ["Beclin-1", "GENE_OR_GENE_PRODUCT", 84, 92], ["serum", "ORGANISM_SUBSTANCE", 96, 101], ["human", "ORGANISM", 110, 115], ["aortic endothelial cells", "CELL", 116, 140], ["LC3-II", "PROTEIN", 73, 79], ["Beclin-1", "PROTEIN", 84, 92], ["serum-starved human aortic endothelial cells", "CELL_LINE", 96, 140], ["human", "SPECIES", 110, 115], ["human", "SPECIES", 110, 115], ["Ang", "TEST", 0, 3], ["dependent upregulation", "PROBLEM", 23, 45], ["autophagic activity", "TEST", 49, 68], ["LC3", "TEST", 73, 76], ["Beclin", "TEST", 84, 90], ["serum", "TEST", 96, 101], ["autophagic activity", "OBSERVATION", 49, 68], ["aortic endothelial", "ANATOMY", 116, 134]]], ["Moreover, a recent report indicated that Ang-(1-7) not only causes a significant reduction in the growth of human nasopharyngeal xenografts but also markedly decreases vessel density [19] .", [["nasopharyngeal xenografts", "ANATOMY", 114, 139], ["vessel", "ANATOMY", 168, 174], ["Ang-(1-7)", "CHEMICAL", 41, 50], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 41, 49], ["human", "ORGANISM", 108, 113], ["nasopharyngeal xenografts", "CANCER", 114, 139], ["vessel", "MULTI-TISSUE_STRUCTURE", 168, 174], ["human", "SPECIES", 108, 113], ["human", "SPECIES", 108, 113], ["Ang", "TEST", 41, 44], ["a significant reduction", "PROBLEM", 67, 90], ["human nasopharyngeal xenografts", "PROBLEM", 108, 139], ["markedly decreases vessel density", "PROBLEM", 149, 182], ["significant", "OBSERVATION_MODIFIER", 69, 80], ["reduction", "OBSERVATION_MODIFIER", 81, 90], ["growth", "OBSERVATION_MODIFIER", 98, 104], ["nasopharyngeal xenografts", "OBSERVATION", 114, 139], ["markedly", "OBSERVATION_MODIFIER", 149, 157], ["decreases", "OBSERVATION_MODIFIER", 158, 167], ["vessel", "ANATOMY", 168, 174]]], ["Ang-(1-7) may inhibit the growth of human lung adenocarcinoma xenografts in nude mice by reducing cyclooxygenase-2 [13] .", [["lung adenocarcinoma xenografts", "ANATOMY", 42, 72], ["Ang-(1-7)", "CHEMICAL", 0, 9], ["lung adenocarcinoma", "DISEASE", 42, 61], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 0, 8], ["human", "ORGANISM", 36, 41], ["lung adenocarcinoma xenografts", "CANCER", 42, 72], ["nude mice", "ORGANISM", 76, 85], ["cyclooxygenase-2", "GENE_OR_GENE_PRODUCT", 98, 114], ["cyclooxygenase", "PROTEIN", 98, 112], ["human", "SPECIES", 36, 41], ["mice", "SPECIES", 81, 85], ["human", "SPECIES", 36, 41], ["mice", "SPECIES", 81, 85], ["Ang", "TEST", 0, 3], ["human lung adenocarcinoma xenografts", "PROBLEM", 36, 72], ["cyclooxygenase", "TEST", 98, 112], ["lung", "ANATOMY", 42, 46], ["adenocarcinoma", "OBSERVATION", 47, 61]]], ["In this study, we hypothesized that the regulatory function of the Ang-(1-7)/MasR axis is related to autophagy in NPC in vivo.", [["NPC", "ANATOMY", 114, 117], ["Ang", "CHEMICAL", 67, 70], ["NPC", "DISEASE", 114, 117], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 67, 75], ["MasR", "GENE_OR_GENE_PRODUCT", 77, 81], ["NPC", "CANCER", 114, 117], ["MasR", "PROTEIN", 77, 81], ["this study", "TEST", 3, 13], ["the Ang", "TEST", 63, 70], ["MasR axis", "PROBLEM", 77, 86], ["autophagy", "PROBLEM", 101, 110], ["related to", "UNCERTAINTY", 90, 100], ["autophagy", "OBSERVATION", 101, 110]]], ["Therefore, we established two xenograft mouse models (preand post-treatment) to evaluate tumor size and autophagy/cell death-associated proteins.", [["xenograft", "ANATOMY", 30, 39], ["tumor", "ANATOMY", 89, 94], ["cell", "ANATOMY", 114, 118], ["tumor", "DISEASE", 89, 94], ["death", "DISEASE", 119, 124], ["xenograft", "CANCER", 30, 39], ["mouse", "ORGANISM", 40, 45], ["tumor", "CANCER", 89, 94], ["cell", "CELL", 114, 118], ["associated proteins", "PROTEIN", 125, 144], ["mouse", "SPECIES", 40, 45], ["mouse", "SPECIES", 40, 45], ["two xenograft mouse models", "TREATMENT", 26, 52], ["preand post-treatment", "TREATMENT", 54, 75], ["tumor size", "PROBLEM", 89, 99], ["autophagy", "PROBLEM", 104, 113], ["cell death", "PROBLEM", 114, 124], ["associated proteins", "PROBLEM", 125, 144], ["tumor", "OBSERVATION", 89, 94], ["size", "OBSERVATION_MODIFIER", 95, 99], ["cell death", "OBSERVATION", 114, 124]]], ["A high Ang-(1-7) concentration (1 \u03bcg/kg/day) inhibited tumor size post-treatment, but a lower concentration (0.2 \u03bcg/kg/day) had no significant effect.", [["tumor", "ANATOMY", 55, 60], ["Ang-(1-7)", "CHEMICAL", 7, 16], ["tumor", "DISEASE", 55, 60], ["tumor", "CANCER", 55, 60], ["A high Ang", "TREATMENT", 0, 10], ["tumor size post-treatment", "TREATMENT", 55, 80], ["a lower concentration", "TREATMENT", 86, 107], ["tumor", "OBSERVATION", 55, 60], ["size", "OBSERVATION_MODIFIER", 61, 65], ["no", "UNCERTAINTY", 128, 130], ["significant", "OBSERVATION_MODIFIER", 131, 142], ["effect", "OBSERVATION", 143, 149]]], ["However, the expression of autophagy-associated proteins was not affected (Fig. 4) .", [["autophagy-associated proteins", "PROTEIN", 27, 56], ["autophagy", "PROBLEM", 27, 36], ["associated proteins", "PROBLEM", 37, 56]]], ["Therefore, we hypothesize that Ang-(1-7) may induce apoptosis by degrading pro-caspase-3 (Fig. S4 ).", [["Ang-(1-7)", "CHEMICAL", 31, 40], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 31, 39], ["pro-caspase-3", "GENE_OR_GENE_PRODUCT", 75, 88], ["pro-caspase-3", "PROTEIN", 75, 88], ["S4", "PROTEIN", 95, 97], ["Ang", "TEST", 31, 34], ["apoptosis", "PROBLEM", 52, 61]]], ["In contrast, our results demonstrated that both low-and high-dose Ang-(1-7) inhibited tumor proliferation pre-treatment by directly affecting tumor size and by indirectly inducing autophagy by suppressing the phosphorylation of proteins involved in the PI3K/Akt/mTOR signaling pathway (Figs.", [["tumor", "ANATOMY", 86, 91], ["tumor", "ANATOMY", 142, 147], ["Ang-(1-7)", "CHEMICAL", 66, 75], ["tumor", "DISEASE", 86, 91], ["tumor", "DISEASE", 142, 147], ["Ang-(1-7", "SIMPLE_CHEMICAL", 66, 74], ["tumor", "CANCER", 86, 91], ["tumor", "CANCER", 142, 147], ["PI3K", "GENE_OR_GENE_PRODUCT", 253, 257], ["Akt", "GENE_OR_GENE_PRODUCT", 258, 261], ["mTOR", "GENE_OR_GENE_PRODUCT", 262, 266], ["PI3K", "PROTEIN", 253, 257], ["Akt", "PROTEIN", 258, 261], ["mTOR", "PROTEIN", 262, 266], ["Ang", "TEST", 66, 69], ["tumor proliferation pre-treatment", "TREATMENT", 86, 119], ["tumor proliferation", "OBSERVATION", 86, 105], ["tumor", "OBSERVATION", 142, 147], ["size", "OBSERVATION_MODIFIER", 148, 152]]], ["Ang-(1-7) exerted its tumor inhibition effect at a five fold higher concentration post-treatment compared with pre-treatment, suggesting that Ang-(1-7) is more efficient as a preventive than a curative agent in vivo because it caused autophagic activity in NPC.DiscussionAng-(1-7) exerts its anti-proliferative and anti-invasive effects by activating MasR, and A-779, a selective antagonist of MasR, blocks most of these responses to Ang-(1-7) [32] ; the concentrations of Ang-(1-7) required to exert its effects are 44.5 and 32.3 pg/ml in women and men, respectively [33] , and 15 pg/ml in mice [34] .", [["tumor", "ANATOMY", 22, 27], ["autophagic", "ANATOMY", 234, 244], ["NPC", "ANATOMY", 257, 260], ["Ang-(1-7)", "CHEMICAL", 0, 9], ["tumor", "DISEASE", 22, 27], ["Ang-(1-7", "CHEMICAL", 142, 150], ["DiscussionAng-(1-7)", "CHEMICAL", 261, 280], ["A-779", "CHEMICAL", 361, 366], ["Ang", "CHEMICAL", 434, 437], ["Ang-(1-7", "CHEMICAL", 473, 481], ["A-779", "CHEMICAL", 361, 366], ["Ang-(1-7", "SIMPLE_CHEMICAL", 0, 8], ["tumor", "CANCER", 22, 27], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 142, 150], ["NPC", "CANCER", 257, 260], ["DiscussionAng-(1-7", "SIMPLE_CHEMICAL", 261, 279], ["MasR", "GENE_OR_GENE_PRODUCT", 351, 355], ["A-779", "SIMPLE_CHEMICAL", 361, 366], ["MasR", "GENE_OR_GENE_PRODUCT", 394, 398], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 473, 481], ["women", "ORGANISM", 540, 545], ["men", "ORGANISM", 550, 553], ["mice", "ORGANISM", 591, 595], ["MasR", "PROTEIN", 351, 355], ["MasR", "PROTEIN", 394, 398], ["women", "SPECIES", 540, 545], ["men", "SPECIES", 550, 553], ["mice", "SPECIES", 591, 595], ["mice", "SPECIES", 591, 595], ["Ang", "TEST", 0, 3], ["its tumor inhibition effect", "PROBLEM", 18, 45], ["treatment", "TREATMENT", 87, 96], ["pre-treatment", "TEST", 111, 124], ["Ang", "TEST", 142, 145], ["a curative agent", "TREATMENT", 191, 207], ["autophagic activity in NPC", "PROBLEM", 234, 260], ["a selective antagonist of MasR", "TREATMENT", 368, 398], ["Ang", "TEST", 434, 437], ["Ang", "TEST", 473, 476], ["tumor", "OBSERVATION", 22, 27], ["Ang", "OBSERVATION", 142, 145], ["autophagic activity", "OBSERVATION", 234, 253]]], ["In addition, Ang-(1-7) is an anti-angiogenic drug with anti-cancer activity that is associated with a reduction in plasma placental growth factor levels at a recommended phase II dose of 400 \u03bcg/kg [35] .", [["plasma", "ANATOMY", 115, 121], ["Ang-(1-7)", "CHEMICAL", 13, 22], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 13, 21], ["anti-cancer", "CANCER", 55, 66], ["plasma", "ORGANISM_SUBSTANCE", 115, 121], ["placental growth factor", "GENE_OR_GENE_PRODUCT", 122, 145], ["plasma placental growth factor", "PROTEIN", 115, 145], ["Ang", "TEST", 13, 16], ["an anti-angiogenic drug", "TREATMENT", 26, 49], ["anti-cancer activity", "PROBLEM", 55, 75], ["a reduction in plasma placental growth factor levels", "PROBLEM", 100, 152], ["a recommended phase II dose", "TREATMENT", 156, 183], ["anti-cancer activity", "OBSERVATION", 55, 75]]], ["Ang- (1-7) , at a dose of 20 mg daily, was well-tolerated in a phase II trial for the treatment of patients with metastatic sarcoma [36] .", [["metastatic sarcoma", "ANATOMY", 113, 131], ["Ang- (1-7)", "CHEMICAL", 0, 10], ["sarcoma", "DISEASE", 124, 131], ["Ang- (1-7", "SIMPLE_CHEMICAL", 0, 9], ["patients", "ORGANISM", 99, 107], ["metastatic sarcoma", "CANCER", 113, 131], ["patients", "SPECIES", 99, 107], ["Ang", "TEST", 0, 3], ["a phase II trial", "TREATMENT", 61, 77], ["the treatment", "TREATMENT", 82, 95], ["metastatic sarcoma", "PROBLEM", 113, 131], ["metastatic", "OBSERVATION_MODIFIER", 113, 123], ["sarcoma", "OBSERVATION", 124, 131]]], ["In this study, we may use a low-dose of Ang-(1-7) for the pretreatment model, suggesting alleviation the incidence and reduction in the severity of NPC.", [["NPC", "ANATOMY", 148, 151], ["Ang", "CHEMICAL", 40, 43], ["NPC", "DISEASE", 148, 151], ["NPC", "CANCER", 148, 151], ["this study", "TEST", 3, 13], ["a low-dose of Ang", "TREATMENT", 26, 43], ["the pretreatment model", "TREATMENT", 54, 76], ["the severity of NPC", "PROBLEM", 132, 151], ["reduction", "OBSERVATION_MODIFIER", 119, 128]]], ["Furthermore, while the treatment results for the primary NPC have been encouraging; management of recurrent NPC has been challenging [5, 6] .", [["primary NPC", "ANATOMY", 49, 60], ["NPC", "ANATOMY", 108, 111], ["NPC", "DISEASE", 57, 60], ["NPC", "DISEASE", 108, 111], ["NPC", "CANCER", 57, 60], ["NPC", "CANCER", 108, 111], ["the primary NPC", "PROBLEM", 45, 60], ["recurrent NPC", "PROBLEM", 98, 111]]], ["Therefore, Ang-(1-7) represents a novel preventive agent against NPC via its autophagic effects and may aid in the development of other protective therapeutics against recurrent NPC in the future.", [["NPC", "ANATOMY", 65, 68], ["NPC", "ANATOMY", 178, 181], ["Ang-(1-7", "CHEMICAL", 11, 19], ["NPC", "DISEASE", 65, 68], ["NPC", "DISEASE", 178, 181], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 11, 19], ["NPC", "CANCER", 65, 68], ["NPC", "CANCER", 178, 181], ["Ang", "TEST", 11, 14], ["a novel preventive agent", "TREATMENT", 32, 56], ["NPC", "PROBLEM", 65, 68], ["recurrent NPC", "PROBLEM", 168, 181], ["autophagic effects", "OBSERVATION", 77, 95]]], ["Moreover, our results suggest that Ang-(1-7) may provide a preventive treatment in NPC with high risk factors associated with family history, salt-cured fish and meet of diet, smoking or alcohol exposures and infection with the Epstein-Barr virus.", [["NPC", "ANATOMY", 83, 86], ["Ang-(1-7", "CHEMICAL", 35, 43], ["NPC", "DISEASE", 83, 86], ["smoking", "CHEMICAL", 176, 183], ["alcohol", "CHEMICAL", 187, 194], ["infection", "DISEASE", 209, 218], ["alcohol", "CHEMICAL", 187, 194], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 35, 43], ["NPC", "CANCER", 83, 86], ["alcohol", "SIMPLE_CHEMICAL", 187, 194], ["Epstein-Barr virus", "ORGANISM", 228, 246], ["Epstein-Barr virus", "SPECIES", 228, 246], ["a preventive treatment", "TREATMENT", 57, 79], ["infection", "PROBLEM", 209, 218], ["the Epstein-Barr virus", "PROBLEM", 224, 246], ["Barr virus", "OBSERVATION", 236, 246]]], ["However, Ang-(1-7) may exert favorable preventive and antitumor activity of NPC or recurrent NPC in clinical, further clinical investigations are needed in our team.DiscussionIn conclusion, pre-treatment with a low dose of Ang-(1-7) inhibited tumor proliferation via autophagy induction mediated by the PI3K/Akt/mTOR pathway.", [["antitumor", "ANATOMY", 54, 63], ["NPC", "ANATOMY", 76, 79], ["NPC", "ANATOMY", 93, 96], ["tumor", "ANATOMY", 243, 248], ["Ang-(1-7)", "CHEMICAL", 9, 18], ["NPC", "DISEASE", 76, 79], ["NPC", "DISEASE", 93, 96], ["Ang-(1-7)", "CHEMICAL", 223, 232], ["tumor", "DISEASE", 243, 248], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 9, 17], ["antitumor", "CANCER", 54, 63], ["NPC", "CANCER", 76, 79], ["NPC", "CANCER", 93, 96], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 223, 231], ["tumor", "CANCER", 243, 248], ["PI3K", "GENE_OR_GENE_PRODUCT", 303, 307], ["Akt", "GENE_OR_GENE_PRODUCT", 308, 311], ["mTOR", "GENE_OR_GENE_PRODUCT", 312, 316], ["PI3K", "PROTEIN", 303, 307], ["Akt", "PROTEIN", 308, 311], ["mTOR", "PROTEIN", 312, 316], ["Ang", "TEST", 9, 12], ["NPC", "PROBLEM", 76, 79], ["recurrent NPC", "PROBLEM", 83, 96], ["further clinical investigations", "TEST", 110, 141], ["a low dose of Ang", "TREATMENT", 209, 226], ["tumor proliferation", "PROBLEM", 243, 262], ["autophagy induction", "TREATMENT", 267, 286], ["Akt/mTOR pathway", "TREATMENT", 308, 324], ["favorable", "OBSERVATION_MODIFIER", 29, 38], ["recurrent", "OBSERVATION_MODIFIER", 83, 92], ["NPC", "OBSERVATION", 93, 96]]], ["Thus, administration of Ang-(1-7) may provide a novel preventive and promising approach for the treatment of NPC or recurrent NPC.", [["NPC", "ANATOMY", 109, 112], ["NPC", "ANATOMY", 126, 129], ["Ang-(1-7)", "CHEMICAL", 24, 33], ["NPC", "DISEASE", 109, 112], ["NPC", "DISEASE", 126, 129], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 24, 32], ["NPC", "CANCER", 109, 112], ["NPC", "CANCER", 126, 129], ["Ang", "TREATMENT", 24, 27], ["the treatment", "TREATMENT", 92, 105], ["NPC", "PROBLEM", 109, 112], ["recurrent NPC", "PROBLEM", 116, 129], ["recurrent", "OBSERVATION_MODIFIER", 116, 125], ["NPC", "OBSERVATION", 126, 129]]]], "2a6241610ed600f734487193921d7e8538f9e283": [["IntroductionWith the prevalence of social media, social platforms like Twitter and Instagram, have become part of our daily lives and played an important role in people's communication.", [["people", "ORGANISM", 162, 168], ["people", "SPECIES", 162, 168]]], ["As a result of the increasing multimodality of social networks, there are more and more multimodal data which combine images and texts in social platforms.", [["social networks", "MULTI-TISSUE_STRUCTURE", 47, 62]]], ["Though providing great conveniences for people communication, multimodal data bring growing challenges for social media analytics.", [["people", "ORGANISM", 40, 46], ["people", "SPECIES", 40, 46]]], ["This paper studies the task of sentiment analysis for social media, which contains both visual and textual contents.", [["sentiment analysis", "TEST", 31, 49], ["social media", "PROBLEM", 54, 66]]], ["Sentiment analysis is a core task of natural language processing, and aims to identify sentiment polarity towards opinions, emotions, and evaluations.", [["Sentiment analysis", "TEST", 0, 18], ["evaluations", "TEST", 138, 149]]], ["Traditional methods [14, 21] for text-only sentiment analysis are mainly statistical methods which highly rely on the quality of feature selection.", [["sentiment analysis", "TEST", 43, 61]]], ["With the rapid development of machine learning techniques and deep neural network, researchers introduce many dedicated methods [7, 13] , which achieve significantly improved results.", [["neural network", "ANATOMY", 67, 81], ["neural network", "MULTI-TISSUE_STRUCTURE", 67, 81], ["machine learning techniques", "TREATMENT", 30, 57], ["deep neural network", "PROBLEM", 62, 81], ["rapid", "OBSERVATION_MODIFIER", 9, 14], ["deep", "ANATOMY_MODIFIER", 62, 66], ["neural network", "ANATOMY", 67, 81]]], ["In contrast to single modality based sentiment analysis, multimodal sentiment analysis attracts more and more attention in recent works [20, 24, 26, 28] .IntroductionHowever, most previous works cannot effectively utilize the relationship and influence between visual and textual information.", [["sentiment analysis", "TEST", 37, 55], ["multimodal sentiment analysis", "TEST", 57, 86]]], ["Nevertheless, the co-memory network only applies a weighted textual/visual vector as the guide to learn attention weights on visual/textual representation.", [["visual/textual representation", "TEST", 125, 154]]], ["It can be seen as a coarse-grained attention mechanism and may cause information loss because attending multiple contents with one attention vector may hide the characteristic of each attended content.", [["information loss", "DISEASE", 69, 85], ["a coarse-grained attention mechanism", "PROBLEM", 18, 54], ["information loss", "PROBLEM", 69, 85], ["one attention vector", "TREATMENT", 127, 147]]], ["Further, the previous studies directly apply multimodal representations for final sentiment classification.", [["the previous studies", "TEST", 9, 29]]], ["However, there is partial redundancy information which may bring confusion and is not beneficial for final sentiment classification.IntroductionThis paper proposes a new architecture, named Fusion-Extraction Network (FENet), to solve the above issues for the task of multimodal sentiment classification.", [["confusion", "DISEASE", 65, 74], ["confusion", "PROBLEM", 65, 74], ["a new architecture", "TREATMENT", 164, 182], ["partial", "OBSERVATION_MODIFIER", 18, 25], ["redundancy", "OBSERVATION", 26, 36]]], ["It can focus on the relevant parts of texts and images, and fuse the most useful information for both single modality.", [["images", "TEST", 48, 54]]], ["Second, a gated convolution mechanism is introduced to extract informative features and generate expressive representation vectors.", [["a gated convolution mechanism", "PROBLEM", 8, 37]]], ["The powerful capability of Convolution Neural Networks (CNNs) for image classification has been verified [8, 19] .", [["Convolution Neural Networks", "PROTEIN", 27, 54], ["image classification", "TEST", 66, 86]]], ["It is a common way that applying CNNs to extract relativeness of different regions of an image.", [["CNNs", "TREATMENT", 33, 37], ["an image", "TEST", 86, 94]]], ["For textual information, it deserves to be pointed out that CNNs also have strong ability to process [25] .", [["CNNs", "SIMPLE_CHEMICAL", 60, 64]]], ["CNNs have been observed that they are capable of extracting the informative n-gram features as sentence representations [10] .", [["CNNs", "CELL_TYPE", 0, 4]]], ["Thus, the convolution mechanism is quite suitable for the extraction task in the multimodal sentiment classification.", [["the extraction task", "TREATMENT", 54, 73]]], ["Meanwhile, we argue that there should be a mechanism controlling how much part of each multimodal representation can flow to the final sentiment classification procedure.", [["classification procedure", "TREATMENT", 145, 169]]], ["The proposed gate architecture mechanism plays the role to modulate the proportion of multimodal features.", [["gate architecture", "OBSERVATION", 13, 30], ["multimodal features", "OBSERVATION", 86, 105]]], ["The experimental results on two public multimodal sentiment datasets show that FENet outperforms existing state-of-the-art methods.IntroductionThe contributions of our work are as follows:Introduction\u2022 We introduce an Interactive Information Fusion (IIF) mechanism to learn fine-grained fusion features.", [["FENet", "PROTEIN", 79, 84], ["grained fusion features", "PROBLEM", 279, 302], ["fusion", "OBSERVATION", 287, 293]]], ["IIF is based on cross-modality attention mechanisms, aiming to generate the visual-specific textual representation and the textual-specific visual representation for both two modality contents. \u2022 We propose a Specific Information Extraction (SIE) mechanism to extract the informative features for textual and visual information, and leverage the extracted visual and textual information for sentiment prediction.", [["IIF", "PROTEIN", 0, 3], ["IIF", "TEST", 0, 3]]], ["To the best of our knowledge, no CNN-gated extraction mechanism for both textual and visual information has been proposed in the field of multimodal sentiment analysis so far.Related WorkVarious approaches [1, 4, 5] have been proposed to model sentiment from textonly data.", [["multimodal sentiment analysis", "TEST", 138, 167]]], ["With the prevalence of multimodal user-generated contents in social network sites, multimodal sentiment analysis becomes an emerging research field which combines textual and non-textual information.", [["network sites", "MULTI-TISSUE_STRUCTURE", 68, 81], ["multimodal sentiment analysis", "TEST", 83, 112]]], ["However, these feature-based methods highly depend on the laborious feature engineering, and fail to model the relation between visual and textual information, which is critical for multimodal sentiment analysis.Related WorkWith the development of deep learning, deep neural networks have been employed for multimodal sentiment classification.", [["neural networks", "ANATOMY", 268, 283], ["neural networks", "MULTI-TISSUE_STRUCTURE", 268, 283], ["multimodal sentiment analysis", "TEST", 182, 211], ["deep learning, deep neural networks", "PROBLEM", 248, 283], ["deep", "ANATOMY_MODIFIER", 248, 252], ["deep", "ANATOMY_MODIFIER", 263, 267], ["neural", "ANATOMY", 268, 274]]], ["Cai et al. [3] and Yu et al. [27] use CNN-based networks to extract feature representations from texts and images, and achieve significant progress.", [["CNN", "PROTEIN", 38, 41], ["images", "TEST", 107, 113]]], ["In order to model the relatedness between text and image, Xu et al. [22] extract scene and object features from image, and absorb text words with these visual semantic features.", [["image", "TEST", 112, 117]]], ["However, they only consider the visual information for textual representation, and ignore the mutual promotion of text and image.", [["textual representation", "TEST", 55, 77]]], ["Thus, Xu et al. [23] propose a co-memory attentional mechanism to interactively model the interaction between text and image.", [["a co-memory attentional mechanism", "TREATMENT", 29, 62]]], ["Though taking the mutual influence of text and image into consideration, Xu et al. [23] adopt a coarsegrained attention mechanism which may not have enough capacity to extract sufficient information.", [["a coarsegrained attention mechanism", "TREATMENT", 94, 129]]], ["Instead, our model applies a fine-grained information fusion layer, and introduces an information extraction layer to extract and leverage visual and textual information for sentiment prediction.Our ModelGiven a text-image pair (T, I), where T = {T 1 , T 2 , . . . , T M } and I is a single image, the goal of our model is to predict the sentiment label y \u2208 {positive, neutral, negative} towards the text-image pair.Our ModelThe overall architecture of the proposed FENet is shown in Fig. 1 .", [["FENet", "DNA", 466, 471], ["a single image", "TEST", 282, 296]]], ["The bottom layer includes a text encoding layer and an image encoding layer, which transforms the textOur Modeland transforms image to a fixed size vector separately, where d w denotes the dimensions of the word embeddings.", [["a text encoding layer", "TREATMENT", 26, 47], ["an image encoding layer", "TREATMENT", 52, 75], ["a fixed size vector", "TREATMENT", 135, 154], ["bottom", "OBSERVATION_MODIFIER", 4, 10], ["layer", "OBSERVATION_MODIFIER", 11, 16], ["layer", "OBSERVATION_MODIFIER", 42, 47], ["layer", "OBSERVATION_MODIFIER", 70, 75], ["size", "OBSERVATION_MODIFIER", 143, 147], ["word embeddings", "OBSERVATION", 207, 222]]], ["The middle part of our model is an interactive information fusion (IIF) layer simultaneously used to interactively learn cross-modality fusion for text and image.", [["cross-modality fusion", "TREATMENT", 121, 142], ["image", "TEST", 156, 161], ["middle", "ANATOMY_MODIFIER", 4, 10]]], ["The IIF layer contains a fine-grained attention mechanism and identity mapping [9] , which allows fuse one modality information with another modality data and learns more specific features.", [["identity mapping", "TEST", 62, 78], ["another modality data", "TEST", 133, 154], ["layer", "OBSERVATION_MODIFIER", 8, 13], ["fine", "OBSERVATION_MODIFIER", 25, 29]]], ["The top part is a specific information extraction (SIE) layer, which consists of two gated convolution layers and a max-pooling layer.", [["top", "OBSERVATION_MODIFIER", 4, 7], ["convolution", "OBSERVATION_MODIFIER", 91, 102], ["layers", "OBSERVATION_MODIFIER", 103, 109], ["layer", "OBSERVATION_MODIFIER", 128, 133]]], ["The SIE layer first utilizes convolution to extract informative features, and then selectively adjusts and generates expressive representations with gate mechanisms and a max-pooling layer.", [["gate mechanisms", "TREATMENT", 149, 164], ["a max-pooling layer", "TREATMENT", 169, 188]]], ["Finally, the visual-specific textual representation and the textual-specific visual representation from the SIE layer are concatenated for sentiment classification.Text Encoding LayerThe function of the text encoding layer is mapping each word into a low dimensional, continuous and real-valued vector, also known as word embedding.", [["SIE layer", "ANATOMY", 108, 117], ["SIE layer", "CANCER", 108, 117], ["Layer", "OBSERVATION_MODIFIER", 178, 183], ["low dimensional", "OBSERVATION_MODIFIER", 251, 266]]], ["Traditional word embedding can be treated as parameters of neural networks or pretrained from proper corpus via unsupervised methods such as Glove [17] .", [["neural networks", "ANATOMY", 59, 74], ["corpus", "ANATOMY", 101, 107], ["neural networks", "MULTI-TISSUE_STRUCTURE", 59, 74], ["corpus", "MULTI-TISSUE_STRUCTURE", 101, 107], ["Traditional word embedding", "TREATMENT", 0, 26], ["neural networks", "TREATMENT", 59, 74]]], ["We applies Glovebased embedding for basic embedding and BERT-based embedding for extension embedding.", [["Glovebased embedding", "TREATMENT", 11, 31], ["basic embedding", "TREATMENT", 36, 51], ["BERT-based embedding", "TREATMENT", 56, 76], ["extension embedding", "TREATMENT", 81, 100]]], ["The model variants are named FENet-Glove and FENet-BERT, respectively.Text Encoding Layer\u2022 FENet-Glove.", [["FENet-Glove and FENet-BERT", "DNA", 29, 55], ["model variants", "OBSERVATION", 4, 18]]], ["It applies Glove as the basic embedding to obtain the word embedding of each word.", [["Glove", "TREATMENT", 11, 16]]], ["Specifically, we employ a word embedding matrix L \u2208 R dw\u00d7|V | to preserve all the word vectors, where d w is the dimension of word vector and |V | is the vocabulary size.", [["vocabulary", "OBSERVATION_MODIFIER", 154, 164], ["size", "OBSERVATION_MODIFIER", 165, 169]]], ["The word embedding of a word w i can be notated as l \u2208 R dw , which is a column of the embedding matrix L. \u2022 FENet-BERT.", [["FENet", "DNA", 109, 114], ["BERT", "DNA", 115, 119]]], ["It uses BERT as the extension embedding to obtain the word representation of each word.", [["BERT", "DNA", 8, 12], ["the extension embedding", "TREATMENT", 16, 39]]], ["Specifically, we use the last layer of BERT-base 1 to obtain a fixed-dimensional representation sequence of the input sequence.Image Encoding LayerGiven an image I p , where I p indicates the image I rescaled to 224 \u00d7 224 pixels, we use Convolutional Neural Networks (CNNs) to obtain the representations of images.", [["BERT", "PROTEIN", 39, 43], ["Convolutional Neural Networks", "PROTEIN", 237, 266], ["the input sequence", "TEST", 108, 126], ["images", "TEST", 307, 313]]], ["Specifically, the visual embedding V is obtained from the last convolutional layer of ResNet152 2 [8] pretrained on ImageNet [18] classification.", [["Res", "CHEMICAL", 86, 89]]], ["2048 denotes the number of feature maps, 7 \u00d7 7 means the shape of each feature maps.", [["feature maps", "TEST", 27, 39]]], ["We then flatten each feature map into 1-D feature vector v i corresponded to a part of an image.Interactive Information Fusion LayerThe above encoding representation only considers their single modality, and the attention mechanism is often applied to capture the interactions between different modality representations.", [["an image", "TEST", 87, 95], ["flatten", "OBSERVATION_MODIFIER", 8, 15], ["1-D feature", "OBSERVATION_MODIFIER", 38, 49]]], ["However, previous works [22, 23] adopt coarsegrained attention which may cause information loss, as the text contains multiple words and the image presentation contains multiple feature maps.", [["information loss", "PROBLEM", 79, 95]]], ["In contrast, as shown in the middle part of Fig. 1 , we adopt the IIF layer to solve this problem and the detail of the IIF mechanism is shown in Fig. 2(a) .", [["IIF", "PROTEIN", 120, 123], ["the IIF mechanism", "TEST", 116, 133], ["middle", "ANATOMY_MODIFIER", 29, 35], ["Fig", "OBSERVATION", 44, 47]]], ["Specifically, given a target input S = {S 1 , S 2 , . . . , S n } \u2208 R ds\u00d7n and an auxiliary input A = {A 1 , A 2 , . . . , A l } \u2208 R da\u00d7l , we first project the target input S and the auxiliary input A into the same shared space.", [["a target input S", "TEST", 20, 36], ["A l } \u2208 R da\u00d7l", "PROBLEM", 123, 137]]], ["The projecting process can be depicted as follows:Interactive Information Fusion Layerwhere For each row of M , a softmax function is applied for quantifying the importance of each piece of auxiliary input to a specific piece of target input as follows:Interactive Information Fusion LayerThen, the fine-grained attention output F is formulated as follows:Interactive Information Fusion Layerwhere F \u2208 R da\u00d7n and \"\u00b7\" denotes matrix multiplication.", [["matrix", "ANATOMY", 425, 431], ["matrix", "CELLULAR_COMPONENT", 425, 431]]], ["Finally, the concatenation of the target input S and the fine-grained attention output F is fed into a full connection layer to obtain the specific representation G = {G 1 , G 2 , . . . , G n } of the target input:Interactive Information Fusion Layerwhere G i \u2208 R ds and W g \u2208 R ds\u00d7(ds+da) .", [["a full connection layer", "TREATMENT", 101, 124], ["G", "TEST", 163, 164]]], ["Thus, the overall process of IIF can be summarized as follows:Interactive Information Fusion LayerTherefore, the textual-specific visual representation V g and the visual-specific textual representation X g are obtained as follows:Specific Information Extraction LayerAfter interactively fusing two modality information, we need to extract the most informative representation and control the proportion contributing to the final sentiment classification.", [["IIF", "PROTEIN", 29, 32]]], ["As shown in the top part of Fig. 1 , we introduce the SIE layer for this task and the details of the SIE layer is depicted in Fig. 2(b) .", [["SIE layer", "ANATOMY", 101, 110], ["this task", "TREATMENT", 68, 77]]], ["The SIE layer is based on convolutional layers and gated units.", [["convolutional layers and gated units", "TREATMENT", 26, 62], ["layer", "OBSERVATION_MODIFIER", 8, 13]]], ["Given a padded input vector Q = {q 1 , q 2 , . . . , q k } \u2208 R dq\u00d7k , we pass it through the SIE layer to get the final representation.", [["a padded input vector", "TREATMENT", 6, 27]]], ["First, n k one dimensional convolutional kernel pairs are applied to capture the active local features.", [["the active local features", "PROBLEM", 77, 102], ["kernel pairs", "OBSERVATION", 41, 53], ["active", "OBSERVATION_MODIFIER", 81, 87], ["local features", "OBSERVATION", 88, 102]]], ["Each kernel corresponds a feature detector which extracts a specific pattern of active local features [11] .", [["active local features", "PROBLEM", 80, 101], ["specific", "OBSERVATION_MODIFIER", 60, 68], ["pattern", "OBSERVATION_MODIFIER", 69, 76], ["active", "OBSERVATION_MODIFIER", 80, 86], ["local", "OBSERVATION_MODIFIER", 87, 92]]], ["However, there are differences within the kernel pairs for their different nonlinearity activation function.", [["different", "OBSERVATION_MODIFIER", 65, 74], ["nonlinearity activation function", "OBSERVATION", 75, 107]]], ["The first kernel of kernel pairs is adopted to transform the information and obtain informative representation.", [["kernel pairs", "DNA", 20, 32]]], ["While the second kernel of kernel pairs is a gate which controls the proportion of the result of the first kernel flowing to the final representation.", [["kernel pairs", "DNA", 27, 39]]], ["Specifically, a convolution kernel pair of W a and W b maps r columns in the receptive field to a single feature a and b with tanh and sigmoid activation function, respectively. e is the result of multiplication of a and b, which stands for the representation after extraction and adjustment.", [["a convolution kernel pair", "TEST", 14, 39], ["a and W b maps r columns", "TREATMENT", 45, 69], ["extraction", "TREATMENT", 266, 276], ["adjustment", "TREATMENT", 281, 291], ["sigmoid", "ANATOMY", 135, 142]]], ["As the filter slide across the whole sentence, a sequence of new feature e = {e 1 , e 2 , . . . , e k\u2212r+1 } is obtained by:Specific Information Extraction Layerwhere W a , W b \u2208 R dq\u00d7r are weights of the convolution kernel pair, and b a , b b \u2208 R are bias of the convolution kernel pair. \" * \" denotes the convolution operation.", [["new feature e", "TEST", 61, 74], ["the convolution operation", "TREATMENT", 302, 327], ["filter", "OBSERVATION", 7, 13]]], ["As there are n k kernel pairs, the output features can form a matrix E \u2208 R (k\u2212r+1)\u00d7n k .", [["the output features", "TEST", 31, 50], ["a matrix E", "TEST", 60, 70], ["k\u2212r", "TEST", 76, 79]]], ["Finally, we apply a max-pooling layer to obtain the most informative features for each convolution kernel pair, which results in a fixedsize vector z whose size is equal to the number of filter pairs n k as follows:Specific Information Extraction LayerThe above process can be summarized as follows:Specific Information Extraction LayerWe treat V g and X g as the input of SIE to obtain the final visual and textual representation, respectively.", [["SIE", "DNA", 373, 376], ["a max-pooling layer", "TREATMENT", 18, 37], ["size", "OBSERVATION_MODIFIER", 156, 160], ["Layer", "OBSERVATION_MODIFIER", 247, 252]]], ["The process is formulated as follows:Output LayerAfter obtaining the final feature representation vectors for image and text, we concatenate them as the input of a fully connected layer for classification:Output Layerwhere W p \u2208 R class\u00d72n k and b p \u2208 R class are learnable parameters.Datasets and SettingsDatasets.", [["Output", "TEST", 205, 211], ["b p \u2208 R class", "TREATMENT", 246, 259], ["SettingsDatasets", "TREATMENT", 298, 314]]], ["We use MVSA-Single and MVSA-Multiple [15] two datasets.", [["MVSA", "TEST", 7, 11], ["MVSA", "TEST", 23, 27]]], ["The former contains 5129 text-image pairs from Twitter and is labeled by a single annotator.", [["5129 text-image pairs", "DNA", 20, 41]]], ["For fair comparison, we process the original two MVSA datasets on the same way used in [22, 23] .", [["MVSA datasets", "DNA", 49, 62]]], ["We randomly split the datasets into training set, validation set and test set by using the split ratio 8:1:1.Datasets and SettingsTokenization.", [["validation set and test set", "TEST", 50, 77]]], ["On the one hand, to tokenize the sentences for Glove-based embedding method, we apply the same rule as [16] , except we separate the tag '@' and '#' with the words after.", [["Glove-based embedding method", "TREATMENT", 47, 75]]], ["On the other hand, we use the WordPiece tokenization introduced in [6] for BERT-based embedding method.", [["the WordPiece tokenization", "TREATMENT", 26, 52], ["BERT-based embedding method", "TREATMENT", 75, 102]]], ["To initialize words as vectors, FENet-Glove uses the 300-dimensional pretrained Glove embeddings, and FENet-BERT applies 768dimensional pretrained BERT embeddings which contains 110M parameters.", [["FENet", "DNA", 32, 37], ["300-dimensional pretrained Glove embeddings", "DNA", 53, 96], ["FENet", "DNA", 102, 107], ["BERT", "DNA", 108, 112], ["FENet", "TREATMENT", 32, 37], ["Glove", "TREATMENT", 38, 43], ["Glove embeddings", "TREATMENT", 80, 96], ["FENet", "TREATMENT", 102, 107]]], ["Pretrained CNNs.", [["CNNs", "CELL_TYPE", 11, 15]]], ["We use the pretrained ResNet152 [8] from Pytorch.", [["Res", "CHEMICAL", 22, 25]]], ["Learning rate is set to 1e\u22123 and 2e\u22125 for Glove-based and BERT-based embedding, respectively.", [["BERT", "DNA", 58, 62], ["Learning rate", "TREATMENT", 0, 13], ["Glove", "TREATMENT", 42, 47]]], ["We list the hyper-parameters during our training process in Table 1 .", [["our training process", "TREATMENT", 36, 56], ["hyper", "OBSERVATION", 12, 17]]], ["All hyper-parameters are tuned on the validation set, and the hyperparameters collection producing the highest accuracy score is used for testing.Compared MethodsWe compare with the following baseline methods on MVSA datasets.", [["the hyperparameters collection", "PROBLEM", 58, 88], ["testing", "TEST", 138, 145], ["hyper", "OBSERVATION", 4, 9]]], ["SentiBank & SentiStrength [2] extracts 1200 adjective-noun pairs as the middle-level features of image and calculates the sentiment scores based on English grammar and spelling style of texts.", [["SentiBank", "TEST", 0, 9]]], ["CNN-Multi [3] learns textual features and visual features by applying two individual CNN, and uses another CNN to exploiting the internal relation between text and image for sentiment classification.", [["CNN", "PROTEIN", 85, 88], ["CNN", "PROTEIN", 107, 110], ["visual features", "PROBLEM", 42, 57]]], ["DNN-LR [27] trains a CNN for text and employs a deep convolutional neural network for image, and uses average strategy to aggregate probabilistic results which is the output of logistics regression.Compared MethodsMultiSentiNet [22] extracts deep semantic features of images and introduces a visual feature attention LSTM model to absorb the text words with these visual semantic features.", [["neural network", "MULTI-TISSUE_STRUCTURE", 67, 81], ["DNN", "PROTEIN", 0, 3], ["images", "TEST", 268, 274]]], ["CoMN [23] proposes a memory network to iteratively model the interactions between visual contents and textual words for sentiment prediction.Compared MethodsBesides, this paper also presents two ablations of FENet to evaluate the contribution of our components.", [["CoMN", "CHEMICAL", 0, 4], ["FENet", "TREATMENT", 208, 213]]], ["As shown in Table 2 , we have the following observations.Results and Analysis(1) SentiBank & SentiStrength is the worst since it only uses traditional statistical features to present image and text multimodality information, which can not make full of the high-level characteristic of multimodal data.", [["Analysis", "TEST", 69, 77]]], ["Both CNN-Multi and DNN-LR are better than SentiBank & Sen-tiStrength and achieve close performances by applying CNN architecture to learn two modality representation.", [["CNN", "GENE_OR_GENE_PRODUCT", 5, 8], ["DNN-LR", "GENE_OR_GENE_PRODUCT", 19, 25], ["CNN-Multi and DNN-LR", "DNA", 5, 25], ["LR", "TREATMENT", 23, 25], ["LR", "ANATOMY", 23, 25]]], ["CoMN is slightly better than MultiSentiNet because Mul-tiSentiNet only considers the single-direction influence of image to text and ignores the mutual reinforcing and complementary characteristics between visual and textual information.", [["CoMN", "PROTEIN", 0, 4], ["slightly", "OBSERVATION_MODIFIER", 8, 16], ["better", "OBSERVATION", 17, 23]]], ["However, CoMN employs the coarse-grained attention mechanism which may cause information loss, and directly uses redundant textual and visual representations for final sentiment classification.", [["CoMN", "CHEMICAL", 9, 13], ["CoMN", "PROTEIN", 9, 13]]], ["In contrast, FENet applies an information-fusion layer based on finegrained attention mechanisms, and leverages visual and textual information for sentiment prediction by adopting an information extraction layer.", [["FENet", "PROTEIN", 13, 18], ["an information-fusion layer", "TREATMENT", 27, 54]]], ["Thus, FENet variants perform better than CoMN and achieves a new state-ofthe-art performance.", [["FENet", "GENE_OR_GENE_PRODUCT", 6, 11], ["FENet variants", "CELL_LINE", 6, 20]]], ["Figure 3 shows a example of visual and textual attention visualization.", [["visual and textual attention visualization", "TEST", 28, 70]]], ["As shown in Fig. 3(b) , our model pay more attention to the head and seat of broken car according to the sentence context.", [["head", "ANATOMY", 60, 64], ["head", "ORGANISM_SUBDIVISION", 60, 64], ["head", "ANATOMY", 60, 64]]], ["Thus, our model correctly catches the important parts of text and image, and predicts the sentiment of this sample as negative.ConclusionThis paper proposes FENet for sentiment analysis in multimodal social media.", [["image", "TEST", 66, 71], ["this sample", "TEST", 103, 114], ["sentiment analysis", "TEST", 167, 185]]], ["Compared with the previous works, we employ a fine-grained attention mechanism to effectively extract the relationship and influence between text and image.", [["image", "TEST", 150, 155]]], ["Besides, we explore a new approach based on gated convolution mechanisms to extract and leverage visual and textual information for sentiment prediction.", [["a new approach", "TREATMENT", 20, 34], ["sentiment prediction", "TEST", 132, 152]]]], "32d5b5c7b38c1dd14b316de97bce86e5ab252f91": [["BackgroundDengue is a serious disease of public importance with increasing worldwide spread.", [["BackgroundDengue", "DISEASE", 0, 16], ["a serious disease of public importance", "PROBLEM", 20, 58], ["increasing worldwide spread", "PROBLEM", 64, 91], ["serious", "OBSERVATION_MODIFIER", 22, 29], ["increasing", "OBSERVATION_MODIFIER", 64, 74], ["worldwide", "OBSERVATION_MODIFIER", 75, 84], ["spread", "OBSERVATION_MODIFIER", 85, 91]]], ["It is caused by an infection with any one of the four antigenically distinct dengue virus serotypes (DENV1-4).", [["infection", "DISEASE", 19, 28], ["dengue", "DISEASE", 77, 83], ["dengue virus serotypes", "ORGANISM", 77, 99], ["DENV1-4", "CELL", 101, 108], ["dengue virus serotypes", "SPECIES", 77, 99], ["dengue virus", "SPECIES", 77, 89], ["an infection", "PROBLEM", 16, 28], ["the four antigenically distinct dengue virus serotypes", "PROBLEM", 45, 99], ["infection", "OBSERVATION", 19, 28], ["distinct", "OBSERVATION_MODIFIER", 68, 76], ["dengue virus serotypes", "OBSERVATION", 77, 99]]], ["Current diagnosis of an acute DENV infection primarily relies on reverse transcription polymerase chain reaction (RT-PCR), a highly sophisticated test.", [["DENV infection", "DISEASE", 30, 44], ["DENV", "SPECIES", 30, 34], ["an acute DENV infection", "PROBLEM", 21, 44], ["reverse transcription polymerase chain reaction", "PROBLEM", 65, 112], ["RT-PCR", "TEST", 114, 120], ["acute", "OBSERVATION_MODIFIER", 24, 29], ["DENV", "OBSERVATION_MODIFIER", 30, 34], ["infection", "OBSERVATION", 35, 44]]], ["To improve dengue case detection in dengue endemic countries, a highly sensitive, specific and simple rapid assay is needed to provide early support for patients and to accurately differentiate dengue from other acute febrile illnesses.", [["dengue", "DISEASE", 11, 17], ["dengue", "DISEASE", 36, 42], ["dengue", "DISEASE", 194, 200], ["febrile illnesses", "DISEASE", 218, 235], ["patients", "ORGANISM", 153, 161], ["patients", "SPECIES", 153, 161], ["dengue", "SPECIES", 11, 17], ["dengue", "SPECIES", 36, 42], ["dengue", "SPECIES", 194, 200], ["dengue endemic countries", "PROBLEM", 36, 60], ["simple rapid assay", "TEST", 95, 113], ["dengue", "PROBLEM", 194, 200], ["other acute febrile illnesses", "PROBLEM", 206, 235], ["acute", "OBSERVATION_MODIFIER", 212, 217]]], ["DENV non-structural protein 1 (NS1) is a unique diagnostic marker for early detection of DENV compared to serological tests (i.e., anti-DENV IgM) because it is detected in the serum of DENV-infected patients as early as one day post onset of symptoms (DPO) to 18 DPO at concentration up to 50 \u03bcg/ml and it is a confirmatory test [1] .", [["serum", "ANATOMY", 176, 181], ["DENV-infected", "DISEASE", 185, 198], ["DPO", "CHEMICAL", 263, 266], ["DENV non-structural protein 1", "GENE_OR_GENE_PRODUCT", 0, 29], ["NS1", "GENE_OR_GENE_PRODUCT", 31, 34], ["DENV", "ORGANISM", 89, 93], ["anti-DENV IgM", "GENE_OR_GENE_PRODUCT", 131, 144], ["serum", "ORGANISM_SUBSTANCE", 176, 181], ["DENV", "ORGANISM", 185, 189], ["patients", "ORGANISM", 199, 207], ["DENV non-structural protein 1", "PROTEIN", 0, 29], ["NS1", "PROTEIN", 31, 34], ["anti-DENV IgM", "PROTEIN", 131, 144], ["patients", "SPECIES", 199, 207], ["DENV", "SPECIES", 0, 4], ["DENV", "SPECIES", 89, 93], ["anti-DENV", "SPECIES", 131, 140], ["DENV", "SPECIES", 185, 189], ["DENV non-structural protein", "TEST", 0, 27], ["DENV", "PROBLEM", 89, 93], ["serological tests", "TEST", 106, 123], ["anti-DENV IgM", "TEST", 131, 144], ["DENV", "PROBLEM", 185, 189], ["symptoms", "PROBLEM", 242, 250], ["a confirmatory test", "TEST", 309, 328], ["non-structural protein", "OBSERVATION", 5, 27], ["DENV", "OBSERVATION", 89, 93], ["DENV", "OBSERVATION", 185, 189], ["infected", "OBSERVATION", 190, 198]]], ["Whereas anti-DENV IgM is not present until five days after illness onset, can cross react with other flaviviruses thus not considered a confirmatory test especially in regions where multiple flaviviruses co-circulate.", [["anti-DENV IgM", "GENE_OR_GENE_PRODUCT", 8, 21], ["flaviviruses", "ORGANISM", 191, 203], ["anti-DENV IgM", "PROTEIN", 8, 21], ["anti-DENV", "SPECIES", 8, 17], ["other flaviviruses", "PROBLEM", 95, 113], ["a confirmatory test", "TEST", 134, 153], ["multiple flaviviruses co-circulate", "PROBLEM", 182, 216], ["IgM", "OBSERVATION", 18, 21], ["multiple", "OBSERVATION_MODIFIER", 182, 190], ["flaviviruses", "OBSERVATION", 191, 203]]], ["NS1 is highly conserved glycoprotein and possesses both group-specific and serotype-specific epitopes hence it can discern DENV from other flaviviruses and has the potential to differentiate between DENV serotypes [2] .BackgroundRapid tests such as the NS1 enzyme-linked immunosorbent assay (ELISA) are commercially available for DENV with relatively good sensitivity and specificity [3] .BackgroundRecently several studies have critically evaluated the performance of the current commercial NS1 ELISA kits by DENV serotype.", [["NS1", "GENE_OR_GENE_PRODUCT", 0, 3], ["DENV", "ORGANISM", 123, 127], ["DENV", "ORGANISM", 330, 334], ["NS1", "GENE_OR_GENE_PRODUCT", 492, 495], ["NS1", "PROTEIN", 0, 3], ["glycoprotein", "PROTEIN", 24, 36], ["serotype-specific epitopes", "PROTEIN", 75, 101], ["NS1 enzyme", "PROTEIN", 253, 263], ["NS1", "PROTEIN", 492, 495], ["DENV", "SPECIES", 123, 127], ["DENV", "SPECIES", 199, 203], ["DENV", "SPECIES", 330, 334], ["DENV", "SPECIES", 510, 514], ["NS1", "PROBLEM", 0, 3], ["serotype-specific epitopes", "TREATMENT", 75, 101], ["DENV", "PROBLEM", 123, 127], ["other flaviviruses", "PROBLEM", 133, 151], ["DENV serotypes", "PROBLEM", 199, 213], ["BackgroundRapid tests", "TEST", 219, 240], ["the NS1 enzyme", "TEST", 249, 263], ["immunosorbent assay", "TEST", 271, 290], ["DENV", "PROBLEM", 330, 334], ["DENV serotype", "PROBLEM", 510, 523]]], ["Results from these studies showed that these tests had lower sensitivity for the detection of DENV-4.", [["DENV-4", "ORGANISM", 94, 100], ["DENV-4", "SPECIES", 94, 100], ["these studies", "TEST", 13, 26], ["these tests", "TEST", 39, 50], ["the detection", "TEST", 77, 90], ["DENV", "PROBLEM", 94, 98], ["DENV", "OBSERVATION", 94, 98]]], ["Additionally, these commercial tests had decreased sensitivity in detecting secondary dengue infections, common in dengue endemic countries [3] [4] [5] [6] [7] [8] [9] .", [["dengue infections", "DISEASE", 86, 103], ["dengue", "DISEASE", 115, 121], ["[3] [4] [5] [6] [7] [8]", "CHEMICAL", 140, 163], ["[3] [4] [5] [6] [7] [8] [9]", "SIMPLE_CHEMICAL", 140, 167], ["dengue", "SPECIES", 86, 92], ["these commercial tests", "TEST", 14, 36], ["decreased sensitivity", "PROBLEM", 41, 62], ["secondary dengue infections", "PROBLEM", 76, 103], ["secondary", "OBSERVATION_MODIFIER", 76, 85], ["dengue infections", "OBSERVATION", 86, 103]]], ["Commercially available NS1 antigen (Ag) tests manufactured by BioRad (Platelia) and Panbio (Dengue Early) both have low sensitivity to DENV-4 infections [8, [10] [11] [12] .", [["Ag", "CHEMICAL", 36, 38], ["infections", "DISEASE", 142, 152], ["Ag", "CHEMICAL", 36, 38], ["NS1 antigen", "GENE_OR_GENE_PRODUCT", 23, 34], ["DENV-4", "ORGANISM", 135, 141], ["NS1 antigen", "PROTEIN", 23, 34], ["Ag", "PROTEIN", 36, 38], ["DENV-4", "SPECIES", 135, 141], ["low sensitivity", "PROBLEM", 116, 131], ["DENV", "PROBLEM", 135, 139]]], ["Previous evaluations of Dengue Early test showed a sensitivity as low as 19% for DENV4 [6, 8, [13] [14] [15] .", [["Dengue", "DISEASE", 24, 30], ["DENV4", "CHEMICAL", 81, 86], ["Dengue", "ORGANISM", 24, 30], ["Previous evaluations", "TEST", 0, 20], ["Dengue Early test", "TEST", 24, 41], ["a sensitivity", "TEST", 49, 62], ["DENV4", "TEST", 81, 86]]], ["Although the overall sensitivity of Platelia test was good however when comparing the sensitivities between all DENV serotypes, the BioRad test had the lowest sensitivity for DENV-4 (58.3%) [10] .BackgroundOur rationale to develop a DENV4 ELISA was due to the limited sensitivity of NS1 tests for detection DENV-4 infections.", [["infections", "DISEASE", 314, 324], ["NS1", "ORGANISM", 283, 286], ["DENV-4", "ORGANISM", 307, 313], ["NS1", "PROTEIN", 283, 286], ["DENV", "SPECIES", 112, 116], ["DENV-4", "SPECIES", 175, 181], ["DENV-4", "SPECIES", 307, 313], ["Platelia test", "TEST", 36, 49], ["the sensitivities", "TEST", 82, 99], ["all DENV serotypes", "PROBLEM", 108, 126], ["the BioRad test", "TEST", 128, 143], ["DENV", "TEST", 175, 179], ["a DENV4 ELISA", "TEST", 231, 244], ["NS1 tests", "TEST", 283, 292], ["DENV", "PROBLEM", 307, 311], ["4 infections", "PROBLEM", 312, 324]]], ["Recent evaluation study using retrospective samples from South America showed lower sensitivity of seven commercially available NS1 Ag tests for DENV-4 compared to the other three serotypes [7] .", [["Ag", "CHEMICAL", 132, 134], ["NS1", "ORGANISM", 128, 131], ["DENV-4", "ORGANISM", 145, 151], ["NS1 Ag", "PROTEIN", 128, 134], ["DENV-4", "SPECIES", 145, 151], ["Recent evaluation study", "TEST", 0, 23], ["retrospective samples", "TEST", 30, 51], ["NS1 Ag tests", "TEST", 128, 140], ["DENV", "PROBLEM", 145, 149]]], ["Also, metaanalysis for DENV detection in Asia showed the lowest sensitivity of the commercial NS1 Ag tests was against DENV-4 detection [16] .", [["NS1 Ag", "CHEMICAL", 94, 100], ["Ag", "CHEMICAL", 98, 100], ["NS1", "ORGANISM", 94, 97], ["DENV-4", "ORGANISM", 119, 125], ["NS1 Ag", "PROTEIN", 94, 100], ["DENV", "SPECIES", 23, 27], ["DENV-4", "SPECIES", 119, 125], ["DENV detection", "TEST", 23, 37], ["the commercial NS1 Ag tests", "TEST", 79, 106], ["DENV", "PROBLEM", 119, 123]]], ["Further, studies conducted in Brazil showed the lower sensitivity of Platelia NS1 Ag ELISA (BioRad) for DENV4 detection [13, 14] .", [["Ag", "CHEMICAL", 82, 84], ["Platelia NS1 Ag", "PROTEIN", 69, 84], ["DENV4", "PROTEIN", 104, 109], ["Further, studies", "TEST", 0, 16], ["DENV4 detection", "TEST", 104, 119]]], ["Collectively, these data suggest the need for development of new NS1 Ag detection test that incorporates monoclonal antibodies (MAbs) with higher sensitivity to In order to improve the performance of NS1 Ag detection tests with higher sensitivity to DENV-4, it is important to understand why the current NS1 Ag detection tests failed to detect DENV4 infections efficiently.", [["infections", "DISEASE", 350, 360], ["Ag", "CHEMICAL", 69, 71], ["Ag", "CHEMICAL", 204, 206], ["Ag", "CHEMICAL", 308, 310], ["NS1", "ORGANISM", 65, 68], ["NS1", "ORGANISM", 200, 203], ["Ag", "GENE_OR_GENE_PRODUCT", 204, 206], ["DENV-4", "ORGANISM", 250, 256], ["NS1", "ORGANISM", 304, 307], ["Ag", "GENE_OR_GENE_PRODUCT", 308, 310], ["NS1 Ag", "PROTEIN", 65, 71], ["monoclonal antibodies", "PROTEIN", 105, 126], ["MAbs", "PROTEIN", 128, 132], ["NS1", "PROTEIN", 200, 203], ["Ag", "PROTEIN", 204, 206], ["NS1", "PROTEIN", 304, 307], ["Ag", "PROTEIN", 308, 310], ["NS1", "SPECIES", 200, 203], ["DENV4", "SPECIES", 344, 349], ["new NS1 Ag detection test", "TEST", 61, 86], ["monoclonal antibodies", "TEST", 105, 126], ["higher sensitivity", "PROBLEM", 139, 157], ["Ag detection tests", "TEST", 204, 222], ["higher sensitivity to DENV", "PROBLEM", 228, 254], ["Ag detection tests", "TEST", 308, 326], ["DENV4 infections", "PROBLEM", 344, 360], ["infections", "OBSERVATION", 350, 360]]], ["Almost all the present commercial NS1 Ag detection tests are based on cross-reactive anti-NS1 MAbs to all four DENV serotypes due to common epitopes.", [["Ag", "CHEMICAL", 38, 40], ["NS1", "ORGANISM", 34, 37], ["Ag", "GENE_OR_GENE_PRODUCT", 38, 40], ["anti-NS1 MAbs", "GENE_OR_GENE_PRODUCT", 85, 98], ["NS1", "PROTEIN", 34, 37], ["Ag", "PROTEIN", 38, 40], ["anti-NS1 MAbs", "PROTEIN", 85, 98], ["DENV", "SPECIES", 111, 115], ["Ag detection tests", "TEST", 38, 56], ["cross-reactive anti-NS1 MAbs", "TREATMENT", 70, 98], ["all four DENV serotypes", "PROBLEM", 102, 125], ["common epitopes", "PROBLEM", 133, 148]]], ["Epitope mapping studies have identified epitopes LX1 (113-YSWKTWG-119) and LD2 that are common to all four DENV serotype [2, 17, 18] .", [["LX1", "GENE_OR_GENE_PRODUCT", 49, 52], ["113-YSWKTWG-119", "GENE_OR_GENE_PRODUCT", 54, 69], ["LD2", "GENE_OR_GENE_PRODUCT", 75, 78], ["epitopes", "PROTEIN", 40, 48], ["LX1", "PROTEIN", 49, 52], ["113", "PROTEIN", 54, 57], ["LD2", "PROTEIN", 75, 78], ["DENV", "SPECIES", 107, 111], ["Epitope mapping studies", "TEST", 0, 23], ["epitopes LX1", "TEST", 40, 52], ["YSWKTWG", "TEST", 58, 65], ["LD2", "TEST", 75, 78], ["DENV", "OBSERVATION", 107, 111]]], ["Several studies showed the absence of significant amino acid sequence variation in the epitopes of serotype-crossreactive MAbs [2, 19, 20] .", [["amino acid", "CHEMICAL", 50, 60], ["amino acid", "CHEMICAL", 50, 60], ["amino acid", "AMINO_ACID", 50, 60], ["epitopes", "PROTEIN", 87, 95], ["serotype-crossreactive MAbs", "PROTEIN", 99, 126], ["Several studies", "TEST", 0, 15], ["significant amino acid sequence variation", "PROBLEM", 38, 79], ["serotype-crossreactive MAbs", "TEST", 99, 126]]], ["This is consistent with Aryati and colleagues observation that there was no link between NS1 gene (amino acid) sequence variation and the poor performance of Dengue Early (Panbio) for DENV-4 detection [6] .", [["amino acid", "CHEMICAL", 99, 109], ["Dengue", "DISEASE", 158, 164], ["amino acid", "CHEMICAL", 99, 109], ["NS1", "GENE_OR_GENE_PRODUCT", 89, 92], ["amino acid", "AMINO_ACID", 99, 109], ["DENV-4", "ORGANISM", 184, 190], ["NS1 gene", "DNA", 89, 97], ["DENV-4", "SPECIES", 184, 190], ["NS1 gene (amino acid)", "TREATMENT", 89, 110], ["sequence variation", "TEST", 111, 129], ["DENV", "PROBLEM", 184, 188], ["consistent with", "UNCERTAINTY", 8, 23]]], ["Factors other than NS1 gene (and/or amino acid) sequence variation may impact the bio-accessibility and/or binding of the conserved epitopes to MAbs depending on the serotype.", [["amino acid", "CHEMICAL", 36, 46], ["amino acid", "CHEMICAL", 36, 46], ["NS1", "GENE_OR_GENE_PRODUCT", 19, 22], ["amino acid", "AMINO_ACID", 36, 46], ["NS1 gene", "DNA", 19, 27], ["conserved epitopes", "PROTEIN", 122, 140], ["MAbs", "PROTEIN", 144, 148], ["NS1 gene (and/or amino acid)", "TREATMENT", 19, 47], ["the bio-accessibility", "PROBLEM", 78, 99], ["the serotype", "PROBLEM", 162, 174]]], ["For example, the bio-accessibility of the conserved epitopes may vary according to the serotype/genotype when the NS1 protein is folded and assembled to form the NS1 hexamer.", [["NS1", "GENE_OR_GENE_PRODUCT", 114, 117], ["NS1", "GENE_OR_GENE_PRODUCT", 162, 165], ["NS1 protein", "PROTEIN", 114, 125], ["NS1 hexamer", "PROTEIN", 162, 173], ["the conserved epitopes", "PROBLEM", 38, 60], ["the NS1 protein", "TEST", 110, 125]]], ["Hence, this suggest the common linear epitopes targeted by MAbs could be partially accessible on the NS1 hexamer isoform of DENV-4.", [["MAbs", "GENE_OR_GENE_PRODUCT", 59, 63], ["NS1", "GENE_OR_GENE_PRODUCT", 101, 104], ["DENV-4", "ORGANISM", 124, 130], ["MAbs", "PROTEIN", 59, 63], ["NS1 hexamer isoform", "PROTEIN", 101, 120], ["DENV-4", "PROTEIN", 124, 130], ["the common linear epitopes", "PROBLEM", 20, 46], ["DENV", "PROBLEM", 124, 128], ["DENV", "OBSERVATION", 124, 128]]], ["The crystal structure by Akey and colleagues identified 108 linear epitopes that were mapped to the hexamer form of the protein primarily to the wing domain, C-terminal tip of the Beta bladder and Beta roll which are the most exposed epitopes.", [["wing domain", "ANATOMY", 145, 156], ["bladder", "ANATOMY", 185, 192], ["C", "CHEMICAL", 158, 159], ["bladder", "ORGAN", 185, 192], ["Beta roll", "GENE_OR_GENE_PRODUCT", 197, 206], ["wing domain", "PROTEIN", 145, 156], ["C-terminal tip", "PROTEIN", 158, 172], ["Beta bladder and Beta roll", "PROTEIN", 180, 206], ["epitopes", "PROTEIN", 234, 242], ["linear epitopes", "PROBLEM", 60, 75], ["the Beta bladder", "TREATMENT", 176, 192], ["Beta roll", "TREATMENT", 197, 206], ["crystal", "OBSERVATION_MODIFIER", 4, 11], ["terminal", "OBSERVATION_MODIFIER", 160, 168], ["tip", "OBSERVATION_MODIFIER", 169, 172], ["Beta bladder", "ANATOMY", 180, 192], ["Beta roll", "OBSERVATION", 197, 206]]], ["This study also demonstrated that the Beta rolls are most likely unexposed epitopes and the spaghetti loop and glycosylation sites are exposed epitopes [21] .", [["spaghetti loop", "PROTEIN", 92, 106], ["glycosylation sites", "PROTEIN", 111, 130], ["This study", "TEST", 0, 10], ["the Beta rolls", "TREATMENT", 34, 48], ["unexposed epitopes", "PROBLEM", 65, 83], ["the spaghetti loop", "TREATMENT", 88, 106], ["glycosylation sites", "PROBLEM", 111, 130], ["most likely", "UNCERTAINTY", 53, 64], ["spaghetti loop", "OBSERVATION", 92, 106]]], ["Future studies may be able to use the crystal structure predicted exposed epitopes to design novel NS1 immunogenic MAbs.BackgroundTo overcome the current limitations of the MAbs for NS1 tests, we used a small-ubiquitin-like modifier (SUMO) vectorTotal viral RNA was isolated from viral seeds of DENV4 (H421, a prototype strain) infected C6/36 cells (Aedes albopictus cell line, ATCC) using the QIAamp Viral RNA Mini kit (QIAGEN, Gaithersburg, MD, USA), and a complimentary DNA (cDNA) of DENV-4 NS1 gene was reverse transcribed using Super Script III one step reverse transcription polymerase chain reaction (RT PCR) kit (Invitrogen, Carlsbad, CA, USA) and paired primers (forward: 5'-ATACGTCTCTAGGTGACACGGGTTGTGCG GTG-3\u2032) and (reverse; 5'-GCGTCTAGATTAGGCCGA-TACCTGTGATTT-3), according to manufacturer's instructions.", [["seeds", "ANATOMY", 286, 291], ["strain", "ANATOMY", 320, 326], ["C6/36 cells", "ANATOMY", 337, 348], ["cell line", "ANATOMY", 367, 376], ["ATCC", "ANATOMY", 378, 382], ["NS1", "ORGANISM", 99, 102], ["NS1", "GENE_OR_GENE_PRODUCT", 182, 185], ["SUMO", "GENE_OR_GENE_PRODUCT", 234, 238], ["DENV4 (H421", "CELL", 295, 306], ["C6/36 cells", "CELL", 337, 348], ["Aedes albopictus cell line", "CELL", 350, 376], ["ATCC", "CELL", 378, 382], ["DNA", "CELLULAR_COMPONENT", 473, 476], ["DENV-4", "ORGANISM", 487, 493], ["NS1", "ORGANISM", 494, 497], ["NS1 immunogenic MAbs", "PROTEIN", 99, 119], ["NS1", "PROTEIN", 182, 185], ["small-ubiquitin-like modifier (SUMO) vectorTotal viral RNA", "RNA", 203, 261], ["DENV4 (H421, a prototype strain) infected C6/36 cells", "CELL_LINE", 295, 348], ["Aedes albopictus cell line", "CELL_LINE", 350, 376], ["ATCC", "CELL_LINE", 378, 382], ["complimentary DNA", "DNA", 459, 476], ["cDNA", "DNA", 478, 482], ["DENV-4 NS1 gene", "DNA", 487, 502], ["paired primers", "DNA", 656, 670], ["Aedes albopictus", "SPECIES", 350, 366], ["DENV4", "SPECIES", 295, 300], ["Aedes albopictus", "SPECIES", 350, 366], ["DENV-4", "SPECIES", 487, 493], ["Future studies", "TEST", 0, 14], ["the crystal structure", "PROBLEM", 34, 55], ["novel NS1 immunogenic MAbs", "TREATMENT", 93, 119], ["the MAbs", "TEST", 169, 177], ["NS1 tests", "TEST", 182, 191], ["a small-ubiquitin-like modifier (SUMO) vectorTotal viral RNA", "TREATMENT", 201, 261], ["infected C6/36 cells", "PROBLEM", 328, 348], ["Aedes albopictus cell line", "TREATMENT", 350, 376], ["DENV", "PROBLEM", 487, 491], ["NS1 gene", "TREATMENT", 494, 502], ["chain reaction", "TEST", 592, 606], ["RT PCR", "TEST", 608, 614], ["Invitrogen", "TEST", 621, 631], ["Carlsbad", "TEST", 633, 641], ["GTG", "TEST", 714, 717]]], ["These primers were designed to introduce restriction sites for BmsB1 and Xbal in order to clone the full length of DENV-4 NS1 gene into a directional pI-secSUMO* cloning vector (LifeSensors, Malvern, PA, USA).", [["BmsB1", "GENE_OR_GENE_PRODUCT", 63, 68], ["Xbal", "GENE_OR_GENE_PRODUCT", 73, 77], ["DENV-4", "ORGANISM", 115, 121], ["NS1", "ORGANISM", 122, 125], ["restriction sites", "DNA", 41, 58], ["BmsB1", "DNA", 63, 68], ["Xbal", "DNA", 73, 77], ["DENV-4 NS1 gene", "DNA", 115, 130], ["directional pI-secSUMO* cloning vector", "DNA", 138, 176], ["DENV-4 NS1", "SPECIES", 115, 125], ["restriction sites", "TREATMENT", 41, 58], ["BmsB1 and Xbal", "TREATMENT", 63, 77], ["DENV", "PROBLEM", 115, 119]]], ["Prior to primer design, we checked for the complete absence of BmsB1 and Xbal restriction sites in the full-length of DENV4 NS1 gene sequence using a NEBcutter V2.0 (http://nc2.neb.com/NEBcutter2/).Cloning DENV-4 NS1 into pI-secSUMO* vectorThe underlined nucleotide sequences in the forward and reverse primers represent the actual first codons, and the complementary sequence to the last codons of the DENV4 NS1 gene, respectively.", [["nucleotide", "CHEMICAL", 255, 265], ["nucleotide", "CHEMICAL", 255, 265], ["BmsB1", "GENE_OR_GENE_PRODUCT", 63, 68], ["Xbal", "GENE_OR_GENE_PRODUCT", 73, 77], ["DENV4 NS1", "GENE_OR_GENE_PRODUCT", 118, 127], ["DENV4 NS1", "GENE_OR_GENE_PRODUCT", 403, 412], ["BmsB1 and Xbal restriction sites", "DNA", 63, 95], ["DENV4 NS1 gene sequence", "DNA", 118, 141], ["NEBcutter V2.0", "DNA", 150, 164], ["NEBcutter2/).Cloning DENV-4 NS1", "DNA", 185, 216], ["pI-secSUMO* vector", "DNA", 222, 240], ["underlined nucleotide sequences", "DNA", 244, 275], ["forward and reverse primers", "DNA", 283, 310], ["complementary sequence", "DNA", 354, 376], ["DENV4 NS1 gene", "DNA", 403, 417], ["BmsB1 and Xbal restriction sites", "TREATMENT", 63, 95], ["a NEBcutter V2.0", "TEST", 148, 164], ["DENV", "PROBLEM", 206, 210], ["nucleotide sequences", "TEST", 255, 275]]], ["In 5\u2032 end of the forward primer (ATA) was added to enhance the efficacy of PCR product end digestion by BmsB1.", [["ATA", "CHEMICAL", 33, 36], ["BmsB1", "GENE_OR_GENE_PRODUCT", 104, 109], ["forward primer", "DNA", 17, 31], ["BmsB1", "PROTEIN", 104, 109], ["PCR product end digestion", "PROBLEM", 75, 100]]], ["The sequence, CGTCTCT, was added as a BmsB1 restriction cleavage site for insertion of NS1 into the multiple cloning sites of the pI-secSUMO* vector, and GGT represented the last codon of the SUMO* tag.", [["CGTCTCT", "GENE_OR_GENE_PRODUCT", 14, 21], ["NS1", "GENE_OR_GENE_PRODUCT", 87, 90], ["pI-secSUMO", "GENE_OR_GENE_PRODUCT", 130, 140], ["GGT", "GENE_OR_GENE_PRODUCT", 154, 157], ["SUMO", "GENE_OR_GENE_PRODUCT", 192, 196], ["CGTCTCT", "DNA", 14, 21], ["BmsB1 restriction cleavage site", "DNA", 38, 69], ["NS1", "PROTEIN", 87, 90], ["multiple cloning sites", "DNA", 100, 122], ["pI-secSUMO* vector", "DNA", 130, 148], ["GGT", "DNA", 154, 157], ["SUMO* tag", "DNA", 192, 201], ["a BmsB1 restriction cleavage site", "TREATMENT", 36, 69], ["insertion of NS1", "TREATMENT", 74, 90], ["GGT", "TEST", 154, 157], ["multiple", "OBSERVATION_MODIFIER", 100, 108]]], ["In the 5\u2032 end of the reverse primer, GCG was added to enhance the efficacy of Xbal restriction digest at the PCR product end, TCTAGA was added to serve as an Xbal restriction cleavage site for insertion of NS1 into the multiple cloning sites of the pI-secSUMO* vector, and TTA represented a reverse complement of the stop codon.Cloning DENV-4 NS1 into pI-secSUMO* vectorThe amplicons generated were visualized by gel electrophoresis using a 1% low melting point agarose (LMPA) (Invitrogen), and the appropriate band was excised, and purified using a QIAGEN Gel Extraction Kit (QIAGEN, Gaithersburg, MD, USA) and double-restriction enzyme digested with BmsB1 and Xbal (New England BioLabs, MA, USA).", [["GCG", "CHEMICAL", 37, 40], ["TCTAGA", "CHEMICAL", 126, 132], ["GCG", "SIMPLE_CHEMICAL", 37, 40], ["Xbal", "GENE_OR_GENE_PRODUCT", 78, 82], ["TCTAGA", "SIMPLE_CHEMICAL", 126, 132], ["NS1", "GENE_OR_GENE_PRODUCT", 206, 209], ["DENV-4", "ORGANISM", 336, 342], ["NS1", "ORGANISM", 343, 346], ["pI-secSUMO", "GENE_OR_GENE_PRODUCT", 352, 362], ["agarose", "SIMPLE_CHEMICAL", 462, 469], ["LMPA", "SIMPLE_CHEMICAL", 471, 475], ["5\u2032 end", "DNA", 7, 13], ["reverse primer", "DNA", 21, 35], ["PCR product end", "DNA", 109, 124], ["TCTAGA", "PROTEIN", 126, 132], ["Xbal restriction cleavage site", "DNA", 158, 188], ["NS1", "PROTEIN", 206, 209], ["multiple cloning sites", "DNA", 219, 241], ["pI-secSUMO* vector", "DNA", 249, 267], ["TTA", "DNA", 273, 276], ["stop codon", "DNA", 317, 327], ["DENV-4 NS1 into pI-secSUMO* vector", "DNA", 336, 370], ["Xbal restriction digest", "TREATMENT", 78, 101], ["TCTAGA", "TREATMENT", 126, 132], ["an Xbal restriction cleavage site", "TREATMENT", 155, 188], ["insertion of NS1", "TREATMENT", 193, 209], ["TTA", "TREATMENT", 273, 276], ["Cloning DENV", "PROBLEM", 328, 340], ["The amplicons", "TREATMENT", 370, 383], ["gel electrophoresis", "TEST", 413, 432], ["a 1% low melting point agarose", "TREATMENT", 439, 469], ["a QIAGEN Gel Extraction", "TREATMENT", 548, 571], ["double-restriction enzyme", "TREATMENT", 612, 637], ["BmsB1", "TEST", 652, 657], ["multiple", "OBSERVATION_MODIFIER", 219, 227]]], ["Since the optimal temperatures and buffers for these two restriction enzymes are different, a two-step restrictions digest was performed.", [["restriction enzymes", "PROTEIN", 57, 76], ["these two restriction enzymes", "TEST", 47, 76], ["a two-step restrictions digest", "TREATMENT", 92, 122]]], ["First, amplicons were digested with Xbal at 37\u00b0C for 1 h, the solution was then centrifuged at 10,000 g for 30 min and supernatant was discarded.", [["supernatant", "ANATOMY", 119, 130], ["Xbal", "CHEMICAL", 36, 40], ["Xbal", "SIMPLE_CHEMICAL", 36, 40], ["amplicons", "TREATMENT", 7, 16], ["Xbal", "TREATMENT", 36, 40], ["the solution", "TREATMENT", 58, 70]]], ["The DNA pellet obtained was washed twice with an ice cold 70% ethanol, air dried, and re-suspended in Milli-Q water.", [["ethanol", "CHEMICAL", 62, 69], ["ethanol", "CHEMICAL", 62, 69], ["DNA", "CELLULAR_COMPONENT", 4, 7], ["ethanol", "SIMPLE_CHEMICAL", 62, 69], ["The DNA pellet", "TREATMENT", 0, 14], ["an ice cold", "TREATMENT", 46, 57]]], ["The re-suspended DNA pellet was digested with BsmB1 for 1 h at 55\u00b0C. Then the pI-secSUMO* plasmids were linearized with BsmB1 in order to generate two overhang ends which are complementary to the double-digested PCR product ends.", [["BsmB1", "CHEMICAL", 46, 51], ["DNA", "CELLULAR_COMPONENT", 17, 20], ["BsmB1", "SIMPLE_CHEMICAL", 46, 51], ["BsmB1", "PROTEIN", 46, 51], ["pI-secSUMO* plasmids", "DNA", 78, 98], ["BsmB1", "DNA", 120, 125], ["overhang ends", "DNA", 151, 164], ["double-digested PCR product ends", "DNA", 196, 228], ["The re-suspended DNA pellet", "TREATMENT", 0, 27], ["the pI-secSUMO* plasmids", "TREATMENT", 74, 98], ["BsmB1", "TREATMENT", 120, 125], ["overhang", "OBSERVATION_MODIFIER", 151, 159]]], ["Both the double-digested PCR products and linearized plasmids were then visualized on a 2% LMPA gel; the appropriate bands were excised, purified, and ligated overnight at 16\u00b0C using T4 DNA Ligase (Invitrogen) with 3:1 ratio of double-restricted amplicons (NS1 gene) to linearized pI-secSUMO* plasmids.", [["plasmids", "ANATOMY", 53, 61], ["LMPA", "SIMPLE_CHEMICAL", 91, 95], ["C", "GENE_OR_GENE_PRODUCT", 175, 176], ["T4 DNA Ligase", "GENE_OR_GENE_PRODUCT", 183, 196], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 198, 208], ["NS1", "GENE_OR_GENE_PRODUCT", 257, 260], ["double-digested PCR products", "DNA", 9, 37], ["linearized plasmids", "DNA", 42, 61], ["T4 DNA Ligase", "PROTEIN", 183, 196], ["NS1 gene", "DNA", 257, 265], ["linearized pI-secSUMO* plasmids", "DNA", 270, 301], ["the double-digested PCR products", "TREATMENT", 5, 37], ["linearized plasmids", "TREATMENT", 42, 61], ["a 2% LMPA gel", "TREATMENT", 86, 99], ["the appropriate bands", "TREATMENT", 101, 122], ["T4 DNA Ligase (Invitrogen", "TREATMENT", 183, 208], ["double-restricted amplicons (NS1 gene", "TREATMENT", 228, 265], ["secSUMO* plasmids", "TREATMENT", 284, 301]]], ["The ligated solution was then immediately transformed into chemically competent DH5\u03b1 E. coli cells (Invitrogen) as per transformation protocol described elsewhere [22] .", [["cells", "ANATOMY", 93, 98], ["DH5\u03b1", "CHEMICAL", 80, 84], ["E. coli cells", "CELL", 85, 98], ["Invitrogen", "CELL", 100, 110], ["DH5\u03b1", "CELL_LINE", 80, 84], ["E. coli cells", "CELL_LINE", 85, 98], ["E. coli", "SPECIES", 85, 92], ["E. coli", "SPECIES", 85, 92], ["The ligated solution", "TREATMENT", 0, 20], ["E. coli cells", "PROBLEM", 85, 98], ["coli cells", "OBSERVATION", 88, 98]]], ["Positive DH5\u03b1 E. coli clones with recombinant SUMO-NS1 fusion construct were then transformed into chemically competent DH10bac E. coli cells (Invitrogen) according to the transformation protocol as previously described [22] .", [["cells", "ANATOMY", 136, 141], ["SUMO", "GENE_OR_GENE_PRODUCT", 46, 50], ["NS1", "GENE_OR_GENE_PRODUCT", 51, 54], ["DH10bac E. coli cells", "CELL", 120, 141], ["Invitrogen", "CELL", 143, 153], ["DH5\u03b1 E. coli clones", "CELL_LINE", 9, 28], ["recombinant SUMO-NS1 fusion construct", "DNA", 34, 71], ["DH10bac E. coli cells", "CELL_LINE", 120, 141], ["E. coli", "SPECIES", 14, 21], ["E. coli", "SPECIES", 128, 135], ["E. coli", "SPECIES", 14, 21], ["E. coli", "SPECIES", 128, 135], ["E. coli clones", "PROBLEM", 14, 28], ["recombinant SUMO-NS1 fusion construct", "TREATMENT", 34, 71], ["coli clones", "OBSERVATION", 17, 28], ["coli cells", "OBSERVATION", 131, 141]]], ["Positive clones were selected by blue and white screening assay followed by colony PCR.", [["clones", "ANATOMY", 9, 15], ["colony", "ANATOMY", 76, 82], ["clones", "CELL", 9, 15], ["Positive clones", "PROBLEM", 0, 15], ["white screening assay", "TEST", 42, 63], ["colony PCR", "TEST", 76, 86], ["clones", "OBSERVATION", 9, 15]]], ["Then recombinant Bacmid DNA was isolated from positive clones using QIAGEN Plasmid DNA Miniprep kit (QIAGEN), and sequenced for integrity in both direction using primer pair polH and Tn7.", [["clones", "ANATOMY", 55, 61], ["Bacmid", "GENE_OR_GENE_PRODUCT", 17, 23], ["DNA", "CELLULAR_COMPONENT", 24, 27], ["polH", "GENE_OR_GENE_PRODUCT", 174, 178], ["recombinant Bacmid DNA", "DNA", 5, 27], ["primer pair polH", "DNA", 162, 178], ["Tn7", "DNA", 183, 186], ["recombinant Bacmid DNA", "TREATMENT", 5, 27], ["positive clones", "PROBLEM", 46, 61], ["QIAGEN Plasmid DNA Miniprep kit (QIAGEN)", "TREATMENT", 68, 108], ["primer pair polH", "TEST", 162, 178], ["positive clones", "OBSERVATION", 46, 61]]], ["The isolated Bacmid DNAs were stored at 4\u00b0C until use.Expression of SUMO-NS1 fusion protein was done in Spodoptera frugiperda (Sf )21 cells (Invitrogen).", [["Sf )21 cells", "ANATOMY", 127, 139], ["Bacmid DNAs", "CELL", 13, 24], ["SUMO", "GENE_OR_GENE_PRODUCT", 68, 72], ["NS1", "GENE_OR_GENE_PRODUCT", 73, 76], ["Spodoptera frugiperda", "ORGANISM", 104, 125], ["Sf )21 cells", "CELL", 127, 139], ["Invitrogen", "CELL", 141, 151], ["Bacmid DNAs", "DNA", 13, 24], ["SUMO", "PROTEIN", 68, 72], ["NS1 fusion protein", "PROTEIN", 73, 91], ["Spodoptera frugiperda (Sf )21 cells", "CELL_LINE", 104, 139], ["Spodoptera frugiperda", "SPECIES", 104, 125], ["Spodoptera frugiperda", "SPECIES", 104, 125], ["The isolated Bacmid DNAs", "TREATMENT", 0, 24], ["SUMO-NS1 fusion protein", "TEST", 68, 91], ["Bacmid DNAs", "OBSERVATION", 13, 24]]], ["Sf21 cells were transfected using 3 \u03bcg of Bacmid DNA for high titer viral stock production, which was later used for infection of these cells at an MOI = 1.", [["Sf21 cells", "ANATOMY", 0, 10], ["cells", "ANATOMY", 136, 141], ["infection", "DISEASE", 117, 126], ["Sf21 cells", "CELL", 0, 10], ["DNA", "CELLULAR_COMPONENT", 49, 52], ["cells", "CELL", 136, 141], ["Sf21 cells", "CELL_LINE", 0, 10], ["Bacmid DNA", "DNA", 42, 52], ["Sf21 cells", "TEST", 0, 10], ["Bacmid DNA", "TREATMENT", 42, 52], ["high titer viral stock production", "PROBLEM", 57, 90], ["infection of these cells", "PROBLEM", 117, 141]]], ["Since pl-secSUMO* plasmid contains an upstream gp67 secretion signal of the SUMO* fusion which results in secretion of the SUMO-NS1 fusion protein with 6xHis-tag) was concentrated (5X) and then purified by immobilized metal affinity chromatograph (IMAC) under native conditions.", [["pl-secSUMO", "GENE_OR_GENE_PRODUCT", 6, 16], ["gp67", "GENE_OR_GENE_PRODUCT", 47, 51], ["SUMO", "GENE_OR_GENE_PRODUCT", 76, 80], ["SUMO", "GENE_OR_GENE_PRODUCT", 123, 127], ["6xHis-tag", "GENE_OR_GENE_PRODUCT", 152, 161], ["pl-secSUMO* plasmid", "DNA", 6, 25], ["gp67", "PROTEIN", 47, 51], ["SUMO", "PROTEIN", 76, 80], ["SUMO", "PROTEIN", 123, 127], ["NS1 fusion protein", "PROTEIN", 128, 146], ["6xHis", "PROTEIN", 152, 157], ["tag", "PROTEIN", 158, 161], ["plasmid", "TREATMENT", 18, 25], ["the SUMO* fusion", "TREATMENT", 72, 88], ["the SUMO", "TEST", 119, 127], ["NS1 fusion protein", "TREATMENT", 128, 146], ["immobilized metal affinity chromatograph", "TREATMENT", 206, 246]]], ["The purity as well as the molecular size of the fusion protein was determined by Coomassie blue stained 12% SDS-PAGE gel (Invitrogen) under both reducing and nonreducing conditions, and confirmed by western blot assay.", [["Coomassie blue", "CHEMICAL", 81, 95], ["Coomassie", "SIMPLE_CHEMICAL", 81, 90], ["Invitrogen", "SIMPLE_CHEMICAL", 122, 132], ["fusion protein", "PROTEIN", 48, 62], ["the fusion protein", "TREATMENT", 44, 62], ["Coomassie blue", "TEST", 81, 95], ["PAGE gel (Invitrogen", "TREATMENT", 112, 132], ["blot assay", "TEST", 207, 217], ["purity", "OBSERVATION", 4, 10], ["size", "OBSERVATION_MODIFIER", 36, 40], ["fusion", "OBSERVATION", 48, 54]]], ["The proper folding of the SUMO* tagged DENV-4 rNS1 protein was confirmed by commercial serotype crossreactive Dengue Early (Panbio), which comprises MAbs reactive to the native hexameric NS1 in serum samples of dengue patients.Western blot analysisFused protein of SUMO-DENV-4 NS1 protein analysis by western blot, the membrane was incubated with anti-HisTag.", [["serum samples", "ANATOMY", 194, 207], ["membrane", "ANATOMY", 319, 327], ["Dengue", "DISEASE", 110, 116], ["dengue", "DISEASE", 211, 217], ["SUMO", "GENE_OR_GENE_PRODUCT", 26, 30], ["DENV-4", "GENE_OR_GENE_PRODUCT", 39, 45], ["rNS1", "GENE_OR_GENE_PRODUCT", 46, 50], ["NS1", "GENE_OR_GENE_PRODUCT", 187, 190], ["serum samples", "ORGANISM_SUBSTANCE", 194, 207], ["patients", "ORGANISM", 218, 226], ["SUMO", "GENE_OR_GENE_PRODUCT", 265, 269], ["membrane", "CELLULAR_COMPONENT", 319, 327], ["Tag", "GENE_OR_GENE_PRODUCT", 355, 358], ["SUMO* tagged DENV-4 rNS1 protein", "PROTEIN", 26, 58], ["MAbs", "PROTEIN", 149, 153], ["hexameric NS1", "PROTEIN", 177, 190], ["SUMO", "PROTEIN", 265, 269], ["DENV-4 NS1 protein", "PROTEIN", 270, 288], ["anti-HisTag", "PROTEIN", 347, 358], ["patients", "SPECIES", 218, 226], ["dengue", "SPECIES", 211, 217], ["DENV", "TEST", 39, 43], ["rNS1 protein", "TEST", 46, 58], ["serum samples", "TEST", 194, 207], ["SUMO", "TEST", 265, 269], ["DENV", "PROBLEM", 270, 274], ["NS1 protein analysis", "TEST", 277, 297], ["western blot", "TEST", 301, 313], ["hexameric NS1", "OBSERVATION", 177, 190]]], ["For the characterization of MAbs elicited from SUMO DENV-4 NS1 fusion protein.", [["MAbs", "GENE_OR_GENE_PRODUCT", 28, 32], ["SUMO", "GENE_OR_GENE_PRODUCT", 47, 51], ["MAbs", "PROTEIN", 28, 32], ["SUMO DENV-4 NS1 fusion protein", "PROTEIN", 47, 77], ["the characterization", "TEST", 4, 24], ["MAbs", "TEST", 28, 32], ["SUMO DENV", "TEST", 47, 56], ["NS1 fusion protein", "TREATMENT", 59, 77]]], ["To produce anti-NS1 MAb-secreting hybridoma clones, female BALB/c mice (6-8 weeks) were immunized with purified soluble SUMO-DENV-4 NS1 fusion protein and unfused DENV-4 rNS1 (expressed in mammalian cells).", [["hybridoma clones", "ANATOMY", 34, 50], ["cells", "ANATOMY", 199, 204], ["NS1", "ORGANISM", 16, 19], ["MAb", "GENE_OR_GENE_PRODUCT", 20, 23], ["hybridoma clones", "CELL", 34, 50], ["female BALB/c mice", "ORGANISM", 52, 70], ["SUMO", "GENE_OR_GENE_PRODUCT", 120, 124], ["DENV-4", "ORGANISM", 163, 169], ["rNS1", "GENE_OR_GENE_PRODUCT", 170, 174], ["mammalian cells", "CELL", 189, 204], ["anti-NS1 MAb-secreting hybridoma clones", "CELL_LINE", 11, 50], ["SUMO", "PROTEIN", 120, 124], ["DENV-4 NS1 fusion protein", "PROTEIN", 125, 150], ["unfused DENV-4 rNS1", "PROTEIN", 155, 174], ["mammalian cells", "CELL_TYPE", 189, 204], ["mice", "SPECIES", 66, 70], ["mice", "SPECIES", 66, 70], ["anti-NS1 MAb", "TREATMENT", 11, 23], ["secreting hybridoma clones", "PROBLEM", 24, 50], ["DENV", "PROBLEM", 125, 129], ["NS1 fusion protein", "TEST", 132, 150], ["unfused DENV", "PROBLEM", 155, 167], ["hybridoma clones", "OBSERVATION", 34, 50], ["mammalian cells", "OBSERVATION", 189, 204]]], ["These primed spleen cells were then fused with SP2/0 cells as previously described (Kohler and Milstein, 1975) .", [["spleen cells", "ANATOMY", 13, 25], ["SP2/0 cells", "ANATOMY", 47, 58], ["spleen cells", "CELL", 13, 25], ["SP2/0 cells", "CELL", 47, 58], ["primed spleen cells", "CELL_LINE", 6, 25], ["SP2/0 cells", "CELL_LINE", 47, 58], ["SP2/0 cells", "TREATMENT", 47, 58], ["spleen", "ANATOMY", 13, 19]]], ["To select desired MAb secreting hybridomas, culture supernatants from each clone was evaluated by indirect ELISA (iELISA) using both SUMO-DENV-4 NS1 fusion protein expressed was the correct conformation of DENV NS1Affinity purified SUMO tag, which is~11.5 kDa, the observed sizes on SDS-PAGE matched to the sizes of monomeric and dimeric DENV4 NS1, respectively.", [["hybridomas", "ANATOMY", 32, 42], ["supernatants", "ANATOMY", 52, 64], ["clone", "ANATOMY", 75, 80], ["MAb", "GENE_OR_GENE_PRODUCT", 18, 21], ["hybridomas", "CELL", 32, 42], ["clone", "CELL", 75, 80], ["SUMO", "GENE_OR_GENE_PRODUCT", 133, 137], ["DENV-4", "ORGANISM", 138, 144], ["NS1", "ORGANISM", 145, 148], ["DENV", "ORGANISM", 206, 210], ["SUMO", "GENE_OR_GENE_PRODUCT", 232, 236], ["DENV4", "GENE_OR_GENE_PRODUCT", 338, 343], ["MAb secreting hybridomas", "CELL_LINE", 18, 42], ["SUMO", "PROTEIN", 133, 137], ["DENV-4 NS1 fusion protein", "PROTEIN", 138, 163], ["DENV NS1Affinity purified SUMO tag", "PROTEIN", 206, 240], ["dimeric DENV4 NS1", "PROTEIN", 330, 347], ["DENV", "SPECIES", 206, 210], ["desired MAb secreting hybridomas", "TREATMENT", 10, 42], ["culture supernatants", "TEST", 44, 64], ["DENV", "PROBLEM", 138, 142], ["NS1 fusion protein", "TREATMENT", 145, 163], ["DENV", "PROBLEM", 206, 210], ["SDS", "TEST", 283, 286], ["SUMO tag", "OBSERVATION", 232, 240], ["11.5 kDa", "OBSERVATION_MODIFIER", 251, 259], ["sizes", "OBSERVATION_MODIFIER", 274, 279]]], ["Also, appearance of a single band on 12% SDS-PAGE (Fig. 2B ) confirmed the purity of the SUMO-DENV rNS1 fusion protein for immunization of mice.", [["SUMO", "GENE_OR_GENE_PRODUCT", 89, 93], ["DENV", "ORGANISM", 94, 98], ["rNS1", "GENE_OR_GENE_PRODUCT", 99, 103], ["mice", "ORGANISM", 139, 143], ["SUMO", "PROTEIN", 89, 93], ["DENV rNS1 fusion protein", "PROTEIN", 94, 118], ["mice", "SPECIES", 139, 143], ["mice", "SPECIES", 139, 143], ["a single band on 12% SDS", "TREATMENT", 20, 44], ["DENV rNS1 fusion protein", "TREATMENT", 94, 118], ["immunization of mice", "TREATMENT", 123, 143]]], ["Our strategy has an advantage over immunization with cleaved DENV-4 NS1 because it avoids the time and effort required to cleave the SUMO* tag from DENV4 NS1.", [["DENV-4 NS1", "ORGANISM", 61, 71], ["SUMO", "GENE_OR_GENE_PRODUCT", 133, 137], ["DENV4 NS1", "GENE_OR_GENE_PRODUCT", 148, 157], ["NS1", "PROTEIN", 68, 71], ["SUMO* tag", "PROTEIN", 133, 142], ["DENV4 NS1", "PROTEIN", 148, 157], ["DENV-4", "SPECIES", 61, 67], ["an advantage over immunization", "TREATMENT", 17, 47], ["NS1", "TREATMENT", 68, 71], ["NS1", "PROBLEM", 154, 157]]], ["In addition, it reduces the loss of protein during cleavage and re-purification steps to remove the SUMO* tag.Characteristics of DENV-4 monoclonal antibodiesA total of six MAb-secreting hybridoma clones were isolated from SUMO tag.", [["hybridoma clones", "ANATOMY", 186, 202], ["SUMO", "GENE_OR_GENE_PRODUCT", 100, 104], ["DENV-4", "ORGANISM", 129, 135], ["MAb", "GENE_OR_GENE_PRODUCT", 172, 175], ["hybridoma clones", "CELL", 186, 202], ["SUMO", "GENE_OR_GENE_PRODUCT", 222, 226], ["SUMO* tag", "PROTEIN", 100, 109], ["DENV-4 monoclonal antibodies", "PROTEIN", 129, 157], ["MAb-secreting hybridoma clones", "CELL_LINE", 172, 202], ["SUMO tag", "PROTEIN", 222, 230], ["DENV-4", "SPECIES", 129, 135], ["the loss of protein during cleavage", "PROBLEM", 24, 59], ["re-purification steps", "TREATMENT", 64, 85], ["DENV", "TEST", 129, 133], ["monoclonal antibodies", "TEST", 136, 157], ["six MAb", "TREATMENT", 168, 175], ["secreting hybridoma clones", "PROBLEM", 176, 202], ["loss", "OBSERVATION_MODIFIER", 28, 32], ["DENV", "OBSERVATION", 129, 133], ["hybridoma clones", "OBSERVATION", 186, 202], ["SUMO tag", "OBSERVATION", 222, 230]]], ["Also, these three MAbs did not cross-react with any of rNS1s from the other three heterologous DENV serotypes and other related flaviviruses (yellow fever virus (YFV) and West Nile virus (WNV)).", [["yellow fever", "DISEASE", 142, 154], ["rNS1s", "GENE_OR_GENE_PRODUCT", 55, 60], ["DENV serotypes", "ORGANISM", 95, 109], ["yellow fever virus", "ORGANISM", 142, 160], ["YFV", "ORGANISM", 162, 165], ["West Nile virus", "ORGANISM", 171, 186], ["WNV", "ORGANISM", 188, 191], ["rNS1s", "PROTEIN", 55, 60], ["yellow fever virus", "SPECIES", 142, 160], ["West Nile virus", "SPECIES", 171, 186], ["DENV", "SPECIES", 95, 99], ["yellow fever virus", "SPECIES", 142, 160], ["YFV", "SPECIES", 162, 165], ["West Nile virus", "SPECIES", 171, 186], ["WNV", "SPECIES", 188, 191], ["the other three heterologous DENV serotypes", "PROBLEM", 66, 109], ["other related flaviviruses", "PROBLEM", 114, 140], ["yellow fever virus", "PROBLEM", 142, 160], ["DENV", "OBSERVATION", 95, 99]]], ["The remaining three (10H10B5, 10H8F7, 4B6C10) were found to be specific to SUMO* tag (Tables 1 and 2 , Figs.", [["SUMO* tag", "PROTEIN", 75, 84]]], ["This result was expected since the mice were immunized with SUMO tag,~11.5 kDa.", [["mice", "ORGANISM", 35, 39], ["SUMO", "GENE_OR_GENE_PRODUCT", 60, 64], ["SUMO tag", "PROTEIN", 60, 68], ["mice", "SPECIES", 35, 39], ["mice", "SPECIES", 35, 39]]], ["The light-chain and heavy-chain isotypes of all the six MAbs, including those which are DENV-4 serotypespecific were IgG2b and \u041a, respectively.", [["MAbs", "GENE_OR_GENE_PRODUCT", 56, 60], ["DENV-4", "ORGANISM", 88, 94], ["IgG2b", "GENE_OR_GENE_PRODUCT", 117, 122], ["\u041a", "GENE_OR_GENE_PRODUCT", 127, 128], ["light-chain", "PROTEIN", 4, 15], ["heavy-chain isotypes", "PROTEIN", 20, 40], ["MAbs", "PROTEIN", 56, 60], ["IgG2b", "PROTEIN", 117, 122], ["\u041a", "PROTEIN", 127, 128], ["heavy-chain isotypes", "TREATMENT", 20, 40], ["DENV", "TEST", 88, 92], ["IgG2b", "TEST", 117, 122], ["chain", "OBSERVATION_MODIFIER", 10, 15], ["heavy", "OBSERVATION_MODIFIER", 20, 25], ["chain isotypes", "OBSERVATION_MODIFIER", 26, 40], ["DENV", "OBSERVATION", 88, 92]]], ["Competition ELISA result (data not shown) in combination with result from sequencing the three complementarity determining regions (CDR1, CDR2, and CDR3) of MAbs (Additional file 1: Figure S1 ) revealed that our three DENV-4 NS1 serotype-specific MAbs were distinct with different binding regions on the DENV-4 NS1.Characteristics of DENV-4 monoclonal antibodiesAnti-DENV-4 monoclonal antibodies were DENV-4 specific and bind to monomeric, dimeric and hexameric DENV-4 NS1 isoforms DENV-4 serotype specificity of MAbs (3H7A9, 6D4B10 and 8A6F2) was demonstrated in fixed cell-ELISA, and in iELISA using both supernatants from DENV (1-4)-infected Vero cell culture and rNS1s of DENV1-4 (NativeAntigen, Oxfordshire, UK).", [["cell", "ANATOMY", 570, 574], ["supernatants", "ANATOMY", 607, 619], ["cell culture", "ANATOMY", 650, 662], ["rNS1s", "ANATOMY", 667, 672], ["CDR1", "GENE_OR_GENE_PRODUCT", 132, 136], ["CDR2", "GENE_OR_GENE_PRODUCT", 138, 142], ["DENV-4", "ORGANISM", 218, 224], ["NS1", "ORGANISM", 225, 228], ["MAbs", "GENE_OR_GENE_PRODUCT", 247, 251], ["DENV-4 NS1", "ORGANISM", 304, 314], ["DENV-4", "ORGANISM", 334, 340], ["DENV-4", "ORGANISM", 401, 407], ["DENV-4 NS1", "ORGANISM", 462, 472], ["DENV-4", "ORGANISM", 482, 488], ["MAbs", "ORGANISM", 513, 517], ["cell", "CELL", 570, 574], ["DENV (1-4", "ORGANISM", 625, 634], ["Vero cell culture", "CELL", 645, 662], ["rNS1s", "CELL", 667, 672], ["DENV1-4", "CELL", 676, 683], ["NativeAntigen", "CELL", 685, 698], ["UK", "GENE_OR_GENE_PRODUCT", 713, 715], ["complementarity determining regions", "PROTEIN", 95, 130], ["CDR1", "DNA", 132, 136], ["CDR2", "DNA", 138, 142], ["CDR3", "DNA", 148, 152], ["MAbs", "PROTEIN", 157, 161], ["DENV-4 NS1 serotype-specific MAbs", "PROTEIN", 218, 251], ["binding regions", "PROTEIN", 281, 296], ["DENV-4 NS1", "PROTEIN", 304, 314], ["DENV-4 monoclonal antibodies", "PROTEIN", 334, 362], ["Anti-DENV-4 monoclonal antibodies", "PROTEIN", 362, 395], ["monomeric, dimeric and hexameric DENV-4 NS1 isoforms", "PROTEIN", 429, 481], ["MAbs", "PROTEIN", 513, 517], ["3H7A9", "PROTEIN", 519, 524], ["6D4B10", "PROTEIN", 526, 532], ["8A6F2", "PROTEIN", 537, 542], ["DENV-4", "SPECIES", 334, 340], ["DENV", "SPECIES", 625, 629], ["Competition ELISA", "TEST", 0, 17], ["CDR2", "TEST", 138, 142], ["MAbs", "TEST", 157, 161], ["our three DENV", "TEST", 208, 222], ["NS1 serotype-specific MAbs", "TREATMENT", 225, 251], ["DENV", "TEST", 334, 338], ["monoclonal antibodies", "TEST", 341, 362], ["Anti-DENV", "TEST", 362, 371], ["monoclonal antibodies", "TEST", 374, 395], ["DENV", "TEST", 401, 405], ["monomeric", "TEST", 429, 438], ["hexameric DENV", "TEST", 452, 466], ["NS1 isoforms", "TEST", 469, 481], ["DENV", "TEST", 482, 486], ["MAbs", "TEST", 513, 517], ["fixed cell-ELISA", "TEST", 564, 580], ["DENV", "PROBLEM", 625, 629], ["infected Vero cell culture", "TEST", 636, 662], ["rNS1s", "TEST", 667, 672], ["DENV1", "TEST", 676, 681], ["DENV", "OBSERVATION", 304, 308], ["DENV", "OBSERVATION", 334, 338], ["fixed cell", "OBSERVATION", 564, 574], ["Vero cell", "OBSERVATION", 645, 654]]], ["Western blot analysis of supernatants from the six clones after SDS-PAGE separation of SUMO-NS1 fusion proteinMAbculture supernatants obtained from DENV1-4 infected Vero cells.", [["supernatants", "ANATOMY", 25, 37], ["clones", "ANATOMY", 51, 57], ["supernatants", "ANATOMY", 121, 133], ["DENV1-4", "ANATOMY", 148, 155], ["Vero cells", "ANATOMY", 165, 175], ["SUMO-NS1", "GENE_OR_GENE_PRODUCT", 87, 95], ["DENV1-4", "CELL", 148, 155], ["Vero cells", "CELL", 165, 175], ["SUMO", "PROTEIN", 87, 91], ["NS1", "PROTEIN", 92, 95], ["DENV1-4 infected Vero cells", "CELL_LINE", 148, 175], ["blot analysis", "TEST", 8, 21], ["supernatants", "PROBLEM", 25, 37], ["SDS", "TEST", 64, 67], ["SUMO", "TEST", 87, 91], ["NS1 fusion proteinMAbculture supernatants", "TEST", 92, 133], ["DENV1", "TEST", 148, 153], ["infected Vero cells", "PROBLEM", 156, 175], ["Vero cells", "OBSERVATION", 165, 175]]], ["As expected, only culture supernatants from DENV-4 infected Vero cells showed reactivity whereas culture supernatants from the other three DENV serotypes-infected Vero cell showed no reactivity.DiscussionIn this study, we expressed SUMO expression was superior to E. Coli and standard baculovirus antigen expression because SUMO* tagged DENV-4 rNS1 was secreted as soluble molecule in culture medium and our previous studies with E.Coli protein expression did not yield any immunogenic MAbs.", [["supernatants", "ANATOMY", 26, 38], ["Vero cells", "ANATOMY", 60, 70], ["supernatants", "ANATOMY", 105, 117], ["Vero cell", "ANATOMY", 163, 172], ["DENV-4", "ORGANISM", 44, 50], ["Vero cells", "CELL", 60, 70], ["DENV", "ORGANISM", 139, 143], ["Vero cell", "CELL", 163, 172], ["SUMO", "GENE_OR_GENE_PRODUCT", 232, 236], ["E. Coli", "ORGANISM", 264, 271], ["baculovirus antigen", "GENE_OR_GENE_PRODUCT", 285, 304], ["SUMO", "GENE_OR_GENE_PRODUCT", 324, 328], ["DENV-4", "ORGANISM", 337, 343], ["rNS1", "GENE_OR_GENE_PRODUCT", 344, 348], ["E.Coli", "GENE_OR_GENE_PRODUCT", 430, 436], ["Vero cells", "CELL_LINE", 60, 70], ["SUMO", "PROTEIN", 232, 236], ["SUMO* tagged DENV-4 rNS1", "PROTEIN", 324, 348], ["E.Coli protein", "PROTEIN", 430, 444], ["immunogenic MAbs", "PROTEIN", 474, 490], ["E. Coli", "SPECIES", 264, 271], ["DENV-4", "SPECIES", 44, 50], ["DENV", "SPECIES", 139, 143], ["E. Coli", "SPECIES", 264, 271], ["baculovirus", "SPECIES", 285, 296], ["culture supernatants", "TEST", 18, 38], ["DENV", "PROBLEM", 44, 48], ["infected Vero cells", "PROBLEM", 51, 70], ["reactivity", "TEST", 78, 88], ["culture supernatants", "TEST", 97, 117], ["DENV serotypes", "TEST", 139, 153], ["infected Vero cell", "TEST", 154, 172], ["reactivity", "PROBLEM", 183, 193], ["this study", "TEST", 207, 217], ["E. Coli", "PROBLEM", 264, 271], ["standard baculovirus antigen expression", "TREATMENT", 276, 315], ["tagged DENV", "TEST", 330, 341], ["soluble molecule in culture medium", "PROBLEM", 365, 399], ["our previous studies", "TEST", 404, 424], ["E.Coli protein expression", "PROBLEM", 430, 455], ["Vero cell", "OBSERVATION", 163, 172], ["no", "UNCERTAINTY", 180, 182], ["reactivity", "OBSERVATION_MODIFIER", 183, 193]]], ["Furthermore, the purified SUMO* tagged DENV NS1 did not require complex multi-steps for solubilizing and refolding as required by E.Coli protein expression.", [["SUMO", "GENE_OR_GENE_PRODUCT", 26, 30], ["DENV NS1", "ORGANISM", 39, 47], ["E.Coli", "GENE_OR_GENE_PRODUCT", 130, 136], ["SUMO", "PROTEIN", 26, 30], ["DENV NS1", "PROTEIN", 39, 47], ["E.Coli protein", "PROTEIN", 130, 144], ["complex multi-steps", "TREATMENT", 64, 83], ["solubilizing and refolding", "TREATMENT", 88, 114]]], ["We used SUMO* as an N-terminal tag to enhance the solubility, stability and correct folding of DENV-4 rNS1 [22, [28] [29] [30] .", [["N", "CHEMICAL", 20, 21], ["SUMO", "GENE_OR_GENE_PRODUCT", 8, 12], ["[28] [29] [30]", "SIMPLE_CHEMICAL", 112, 126], ["SUMO", "PROTEIN", 8, 12], ["N-terminal tag", "PROTEIN", 20, 34], ["an N-terminal tag", "TREATMENT", 17, 34], ["the solubility", "TEST", 46, 60], ["DENV", "TEST", 95, 99], ["rNS1", "TEST", 102, 106]]], ["SUMO fusion technology has previously been used for successful expression of functional hexameric DENV-2 rNS1 in insect cell lines, and the rNS1 protein product was properly glycosylated as it exist in its native form [31] .", [["cell lines", "ANATOMY", 120, 130], ["SUMO", "GENE_OR_GENE_PRODUCT", 0, 4], ["DENV-2", "ORGANISM", 98, 104], ["rNS1", "GENE_OR_GENE_PRODUCT", 105, 109], ["insect cell lines", "CELL", 113, 130], ["rNS1", "GENE_OR_GENE_PRODUCT", 140, 144], ["SUMO", "PROTEIN", 0, 4], ["hexameric DENV-2 rNS1", "PROTEIN", 88, 109], ["insect cell lines", "CELL_LINE", 113, 130], ["rNS1 protein product", "PROTEIN", 140, 160], ["SUMO fusion technology", "TREATMENT", 0, 22], ["functional hexameric DENV", "PROBLEM", 77, 102], ["insect cell lines", "TREATMENT", 113, 130], ["the rNS1 protein product", "TREATMENT", 136, 160], ["fusion", "OBSERVATION", 5, 11], ["cell lines", "OBSERVATION", 120, 130]]], ["However, to the best of our knowledge, this is the first report regarding a successful expression of soluble and stable DENV-4 NS1 with a correct folding using SUMO* fusion technology.", [["DENV-4 NS1", "ORGANISM", 120, 130], ["SUMO", "GENE_OR_GENE_PRODUCT", 160, 164], ["DENV-4 NS1", "PROTEIN", 120, 130], ["SUMO", "PROTEIN", 160, 164], ["SUMO* fusion technology", "TREATMENT", 160, 183]]], ["We then demonstrated the utility of purified SUMO-DENV-4 NS1 fusion protein were generated of which three were reactive to SUMO* tag.", [["SUMO", "GENE_OR_GENE_PRODUCT", 45, 49], ["NS1", "ORGANISM", 57, 60], ["SUMO* tag", "GENE_OR_GENE_PRODUCT", 123, 132], ["SUMO", "PROTEIN", 45, 49], ["DENV-4 NS1 fusion protein", "PROTEIN", 50, 75], ["SUMO* tag", "PROTEIN", 123, 132], ["purified SUMO", "TEST", 36, 49], ["NS1 fusion protein", "TEST", 57, 75], ["reactive", "OBSERVATION_MODIFIER", 111, 119]]], ["The remaining three MAbs (3H7A9, 6D4B10 and 8A6F2) were found to be DENV-4 serotype-specific.", [["3H7A9", "GENE_OR_GENE_PRODUCT", 26, 31], ["6D4B10", "GENE_OR_GENE_PRODUCT", 33, 39], ["8A6F2", "GENE_OR_GENE_PRODUCT", 44, 49], ["DENV-4 serotype", "ORGANISM", 68, 83], ["3H7A9", "PROTEIN", 26, 31], ["6D4B10", "PROTEIN", 33, 39], ["8A6F2", "PROTEIN", 44, 49], ["The remaining three MAbs", "TEST", 0, 24], ["DENV", "PROBLEM", 68, 72], ["DENV", "OBSERVATION", 68, 72]]], ["Serotype-specific anti-DENV NS1 MAbs is crucial for development of NS1 test that detects dengue early in the course of illness and simultaneously determines the infecting DENV serotype.", [["dengue", "DISEASE", 89, 95], ["NS1", "ORGANISM", 67, 70], ["DENV", "ORGANISM", 171, 175], ["Serotype-specific anti-DENV NS1 MAbs", "PROTEIN", 0, 36], ["NS1", "PROTEIN", 67, 70], ["anti-DENV", "SPECIES", 18, 27], ["dengue", "SPECIES", 89, 95], ["DENV", "SPECIES", 171, 175], ["Serotype-specific anti-DENV NS1 MAbs", "TREATMENT", 0, 36], ["NS1 test", "TEST", 67, 75], ["dengue", "PROBLEM", 89, 95], ["illness", "PROBLEM", 119, 126], ["the infecting DENV serotype", "PROBLEM", 157, 184], ["NS1 MAbs", "OBSERVATION", 28, 36], ["infecting", "OBSERVATION_MODIFIER", 161, 170], ["DENV", "OBSERVATION", 171, 175]]], ["Our newly developed MAbs (3H7A9, 6D4B10 and 8A6F2) are highly specific to DENV-4 as demonstrated by two different methods, fixed cell ELISA and iELISA.", [["cell", "ANATOMY", 129, 133], ["6D4B10", "GENE_OR_GENE_PRODUCT", 33, 39], ["8A6F2", "GENE_OR_GENE_PRODUCT", 44, 49], ["DENV-4", "ORGANISM", 74, 80], ["cell", "CELL", 129, 133], ["3H7A9", "PROTEIN", 26, 31], ["6D4B10", "PROTEIN", 33, 39], ["8A6F2", "PROTEIN", 44, 49], ["DENV-4", "SPECIES", 74, 80], ["MAbs", "TEST", 20, 24], ["DENV", "TEST", 74, 78], ["fixed cell ELISA", "TEST", 123, 139], ["MAbs", "OBSERVATION", 20, 24], ["DENV", "OBSERVATION", 74, 78], ["fixed cell ELISA", "OBSERVATION", 123, 139]]], ["Of the three serotypespecific MAbs, 6D4B10 and 8A6F2 showed higher affinity to the hexameric DENV-4 rNS1 and dimeric DENV-4 NS1 expressed in Vero cells.DiscussionA competition ELISA was performed to determine if the three MAbs bind to the same or distinct epitopes of DENV-4 NS1.", [["Vero cells", "ANATOMY", 141, 151], ["6D4B10", "GENE_OR_GENE_PRODUCT", 36, 42], ["8A6F2", "GENE_OR_GENE_PRODUCT", 47, 52], ["DENV-4", "ORGANISM", 93, 99], ["rNS1", "GENE_OR_GENE_PRODUCT", 100, 104], ["DENV-4", "ORGANISM", 117, 123], ["NS1", "ORGANISM", 124, 127], ["Vero cells", "CELL", 141, 151], ["DENV-4 NS1", "ORGANISM", 268, 278], ["serotypespecific MAbs", "PROTEIN", 13, 34], ["6D4B10", "PROTEIN", 36, 42], ["8A6F2", "PROTEIN", 47, 52], ["hexameric DENV-4 rNS1", "PROTEIN", 83, 104], ["dimeric DENV-4 NS1", "PROTEIN", 109, 127], ["Vero cells", "CELL_LINE", 141, 151], ["MAbs", "PROTEIN", 222, 226], ["epitopes", "PROTEIN", 256, 264], ["DENV-4 NS1", "PROTEIN", 268, 278], ["DENV-4 NS1", "SPECIES", 268, 278], ["8A6F2", "TEST", 47, 52], ["higher affinity", "PROBLEM", 60, 75], ["the hexameric DENV", "TEST", 79, 97], ["dimeric DENV", "TEST", 109, 121], ["NS1", "PROBLEM", 124, 127], ["DiscussionA competition ELISA", "TEST", 152, 181], ["DENV", "PROBLEM", 268, 272], ["DENV", "OBSERVATION", 93, 97], ["DENV", "OBSERVATION", 117, 121], ["Vero cells", "OBSERVATION", 141, 151], ["DENV", "OBSERVATION", 268, 272]]], ["The results (data not shown) confirmed that all the three MAbs bind to distinct non-overlapping regions and can be used to develop sandwich immunodiagnostic assay.", [["MAbs", "PROTEIN", 58, 62], ["sandwich immunodiagnostic assay", "TEST", 131, 162]]], ["The distinctness of these three MAbs was further verified by sequencing the three complementarity determining regions (CDR1, CDR2, and CDR3) of MAbs.", [["CDR1", "GENE_OR_GENE_PRODUCT", 119, 123], ["CDR2", "GENE_OR_GENE_PRODUCT", 125, 129], ["MAbs", "GENE_OR_GENE_PRODUCT", 144, 148], ["MAbs", "PROTEIN", 32, 36], ["complementarity determining regions", "PROTEIN", 82, 117], ["CDR1", "DNA", 119, 123], ["CDR2", "DNA", 125, 129], ["CDR3", "DNA", 135, 139], ["MAbs", "PROTEIN", 144, 148], ["CDR2", "TEST", 125, 129], ["MAbs", "TEST", 144, 148], ["distinctness", "OBSERVATION_MODIFIER", 4, 16], ["three", "OBSERVATION_MODIFIER", 26, 31], ["MAbs", "OBSERVATION", 32, 36]]], ["MAb 3H7A9 was DENV-4 serotypespecific but had weak affinity to DENV-4 hence was not used for assay development.", [["DENV-4 serotypespecific", "CHEMICAL", 14, 37], ["DENV-4", "ORGANISM", 14, 20], ["DENV-4", "ORGANISM", 63, 69], ["DENV", "PROBLEM", 14, 18], ["weak affinity", "PROBLEM", 46, 59], ["DENV", "PROBLEM", 63, 67]]], ["Only MAbs 6D4B10 and 8A6F2 were chosen to develop an NS1 capture ELISA.", [["MAbs 6D4B10", "GENE_OR_GENE_PRODUCT", 5, 16], ["8A6F2", "GENE_OR_GENE_PRODUCT", 21, 26], ["NS1", "GENE_OR_GENE_PRODUCT", 53, 56], ["MAbs 6D4B10", "PROTEIN", 5, 16], ["8A6F2", "PROTEIN", 21, 26], ["NS1", "PROTEIN", 53, 56], ["MAbs 6D4B10", "TREATMENT", 5, 16], ["8A6F2", "TREATMENT", 21, 26], ["NS1 capture", "OBSERVATION", 53, 64]]], ["In order to use biotin-streptavidin based capture ELISA format, different pairs of unbiotinylated and biotinylated MAbs were evaluated.", [["biotin", "CHEMICAL", 16, 22], ["biotin", "CHEMICAL", 16, 22], ["biotin", "SIMPLE_CHEMICAL", 16, 22], ["streptavidin", "SIMPLE_CHEMICAL", 23, 35], ["unbiotinylated", "SIMPLE_CHEMICAL", 83, 97], ["MAbs", "GENE_OR_GENE_PRODUCT", 115, 119], ["unbiotinylated and biotinylated MAbs", "PROTEIN", 83, 119], ["biotin-streptavidin", "TREATMENT", 16, 35], ["unbiotinylated and biotinylated MAbs", "TREATMENT", 83, 119]]], ["Subsequently, a match pair of unbiotinylated 8A6F2 as a capture antibody and biotinylated (B)-6D4B10 as a detection antibody provided the most robust results compared to 6D4B10 as capture and B-8A6F2 as the detector.", [["8A6F2", "CHEMICAL", 45, 50], ["B-8A6F2", "CHEMICAL", 192, 199], ["8A6F2", "SIMPLE_CHEMICAL", 45, 50], ["biotinylated (B)-6D4B10", "SIMPLE_CHEMICAL", 77, 100], ["6D4B10", "SIMPLE_CHEMICAL", 170, 176], ["B-8A6F2", "SIMPLE_CHEMICAL", 192, 199], ["unbiotinylated 8A6F2", "PROTEIN", 30, 50], ["capture antibody", "PROTEIN", 56, 72], ["biotinylated (B)-6D4B10", "PROTEIN", 77, 100], ["6D4B10", "PROTEIN", 170, 176], ["B", "PROTEIN", 192, 193], ["8A6F2", "PROTEIN", 194, 199], ["a capture antibody", "TEST", 54, 72], ["a detection antibody", "TEST", 104, 124]]], ["The reason for the poor performance of the later matched pair MAbs may be due to: (i) the denaturation/random orientation of 6D4B10 as a result of direct binding to the microtiter plate, (ii) biotin molecules binding to the antigen binding region of 8A6F2, or (iii) a combination of these two [24, 25] .", [["biotin", "CHEMICAL", 192, 198], ["biotin", "CHEMICAL", 192, 198], ["biotin", "SIMPLE_CHEMICAL", 192, 198], ["6D4B10", "PROTEIN", 125, 131], ["biotin molecules", "PROTEIN", 192, 208], ["antigen binding region", "PROTEIN", 224, 246], ["8A6F2", "PROTEIN", 250, 255], ["the later matched pair MAbs", "TREATMENT", 39, 66], ["the denaturation", "PROBLEM", 86, 102], ["direct binding", "PROBLEM", 147, 161], ["the microtiter plate", "TEST", 165, 185], ["biotin molecules binding", "PROBLEM", 192, 216]]], ["Nevertheless, a direct ELISA (data not shown), in which microtiter plate-wells were coated with DENV-4 rNS1, and detected by B-8A6F2 showed reactivity of the biotinylated 8A6F2 to DENV-4 rNS1 protein, suggesting the loss of antigen-antibody binding in NS1 capture ELISA format (capture with 6D4B10 and detect with B-86FA2) was not due to the biotinlyation.", [["B-8A6F2", "CHEMICAL", 125, 132], ["rNS1", "GENE_OR_GENE_PRODUCT", 103, 107], ["B-8A6F2", "GENE_OR_GENE_PRODUCT", 125, 132], ["8A6F2", "GENE_OR_GENE_PRODUCT", 171, 176], ["DENV-4", "ORGANISM", 180, 186], ["rNS1", "GENE_OR_GENE_PRODUCT", 187, 191], ["antigen-antibody", "GENE_OR_GENE_PRODUCT", 224, 240], ["NS1", "ORGANISM", 252, 255], ["B-86FA2", "GENE_OR_GENE_PRODUCT", 314, 321], ["rNS1", "PROTEIN", 103, 107], ["B", "PROTEIN", 125, 126], ["8A6F2", "PROTEIN", 171, 176], ["DENV-4 rNS1 protein", "PROTEIN", 180, 199], ["NS1", "PROTEIN", 252, 255], ["6D4B10", "PROTEIN", 291, 297], ["B", "PROTEIN", 314, 315], ["86FA2", "PROTEIN", 316, 321], ["B-8A6F2", "SPECIES", 125, 132], ["a direct ELISA", "TEST", 14, 28], ["microtiter plate", "TEST", 56, 72], ["DENV", "TEST", 96, 100], ["DENV", "TEST", 180, 184], ["rNS1 protein", "TEST", 187, 199], ["the loss of antigen-antibody binding", "PROBLEM", 212, 248]]], ["This MAb pair may function efficiently if one avoids direct binding of this MAb to the microplate surface by using lower affinity capture MAb, 6D4B10 immobilization method or a linker.", [["surface", "ANATOMY", 98, 105], ["MAb", "GENE_OR_GENE_PRODUCT", 5, 8], ["MAb", "GENE_OR_GENE_PRODUCT", 76, 79], ["6D4B10", "SIMPLE_CHEMICAL", 143, 149], ["MAb", "PROTEIN", 76, 79], ["6D4B10", "PROTEIN", 143, 149], ["This MAb pair", "TREATMENT", 0, 13], ["this MAb", "TREATMENT", 71, 79], ["the microplate surface", "TREATMENT", 83, 105], ["lower affinity capture MAb", "TREATMENT", 115, 141], ["6D4B10 immobilization method", "TREATMENT", 143, 171], ["a linker", "TREATMENT", 175, 183]]], ["The newly developed DENV-4 NS1 specific capture ELISA therefore used 8A6F2 as the capture and B-6D4B10 as the detection antibody.", [["DENV-4", "ORGANISM", 20, 26], ["NS1", "ORGANISM", 27, 30], ["8A6F2", "SIMPLE_CHEMICAL", 69, 74], ["B-6D4B10", "GENE_OR_GENE_PRODUCT", 94, 102], ["NS1", "PROTEIN", 27, 30], ["8A6F2", "PROTEIN", 69, 74], ["B", "PROTEIN", 94, 95], ["6D4B10", "PROTEIN", 96, 102], ["detection antibody", "PROTEIN", 110, 128], ["DENV-4 NS1", "SPECIES", 20, 30], ["DENV", "PROBLEM", 20, 24], ["the detection antibody", "TEST", 106, 128], ["DENV", "OBSERVATION", 20, 24]]], ["The DENV-4 serotype-specificity was assessed using rNS1 of flaviviruses, including all four DENV serotypes and culture supernatants from Vero cell-infected with all four DENV serotypes.", [["supernatants", "ANATOMY", 119, 131], ["cell", "ANATOMY", 142, 146], ["DENV-4", "ORGANISM", 4, 10], ["rNS1", "GENE_OR_GENE_PRODUCT", 51, 55], ["Vero cell", "CELL", 137, 146], ["rNS1", "PROTEIN", 51, 55], ["DENV", "SPECIES", 92, 96], ["DENV", "SPECIES", 170, 174], ["The DENV", "PROBLEM", 0, 8], ["flaviviruses", "PROBLEM", 59, 71], ["all four DENV serotypes", "PROBLEM", 83, 106], ["culture supernatants", "TEST", 111, 131], ["Vero cell", "PROBLEM", 137, 146], ["all four DENV serotypes", "PROBLEM", 161, 184], ["DENV", "OBSERVATION", 4, 8], ["Vero cell", "OBSERVATION", 137, 146], ["DENV serotypes", "OBSERVATION", 170, 184]]], ["Because flaviviruses family of viruses may cross react in immunodiagnostic test due to their highly antigenic similarities, we included YFV and WNV to ensure DENV specificity.", [["YFV", "ORGANISM", 136, 139], ["WNV", "ORGANISM", 144, 147], ["DENV", "ORGANISM", 158, 162], ["YFV", "SPECIES", 136, 139], ["WNV", "SPECIES", 144, 147], ["DENV", "SPECIES", 158, 162], ["flaviviruses family of viruses", "PROBLEM", 8, 38], ["immunodiagnostic test", "TEST", 58, 79], ["YFV", "TREATMENT", 136, 139], ["WNV", "TREATMENT", 144, 147], ["DENV specificity", "TEST", 158, 174]]], ["The results confirmed that these MAbs specifically bound to DENV-4 in the NS1 capture ELISA and not to other flaviviruses (WNV, YFV).DiscussionAnother factor that could have contributed to the poor sensitivity of NS1 Ag detection tests for DENV-4 is the low level expression of NS1 in DENV-4-infected patients as compared to in dengue patients infected with the other three serotypes [5, 36] .", [["DENV-4-infected", "DISEASE", 285, 300], ["dengue", "DISEASE", 328, 334], ["Ag", "CHEMICAL", 217, 219], ["DENV-4", "ORGANISM", 60, 66], ["NS1", "GENE_OR_GENE_PRODUCT", 74, 77], ["WNV", "ORGANISM", 123, 126], ["YFV", "ORGANISM", 128, 131], ["NS1", "ORGANISM", 213, 216], ["Ag", "GENE_OR_GENE_PRODUCT", 217, 219], ["DENV-4", "ORGANISM", 240, 246], ["NS1", "GENE_OR_GENE_PRODUCT", 278, 281], ["DENV-4", "ORGANISM", 285, 291], ["patients", "ORGANISM", 301, 309], ["patients", "ORGANISM", 335, 343], ["MAbs", "PROTEIN", 33, 37], ["DENV-4", "DNA", 60, 66], ["NS1", "PROTEIN", 74, 77], ["NS1", "PROTEIN", 213, 216], ["Ag", "PROTEIN", 217, 219], ["NS1", "PROTEIN", 278, 281], ["patients", "SPECIES", 301, 309], ["patients", "SPECIES", 335, 343], ["WNV", "SPECIES", 123, 126], ["YFV", "SPECIES", 128, 131], ["NS1", "SPECIES", 213, 216], ["DENV-4", "SPECIES", 285, 291], ["dengue", "SPECIES", 328, 334], ["these MAbs", "TEST", 27, 37], ["DENV", "PROBLEM", 60, 64], ["the NS1 capture ELISA", "TEST", 70, 91], ["WNV", "PROBLEM", 123, 126], ["the poor sensitivity of NS1", "PROBLEM", 189, 216], ["Ag detection tests", "TEST", 217, 235], ["DENV", "PROBLEM", 240, 244], ["NS1", "PROBLEM", 278, 281], ["DENV", "PROBLEM", 285, 289], ["NS1", "OBSERVATION", 278, 281]]], ["An NS1 capture ELISA specific to DENV-4 could improve the detection of DENV-4 cases and a serotype-specific NS1 Ag test can identify dengue and the infecting DENV serotype [37] .", [["Ag", "CHEMICAL", 112, 114], ["dengue", "DISEASE", 133, 139], ["Ag", "CHEMICAL", 112, 114], ["NS1", "GENE_OR_GENE_PRODUCT", 3, 6], ["DENV-4", "ORGANISM", 33, 39], ["DENV-4", "ORGANISM", 71, 77], ["NS1", "ORGANISM", 108, 111], ["Ag", "GENE_OR_GENE_PRODUCT", 112, 114], ["DENV serotype", "ORGANISM", 158, 171], ["NS1", "PROTEIN", 3, 6], ["NS1", "PROTEIN", 108, 111], ["Ag", "PROTEIN", 112, 114], ["DENV-4", "SPECIES", 33, 39], ["DENV-4", "SPECIES", 71, 77], ["dengue", "SPECIES", 133, 139], ["DENV", "SPECIES", 158, 162], ["An NS1 capture ELISA", "TEST", 0, 20], ["DENV", "PROBLEM", 33, 37], ["the detection", "TEST", 54, 67], ["DENV", "PROBLEM", 71, 75], ["Ag test", "TEST", 112, 119], ["dengue", "PROBLEM", 133, 139], ["the infecting DENV serotype", "PROBLEM", 144, 171]]], ["NS1 ELISAs for each one of the four DENV serotypes have been previously described [38] [39] [40] however, none of them are commercially available and hence currently the only commonly used laboratory methods to determine DENV serotype is RT-PCR.", [["NS1", "GENE_OR_GENE_PRODUCT", 0, 3], ["DENV", "ORGANISM", 36, 40], ["DENV", "ORGANISM", 221, 225], ["NS1", "PROTEIN", 0, 3], ["DENV", "SPECIES", 36, 40], ["DENV", "SPECIES", 221, 225], ["NS1 ELISAs", "TEST", 0, 10], ["the four DENV serotypes", "PROBLEM", 27, 50], ["laboratory methods", "TEST", 189, 207], ["DENV serotype", "TEST", 221, 234]]], ["There are two main advantages in identifying the DENV serotype: (i) risk factors for severe dengue have associated to more pathogenic DENV serotypes, and (ii) the sequence of infection of DENV serotype in primary and secondary infections is also believed to be a risk factor for severe disease.", [["dengue", "DISEASE", 92, 98], ["infection", "DISEASE", 175, 184], ["primary and secondary infections", "DISEASE", 205, 237], ["DENV serotype", "ORGANISM", 188, 201], ["DENV", "SPECIES", 49, 53], ["dengue", "SPECIES", 92, 98], ["DENV", "SPECIES", 134, 138], ["DENV", "SPECIES", 188, 192], ["severe dengue", "PROBLEM", 85, 98], ["pathogenic DENV serotypes", "PROBLEM", 123, 148], ["infection", "PROBLEM", 175, 184], ["DENV serotype", "PROBLEM", 188, 201], ["secondary infections", "PROBLEM", 217, 237], ["severe disease", "PROBLEM", 279, 293], ["main", "OBSERVATION_MODIFIER", 14, 18], ["DENV", "OBSERVATION", 49, 53], ["infection", "OBSERVATION", 175, 184], ["DENV", "OBSERVATION", 188, 192], ["infections", "OBSERVATION", 227, 237], ["severe", "OBSERVATION_MODIFIER", 279, 285], ["disease", "OBSERVATION", 286, 293]]], ["Taken together, there is a need for improvement of the current NS1 assay for detection of DENV-4 serotype.", [["NS1", "ORGANISM", 63, 66], ["DENV-4 serotype", "ORGANISM", 90, 105], ["NS1", "PROTEIN", 63, 66], ["DENV-4", "SPECIES", 90, 96], ["the current NS1 assay", "TEST", 51, 72], ["DENV", "PROBLEM", 90, 94], ["DENV", "OBSERVATION", 90, 94]]], ["This could be done by developing multiplex lateral flow assay (LFA) that utilize broadly binding anti-DENV NS1 MAbs as well as our MAbs specific to DENV-4 NS1.", [["DENV-4 NS1", "ORGANISM", 148, 158], ["anti-DENV NS1 MAbs", "PROTEIN", 97, 115], ["MAbs", "PROTEIN", 131, 135], ["DENV-4 NS1", "PROTEIN", 148, 158], ["DENV-4 NS1", "SPECIES", 148, 158], ["multiplex lateral flow assay", "TEST", 33, 61], ["broadly binding anti-DENV NS1 MAbs", "TREATMENT", 81, 115], ["DENV", "PROBLEM", 148, 152], ["lateral", "OBSERVATION_MODIFIER", 43, 50], ["flow", "OBSERVATION", 51, 55]]], ["However, this requires an investigation on the utility of our DENV-4 -specific MAbs for LFA.ConclusionIn conclusion, we generated three DENV-4-specific MAbs directed against SUMO*-DENV-4 rNS1 fusion protein.", [["DENV-4", "ORGANISM", 62, 68], ["LFA", "GENE_OR_GENE_PRODUCT", 88, 91], ["DENV-4", "ORGANISM", 136, 142], ["SUMO", "GENE_OR_GENE_PRODUCT", 174, 178], ["rNS1", "GENE_OR_GENE_PRODUCT", 187, 191], ["DENV-4 -specific MAbs", "PROTEIN", 62, 83], ["LFA", "PROTEIN", 88, 91], ["DENV-4-specific MAbs", "PROTEIN", 136, 156], ["SUMO*-DENV-4 rNS1 fusion protein", "PROTEIN", 174, 206], ["an investigation", "TEST", 23, 39], ["our DENV", "TEST", 58, 66], ["specific MAbs", "TREATMENT", 143, 156], ["DENV", "PROBLEM", 180, 184], ["rNS1 fusion protein", "TREATMENT", 187, 206]]], ["Based on our characterization results and competition ELISA, the NS1 capture ELISA for potential early detection DENV-4 infection was established using a combination of two highly sensitive MAbs: 8A6F2 as coating antibody, biotinylated 6D4B10 as detection antibody and an optimized protocol was developed.", [["infection", "DISEASE", 120, 129], ["NS1", "GENE_OR_GENE_PRODUCT", 65, 68], ["DENV-4", "ORGANISM", 113, 119], ["8A6F2", "SIMPLE_CHEMICAL", 196, 201], ["6D4B10", "SIMPLE_CHEMICAL", 236, 242], ["NS1", "PROTEIN", 65, 68], ["8A6F2", "PROTEIN", 196, 201], ["coating antibody", "PROTEIN", 205, 221], ["biotinylated 6D4B10 as detection antibody", "PROTEIN", 223, 264], ["DENV-4", "SPECIES", 113, 119], ["our characterization", "TEST", 9, 29], ["competition ELISA", "TEST", 42, 59], ["the NS1 capture ELISA", "TEST", 61, 82], ["potential early detection DENV", "PROBLEM", 87, 117], ["4 infection", "PROBLEM", 118, 129], ["coating antibody", "TEST", 205, 221], ["detection antibody", "TEST", 246, 264], ["an optimized protocol", "TEST", 269, 290]]], ["The assay was specific to DENV-4 with no cross-reactivity to other three DENV serotypes and other heterologous flaviviruses.", [["flaviviruses", "DISEASE", 111, 123], ["DENV-4", "ORGANISM", 26, 32], ["DENV-4", "SPECIES", 26, 32], ["DENV", "SPECIES", 73, 77], ["The assay", "TEST", 0, 9], ["DENV", "PROBLEM", 26, 30], ["cross-reactivity", "PROBLEM", 41, 57], ["three DENV serotypes", "PROBLEM", 67, 87], ["other heterologous flaviviruses", "PROBLEM", 92, 123]]], ["Our preliminary results indicated that our MAbs are useful reagents for development immunodiagnostic assays (e.g., ELISAs and LFA) that specifically detect DENV-4 infection.", [["infection", "DISEASE", 163, 172], ["DENV-4", "ORGANISM", 156, 162], ["LFA", "PROTEIN", 126, 129], ["DENV-4", "SPECIES", 156, 162], ["our MAbs", "TEST", 39, 47], ["immunodiagnostic assays", "TEST", 84, 107], ["ELISAs", "TEST", 115, 121], ["DENV", "PROBLEM", 156, 160], ["4 infection", "PROBLEM", 161, 172], ["DENV", "OBSERVATION", 156, 160], ["infection", "OBSERVATION", 163, 172]]], ["These DENV serotype specific MAbs have the potential to change the way we detect dengue by providing tests that are user friendly to resource poor regions to adopt them for diagnosing dengue.", [["dengue", "DISEASE", 81, 87], ["dengue", "DISEASE", 184, 190], ["MAbs", "GENE_OR_GENE_PRODUCT", 29, 33], ["DENV serotype specific MAbs", "PROTEIN", 6, 33], ["DENV", "SPECIES", 6, 10], ["dengue", "SPECIES", 81, 87], ["dengue", "SPECIES", 184, 190], ["These DENV serotype specific MAbs", "PROBLEM", 0, 33], ["dengue", "PROBLEM", 81, 87], ["diagnosing dengue", "PROBLEM", 173, 190]]], ["Given that the current commercial NS1 tests are less sensitivity to DENV-4, our paired MAbs could be useful for development of multiplex assay that detects all four serotypes simultaneously in regions where DENV-4 circulates.", [["NS1", "GENE_OR_GENE_PRODUCT", 34, 37], ["DENV-4", "ORGANISM", 68, 74], ["DENV-4", "ORGANISM", 207, 213], ["NS1", "PROTEIN", 34, 37], ["DENV-4", "SPECIES", 207, 213], ["the current commercial NS1 tests", "TEST", 11, 43], ["DENV", "PROBLEM", 68, 72], ["our paired MAbs", "TEST", 76, 91], ["multiplex assay", "TEST", 127, 142], ["DENV", "PROBLEM", 207, 211], ["DENV", "OBSERVATION", 207, 211]]], ["However, one major limitation of this study is that these MAbs were not tested using DENV-4 clinical specimens thus these MAbs require further validation.", [["specimens", "ANATOMY", 101, 110], ["MAbs", "GENE_OR_GENE_PRODUCT", 58, 62], ["DENV-4", "ORGANISM", 85, 91], ["this study", "TEST", 33, 43], ["these MAbs", "TEST", 52, 62], ["DENV", "PROBLEM", 85, 89], ["clinical specimens", "TEST", 92, 110], ["these MAbs", "TEST", 116, 126], ["further validation", "TEST", 135, 153]]], ["Furthermore a full validation testing should be conducted to better understand the limitations of these MAbs in flavivirus clinical specimens.Additional filesAdditional file 1: Figure S1 .", [["specimens", "ANATOMY", 132, 141], ["flavivirus", "DISEASE", 112, 122], ["a full validation testing", "TEST", 12, 37], ["these MAbs", "TEST", 98, 108], ["flavivirus clinical specimens", "TEST", 112, 141]]], ["The alignment of the sequences of the three complimentary determining regions (CDR1, CDR2, CDR3) of monoclonal antibodies 3H7A9, 8A6F2 and 6D4B10 showing they are distinct.", [["CDR1", "GENE_OR_GENE_PRODUCT", 79, 83], ["CDR2", "GENE_OR_GENE_PRODUCT", 85, 89], ["8A6F2", "GENE_OR_GENE_PRODUCT", 129, 134], ["6D4B10", "GENE_OR_GENE_PRODUCT", 139, 145], ["complimentary determining regions", "DNA", 44, 77], ["CDR1", "DNA", 79, 83], ["CDR2", "DNA", 85, 89], ["CDR3", "DNA", 91, 95], ["monoclonal antibodies", "PROTEIN", 100, 121], ["3H7A9", "PROTEIN", 122, 127], ["8A6F2", "PROTEIN", 129, 134], ["6D4B10", "PROTEIN", 139, 145], ["monoclonal antibodies", "TEST", 100, 121], ["distinct", "OBSERVATION_MODIFIER", 163, 171]]]], "d7b3663559b1af765ae7a9363aab7795ac66c685": [["IntroductionThe genus Flavivirus comprises over 70 RNA viruses, many of which are important human pathogens.", [["human", "ORGANISM", 92, 97], ["human", "SPECIES", 92, 97], ["human", "SPECIES", 92, 97], ["The genus Flavivirus", "PROBLEM", 12, 32], ["70 RNA viruses", "PROBLEM", 48, 62], ["genus Flavivirus", "OBSERVATION", 16, 32]]], ["Dengue virus (Dv), as an example, is estimated to infect about 50 million people a year, causing 24,000 deaths (Guha-Sapir and Schimmer, 2005) .", [["Dengue", "DISEASE", 0, 6], ["deaths", "DISEASE", 104, 110], ["Dengue virus", "ORGANISM", 0, 12], ["people", "ORGANISM", 74, 80], ["Dengue virus", "SPECIES", 0, 12], ["people", "SPECIES", 74, 80], ["Dengue virus", "SPECIES", 0, 12], ["Dv", "SPECIES", 14, 16], ["Dengue virus", "PROBLEM", 0, 12]]], ["Currently, no specific antiviral drugs are available against flaviviral infections, and their development has been an active field of research during recent years (Sampath and Padmanabhan, 2009) .IntroductionThe flaviviral genome consists of 11 kb; it is decorated with a 'cap-1' structure at the strictly conserved 5 terminus Abbreviations: RdRp, RNA dependent RNA polymerase; N7 MTase, guanine N7 methyltransferase; 2 O MTase, nucleoside-2 O methyltransferase; AdoMet, Sadenosyl-l-methionine; AdoHcy, S-adenosyl-l-homocysteine; Wv, Wesselsbron virus; NS, non-structural protein; GMP, guanosine monophosphate; GTP, guanosine triphosphate; Dv, Dengue virus; WNv, West Nile virus; LBS, putative low affinity RNA binding site; HBS, high affinity RNA binding site; ATA, aurintricarboxylic acid; PPNDS, pyridoxal-5 -phosphate-6-(2 -naphthylazo-6 -nitro-4 ,8 -disulfonate) tetrasodium salt; PMSF, phenylmethylsulphonyl fluoride; TLC, thin-layer chromatography.Introduction* Corresponding author.", [["flaviviral infections", "DISEASE", 61, 82], ["guanine", "CHEMICAL", 388, 395], ["nucleoside", "CHEMICAL", 429, 439], ["AdoMet", "CHEMICAL", 463, 469], ["Sadenosyl-l-methionine", "CHEMICAL", 471, 493], ["AdoHcy", "CHEMICAL", 495, 501], ["S-adenosyl-l-homocysteine", "CHEMICAL", 503, 528], ["GMP", "CHEMICAL", 581, 584], ["guanosine", "CHEMICAL", 586, 595], ["GTP", "CHEMICAL", 611, 614], ["guanosine", "CHEMICAL", 616, 625], ["aurintricarboxylic acid", "CHEMICAL", 767, 790], ["PPNDS", "CHEMICAL", 792, 797], ["pyridoxal-5 -phosphate-6-(2 -naphthylazo-6 -nitro-4 ,8 -disulfonate", "CHEMICAL", 799, 866], ["phenylmethylsulphonyl fluoride", "CHEMICAL", 892, 922], ["guanine", "CHEMICAL", 388, 395], ["nucleoside", "CHEMICAL", 429, 439], ["O", "CHEMICAL", 442, 443], ["AdoMet", "CHEMICAL", 463, 469], ["Sadenosyl-l-methionine", "CHEMICAL", 471, 493], ["AdoHcy", "CHEMICAL", 495, 501], ["S-adenosyl-l-homocysteine", "CHEMICAL", 503, 528], ["GMP", "CHEMICAL", 581, 584], ["guanosine monophosphate", "CHEMICAL", 586, 609], ["GTP", "CHEMICAL", 611, 614], ["guanosine triphosphate", "CHEMICAL", 616, 638], ["aurintricarboxylic acid", "CHEMICAL", 767, 790], ["PPNDS", "CHEMICAL", 792, 797], ["pyridoxal-5 -phosphate-6-(2 -naphthylazo-6 -nitro-4 ,8 -disulfonate) tetrasodium salt", "CHEMICAL", 799, 884], ["PMSF", "CHEMICAL", 886, 890], ["phenylmethylsulphonyl fluoride", "CHEMICAL", 892, 922], ["TLC", "CHEMICAL", 924, 927], ["RdRp", "GENE_OR_GENE_PRODUCT", 342, 346], ["N7 MTase", "GENE_OR_GENE_PRODUCT", 378, 386], ["guanine N7 methyltransferase", "GENE_OR_GENE_PRODUCT", 388, 416], ["2 O MTase", "SIMPLE_CHEMICAL", 418, 427], ["nucleoside-2 O methyltransferase", "SIMPLE_CHEMICAL", 429, 461], ["AdoMet", "SIMPLE_CHEMICAL", 463, 469], ["Sadenosyl-l-methionine", "SIMPLE_CHEMICAL", 471, 493], ["AdoHcy", "SIMPLE_CHEMICAL", 495, 501], ["S-adenosyl-l-homocysteine", "SIMPLE_CHEMICAL", 503, 528], ["Wv", "SIMPLE_CHEMICAL", 530, 532], ["Wesselsbron virus", "ORGANISM", 534, 551], ["GMP", "SIMPLE_CHEMICAL", 581, 584], ["guanosine monophosphate", "SIMPLE_CHEMICAL", 586, 609], ["GTP", "SIMPLE_CHEMICAL", 611, 614], ["guanosine triphosphate", "SIMPLE_CHEMICAL", 616, 638], ["Dv", "SIMPLE_CHEMICAL", 640, 642], ["Dengue virus", "ORGANISM", 644, 656], ["WNv", "GENE_OR_GENE_PRODUCT", 658, 661], ["West Nile virus", "ORGANISM", 663, 678], ["LBS", "GENE_OR_GENE_PRODUCT", 680, 683], ["ATA", "SIMPLE_CHEMICAL", 762, 765], ["aurintricarboxylic acid", "SIMPLE_CHEMICAL", 767, 790], ["PPNDS", "SIMPLE_CHEMICAL", 792, 797], ["pyridoxal-5 -phosphate-6-(2 -naphthylazo-6 -nitro-4 ,8 -disulfonate) tetrasodium salt", "SIMPLE_CHEMICAL", 799, 884], ["PMSF", "SIMPLE_CHEMICAL", 886, 890], ["phenylmethylsulphonyl fluoride", "SIMPLE_CHEMICAL", 892, 922], ["TLC", "SIMPLE_CHEMICAL", 924, 927], ["flaviviral genome", "DNA", 212, 229], ["cap-1' structure", "DNA", 273, 289], ["5 terminus", "DNA", 316, 326], ["RdRp, RNA dependent RNA polymerase", "PROTEIN", 342, 376], ["N7 MTase", "PROTEIN", 378, 386], ["guanine N7 methyltransferase", "PROTEIN", 388, 416], ["O MTase", "PROTEIN", 420, 427], ["nucleoside-2 O methyltransferase", "PROTEIN", 429, 461], ["non-structural protein", "PROTEIN", 557, 579], ["putative low affinity RNA binding site", "PROTEIN", 685, 723], ["HBS", "PROTEIN", 725, 728], ["high affinity RNA binding site", "PROTEIN", 730, 760], ["West Nile virus", "SPECIES", 663, 678], ["Wesselsbron virus", "SPECIES", 534, 551], ["Dengue virus", "SPECIES", 644, 656], ["West Nile virus", "SPECIES", 663, 678], ["specific antiviral drugs", "TREATMENT", 14, 38], ["flaviviral infections", "PROBLEM", 61, 82], ["RdRp, RNA dependent RNA polymerase", "TREATMENT", 342, 376], ["guanine N7 methyltransferase", "TREATMENT", 388, 416], ["nucleoside", "TREATMENT", 429, 439], ["methyltransferase", "TREATMENT", 444, 461], ["AdoMet", "TEST", 463, 469], ["Sadenosyl", "TEST", 471, 480], ["methionine", "TREATMENT", 483, 493], ["AdoHcy", "TEST", 495, 501], ["S-adenosyl", "TEST", 503, 513], ["homocysteine", "TREATMENT", 516, 528], ["Wesselsbron virus", "PROBLEM", 534, 551], ["NS", "TREATMENT", 553, 555], ["non-structural protein", "TREATMENT", 557, 579], ["GMP", "TEST", 581, 584], ["guanosine monophosphate", "TREATMENT", 586, 609], ["GTP", "TREATMENT", 611, 614], ["guanosine triphosphate", "TREATMENT", 616, 638], ["Dv", "PROBLEM", 640, 642], ["Dengue virus", "PROBLEM", 644, 656], ["WNv", "PROBLEM", 658, 661], ["putative low affinity RNA binding site", "PROBLEM", 685, 723], ["HBS", "TEST", 725, 728], ["high affinity RNA binding site", "PROBLEM", 730, 760], ["ATA", "TEST", 762, 765], ["aurintricarboxylic acid", "TEST", 767, 790], ["PPNDS", "TEST", 792, 797], ["pyridoxal", "TEST", 799, 808], ["phosphate", "TEST", 812, 821], ["naphthylazo", "TEST", 828, 839], ["nitro", "TREATMENT", 843, 848], ["tetrasodium salt", "TREATMENT", 868, 884], ["PMSF", "TREATMENT", 886, 890], ["phenylmethylsulphonyl fluoride", "TREATMENT", 892, 922], ["TLC", "TREATMENT", 924, 927], ["thin-layer chromatography", "TREATMENT", 929, 954], ["no", "UNCERTAINTY", 11, 13], ["specific", "OBSERVATION_MODIFIER", 14, 22], ["antiviral drugs", "OBSERVATION", 23, 38], ["active", "OBSERVATION_MODIFIER", 118, 124], ["field", "OBSERVATION_MODIFIER", 125, 130], ["TLC", "ANATOMY", 924, 927]]], ["Tel.: +39 02 50314893; fax: +39 02 50314895.IntroductionE-mail address: martino.bolognesi@unimi.it (M. Bolognesi).IntroductionN7Me GpppA 2 OMe G-RNA.", [["+39 02 50314893", "CHEMICAL", 6, 21], ["GpppA 2 OMe G-RNA", "DNA", 131, 148]]], ["The genome encodes a 370-kDa polyprotein precursor, which is processed by viral and cellular proteases into three structural proteins and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) involved in virus replication (Fields et al., 2001) .", [["cellular", "ANATOMY", 84, 92], ["cellular", "CELL", 84, 92], ["NS1", "GENE_OR_GENE_PRODUCT", 169, 172], ["NS2A", "GENE_OR_GENE_PRODUCT", 174, 178], ["NS2B", "GENE_OR_GENE_PRODUCT", 180, 184], ["NS3", "GENE_OR_GENE_PRODUCT", 186, 189], ["NS4A", "GENE_OR_GENE_PRODUCT", 191, 195], ["NS4B", "GENE_OR_GENE_PRODUCT", 197, 201], ["NS5", "GENE_OR_GENE_PRODUCT", 206, 209], ["370-kDa polyprotein precursor", "PROTEIN", 21, 50], ["viral and cellular proteases", "PROTEIN", 74, 102], ["structural proteins", "PROTEIN", 114, 133], ["non-structural proteins", "PROTEIN", 144, 167], ["NS1", "PROTEIN", 169, 172], ["NS2A", "PROTEIN", 174, 178], ["NS2B", "PROTEIN", 180, 184], ["NS3", "PROTEIN", 186, 189], ["NS4A", "PROTEIN", 191, 195], ["NS4B", "PROTEIN", 197, 201], ["NS5", "PROTEIN", 206, 209], ["viral and cellular proteases", "PROBLEM", 74, 102], ["non-structural proteins", "TEST", 144, 167], ["NS1", "TEST", 169, 172], ["NS2A", "TEST", 174, 178], ["NS2B", "TEST", 180, 184], ["NS3", "TREATMENT", 186, 189], ["NS4A", "TREATMENT", 191, 195], ["NS4B", "TREATMENT", 197, 201], ["NS5", "TREATMENT", 206, 209], ["cellular proteases", "OBSERVATION", 84, 102]]], ["Among other proteins, the multifunctional protein NS5 is particularly important for viral replication.", [["NS5", "GENE_OR_GENE_PRODUCT", 50, 53], ["multifunctional protein NS5", "PROTEIN", 26, 53], ["the multifunctional protein NS5", "TREATMENT", 22, 53], ["viral replication", "TREATMENT", 84, 101]]], ["The C-terminal domain of NS5 is endowed with RNA-dependent RNA polymerase (RdRp) activity, while its N-terminal domain contains S-adenosyl-l-methionine (AdoMet)-dependent methyltransferase (MTase) activity.", [["S-adenosyl-l-methionine", "CHEMICAL", 128, 151], ["AdoMet", "CHEMICAL", 153, 159], ["N", "CHEMICAL", 101, 102], ["S-adenosyl-l-methionine", "CHEMICAL", 128, 151], ["AdoMet", "CHEMICAL", 153, 159], ["NS5", "GENE_OR_GENE_PRODUCT", 25, 28], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 45, 73], ["S-adenosyl-l-methionine", "SIMPLE_CHEMICAL", 128, 151], ["AdoMet", "SIMPLE_CHEMICAL", 153, 159], [")-dependent methyltransferase", "GENE_OR_GENE_PRODUCT", 159, 188], ["MTase", "GENE_OR_GENE_PRODUCT", 190, 195], ["C-terminal domain", "PROTEIN", 4, 21], ["NS5", "PROTEIN", 25, 28], ["RNA-dependent RNA polymerase", "PROTEIN", 45, 73], ["RdRp", "PROTEIN", 75, 79], ["N-terminal domain", "PROTEIN", 101, 118], ["S-adenosyl-l-methionine (AdoMet)-dependent methyltransferase", "PROTEIN", 128, 188], ["MTase", "PROTEIN", 190, 195], ["The C-terminal domain of NS5", "TREATMENT", 0, 28], ["RNA-dependent RNA polymerase", "TREATMENT", 45, 73], ["its N-terminal domain", "TREATMENT", 97, 118], ["S-adenosyl-l-methionine (AdoMet)", "TREATMENT", 128, 160], ["dependent methyltransferase (MTase) activity", "TREATMENT", 161, 205], ["NS5", "OBSERVATION", 25, 28]]], ["The MTase domain is involved in the last two steps of the capping process that starts with the conversion of the 5 -triphosphate end of the nascent RNA into a 5 -diphosphate (RNA triphosphatase activity), followed by the addition of a GMP unit via a 5 -5 phosphodiester bond (guanylyltransferase activity).", [["5 -triphosphate", "CHEMICAL", 113, 128], ["5 -diphosphate", "CHEMICAL", 159, 173], ["GMP", "CHEMICAL", 235, 238], ["5 -5 phosphodiester", "CHEMICAL", 250, 269], ["5 -triphosphate", "CHEMICAL", 113, 128], ["5 -diphosphate", "CHEMICAL", 159, 173], ["GMP", "CHEMICAL", 235, 238], ["phosphodiester", "CHEMICAL", 255, 269], ["5 -triphosphate", "SIMPLE_CHEMICAL", 113, 128], ["5 -diphosphate", "SIMPLE_CHEMICAL", 159, 173], ["GMP", "SIMPLE_CHEMICAL", 235, 238], ["5 -5 phosphodiester bond", "SIMPLE_CHEMICAL", 250, 274], ["guanylyltransferase", "SIMPLE_CHEMICAL", 276, 295], ["MTase domain", "PROTEIN", 4, 16], ["5 -triphosphate end", "RNA", 113, 132], ["nascent RNA", "RNA", 140, 151], ["RNA triphosphatase", "PROTEIN", 175, 193], ["the capping process", "TREATMENT", 54, 73], ["the nascent RNA", "TREATMENT", 136, 151], ["a 5 -diphosphate (RNA triphosphatase activity", "TREATMENT", 157, 202], ["a GMP unit", "TREATMENT", 233, 243], ["a 5 -5 phosphodiester bond (guanylyltransferase activity", "TREATMENT", 248, 304], ["capping process", "OBSERVATION", 58, 73]]], ["MTase, then, transfers a methyl group from AdoMet to the N7atom of the cap guanine and, successively, to the ribose 2 O-atom of the first RNA nucleotide forming the 'cap 0' and 'cap 1' structures, respectively.", [["methyl", "CHEMICAL", 25, 31], ["AdoMet", "CHEMICAL", 43, 49], ["guanine", "CHEMICAL", 75, 82], ["ribose", "CHEMICAL", 109, 115], ["nucleotide", "CHEMICAL", 142, 152], ["methyl", "CHEMICAL", 25, 31], ["AdoMet", "CHEMICAL", 43, 49], ["guanine", "CHEMICAL", 75, 82], ["ribose", "CHEMICAL", 109, 115], ["O", "CHEMICAL", 118, 119], ["nucleotide", "CHEMICAL", 142, 152], ["methyl", "SIMPLE_CHEMICAL", 25, 31], ["AdoMet", "SIMPLE_CHEMICAL", 43, 49], ["guanine", "SIMPLE_CHEMICAL", 75, 82], ["MTase", "PROTEIN", 0, 5], ["ribose 2 O-atom", "PROTEIN", 109, 124], ["the first RNA nucleotide", "TREATMENT", 128, 152]]], ["The crystal structures of the MTase domain from several viruses, in complex with AdoMet, S-adenosyl-l-homocysteine (the co-product of methyl transfer, AdoHcy), with GTP or with capanalogues (Assenberg et al., 2007; Bollati et al., 2009; Egloff et al., 2002 Egloff et al., , 2007 are taken here as starting data for an analysis of the main structural and mechanistic features related to MTase activity.", [["AdoMet", "CHEMICAL", 81, 87], ["S-adenosyl-l-homocysteine", "CHEMICAL", 89, 114], ["methyl", "CHEMICAL", 134, 140], ["AdoHcy", "CHEMICAL", 151, 157], ["GTP", "CHEMICAL", 165, 168], ["AdoMet", "CHEMICAL", 81, 87], ["S-adenosyl-l-homocysteine", "CHEMICAL", 89, 114], ["methyl", "CHEMICAL", 134, 140], ["AdoHcy", "CHEMICAL", 151, 157], ["GTP", "CHEMICAL", 165, 168], ["AdoMet", "SIMPLE_CHEMICAL", 81, 87], ["S-adenosyl-l-homocysteine", "SIMPLE_CHEMICAL", 89, 114], ["methyl", "SIMPLE_CHEMICAL", 134, 140], ["AdoHcy", "SIMPLE_CHEMICAL", 151, 157], ["GTP", "SIMPLE_CHEMICAL", 165, 168], ["MTase", "GENE_OR_GENE_PRODUCT", 386, 391], ["MTase domain", "PROTEIN", 30, 42], ["MTase", "PROTEIN", 386, 391], ["the MTase domain", "PROBLEM", 26, 42], ["several viruses", "PROBLEM", 48, 63], ["AdoMet", "TREATMENT", 81, 87], ["S-adenosyl", "TREATMENT", 89, 99], ["homocysteine", "TREATMENT", 102, 114], ["GTP", "TREATMENT", 165, 168], ["capanalogues", "TREATMENT", 177, 189], ["an analysis", "TEST", 315, 326], ["several", "OBSERVATION_MODIFIER", 48, 55], ["viruses", "OBSERVATION", 56, 63]]], ["Since flaviviral MTase displays both N7 and 2 O activities (Ray et al., 2006; Zhou et al., 2007) , in order for capped RNA to be methylated at the two different sites the nucleic acid substrate must adopt two distinct binding modes relative to the enzyme active site.", [["nucleic acid", "CHEMICAL", 171, 183], ["flaviviral MTase", "GENE_OR_GENE_PRODUCT", 6, 22], ["flaviviral MTase", "PROTEIN", 6, 22], ["capped RNA", "RNA", 112, 122], ["enzyme active site", "PROTEIN", 248, 266], ["capped RNA", "PROBLEM", 112, 122], ["the nucleic acid substrate", "TREATMENT", 167, 193], ["the enzyme active site", "PROBLEM", 244, 266]]], ["In particular, many structural results (Assenberg et al., 2007; Bollati et al., 2009; Egloff et al., 2002 Egloff et al., , 2007 show that small capped RNA analogues bind to a MTase high affinity binding site (HBS), where they are supposed to be held during 2 O methylation.", [["O", "CHEMICAL", 259, 260], ["MTase high affinity binding site", "PROTEIN", 175, 207], ["small capped RNA analogues", "TREATMENT", 138, 164], ["a MTase high affinity binding site", "PROBLEM", 173, 207]]], ["On the contrary, structural details on a distinct binding site occupied by capped RNA during N7 methylation are missing.", [["binding site", "DNA", 50, 62], ["capped RNA", "RNA", 75, 85], ["a distinct binding site", "PROBLEM", 39, 62], ["N7 methylation", "TREATMENT", 93, 107], ["capped RNA", "OBSERVATION", 75, 85]]], ["Structural considerations, however, suggest the existence of a secondary, putative low affinity binding site (LBS) (Dong et al., 2008a; Mastrangelo et al., 2007) located in a positively charged region close to the AdoMet binding site.", [["AdoMet", "CHEMICAL", 214, 220], ["AdoMet", "CHEMICAL", 214, 220], ["AdoMet", "SIMPLE_CHEMICAL", 214, 220], ["putative low affinity binding site", "PROTEIN", 74, 108], ["AdoMet binding site", "DNA", 214, 233], ["a secondary, putative low affinity binding site", "PROBLEM", 61, 108], ["low affinity", "OBSERVATION_MODIFIER", 83, 95], ["AdoMet binding", "OBSERVATION", 214, 228]]], ["Here, we first present a model of a short capped RNA (Gpp-pAGUp) bound to the LBS of Wesselsbron virus MTase ( Wv MTase), that is used to explore the details of protein/RNA interaction during N7 methyl transfer.", [["N7 methyl", "CHEMICAL", 192, 201], ["N7 methyl", "CHEMICAL", 192, 201], ["Gpp-pAGUp", "GENE_OR_GENE_PRODUCT", 54, 63], ["Wesselsbron virus MTase", "GENE_OR_GENE_PRODUCT", 85, 108], ["Wv MTase", "GENE_OR_GENE_PRODUCT", 111, 119], ["N7 methyl", "SIMPLE_CHEMICAL", 192, 201], ["short capped RNA", "RNA", 36, 52], ["Gpp", "PROTEIN", 54, 57], ["AGUp", "PROTEIN", 59, 63], ["LBS", "PROTEIN", 78, 81], ["Wesselsbron virus MTase", "PROTEIN", 85, 108], ["Wv MTase", "PROTEIN", 111, 119], ["Wesselsbron virus", "SPECIES", 85, 102], ["a short capped RNA", "PROBLEM", 34, 52], ["Gpp", "TEST", 54, 57], ["Wesselsbron virus MTase", "TREATMENT", 85, 108], ["protein/RNA interaction", "PROBLEM", 161, 184], ["N7 methyl transfer", "TREATMENT", 192, 210]]], ["Based on this analysis, we then discussed an in silico search that allowed to select three synthetic compounds, predicted to display low free energy of binding to Wv MTase.", [["Wv MTase", "GENE_OR_GENE_PRODUCT", 163, 171], ["Wv MTase", "PROTEIN", 163, 171], ["this analysis", "TEST", 9, 22]]], ["The compounds selected were tested in vitro on Wv MTase and Dv MTase in 2 O and N7 methyltransferase activity assays.", [["Wv MTase", "GENE_OR_GENE_PRODUCT", 47, 55], ["Dv MTase", "GENE_OR_GENE_PRODUCT", 60, 68], ["2 O", "SIMPLE_CHEMICAL", 72, 75], ["N7 methyltransferase", "GENE_OR_GENE_PRODUCT", 80, 100], ["Wv MTase", "PROTEIN", 47, 55], ["Dv MTase", "PROTEIN", 60, 68], ["Dv MTase", "TREATMENT", 60, 68], ["N7 methyltransferase activity assays", "TREATMENT", 80, 116]]], ["The results of the combined computational and experimental screening allowed us to identify aurintricarboxylic acid (ATA) as the most potent flaviviral MTase inhibitor known to date.", [["aurintricarboxylic acid", "CHEMICAL", 92, 115], ["ATA", "CHEMICAL", 117, 120], ["aurintricarboxylic acid", "CHEMICAL", 92, 115], ["ATA", "CHEMICAL", 117, 120], ["aurintricarboxylic acid", "SIMPLE_CHEMICAL", 92, 115], ["ATA", "SIMPLE_CHEMICAL", 117, 120], ["experimental screening", "TEST", 46, 68], ["aurintricarboxylic acid", "TEST", 92, 115], ["the most potent flaviviral MTase inhibitor", "TREATMENT", 125, 167]]], ["The inhibitory effect of ATA is discussed here on the basis of existing models of the flaviviral MTase mechanism for N7 and 2 O cap methylation.", [["ATA", "CHEMICAL", 25, 28], ["N7", "CHEMICAL", 117, 119], ["ATA", "SIMPLE_CHEMICAL", 25, 28], ["N7", "SIMPLE_CHEMICAL", 117, 119], ["flaviviral MTase", "PROTEIN", 86, 102], ["the flaviviral MTase mechanism", "TREATMENT", 82, 112], ["N7 and 2 O cap methylation", "TREATMENT", 117, 143]]], ["Since flavivirus MTase has been shown by mutagenesis to be crucial for viral replication (Zhou et al., 2007) , shedding light on MTase inhibition may prove a productive path towards the development of therapeutics against life threatening flaviviral diseases (Dong et al., 2008a,b) .Chemical database for virtual screening and reagentsThe virtual Library of Pharmacologically Active Compounds (LOPAC) used for the docking analysis was provided by Sigma-Aldrich, and included 1280 commercially available compounds (www.sigmaaldrich.com).", [["flaviviral diseases", "DISEASE", 239, 258], ["flavivirus MTase", "ORGANISM", 6, 22], ["MTase", "GENE_OR_GENE_PRODUCT", 129, 134], ["flavivirus MTase", "PROTEIN", 6, 22], ["MTase", "PROTEIN", 129, 134], ["flavivirus MTase", "PROBLEM", 6, 22], ["viral replication", "PROBLEM", 71, 88], ["MTase inhibition", "TREATMENT", 129, 145], ["life threatening flaviviral diseases", "PROBLEM", 222, 258], ["virtual screening", "TEST", 305, 322], ["reagents", "TREATMENT", 327, 335], ["Compounds (LOPAC)", "TREATMENT", 383, 400], ["the docking analysis", "TEST", 410, 430], ["Pharmacologically", "OBSERVATION_MODIFIER", 358, 375], ["Active", "OBSERVATION_MODIFIER", 376, 382]]], ["AdoMet was purchased from New England BioLabs.", [["Ado", "CHEMICAL", 0, 3], ["AdoMet", "CHEMICAL", 0, 6], ["AdoMet", "SIMPLE_CHEMICAL", 0, 6]]], ["The compounds tested in vitro, ATA, nilutamide and pyridoxal-5 -phosphate-6-(2 -naphthylazo-6nitro-4 ,8 -disulfonate) tetrasodium salt (PPNDS), were from Sigma-Aldrich.", [["ATA", "CHEMICAL", 31, 34], ["nilutamide", "CHEMICAL", 36, 46], ["pyridoxal-5 -phosphate-6-(2 -naphthylazo-6nitro-4 ,8 -disulfonate", "CHEMICAL", 51, 116], ["tetrasodium salt", "CHEMICAL", 118, 134], ["PPNDS", "CHEMICAL", 136, 141], ["nilutamide", "CHEMICAL", 36, 46], ["pyridoxal-5 -phosphate-6-(2 -naphthylazo-6nitro-4 ,8 -disulfonate) tetrasodium salt", "CHEMICAL", 51, 134], ["PPNDS", "CHEMICAL", 136, 141], ["ATA", "SIMPLE_CHEMICAL", 31, 34], ["nilutamide", "SIMPLE_CHEMICAL", 36, 46], ["pyridoxal-5 -phosphate-6-(2 -naphthylazo-6nitro-4 ,8 -disulfonate) tetrasodium salt", "SIMPLE_CHEMICAL", 51, 134], ["PPNDS", "SIMPLE_CHEMICAL", 136, 141], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 154, 167], ["The compounds", "TEST", 0, 13], ["nilutamide", "TREATMENT", 36, 46], ["pyridoxal", "TREATMENT", 51, 60], ["phosphate", "TREATMENT", 64, 73], ["naphthylazo", "TREATMENT", 80, 91], ["6nitro", "TREATMENT", 92, 98]]], ["Compounds were dissolved at 20 mM in H 2 O, or at 8 mM in 0.1 mM NaOH (ATA), and stored at \u221220 \u2022 C.Locating a short capped RNA in the LBSIn order to produce an MTase model suitable for the analysis of the N7 methylation process, the crystal structure of Wv MTase in its complex with AdoMet and with an HBS-bound small capped RNA analog, N7Me GpppG, solved at 1.9 \u00c5 resolution (pdb 3ELW) (Bollati et al., 2009 ) was used.", [["H 2 O", "CHEMICAL", 37, 42], ["NaOH", "CHEMICAL", 65, 69], ["ATA", "CHEMICAL", 71, 74], ["AdoMet", "CHEMICAL", 283, 289], ["H 2 O", "CHEMICAL", 37, 42], ["NaOH", "CHEMICAL", 65, 69], ["N7", "CHEMICAL", 205, 207], ["AdoMet", "CHEMICAL", 283, 289], ["H 2 O", "SIMPLE_CHEMICAL", 37, 42], ["ATA", "SIMPLE_CHEMICAL", 71, 74], ["Wv MTase", "GENE_OR_GENE_PRODUCT", 254, 262], ["AdoMet", "SIMPLE_CHEMICAL", 283, 289], ["N7Me GpppG", "SIMPLE_CHEMICAL", 337, 347], ["short capped RNA", "RNA", 110, 126], ["Wv MTase", "PROTEIN", 254, 262], ["HBS", "PROTEIN", 302, 305], ["N7Me GpppG", "PROTEIN", 337, 347], ["pdb 3ELW", "PROTEIN", 377, 385], ["a short capped RNA", "PROBLEM", 108, 126], ["the analysis", "TEST", 185, 197], ["the N7 methylation process", "TREATMENT", 201, 227], ["AdoMet", "TREATMENT", 283, 289], ["an HBS", "TEST", 299, 305], ["small capped RNA analog", "PROBLEM", 312, 335], ["N7Me GpppG", "TREATMENT", 337, 347], ["small", "OBSERVATION_MODIFIER", 312, 317], ["capped RNA", "OBSERVATION", 318, 328]]], ["Hydrogen atoms and computed Gasteiger charges (Gasteiger and Marsili, 1978) were added after removing the HBS-bound RNA analog, maintaining the AdoMet cofactor bound to the protein.", [["Hydrogen atoms", "CHEMICAL", 0, 14], ["AdoMet", "CHEMICAL", 144, 150], ["Hydrogen", "CHEMICAL", 0, 8], ["AdoMet", "CHEMICAL", 144, 150], ["Hydrogen atoms", "SIMPLE_CHEMICAL", 0, 14], ["AdoMet", "SIMPLE_CHEMICAL", 144, 150], ["HBS", "PROTEIN", 106, 109], ["AdoMet cofactor", "PROTEIN", 144, 159], ["Hydrogen atoms", "PROBLEM", 0, 14], ["computed Gasteiger charges", "TREATMENT", 19, 45], ["the HBS", "TEST", 102, 109], ["bound RNA analog", "TREATMENT", 110, 126]]], ["A squared grid (30 \u00c5 side) centered roughly in the LBS region between Ser56 and Arg84 (Auto-grid4; step size 0.375 \u00c5, 80 \u00d7 80 \u00d7 80 = 512,000 points) (Goodford, 1985) was subsequently built and used as the volume explored in the capped RNA docking searches.", [["Ser56", "CHEMICAL", 70, 75], ["Arg84", "CHEMICAL", 80, 85], ["Ser56", "GENE_OR_GENE_PRODUCT", 70, 75], ["LBS region", "PROTEIN", 51, 61], ["Ser56", "PROTEIN", 70, 75], ["Arg84", "PROTEIN", 80, 85], ["Auto", "PROTEIN", 87, 91], ["grid4", "PROTEIN", 92, 97], ["A squared grid", "TEST", 0, 14], ["Auto", "TEST", 87, 91], ["size", "TEST", 104, 108], ["squared", "OBSERVATION_MODIFIER", 2, 9], ["LBS", "ANATOMY_MODIFIER", 51, 54], ["region", "ANATOMY_MODIFIER", 55, 61]]], ["The short capped RNA GpppAGUp molecule was then built using the program Ghemical (http://www.bioinformatics.org/ghemical).", [["short capped RNA GpppAGUp molecule", "PROTEIN", 4, 38], ["The short capped RNA GpppAGUp molecule", "PROBLEM", 0, 38], ["short", "OBSERVATION_MODIFIER", 4, 9]]], ["Seventy genetic algorithm searches were performed using Autodock4, moving Gpp-pAGUp within the described grid and using 32 active torsions in the ligand molecule (with 150 individuals in population and 27,000 generations; Morris et al., 1998) .", [["Gpp-pAGUp", "GENE_OR_GENE_PRODUCT", 74, 83], ["Autodock4", "PROTEIN", 56, 65], ["Gpp", "PROTEIN", 74, 77], ["pAGUp", "DNA", 78, 83], ["ligand molecule", "PROTEIN", 146, 161], ["Autodock4", "TEST", 56, 65], ["moving Gpp", "TEST", 67, 77], ["32 active torsions in the ligand molecule", "PROBLEM", 120, 161], ["active", "OBSERVATION_MODIFIER", 123, 129], ["torsions", "OBSERVATION", 130, 138], ["ligand", "ANATOMY", 146, 152]]], ["The search produced a list of 70 capped RNA positions within the explored LBS volume, ranked by means of the Estimated Free Energy of Binding ( G) that varied between \u22123.32 and \u221212.43 kcal/mol.", [["LBS", "CANCER", 74, 77]]], ["Among the four best G values (in the \u221211.74, \u221212.43 kcal/mol range) the model with the cap Guanine N7 atom closer to the AdoMet methyl group was chosen (\u221211.86 kcal/mol; AdoMet-CH3-N7-RNA distance 7.3 \u00c5).", [["Guanine", "CHEMICAL", 91, 98], ["AdoMet methyl", "CHEMICAL", 121, 134], ["AdoMet", "CHEMICAL", 170, 176], ["Guanine N7", "CHEMICAL", 91, 101], ["AdoMet methyl", "CHEMICAL", 121, 134], ["AdoMet", "CHEMICAL", 170, 176], ["CH3", "CHEMICAL", 177, 180], ["N7", "CHEMICAL", 181, 183], ["Guanine N7 atom", "SIMPLE_CHEMICAL", 91, 106], ["AdoMet methyl", "SIMPLE_CHEMICAL", 121, 134], ["the cap Guanine N7 atom", "TREATMENT", 83, 106], ["the AdoMet methyl group", "TREATMENT", 117, 140], ["AdoMet", "TEST", 170, 176]]], ["Such model ( Wv MTase/GpppAGUp) was then used as starting structure for molecular dynamics (MD) simulations, performed using the program GROMACS (van der Spoel et al., 2005) .", [["Wv MTase", "GENE_OR_GENE_PRODUCT", 13, 21], ["Wv MTase", "PROTEIN", 13, 21], ["GpppAGUp", "PROTEIN", 22, 30], ["Such model ( Wv MTase/GpppAGUp)", "TREATMENT", 0, 31]]], ["Briefly, the protein with AdoMet and the docked capped RNA (GpppAGUp) were enclosed in a box of 61 \u00c5 \u00d7 68 \u00c5 \u00d7 91 \u00c5 filled with 11,688 water molecules and 6 Cl \u2212 ions for charge equilibration.", [["AdoMet", "CHEMICAL", 26, 32], ["Cl", "CHEMICAL", 156, 158], ["AdoMet", "CHEMICAL", 26, 32], ["Cl", "CHEMICAL", 156, 158], ["AdoMet", "SIMPLE_CHEMICAL", 26, 32], ["Cl \u2212 ions", "SIMPLE_CHEMICAL", 156, 165], ["AdoMet", "PROTEIN", 26, 32], ["GpppAGUp", "PROTEIN", 60, 68], ["AdoMet", "TREATMENT", 26, 32], ["the docked capped RNA", "TREATMENT", 37, 58], ["GpppAGUp", "TEST", 60, 68], ["a box", "TEST", 87, 92], ["water molecules", "TEST", 134, 149]]], ["Using the GRO-MACS force field (GROMOS-87 with corrections as in Mark et al., 1994) , the energy was minimized with a steepest descent algorithm, and the system was then equilibrated at 10 K for 1 ps and at 100 K for 5 ps.", [["GRO", "PROTEIN", 10, 13], ["GROMOS", "TEST", 32, 38], ["a steepest descent algorithm", "TREATMENT", 116, 144]]], ["The MD simulation was carried out with time step of 1 fs using a leap-frog algorithm and periodic boundary conditions; electrostatic interactions were treated with Fast Particle-Mesh Ewald algorithm, while van der Waals interactions were cut-off at 12 \u00c5; the simulation was performed at fixed T (300 K) and P (1 atm) using Berendsen coupling (Berendsen et al., 1984) .", [["a leap-frog algorithm", "TREATMENT", 63, 84], ["periodic boundary conditions", "PROBLEM", 89, 117], ["electrostatic interactions", "PROBLEM", 119, 145], ["Fast Particle-Mesh Ewald algorithm", "TREATMENT", 164, 198]]], ["The structure produced after 9 ns was used as final model for the analysis of protein/RNA interaction.In silico search for MTase inhibitorsThe AutoDock4 software package (Morris et al., 1998) was used for a docking search using compounds from the LOPAC library, and Python Molecule Viewer 1.4.5 (MGL-tools package http://www.mgltools.scripps.edu/) to analyze the data.", [["MTase", "GENE_OR_GENE_PRODUCT", 123, 128], ["MTase", "PROTEIN", 123, 128], ["MGL", "PROTEIN", 296, 299], ["9 ns", "TREATMENT", 29, 33], ["the analysis", "TEST", 62, 74], ["MTase inhibitors", "TREATMENT", 123, 139], ["Python Molecule Viewer", "TEST", 266, 288]]], ["As docking model the atomic coordinates of Wv MTase in complex with AdoMet and N7Me GpppG were chosen (pdb 3ELW) (Bollati et al., 2009) , keeping both the protein and the AdoMet molecule and removing water and the cap-analogue.", [["AdoMet", "CHEMICAL", 68, 74], ["AdoMet", "CHEMICAL", 171, 177], ["AdoMet", "CHEMICAL", 68, 74], ["N7Me GpppG", "CHEMICAL", 79, 89], ["AdoMet", "CHEMICAL", 171, 177], ["Wv MTase", "GENE_OR_GENE_PRODUCT", 43, 51], ["AdoMet", "SIMPLE_CHEMICAL", 68, 74], ["N7Me GpppG", "SIMPLE_CHEMICAL", 79, 89], ["AdoMet", "SIMPLE_CHEMICAL", 171, 177], ["water", "SIMPLE_CHEMICAL", 200, 205], ["Wv MTase", "PROTEIN", 43, 51], ["AdoMet", "PROTEIN", 68, 74], ["N7Me GpppG", "PROTEIN", 79, 89], ["pdb 3ELW", "PROTEIN", 103, 111], ["AdoMet molecule", "PROTEIN", 171, 186], ["AdoMet and N7Me GpppG", "TREATMENT", 68, 89], ["the AdoMet molecule", "TREATMENT", 167, 186], ["the cap-analogue", "TREATMENT", 210, 226]]], ["Hydrogen atoms and computed Gasteiger charges were added using the program Autodock4 (Gasteiger and Marsili, 1978 ).", [["Hydrogen atoms", "CHEMICAL", 0, 14], ["Hydrogen", "CHEMICAL", 0, 8], ["Hydrogen atoms", "SIMPLE_CHEMICAL", 0, 14], ["Hydrogen atoms", "PROBLEM", 0, 14], ["computed Gasteiger charges", "TREATMENT", 19, 45]]], ["The protein model was then used to build a discrete grid within a box with dimensions 23 \u00c5 \u00d7 15 \u00c5 \u00d7 26 \u00c5 (Autogrid4; step size 0.375 \u00c5, 60 \u00d7 40 \u00d7 70 = 168,000 points) (Goodford, 1985) for the compound docking search.", [["The protein model", "TEST", 0, 17], ["dimensions", "TEST", 75, 85], ["Autogrid4", "TEST", 106, 115], ["step size", "TEST", 117, 126]]], ["The search (i.e. the grid center position) was centered in a wide crevice located between the AdoMet binding site and the RNA HBS, more precisely between residues Lys182 and Arg213.", [["AdoMet", "CHEMICAL", 94, 100], ["Arg213", "CHEMICAL", 174, 180], ["AdoMet", "CHEMICAL", 94, 100], ["Lys182", "CHEMICAL", 163, 169], ["Arg", "CHEMICAL", 174, 177], ["AdoMet", "SIMPLE_CHEMICAL", 94, 100], ["Arg213", "AMINO_ACID", 174, 180], ["AdoMet binding site", "DNA", 94, 113], ["RNA HBS", "DNA", 122, 129], ["a wide crevice", "TREATMENT", 59, 73], ["the AdoMet binding site", "TREATMENT", 90, 113], ["the RNA HBS", "PROBLEM", 118, 129], ["Arg", "TEST", 174, 177], ["AdoMet binding", "OBSERVATION", 94, 108]]], ["In this way the protein active site, where the methyl transfer from AdoMet occurs, is completely included in the search grid chosen.", [["methyl", "CHEMICAL", 47, 53], ["AdoMet", "CHEMICAL", 68, 74], ["methyl", "CHEMICAL", 47, 53], ["AdoMet", "CHEMICAL", 68, 74], ["methyl", "SIMPLE_CHEMICAL", 47, 53], ["AdoMet", "SIMPLE_CHEMICAL", 68, 74], ["protein active site", "PROTEIN", 16, 35], ["the methyl transfer from AdoMet", "TREATMENT", 43, 74], ["active", "OBSERVATION", 24, 30]]], ["Twenty genetic algorithm searches were run using Autodock4 for each compound in the LOPAC library (with 150 individuals in the population and 27,000 generations) (Morris et al., 1998) .In vitro synthesis of capped RNAThe 7Me GpppAC 5 RNA substrate, used for the 2 O MTase assay, was synthesized by incubating the DNA oligonucleotide CCCCGGGTCT 25 with the bacteriophage T7 DNA primase in the presence of 7Me GpppA and CTP as described .", [["CTP", "CHEMICAL", 418, 421], ["GpppA", "CHEMICAL", 408, 413], ["CTP", "CHEMICAL", 418, 421], ["DNA", "CELLULAR_COMPONENT", 313, 316], ["DNA", "CELLULAR_COMPONENT", 373, 376], ["7Me GpppA", "SIMPLE_CHEMICAL", 404, 413], ["CTP", "SIMPLE_CHEMICAL", 418, 421], ["Autodock4", "DNA", 49, 58], ["LOPAC library", "DNA", 84, 97], ["bacteriophage T7 DNA primase", "DNA", 356, 384], ["Autodock4", "TREATMENT", 49, 58], ["capped RNAThe 7Me GpppAC", "TREATMENT", 207, 231], ["the 2 O MTase assay", "TEST", 258, 277], ["the DNA oligonucleotide CCCCGGGTCT", "TEST", 309, 343], ["the bacteriophage T7 DNA primase", "TEST", 352, 384], ["CTP", "TEST", 418, 421]]], ["The reaction products obtained after a 48 h incubation period were purified by reverse phase chromatography in HPLC.", [["The reaction products", "TREATMENT", 0, 21]]], ["We collected the peak corresponding to 7Me GpppAC 5 as described .In vitro synthesis of capped RNAThe RNA substrate used for N7 MTase assay corresponding to the authentic 5 -terminal 351 nucleotides of the Dv genome (Dv 1-351 RNA) was obtained as follows.", [["nucleotides", "CHEMICAL", 187, 198], ["7Me GpppAC 5", "DNA", 39, 51], ["capped RNAThe RNA substrate", "RNA", 88, 115], ["5 -terminal 351 nucleotides", "DNA", 171, 198], ["Dv genome", "DNA", 206, 215], ["Dv 1", "DNA", 217, 221], ["capped RNAThe RNA substrate", "TREATMENT", 88, 115], ["N7 MTase assay", "TEST", 125, 139]]], ["The 5 UTR of Dv serotype 2, New Guinea C strain was amplified by PCR using the primers BamH1-2.5Dv-5 (s) (CGGGATCCCAGTAATACGACTCACTATTAGTTGTTAG-TCTACGTGGACC) and EcoR1-Dv-351(as) (GGAATTCGGTGGTGCA-GATGAACTTCAG), and cloned in the pUC18 (Fermentas) plasmid using a standard BamH1/EcoR1 restriction-ligation procedure generating the pUC18-2.5-Dv351 plasmid.", [["Dv serotype 2", "ORGANISM", 13, 26], ["New Guinea C strain", "ORGANISM", 28, 47], ["BamH1", "GENE_OR_GENE_PRODUCT", 87, 92], ["EcoR1-Dv-351", "GENE_OR_GENE_PRODUCT", 162, 174], ["GGAATTCGGTGGTGCA-GATGAACTTCAG", "GENE_OR_GENE_PRODUCT", 180, 209], ["pUC18", "GENE_OR_GENE_PRODUCT", 230, 235], ["Fermentas", "GENE_OR_GENE_PRODUCT", 237, 246], ["BamH1", "GENE_OR_GENE_PRODUCT", 273, 278], ["EcoR1", "GENE_OR_GENE_PRODUCT", 279, 284], ["pUC18", "GENE_OR_GENE_PRODUCT", 331, 336], ["5 UTR", "DNA", 4, 9], ["primers BamH1", "DNA", 79, 92], ["EcoR1", "DNA", 162, 167], ["Dv-351", "DNA", 168, 174], ["pUC18 (Fermentas) plasmid", "DNA", 230, 255], ["pUC18-2.5-Dv351 plasmid", "DNA", 331, 354], ["Guinea C strain", "SPECIES", 32, 47], ["Dv serotype", "TREATMENT", 13, 24], ["New Guinea C strain", "TREATMENT", 28, 47], ["the primers BamH1", "TEST", 75, 92], ["Dv", "TEST", 96, 98], ["CGGGATCCCAGTAATACGACTCACTATTAGTTGTTAG", "TEST", 106, 143], ["EcoR1", "TEST", 162, 167], ["the pUC18 (Fermentas) plasmid", "TREATMENT", 226, 255], ["a standard BamH1/EcoR1 restriction", "TREATMENT", 262, 296], ["ligation procedure", "TREATMENT", 297, 315], ["the pUC18", "TREATMENT", 327, 336], ["Dv351 plasmid", "TREATMENT", 341, 354]]], ["The RNA transcription template was synthesized by PCR amplification performed on the pUC18-2.5-Dv351 plasmid using the primers BamH1-2.5Dv-5 (s) and Dv-351(as) (GGTGGTGCAGATGAACTTCAGGG).", [["pUC18", "GENE_OR_GENE_PRODUCT", 85, 90], ["BamH1", "GENE_OR_GENE_PRODUCT", 127, 132], ["Dv-351", "GENE_OR_GENE_PRODUCT", 149, 155], ["RNA transcription template", "DNA", 4, 30], ["pUC18-2.5-Dv351 plasmid", "DNA", 85, 108], ["primers BamH1-2.5Dv-5", "DNA", 119, 140], ["Dv-351", "DNA", 149, 155], ["The RNA transcription template", "TREATMENT", 0, 30], ["PCR amplification", "TEST", 50, 67], ["the pUC18", "TEST", 81, 90], ["the primers BamH1", "TEST", 115, 132], ["Dv", "TEST", 136, 138], ["Dv", "TEST", 149, 151]]], ["The PCR reaction product was purified on agarose gel using the QIAquick gel extraction kit (Qiagen).", [["agarose", "SIMPLE_CHEMICAL", 41, 48], ["The PCR reaction product", "TREATMENT", 0, 24], ["agarose gel", "TREATMENT", 41, 52], ["the QIAquick gel extraction kit", "TREATMENT", 59, 90]]], ["The Dv 1-351 RNA substrate was generated by in vitro transcription using the MEGAshortscript T7 RNA polymerase (Ambion) that recognizes the T7 class II 2.5 promoter (underlined in primer) present in the PCR template and initiates RNA synthesis by pppAG (Coleman et al., 2004) .", [["Dv 1-351", "CHEMICAL", 4, 12], ["Dv 1", "GENE_OR_GENE_PRODUCT", 4, 8], ["Ambion", "GENE_OR_GENE_PRODUCT", 112, 118], ["Dv 1-351 RNA substrate", "DNA", 4, 26], ["MEGAshortscript T7 RNA polymerase", "PROTEIN", 77, 110], ["T7 class II 2.5 promoter", "DNA", 140, 164], ["PCR template", "DNA", 203, 215], ["The Dv", "TEST", 0, 6], ["RNA substrate", "TEST", 13, 26], ["the MEGAshortscript T7 RNA polymerase", "TREATMENT", 73, 110], ["the PCR template", "TREATMENT", 199, 215]]], ["After DNAse (Ambion) treatment, and purification by RNeasy mini kit (Qiagen), the Dv 1-351 RNA was incubated for 1 h at 37 \u2022 C with vaccinia virus capping enzyme (Epicentre, Madison, WI) in presence of 10 Ci [\u2423-32 P]-GTP (PerkinElmer, Boston, MA) and 0.05 units of inorganic pyrophosphatase (Sigma-Aldrich).", [["Dv 1-351", "CHEMICAL", 82, 90], ["\u2423-32 P]-GTP", "CHEMICAL", 209, 220], ["Ci [\u2423-32 P]-GTP", "CHEMICAL", 205, 220], ["DNAse", "GENE_OR_GENE_PRODUCT", 6, 11], ["vaccinia", "ORGANISM", 132, 140], ["Ci [\u2423-32 P]-GTP", "SIMPLE_CHEMICAL", 205, 220], ["inorganic pyrophosphatase", "SIMPLE_CHEMICAL", 265, 290], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 292, 305], ["Dv 1-351 RNA", "RNA", 82, 94], ["vaccinia virus capping enzyme", "PROTEIN", 132, 161], ["inorganic pyrophosphatase", "PROTEIN", 265, 290], ["vaccinia virus", "SPECIES", 132, 146], ["DNAse (Ambion) treatment", "TREATMENT", 6, 30], ["the Dv", "TEST", 78, 84], ["vaccinia virus capping enzyme", "TREATMENT", 132, 161], ["Ci", "TEST", 205, 207], ["GTP (PerkinElmer", "TREATMENT", 217, 233], ["inorganic pyrophosphatase", "TREATMENT", 265, 290], ["Sigma-Aldrich)", "TREATMENT", 292, 306]]], ["Radiolabeled capped Dv 1-351 RNA was then purified with the RNeasy mini kit (Qiagen).2 O MTase inhibition assaysThe activity of Wv and Dv MTases were tested by incubating purified proteins with the small capped RNA substrate 7Me GpppAC 5 in the presence of [ 3 H]AdoMet as described (Luzhkov et al., 2007) .", [["Dv 1-351", "CHEMICAL", 20, 28], ["Ado", "CHEMICAL", 263, 266], ["[ 3 H]AdoMet", "CHEMICAL", 257, 269], ["O MTase", "GENE_OR_GENE_PRODUCT", 87, 94], ["Wv", "GENE_OR_GENE_PRODUCT", 128, 130], ["Dv MTases", "GENE_OR_GENE_PRODUCT", 135, 144], ["[ 3 H]AdoMet", "SIMPLE_CHEMICAL", 257, 269], ["MTase", "PROTEIN", 89, 94], ["Wv and Dv MTases", "PROTEIN", 128, 144], ["GpppAC 5", "PROTEIN", 229, 237], ["the RNeasy mini kit", "TREATMENT", 56, 75], ["MTase inhibition assays", "TEST", 89, 112], ["Dv MTases", "TREATMENT", 135, 144], ["the small capped RNA substrate", "TREATMENT", 194, 224], ["AdoMet", "TREATMENT", 263, 269], ["small", "OBSERVATION_MODIFIER", 198, 203]]], ["Briefly, the MTase activity assays were performed in 30 l samples containing 40 mM Tris, pH 7.5, 5 mM DTT, 5 M AdoMet (0.3-2 Ci [ 3 H]AdoMet, Amersham Biosciences), 1 M of Wv or Dv MTases and 2 M of RNA substrate 7Me GpppAC 5 .", [["samples", "ANATOMY", 58, 65], ["AdoMet", "CHEMICAL", 111, 117], ["Ado", "CHEMICAL", 134, 137], ["Tris", "CHEMICAL", 83, 87], ["DTT", "CHEMICAL", 102, 105], ["AdoMet", "CHEMICAL", 111, 117], ["[ 3 H]AdoMet", "CHEMICAL", 128, 140], ["MTase", "GENE_OR_GENE_PRODUCT", 13, 18], ["DTT", "SIMPLE_CHEMICAL", 102, 105], ["AdoMet", "SIMPLE_CHEMICAL", 111, 117], ["3 H]AdoMet", "SIMPLE_CHEMICAL", 130, 140], ["MTase", "PROTEIN", 13, 18], ["the MTase activity assays", "TEST", 9, 34], ["Tris", "TEST", 83, 87], ["pH", "TEST", 89, 91], ["DTT", "TEST", 102, 105], ["AdoMet", "TEST", 111, 117], ["Dv MTases", "PROBLEM", 178, 187], ["RNA substrate 7Me GpppAC", "TREATMENT", 199, 223]]], ["Recombinant Wv and Dv MTases were produced as previously described (Bollati et al., 2009; Egloff et al., 2002, respectively) .", [["Wv", "GENE_OR_GENE_PRODUCT", 12, 14], ["Dv MTases", "GENE_OR_GENE_PRODUCT", 19, 28], ["Recombinant Wv and Dv MTases", "PROTEIN", 0, 28], ["Dv MTases", "PROBLEM", 19, 28], ["Dv MTases", "ANATOMY", 19, 28]]], ["Enzymes were premixed with the inhibitor candidates and the reactions were started with a premix of AdoMet and RNA substrate.", [["AdoMet", "CHEMICAL", 100, 106], ["AdoMet", "CHEMICAL", 100, 106], ["AdoMet", "SIMPLE_CHEMICAL", 100, 106], ["Enzymes", "TEST", 0, 7], ["the inhibitor candidates", "TREATMENT", 27, 51], ["the reactions", "PROBLEM", 56, 69], ["a premix of AdoMet", "TREATMENT", 88, 106], ["RNA substrate", "PROBLEM", 111, 124]]], ["During a first test series two different final inhibitor concentrations (125 and 25 M) were used.", [["different final inhibitor concentrations", "TREATMENT", 31, 71]]], ["For the determination of IC 50 values of the ATA compound a concentration range from 0.12 to 125 M was tested.", [["ATA", "CHEMICAL", 45, 48], ["ATA", "SIMPLE_CHEMICAL", 45, 48]]], ["Reactions were incubated at 30 \u2022 C. Two 14-l samples were spotted, immediately after mixing and after 3 h, into 96-well plates containing 100 l of 20 M ice cold AdoHcy to stop the reaction.", [["samples", "ANATOMY", 45, 52], ["AdoHcy", "CHEMICAL", 161, 167], ["AdoHcy", "CHEMICAL", 161, 167], ["AdoHcy", "SIMPLE_CHEMICAL", 161, 167], ["cold AdoHcy", "TREATMENT", 156, 167], ["the reaction", "PROBLEM", 176, 188]]], ["The samples were then transferred to glass-fibre filtermats (DEAE filtermat, Wallac) by a Filtermat Harvester (Packard Instruments).", [["samples", "ANATOMY", 4, 11], ["The samples", "TEST", 0, 11], ["a Filtermat Harvester (Packard Instruments", "TREATMENT", 88, 130]]], ["Filtermats were washed twice with 0.01 M ammonium formate, pH 8.0, twice with water and once with ethanol, dried and transferred into sample bags.", [["ammonium formate", "CHEMICAL", 41, 57], ["ethanol", "CHEMICAL", 98, 105], ["ammonium formate", "CHEMICAL", 41, 57], ["ethanol", "CHEMICAL", 98, 105], ["ammonium formate", "SIMPLE_CHEMICAL", 41, 57], ["ethanol", "SIMPLE_CHEMICAL", 98, 105], ["0.01 M ammonium formate", "TREATMENT", 34, 57], ["pH", "TEST", 59, 61], ["ethanol", "TREATMENT", 98, 105]]], ["Liquid scintillation fluid was added and methylation of RNA substrates was measured in counts per minute (cpm) using a Wallac MicroBeta TriLux Liquid Scintillation Counter.", [["Liquid scintillation fluid", "TREATMENT", 0, 26], ["methylation of RNA substrates", "TREATMENT", 41, 70], ["a Wallac MicroBeta TriLux Liquid Scintillation Counter", "TREATMENT", 117, 171], ["scintillation fluid", "OBSERVATION", 7, 26]]], ["The IC 50 (inhibitor concentration at 50% activity) value of the inhibitor compounds was determined.", [["The IC 50 (inhibitor concentration", "TREATMENT", 0, 34], ["the inhibitor compounds", "TREATMENT", 61, 84]]], ["Data were adjusted to a logistic dose-response function [% activity = 100/(1 + [I]/IC 50 ) b , where b corresponds to the slope factor that determines the slope of the curve (DeLean et al., 1978) ].N7 MTase inhibition assaysN7 MTase inhibition assay was performed in 50 mM Tris, pH 7.0, 50 mM NaCl, 2 mM DTT, 80 M AdoMet, 1.5 pmol Wv or Dv MTase and approximately 1 g of radiolabeled capped Dv 1-351 RNAs in a 10 l reaction volume at 22 \u2022 C for 20 min and 1 h.", [["NaCl", "CHEMICAL", 293, 297], ["AdoMet", "CHEMICAL", 314, 320], ["Tris", "CHEMICAL", 273, 277], ["NaCl", "CHEMICAL", 293, 297], ["DTT", "CHEMICAL", 304, 307], ["AdoMet", "CHEMICAL", 314, 320], ["N7 MTase", "GENE_OR_GENE_PRODUCT", 224, 232], ["DTT", "SIMPLE_CHEMICAL", 304, 307], ["AdoMet", "SIMPLE_CHEMICAL", 314, 320], ["a logistic dose", "TEST", 22, 37], ["response function", "TEST", 38, 55], ["activity", "TEST", 59, 67], ["the slope factor", "PROBLEM", 118, 134], ["N7 MTase inhibition", "TREATMENT", 198, 217], ["N7 MTase inhibition assay", "TEST", 224, 249], ["Tris", "TEST", 273, 277], ["pH", "TEST", 279, 281], ["NaCl", "TEST", 293, 297], ["AdoMet", "TREATMENT", 314, 320], ["Dv MTase", "TREATMENT", 337, 345], ["volume", "TEST", 424, 430]]], ["As described in the 2 O MTase assay, enzymes were premixed with the inhibitor candidate and the reactions were started with a premix of AdoMet and RNA substrate.", [["AdoMet", "CHEMICAL", 136, 142], ["AdoMet", "CHEMICAL", 136, 142], ["AdoMet", "SIMPLE_CHEMICAL", 136, 142], ["O MTase", "PROTEIN", 22, 29], ["the 2 O MTase assay", "TEST", 16, 35], ["enzymes", "TEST", 37, 44], ["the reactions", "PROBLEM", 92, 105], ["a premix of AdoMet", "TREATMENT", 124, 142], ["RNA substrate", "PROBLEM", 147, 160]]], ["The reaction was stopped by heating at 70 \u2022 C for 5 min.", [["The reaction", "PROBLEM", 0, 12]]], ["Samples were treated overnight with proteinase K (0.1 g/l).", [["Samples", "ANATOMY", 0, 7], ["K", "CHEMICAL", 47, 48], ["proteinase K", "GENE_OR_GENE_PRODUCT", 36, 48], ["Samples", "TEST", 0, 7], ["proteinase K", "TEST", 36, 48]]], ["Proteinase K was inactivated by heating at 70 \u2022 C (15 min) and addition of 5 mM PMSF.", [["K", "CHEMICAL", 11, 12], ["PMSF", "CHEMICAL", 80, 84], ["Proteinase K", "GENE_OR_GENE_PRODUCT", 0, 12], ["PMSF", "SIMPLE_CHEMICAL", 80, 84], ["Proteinase K", "TEST", 0, 12]]], ["The methylation reaction mixtures were subsequently digested for 4 h with nuclease P1.", [["nuclease P1", "PROTEIN", 74, 85], ["The methylation reaction mixtures", "TREATMENT", 0, 33], ["nuclease P1", "TREATMENT", 74, 85]]], ["The digestion products were separated on polyethyleneimine cellulose thin-layer chromatography (TLC) plates (Macherey Nagel) using 0.45 M (NH 4 ) 2 SO 4 as mobile phase.", [["polyethyleneimine cellulose", "CHEMICAL", 41, 68], ["polyethyleneimine", "CHEMICAL", 41, 58], ["(NH 4 ) 2 SO 4", "CHEMICAL", 138, 152], ["polyethyleneimine", "SIMPLE_CHEMICAL", 41, 58], ["NH 4 ) 2 SO 4", "SIMPLE_CHEMICAL", 139, 152], ["The digestion products", "TREATMENT", 0, 22], ["polyethyleneimine cellulose thin-layer chromatography (TLC) plates (Macherey Nagel)", "TREATMENT", 41, 124]]], ["After drying the TLC plates, the non-labeled standards were visualized by UV shadowing and the cap structure release by nuclease P1 were visualized using phosphorimager (Fluorescent Image Analyzer FLA3000 (Fuji)).", [["nuclease P1", "PROTEIN", 120, 131], ["the TLC plates", "TREATMENT", 13, 27], ["the non-labeled standards", "TREATMENT", 29, 54], ["UV shadowing", "TREATMENT", 74, 86], ["phosphorimager", "TREATMENT", 154, 168], ["TLC", "ANATOMY", 17, 20], ["shadowing", "OBSERVATION_MODIFIER", 77, 86], ["cap", "OBSERVATION_MODIFIER", 95, 98]]], ["The quantification was performed using Image Gauge software.Model of Wv MTase in complex with short capped RNA during N7 methylation: LBSIn order to analyze the MTase region proposed to act as a capped RNA binding site during N7 methylation (the LBS), we produced a docked model of Wv MTase with a short-capped RNA (GpppAGUp; see Section 2), and subsequently relaxed such model through 9 ns MD simulation.", [["Wv MTase", "GENE_OR_GENE_PRODUCT", 69, 77], ["Wv MTase", "GENE_OR_GENE_PRODUCT", 282, 290], ["Wv MTase", "PROTEIN", 69, 77], ["short capped RNA", "RNA", 94, 110], ["MTase region", "DNA", 161, 173], ["capped RNA binding site", "DNA", 195, 218], ["Wv MTase", "PROTEIN", 282, 290], ["short-capped RNA", "DNA", 298, 314], ["GpppAGUp", "PROTEIN", 316, 324], ["The quantification", "TEST", 0, 18], ["Image Gauge software", "TEST", 39, 59], ["short capped RNA", "PROBLEM", 94, 110], ["N7 methylation", "TREATMENT", 118, 132], ["LBSIn order", "TREATMENT", 134, 145], ["the MTase region", "TREATMENT", 157, 173], ["a capped RNA binding site", "PROBLEM", 193, 218], ["a short-capped RNA", "PROBLEM", 296, 314], ["Wv MTase", "OBSERVATION", 69, 77]]], ["The Wv MTase secondary structure elements were thoroughly conserved during the simulation, with the exclusion of part of the C-terminal \u2423-helix (amino acids 275-283).", [["amino acids 275-283", "CHEMICAL", 145, 164], ["C", "CHEMICAL", 125, 126], ["amino acids", "CHEMICAL", 145, 156], ["Wv MTase", "GENE_OR_GENE_PRODUCT", 4, 12], ["amino acids", "AMINO_ACID", 145, 156], ["275-283", "AMINO_ACID", 157, 164], ["Wv MTase secondary structure elements", "DNA", 4, 41], ["C-terminal \u2423-helix", "DNA", 125, 143], ["amino acids 275-283", "PROTEIN", 145, 164], ["amino acids", "TEST", 145, 156], ["structure elements", "OBSERVATION", 23, 41]]], ["Such C-terminal fluctuation is in agreement with observations on several flaviviral MTase crystal structures where the C-terminal helix was not located in the electron density, or displayed very high B-factor values (Bollati et al., 2009) .", [["C", "CHEMICAL", 119, 120], ["electron", "SIMPLE_CHEMICAL", 159, 167], ["B-factor", "GENE_OR_GENE_PRODUCT", 200, 208], ["C-terminal helix", "PROTEIN", 119, 135], ["B-factor", "PROTEIN", 200, 208], ["Such C-terminal fluctuation", "PROBLEM", 0, 27], ["several flaviviral MTase crystal structures", "PROBLEM", 65, 108], ["the C-terminal helix", "PROBLEM", 115, 135], ["terminal helix", "ANATOMY", 121, 135], ["electron density", "OBSERVATION", 159, 175]]], ["In fact, the C-terminal helix present in Fig. 1.", [["C", "CHEMICAL", 13, 14], ["C-terminal helix", "PROTEIN", 13, 29], ["terminal helix", "ANATOMY", 15, 29], ["Fig", "OBSERVATION_MODIFIER", 41, 44]]], ["(A) Model of MTase-capped RNA interaction, at the LBS, after 9 ns of molecular dynamics.", [["MTase", "PROTEIN", 13, 18]]], ["The protein is shown as white surface, AdoMet in yellow, capped RNA in red and five residues (Arg37, Arg59, Arg84, Glu149, and Arg213) shown by Dong et al. (2008a) to impair N7 methyltransferase activity, in blue.", [["white surface", "ANATOMY", 24, 37], ["Ado", "CHEMICAL", 39, 42], ["AdoMet", "CHEMICAL", 39, 45], ["Arg37", "CHEMICAL", 94, 99], ["Arg59", "CHEMICAL", 101, 106], ["Arg84", "CHEMICAL", 108, 113], ["Glu149", "CHEMICAL", 115, 121], ["Arg213", "CHEMICAL", 127, 133], ["white surface", "CELLULAR_COMPONENT", 24, 37], ["AdoMet", "GENE_OR_GENE_PRODUCT", 39, 45], ["Arg37", "GENE_OR_GENE_PRODUCT", 94, 99], ["Arg59", "GENE_OR_GENE_PRODUCT", 101, 106], ["Arg84", "GENE_OR_GENE_PRODUCT", 108, 113], ["Glu149", "GENE_OR_GENE_PRODUCT", 115, 121], ["Arg213", "AMINO_ACID", 127, 133], ["N7 methyltransferase", "GENE_OR_GENE_PRODUCT", 174, 194], ["AdoMet", "PROTEIN", 39, 45], ["yellow, capped RNA", "RNA", 49, 67], ["N7 methyltransferase", "PROTEIN", 174, 194], ["The protein", "TEST", 0, 11], ["white surface", "PROBLEM", 24, 37], ["AdoMet in yellow, capped RNA", "PROBLEM", 39, 67], ["yellow", "OBSERVATION_MODIFIER", 49, 55], ["capped RNA", "OBSERVATION", 57, 67], ["methyltransferase activity", "OBSERVATION", 177, 203]]], ["(B) A closer view into the LBS region showing key RNA recognition residues and AdoMet; the shaded area highlights the volume occupied by the capped RNA analog GpppAGUp.", [["AdoMet", "CHEMICAL", 79, 85], ["AdoMet", "CHEMICAL", 79, 85], ["AdoMet", "SIMPLE_CHEMICAL", 79, 85], ["GpppAGUp", "GENE_OR_GENE_PRODUCT", 159, 167], ["LBS region", "DNA", 27, 37], ["capped RNA", "RNA", 141, 151], ["GpppAGUp", "PROTEIN", 159, 167], ["A closer view", "TEST", 4, 17], ["key RNA recognition residues", "PROBLEM", 46, 74], ["AdoMet", "TREATMENT", 79, 85], ["the shaded area", "PROBLEM", 87, 102], ["LBS", "ANATOMY", 27, 30], ["RNA", "OBSERVATION", 50, 53], ["recognition residues", "OBSERVATION", 54, 74]]], ["Wv MTase was shown to be part of the RdRp domain of West Nile virus (WNv) and Dv Yap et al., 2007) .Model of Wv MTase in complex with short capped RNA during N7 methylation: LBSGrouping the structures produced during MD into clusters, according to their similarity, may help detecting the time evolution of the protein toward new overall conformations.", [["N7", "CHEMICAL", 158, 160], ["Wv MTase", "GENE_OR_GENE_PRODUCT", 0, 8], ["West Nile virus", "ORGANISM", 52, 67], ["Wv MTase", "GENE_OR_GENE_PRODUCT", 109, 117], ["MTase", "PROTEIN", 3, 8], ["RdRp domain", "PROTEIN", 37, 48], ["Wv MTase", "PROTEIN", 109, 117], ["short capped RNA", "RNA", 134, 150], ["Nile virus", "SPECIES", 57, 67], ["West Nile virus", "SPECIES", 52, 67], ["short capped RNA", "PROBLEM", 134, 150], ["N7 methylation", "TREATMENT", 158, 172], ["RdRp", "OBSERVATION", 37, 41], ["Wv MTase", "OBSERVATION", 109, 117]]], ["In performing such analyses, we chose to discard few N-and C-terminal residues of the protein, focusing on amino acids 8-260, thus ignoring the motility of the protein terminals.", [["amino acids 8-260", "CHEMICAL", 107, 124], ["N", "CHEMICAL", 53, 54], ["C", "CHEMICAL", 59, 60], ["amino acids", "CHEMICAL", 107, 118], ["amino acids", "AMINO_ACID", 107, 118], ["8-260", "AMINO_ACID", 119, 124], ["N-and C-terminal residues", "PROTEIN", 53, 78], ["amino acids 8-260", "PROTEIN", 107, 124], ["C-terminal residues of the protein", "TREATMENT", 59, 93], ["amino acids", "TEST", 107, 118]]], ["We used a cut-off of 0.7 \u00c5 in C\u2423 r.m.s.d. to cluster the different structures observed during MD time evolution.", [["a cut-off", "TEST", 8, 17]]], ["With such limitation we found that the structures generated during the simulation could be grouped into nine different clusters, and that the last cluster contained all the states produced after the first 70 ps, suggesting an early stabilization of the protein scaffold during the simulation.", [["protein scaffold", "PROTEIN", 253, 269], ["the protein scaffold", "TREATMENT", 249, 269], ["clusters", "OBSERVATION_MODIFIER", 119, 127], ["early", "OBSERVATION_MODIFIER", 226, 231], ["stabilization", "OBSERVATION", 232, 245], ["protein scaffold", "OBSERVATION", 253, 269]]], ["The same cluster analysis was carried out to investigate the structural evolution of capped RNA during the simulation.", [["capped RNA", "RNA", 85, 95], ["The same cluster analysis", "TEST", 0, 25], ["capped RNA", "PROBLEM", 85, 95], ["capped RNA", "OBSERVATION", 85, 95]]], ["With a 0.8 \u00c5 cut-off, 32 capped RNA clusters were produced, the last one starting at 3.85 ns and lasting through the end of the simulation (9 ns).", [["a 0.8 \u00c5 cut-off", "TREATMENT", 5, 20]]], ["The 0-3.85 ns interval can be interpreted as the time needed for RNA to reach a stable conformation following interaction with the protein, starting from the docked model.", [["RNA", "TREATMENT", 65, 68], ["the protein", "TREATMENT", 127, 138], ["stable", "OBSERVATION", 80, 86]]], ["R.m.s.d. values calculated for the simulated structures vs. the crystal structure, during MD, reached the mean value of 1.5 \u00b1 0.1 \u00c5 r.m.s.d. after about 3 ns of equilibration.", [["R.m.s.d. values", "TEST", 0, 15], ["crystal", "OBSERVATION_MODIFIER", 64, 71], ["structure", "OBSERVATION_MODIFIER", 72, 81]]], ["The protein regions with higher motility during the simulation (considering amino acids 8-260) are the HBS (N-terminal helix-loop-helix motif, amino acids 17-22), Gly58, and a loop (amino acids 106-109) shown to be highly mobile also in the crystal structures, and proposed to be involved in AdoMet binding/AdoHcy release after the methyl transfer to RNA (Bollati et al., 2009) .Model of Wv MTase in complex with short capped RNA during N7 methylation: LBSThe structure produced after 9 ns of MD was used to analyze Wv MTase/capped RNA interactions in the LBS region.", [["LBS region", "ANATOMY", 556, 566], ["amino acids 8-260", "CHEMICAL", 76, 93], ["amino acids", "CHEMICAL", 143, 154], ["amino acids 106-109", "CHEMICAL", 182, 201], ["AdoMet", "CHEMICAL", 292, 298], ["AdoHcy", "CHEMICAL", 307, 313], ["methyl", "CHEMICAL", 332, 338], ["N7", "CHEMICAL", 437, 439], ["amino acids", "CHEMICAL", 76, 87], ["N-", "CHEMICAL", 108, 110], ["amino acids", "CHEMICAL", 143, 154], ["amino acids", "CHEMICAL", 182, 193], ["AdoMet", "CHEMICAL", 292, 298], ["AdoHcy", "CHEMICAL", 307, 313], ["methyl", "CHEMICAL", 332, 338], ["amino acids", "AMINO_ACID", 76, 87], ["amino acids", "AMINO_ACID", 143, 154], ["17-22", "AMINO_ACID", 155, 160], ["Gly58", "GENE_OR_GENE_PRODUCT", 163, 168], ["amino acids", "AMINO_ACID", 182, 193], ["AdoMet", "SIMPLE_CHEMICAL", 292, 298], ["AdoHcy", "SIMPLE_CHEMICAL", 307, 313], ["methyl", "SIMPLE_CHEMICAL", 332, 338], ["Wv MTase", "GENE_OR_GENE_PRODUCT", 388, 396], ["Wv MTase", "GENE_OR_GENE_PRODUCT", 516, 524], ["protein regions", "PROTEIN", 4, 19], ["amino acids 8-260", "PROTEIN", 76, 93], ["HBS", "PROTEIN", 103, 106], ["N-terminal helix-loop-helix motif", "PROTEIN", 108, 141], ["amino acids 17-22", "PROTEIN", 143, 160], ["Gly58", "PROTEIN", 163, 168], ["amino acids 106-109", "PROTEIN", 182, 201], ["Wv MTase", "PROTEIN", 388, 396], ["short capped RNA", "RNA", 413, 429], ["MTase", "PROTEIN", 519, 524], ["LBS region", "DNA", 556, 566], ["higher motility", "PROBLEM", 25, 40], ["the simulation", "TEST", 48, 62], ["amino acids", "TEST", 76, 87], ["the HBS", "TEST", 99, 106], ["N-terminal helix", "TEST", 108, 124], ["loop-helix motif", "TREATMENT", 125, 141], ["amino acids", "TEST", 143, 154], ["a loop (amino acids", "TEST", 174, 193], ["AdoMet binding/AdoHcy release", "TREATMENT", 292, 321], ["short capped RNA", "PROBLEM", 413, 429], ["higher motility", "OBSERVATION", 25, 40], ["highly", "OBSERVATION_MODIFIER", 215, 221], ["mobile", "OBSERVATION", 222, 228], ["Wv MTase", "OBSERVATION", 388, 396], ["capped RNA", "OBSERVATION", 525, 535], ["LBS", "ANATOMY", 556, 559]]], ["In this model ( Fig. 1A and B) , the cap guanine was located close to AdoMet and to residues Glu149 and Arg213; other residues found to interact with capped RNA were: Arg37, Arg41, Leu44, Ser56, Arg57, Arg84, Glu149, Lys112, Ser150, Arg160, Ser215.", [["guanine", "CHEMICAL", 41, 48], ["AdoMet", "CHEMICAL", 70, 76], ["Arg213", "CHEMICAL", 104, 110], ["guanine", "CHEMICAL", 41, 48], ["AdoMet", "CHEMICAL", 70, 76], ["Glu149", "CHEMICAL", 93, 99], ["Arg", "CHEMICAL", 104, 107], ["Arg37", "CHEMICAL", 167, 172], ["Arg41", "CHEMICAL", 174, 179], ["Leu44", "CHEMICAL", 181, 186], ["Ser56", "CHEMICAL", 188, 193], ["Arg57", "CHEMICAL", 195, 200], ["Arg84", "CHEMICAL", 202, 207], ["Glu149", "CHEMICAL", 209, 215], ["Lys", "CHEMICAL", 217, 220], ["Ser150", "CHEMICAL", 225, 231], ["Arg", "CHEMICAL", 233, 236], ["Ser215", "CHEMICAL", 241, 247], ["B", "GENE_OR_GENE_PRODUCT", 28, 29], ["AdoMet", "SIMPLE_CHEMICAL", 70, 76], ["Glu149", "AMINO_ACID", 93, 99], ["Arg213", "AMINO_ACID", 104, 110], ["Arg37", "GENE_OR_GENE_PRODUCT", 167, 172], ["Arg41", "GENE_OR_GENE_PRODUCT", 174, 179], ["Leu44", "GENE_OR_GENE_PRODUCT", 181, 186], ["Ser56", "GENE_OR_GENE_PRODUCT", 188, 193], ["Arg57", "GENE_OR_GENE_PRODUCT", 195, 200], ["Arg84", "GENE_OR_GENE_PRODUCT", 202, 207], ["Glu149", "GENE_OR_GENE_PRODUCT", 209, 215], ["Lys112", "AMINO_ACID", 217, 223], ["Ser150", "GENE_OR_GENE_PRODUCT", 225, 231], ["Arg160", "AMINO_ACID", 233, 239], ["Ser215", "GENE_OR_GENE_PRODUCT", 241, 247], ["capped RNA", "RNA", 150, 160], ["Arg57", "PROTEIN", 195, 200], ["the cap guanine", "TREATMENT", 33, 48], ["residues Glu149", "TEST", 84, 99], ["Arg", "TEST", 104, 107], ["other residues", "PROBLEM", 112, 126], ["Leu44", "TEST", 181, 186], ["Lys", "TEST", 217, 220], ["Arg", "TEST", 233, 236]]], ["It has been recently shown that point mutations of few amino acids dramatically inhibit N7 methyl transfer activity in WNv MTase (Dong et al., 2008a) .", [["amino acids", "CHEMICAL", 55, 66], ["N7 methyl", "CHEMICAL", 88, 97], ["amino acids", "CHEMICAL", 55, 66], ["N7 methyl", "CHEMICAL", 88, 97], ["amino acids", "AMINO_ACID", 55, 66], ["N7 methyl", "SIMPLE_CHEMICAL", 88, 97], ["WNv MTase", "GENE_OR_GENE_PRODUCT", 119, 128], ["WNv MTase", "PROTEIN", 119, 128], ["few amino acids", "PROBLEM", 51, 66]]], ["In particular, seven amino acids (Arg37, Arg57, Arg84, Trp87, Glu149, Arg213, and Tyr220), whose mutation to Ala reduced the mentioned activity below 30%, have been identified.", [["amino acids", "CHEMICAL", 21, 32], ["amino acids", "CHEMICAL", 21, 32], ["Arg37", "CHEMICAL", 34, 39], ["Arg57", "CHEMICAL", 41, 46], ["Arg84", "CHEMICAL", 48, 53], ["Trp87", "CHEMICAL", 55, 60], ["Glu149", "CHEMICAL", 62, 68], ["Arg", "CHEMICAL", 70, 73], ["Tyr220", "CHEMICAL", 82, 88], ["Ala", "CHEMICAL", 109, 112], ["amino acids", "AMINO_ACID", 21, 32], ["Arg37", "GENE_OR_GENE_PRODUCT", 34, 39], ["Arg57", "GENE_OR_GENE_PRODUCT", 41, 46], ["Arg84", "GENE_OR_GENE_PRODUCT", 48, 53], ["Trp87", "GENE_OR_GENE_PRODUCT", 55, 60], ["Glu149", "GENE_OR_GENE_PRODUCT", 62, 68], ["Arg213", "AMINO_ACID", 70, 76], ["Tyr220", "GENE_OR_GENE_PRODUCT", 82, 88], ["Ala", "AMINO_ACID", 109, 112], ["Trp87", "PROTEIN", 55, 60], ["seven amino acids", "TEST", 15, 32], ["Arg", "TEST", 70, 73]]], ["In this context, analyzing the role of interface residues indicated by our Wv MTase/RNA simulated model, we propose to neglect Trp87 and Tyr220.", [["Tyr220", "CHEMICAL", 137, 143], ["Wv MTase", "GENE_OR_GENE_PRODUCT", 75, 83], ["Trp87", "GENE_OR_GENE_PRODUCT", 127, 132], ["Tyr220", "GENE_OR_GENE_PRODUCT", 137, 143], ["Wv MTase", "PROTEIN", 75, 83], ["Trp87", "PROTEIN", 127, 132], ["Tyr220", "PROTEIN", 137, 143], ["interface residues", "PROBLEM", 39, 57]]], ["In fact, these two residues are spatially close to each other, and partly buried in the protein core; it can be expected that their mutation to Ala might critically alter the correct MTase fold.", [["Ala", "CHEMICAL", 144, 147], ["Ala", "CHEMICAL", 144, 147], ["Ala", "AMINO_ACID", 144, 147], ["protein core", "PROTEIN", 88, 100], ["MTase", "PROTEIN", 183, 188], ["their mutation", "PROBLEM", 126, 140], ["two", "OBSERVATION_MODIFIER", 15, 18], ["residues", "OBSERVATION", 19, 27], ["MTase fold", "OBSERVATION", 183, 193]]], ["Moreover, Tyr220 is located at the \"floor\" of the MTase catalytic tetrad region (K-D-K-E: Lys61-Asp146-Lys182-Glu218 in Wv MTase), being hydrogen bonded to Lys61 (3.2 \u00c5) and to Asp146 (2.9 \u00c5); thus it may play a crucial role in the stabilization of the catalytic residues.", [["Glu218", "CHEMICAL", 110, 116], ["hydrogen", "CHEMICAL", 137, 145], ["Lys61", "CHEMICAL", 156, 161], ["Asp", "CHEMICAL", 177, 180], ["Tyr220", "GENE_OR_GENE_PRODUCT", 10, 16], ["Wv MTase", "GENE_OR_GENE_PRODUCT", 120, 128], ["Lys61", "AMINO_ACID", 156, 161], ["Asp146", "AMINO_ACID", 177, 183], ["Tyr220", "PROTEIN", 10, 16], ["MTase catalytic tetrad region", "PROTEIN", 50, 79], ["K", "PROTEIN", 85, 86], ["Asp146-Lys182", "DNA", 96, 109], ["Glu218", "DNA", 110, 116], ["Wv MTase", "PROTEIN", 120, 128], ["catalytic residues", "PROTEIN", 253, 271], ["K", "TEST", 81, 82], ["-D", "TEST", 82, 84], ["K", "TEST", 85, 86], ["Lys61", "TEST", 90, 95], ["Lys61", "TEST", 156, 161], ["Asp", "TEST", 177, 180], ["the catalytic residues", "TREATMENT", 249, 271], ["catalytic residues", "OBSERVATION", 253, 271]]], ["As a result, our Wv MTase/RNA interaction model focuses on the five remaining residues (Arg37, Arg57, Arg84, Glu149, and Arg213; Fig. 1B ).Docking compounds from the LOPAC libraryDifferent criteria have been explored in the past for the discovery of effective MTase inhibitors (Dong et al., 2008a,b) .", [["Arg37", "CHEMICAL", 88, 93], ["Arg57", "CHEMICAL", 95, 100], ["Arg84", "CHEMICAL", 102, 107], ["Glu149", "CHEMICAL", 109, 115], ["Arg213", "CHEMICAL", 121, 127], ["Wv MTase", "GENE_OR_GENE_PRODUCT", 17, 25], ["Arg37", "GENE_OR_GENE_PRODUCT", 88, 93], ["Arg57", "GENE_OR_GENE_PRODUCT", 95, 100], ["Arg84", "GENE_OR_GENE_PRODUCT", 102, 107], ["Glu149", "GENE_OR_GENE_PRODUCT", 109, 115], ["Fig. 1B", "GENE_OR_GENE_PRODUCT", 129, 136], ["Wv MTase", "PROTEIN", 17, 25], ["LOPAC library", "DNA", 166, 179], ["Arg", "TEST", 121, 124], ["effective MTase inhibitors", "TREATMENT", 250, 276]]], ["In particular, the search for compounds competing with AdoMet binding has been considered as one of the promising approaches (Luzhkov et al., 2007; Ray et al., 2006) .", [["Ado", "CHEMICAL", 55, 58], ["Met", "CHEMICAL", 58, 61], ["AdoMet", "CHEMICAL", 55, 61], ["AdoMet", "SIMPLE_CHEMICAL", 55, 61], ["AdoMet binding", "PROBLEM", 55, 69]]], ["AdoMet is the principal biological methyl donor in cells; under normal conditions in humans 6-8 g of AdoMet are generated per day, and most of these are used in transmethylation reactions whereby methyl groups are added to different compounds and AdoMet is converted to Ado-Hcy (Lu, 2000) .", [["cells", "ANATOMY", 51, 56], ["Ado", "CHEMICAL", 0, 3], ["Met", "CHEMICAL", 3, 6], ["AdoMet", "CHEMICAL", 101, 107], ["methyl", "CHEMICAL", 196, 202], ["Ado", "CHEMICAL", 247, 250], ["Hcy", "CHEMICAL", 274, 277], ["AdoMet", "CHEMICAL", 0, 6], ["methyl", "CHEMICAL", 35, 41], ["AdoMet", "CHEMICAL", 101, 107], ["methyl", "CHEMICAL", 196, 202], ["AdoMet", "CHEMICAL", 247, 253], ["Hcy", "CHEMICAL", 274, 277], ["AdoMet", "GENE_OR_GENE_PRODUCT", 0, 6], ["cells", "CELL", 51, 56], ["humans", "ORGANISM", 85, 91], ["AdoMet", "SIMPLE_CHEMICAL", 101, 107], ["methyl groups", "SIMPLE_CHEMICAL", 196, 209], ["AdoMet", "SIMPLE_CHEMICAL", 247, 253], ["Ado-Hcy", "SIMPLE_CHEMICAL", 270, 277], ["humans", "SPECIES", 85, 91], ["humans", "SPECIES", 85, 91], ["the principal biological methyl donor in cells", "TREATMENT", 10, 56], ["AdoMet", "TREATMENT", 101, 107], ["transmethylation reactions", "TREATMENT", 161, 187], ["methyl groups", "TREATMENT", 196, 209], ["methyl donor", "OBSERVATION", 35, 47]]], ["We thus speculated that MTase inhibition based on AdoMet competition might be particularly difficult to achieve.", [["AdoMet", "CHEMICAL", 50, 56], ["AdoMet", "CHEMICAL", 50, 56], ["MTase", "GENE_OR_GENE_PRODUCT", 24, 29], ["AdoMet", "SIMPLE_CHEMICAL", 50, 56], ["MTase", "PROTEIN", 24, 29], ["MTase inhibition", "TREATMENT", 24, 40], ["AdoMet competition", "TREATMENT", 50, 68]]], ["Moreover, since many distinct enzymes require AdoMet as cofactor, an AdoMet mimetic compound (like sinefungin; IC 50 of 14 M on WNv Mtase) (Dong et al., 2008b) may turn out to be generally toxic.", [["AdoMet", "CHEMICAL", 46, 52], ["AdoMet", "CHEMICAL", 69, 75], ["sinefungin", "CHEMICAL", 99, 109], ["AdoMet", "CHEMICAL", 46, 52], ["AdoMet", "CHEMICAL", 69, 75], ["sinefungin", "CHEMICAL", 99, 109], ["AdoMet", "SIMPLE_CHEMICAL", 46, 52], ["AdoMet", "SIMPLE_CHEMICAL", 69, 75], ["sinefungin", "SIMPLE_CHEMICAL", 99, 109], ["many distinct enzymes", "PROBLEM", 16, 37], ["an AdoMet mimetic compound (like sinefungin", "TREATMENT", 66, 109], ["toxic", "OBSERVATION", 189, 194]]], ["Therefore, a different inhibitor search strategy could, in principle, be directed towards blockage of the MTase HBS; however, such class of inhibitory molecules would likely provide inhibition only for the 2 O MTase reaction, but not for the N7 MTase activity.", [["O", "CHEMICAL", 208, 209], ["MTase HBS", "PROTEIN", 106, 115], ["inhibitory molecules", "PROTEIN", 140, 160], ["N7 MTase", "PROTEIN", 242, 250], ["a different inhibitor search strategy", "TREATMENT", 11, 48], ["the MTase HBS", "PROBLEM", 102, 115], ["inhibitory molecules", "PROBLEM", 140, 160], ["the 2 O MTase reaction", "PROBLEM", 202, 224]]], ["Therefore, for the design of new inhibitors, we decided to target the active site of the enzyme with its bound AdoMet cofactor.Docking compounds from the LOPAC libraryAs for most enzymatic reactions, transfer of a methyl group from AdoMet to RNA, in each of the two MTase reactions, requires a precise location of the RNA substrate in the active site, such location being dictated by the position of the AdoMet transferrable methyl group.", [["methyl", "CHEMICAL", 214, 220], ["AdoMet", "CHEMICAL", 232, 238], ["AdoMet", "CHEMICAL", 404, 410], ["methyl", "CHEMICAL", 425, 431], ["AdoMet", "CHEMICAL", 111, 117], ["methyl", "CHEMICAL", 214, 220], ["AdoMet", "CHEMICAL", 232, 238], ["AdoMet", "CHEMICAL", 404, 410], ["methyl", "CHEMICAL", 425, 431], ["AdoMet", "SIMPLE_CHEMICAL", 111, 117], ["methyl", "SIMPLE_CHEMICAL", 214, 220], ["AdoMet", "SIMPLE_CHEMICAL", 232, 238], ["AdoMet", "SIMPLE_CHEMICAL", 404, 410], ["methyl", "SIMPLE_CHEMICAL", 425, 431], ["AdoMet cofactor", "PROTEIN", 111, 126], ["LOPAC library", "DNA", 154, 167], ["MTase", "PROTEIN", 266, 271], ["RNA substrate", "PROTEIN", 318, 331], ["new inhibitors", "TREATMENT", 29, 43], ["the enzyme", "TEST", 85, 95], ["the LOPAC library", "TREATMENT", 150, 167], ["most enzymatic reactions", "PROBLEM", 174, 198], ["a methyl group from AdoMet to RNA", "TREATMENT", 212, 245], ["the two MTase reactions", "PROBLEM", 258, 281], ["the AdoMet transferrable methyl group", "TREATMENT", 400, 437], ["active site", "OBSERVATION", 339, 350]]], ["This consideration suggests that a small ligand, binding to a protein location close to (but not inside) the cofactor-binding site, would potentially impair both N7 and 2 O methylation reac-tions.", [["N7", "CHEMICAL", 162, 164], ["O", "CHEMICAL", 171, 172], ["2 O", "SIMPLE_CHEMICAL", 169, 172], ["cofactor-binding site", "PROTEIN", 109, 130], ["a small ligand, binding", "PROBLEM", 33, 56], ["a protein location", "PROBLEM", 60, 78], ["the cofactor-binding site", "PROBLEM", 105, 130], ["methylation reac", "TREATMENT", 173, 189], ["small", "OBSERVATION_MODIFIER", 35, 40], ["ligand", "OBSERVATION", 41, 47]]], ["Moreover, such a ligand could interact directly with AdoMet or AdoHcy, potentially slowing the release of the latter from the protein during enzyme turnover.", [["AdoMet", "CHEMICAL", 53, 59], ["AdoHcy", "CHEMICAL", 63, 69], ["AdoMet", "CHEMICAL", 53, 59], ["AdoHcy", "CHEMICAL", 63, 69], ["AdoMet", "SIMPLE_CHEMICAL", 53, 59], ["AdoHcy", "SIMPLE_CHEMICAL", 63, 69], ["enzyme", "PROTEIN", 141, 147], ["AdoHcy", "TREATMENT", 63, 69]]], ["As target for ligand docking, we thus selected the active site region, located between the AdoMet binding site, the HBS, and the LBS (Fig 2A) , that had been explored by our simulated model described above.", [["AdoMet", "CHEMICAL", 91, 97], ["AdoMet", "SIMPLE_CHEMICAL", 91, 97], ["AdoMet binding site", "DNA", 91, 110], ["LBS", "DNA", 129, 132], ["ligand docking", "TEST", 14, 28], ["the HBS", "TEST", 112, 119], ["active", "OBSERVATION_MODIFIER", 51, 57], ["AdoMet binding", "OBSERVATION", 91, 105]]], ["The selected region was explored using a library of small molecules (LOPAC library) as described in Section 2.", [["LOPAC library", "DNA", 69, 82], ["a library of small molecules (LOPAC library)", "TREATMENT", 39, 83], ["small", "OBSERVATION_MODIFIER", 52, 57]]], ["The top three ranked compounds produced by the docking search (nilutamide, PPNDS and ATA, Fig. 2A) , displaying the lowest binding energies ( G = \u221216.2, \u221213.4, and \u221212.4 kcal/mol, respectively), were used for in vitro testing of MTase inhibitory activity (Fig. 2B) .Inhibition of 2 O and N7 methylation activities in Dv MTase and Wv MTaseThe inhibitory effect of the three best binders selected in silico was determined on Dv MTase and Wv MTase 2 O MTase activities.", [["nilutamide", "CHEMICAL", 63, 73], ["nilutamide", "CHEMICAL", 63, 73], ["PPNDS", "CHEMICAL", 75, 80], ["O", "CHEMICAL", 282, 283], ["nilutamide", "SIMPLE_CHEMICAL", 63, 73], ["ATA", "SIMPLE_CHEMICAL", 85, 88], ["N7", "SIMPLE_CHEMICAL", 288, 290], ["Dv MTase", "GENE_OR_GENE_PRODUCT", 317, 325], ["Wv MTase", "GENE_OR_GENE_PRODUCT", 330, 338], ["Dv MTase", "GENE_OR_GENE_PRODUCT", 423, 431], ["Wv MTase 2 O MTase", "GENE_OR_GENE_PRODUCT", 436, 454], ["MTase", "PROTEIN", 229, 234], ["Dv MTase", "PROTEIN", 317, 325], ["Wv MTase", "PROTEIN", 330, 338], ["Dv MTase", "PROTEIN", 423, 431], ["nilutamide", "TREATMENT", 63, 73], ["G", "TEST", 142, 143], ["\u2212", "TEST", 153, 154], ["vitro testing", "TEST", 212, 225], ["N7 methylation activities", "TREATMENT", 288, 313], ["Dv MTase", "TREATMENT", 423, 431]]], ["For this purpose, we first tested the inhibition of ATA, nilutamide and PPNDS at 125 and 25 M by measuring the transfer of a [ 3 H]-methyl group to the short 7Me GpppAC 5 substrate yielding 7Me GpppA 2 OMe C 5 .", [["ATA", "CHEMICAL", 52, 55], ["nilutamide", "CHEMICAL", 57, 67], ["PPNDS", "CHEMICAL", 72, 77], ["[ 3 H]-methyl", "CHEMICAL", 125, 138], ["ATA", "CHEMICAL", 52, 55], ["nilutamide", "CHEMICAL", 57, 67], ["PPNDS", "CHEMICAL", 72, 77], ["[ 3 H]-methyl", "CHEMICAL", 125, 138], ["GpppAC", "CHEMICAL", 162, 168], ["OMe C", "CHEMICAL", 202, 207], ["ATA", "SIMPLE_CHEMICAL", 52, 55], ["nilutamide", "SIMPLE_CHEMICAL", 57, 67], ["PPNDS", "SIMPLE_CHEMICAL", 72, 77], ["[ 3 H]-methyl", "SIMPLE_CHEMICAL", 125, 138], ["nilutamide", "TREATMENT", 57, 67], ["PPNDS", "TREATMENT", 72, 77]]], ["Fig. 3A shows that whereas nilutamide and PPDNS did not display efficient inhibition of the flaviviral MTases at the selected concentrations, ATA strongly inhibited both MTases even at 25 M. We therefore determined the IC 50 values for ATA in the 0.12-125 M concentration range.", [["nilutamide", "CHEMICAL", 27, 37], ["PPDNS", "CHEMICAL", 42, 47], ["ATA", "CHEMICAL", 142, 145], ["ATA", "CHEMICAL", 236, 239], ["nilutamide", "CHEMICAL", 27, 37], ["PPDNS", "CHEMICAL", 42, 47], ["ATA", "CHEMICAL", 142, 145], ["nilutamide", "SIMPLE_CHEMICAL", 27, 37], ["PPDNS", "SIMPLE_CHEMICAL", 42, 47], ["flaviviral MTases", "GENE_OR_GENE_PRODUCT", 92, 109], ["ATA", "SIMPLE_CHEMICAL", 142, 145], ["ATA", "SIMPLE_CHEMICAL", 236, 239], ["flaviviral MTases", "PROTEIN", 92, 109], ["the flaviviral MTases", "PROBLEM", 88, 109], ["ATA", "TEST", 236, 239]]], ["(A) Inhibition of nitulamine, PPNDS and ATA.", [["nitulamine", "CHEMICAL", 18, 28], ["PPNDS", "CHEMICAL", 30, 35], ["ATA", "CHEMICAL", 40, 43], ["nitulamine", "CHEMICAL", 18, 28], ["PPNDS", "CHEMICAL", 30, 35], ["ATA", "CHEMICAL", 40, 43], ["nitulamine", "SIMPLE_CHEMICAL", 18, 28], ["PPNDS", "SIMPLE_CHEMICAL", 30, 35], ["ATA", "SIMPLE_CHEMICAL", 40, 43], ["nitulamine", "TREATMENT", 18, 28]]], ["Two concentrations of each inhibitor candidate were tested (125 and 25 M) and a control reaction was carried out in absence of inhibitor candidate.", [["each inhibitor", "TREATMENT", 22, 36], ["a control reaction", "PROBLEM", 78, 96], ["inhibitor candidate", "TREATMENT", 127, 146]]], ["The methyl transfer to the RNA substrate was stopped after 3 h and detected using a filter-binding assay that measured the amount of radioactivity, in cpm, that was transferred to the RNA substrates.", [["methyl", "CHEMICAL", 4, 10], ["methyl", "CHEMICAL", 4, 10], ["methyl", "SIMPLE_CHEMICAL", 4, 10], ["the RNA substrate", "TREATMENT", 23, 40], ["a filter-binding assay", "TEST", 82, 104], ["amount", "OBSERVATION_MODIFIER", 123, 129], ["radioactivity", "OBSERVATION", 133, 146]]], ["MTase activity of 100% was arbitrarily attributed to the MTase activity in absence of inhibitor.", [["MTase", "PROTEIN", 0, 5], ["MTase", "PROTEIN", 57, 62], ["MTase activity", "TEST", 0, 14], ["the MTase activity", "PROBLEM", 53, 71], ["inhibitor", "TREATMENT", 86, 95]]], ["(B) Inhibition of Wv and Dv 2 O MTase activity using increasing concentrations of ATA (125 nM to 125 M).", [["ATA", "CHEMICAL", 82, 85], ["ATA", "CHEMICAL", 82, 85], ["Wv", "GENE_OR_GENE_PRODUCT", 18, 20], ["Dv 2 O MTase", "GENE_OR_GENE_PRODUCT", 25, 37], ["ATA", "SIMPLE_CHEMICAL", 82, 85], ["Wv", "PROTEIN", 18, 20], ["increasing concentrations of ATA", "TREATMENT", 53, 85]]], ["The IC50 values were determined by fitting of the dose response curve as described in Section 2.", [["The IC50 values", "TEST", 0, 15], ["the dose response curve", "TEST", 46, 69]]], ["Each reaction was carried out in triplicate and the standard deviation is plotted.Inhibition of 2 O and N7 methylation activities in Dv MTase and Wv MTasecan be considered the strongest inhibitor of flaviviral 2 O MTase activity known to date.", [["O", "CHEMICAL", 98, 99], ["2 O", "SIMPLE_CHEMICAL", 96, 99], ["N7", "SIMPLE_CHEMICAL", 104, 106], ["Dv MTase", "GENE_OR_GENE_PRODUCT", 133, 141], ["Wv MTasecan", "GENE_OR_GENE_PRODUCT", 146, 157], ["flaviviral 2 O MTase", "GENE_OR_GENE_PRODUCT", 199, 219], ["Dv MTase", "PROTEIN", 133, 141], ["Each reaction", "PROBLEM", 0, 13], ["N7 methylation activities", "TREATMENT", 104, 129], ["Dv MTase", "TREATMENT", 133, 141], ["Wv MTasecan", "TREATMENT", 146, 157], ["the strongest inhibitor", "TREATMENT", 172, 195], ["flaviviral", "TREATMENT", 199, 209]]], ["Flaviviral MTase also mediates guanine N7 methylation, when the enzymatic reaction is performed in the presence of an RNA substrate comprising more than 70 nucleotides including a stem loop structure conserved in the 5 untranslated regions of flavivirus genomes (Ray et al., 2006; Dong et al., 2007) .", [["stem loop", "ANATOMY", 180, 189], ["guanine", "CHEMICAL", 31, 38], ["guanine", "CHEMICAL", 31, 38], ["nucleotides", "CHEMICAL", 156, 167], ["Flaviviral MTase", "GENE_OR_GENE_PRODUCT", 0, 16], ["guanine N7", "SIMPLE_CHEMICAL", 31, 41], ["Flaviviral MTase", "PROTEIN", 0, 16], ["RNA substrate", "RNA", 118, 131], ["stem loop structure", "PROTEIN", 180, 199], ["5 untranslated regions", "DNA", 217, 239], ["Flaviviral MTase", "TREATMENT", 0, 16], ["guanine N7 methylation", "TREATMENT", 31, 53], ["the enzymatic reaction", "PROBLEM", 60, 82], ["an RNA substrate", "PROBLEM", 115, 131], ["a stem loop structure", "PROBLEM", 178, 199], ["flavivirus genomes", "PROBLEM", 243, 261], ["stem loop", "OBSERVATION", 180, 189], ["flavivirus genomes", "OBSERVATION", 243, 261]]], ["In order to determine whether ATA inhibited the flaviviral N7 MTase activity we synthesized an RNA corresponding to the first 351 nucleotides of the Dv genome (Dv 1-351 RNA) using T7 polymerase, and capped the RNA by addition of [\u2423-32 P]-GTP using vaccinia virus guanylyltransferase (see Section 2).", [["ATA", "CHEMICAL", 30, 33], ["[\u2423-32 P]-GTP", "CHEMICAL", 229, 241], ["ATA", "CHEMICAL", 30, 33], ["nucleotides", "CHEMICAL", 130, 141], ["[\u2423-32 P]-GTP", "CHEMICAL", 229, 241], ["ATA", "SIMPLE_CHEMICAL", 30, 33], ["T7 polymerase", "GENE_OR_GENE_PRODUCT", 180, 193], ["[\u2423-32 P]-GTP", "SIMPLE_CHEMICAL", 229, 241], ["vaccinia virus guanylyltransferase", "ORGANISM", 248, 282], ["flaviviral N7 MTase", "PROTEIN", 48, 67], ["Dv genome", "DNA", 149, 158], ["Dv 1", "DNA", 160, 164], ["351 RNA", "RNA", 165, 172], ["T7 polymerase", "PROTEIN", 180, 193], ["vaccinia virus guanylyltransferase", "PROTEIN", 248, 282], ["vaccinia virus", "SPECIES", 248, 262], ["vaccinia virus", "SPECIES", 248, 262], ["ATA", "PROBLEM", 30, 33], ["the flaviviral N7 MTase activity", "PROBLEM", 44, 76], ["the Dv genome", "TEST", 145, 158], ["Dv", "TEST", 160, 162], ["T7 polymerase", "TEST", 180, 193], ["GTP", "TREATMENT", 238, 241], ["vaccinia virus guanylyltransferase", "TREATMENT", 248, 282]]], ["We expected that Dv 1-351 RNA would be an appropriate substrate for Wv MTase because the first three nucleotides of the capped RNA genomes of both viruses are GpppAGU and it had been shown that, besides the presence of the stem loop structure, the conservation of second and third nucleotide were especially important for specific N7 MTase activity .", [["stem loop", "ANATOMY", 223, 232], ["Dv 1-351", "CHEMICAL", 17, 25], ["nucleotide", "CHEMICAL", 281, 291], ["nucleotides", "CHEMICAL", 101, 112], ["nucleotide", "CHEMICAL", 281, 291], ["Dv 1", "GENE_OR_GENE_PRODUCT", 17, 21], ["Wv MTase", "GENE_OR_GENE_PRODUCT", 68, 76], ["GpppAGU", "GENE_OR_GENE_PRODUCT", 159, 166], ["N7 MTase", "GENE_OR_GENE_PRODUCT", 331, 339], ["Dv 1-351 RNA", "RNA", 17, 29], ["Wv MTase", "PROTEIN", 68, 76], ["capped RNA genomes", "DNA", 120, 138], ["N7 MTase", "PROTEIN", 331, 339], ["Dv", "TEST", 17, 19], ["Wv MTase", "TREATMENT", 68, 76], ["the stem loop structure", "PROBLEM", 219, 242], ["second and third nucleotide", "TREATMENT", 264, 291], ["viruses", "OBSERVATION", 147, 154], ["stem loop", "OBSERVATION", 223, 232]]], ["The capped Dv 1-351 RNA was incubated with Wv MTase in the presence of increasing ATA concentrations and the reaction products were analyzed after nuclease P1 digestion by TLC and autoradiography.", [["Dv 1-351", "CHEMICAL", 11, 19], ["ATA", "CHEMICAL", 82, 85], ["ATA", "CHEMICAL", 82, 85], ["Wv MTase", "GENE_OR_GENE_PRODUCT", 43, 51], ["ATA", "SIMPLE_CHEMICAL", 82, 85], ["capped Dv 1-351 RNA", "RNA", 4, 23], ["Wv MTase", "PROTEIN", 43, 51], ["Wv MTase", "TREATMENT", 43, 51], ["increasing ATA concentrations", "PROBLEM", 71, 100], ["the reaction products", "TREATMENT", 105, 126], ["nuclease P1 digestion", "TREATMENT", 147, 168], ["TLC", "TEST", 172, 175], ["autoradiography", "TEST", 180, 195], ["increasing", "OBSERVATION_MODIFIER", 71, 81], ["ATA concentrations", "OBSERVATION", 82, 100]]], ["Fig. 4A shows that in the absence of Wv MTase (CTL-), radiolabeled GpppA released from the substrate RNA by nuclease P1 is detected at the expected position.", [["GpppA", "CHEMICAL", 67, 72], ["Wv MTase", "GENE_OR_GENE_PRODUCT", 37, 45], ["CTL", "GENE_OR_GENE_PRODUCT", 47, 50], ["GpppA", "GENE_OR_GENE_PRODUCT", 67, 72], ["nuclease P1", "GENE_OR_GENE_PRODUCT", 108, 119], ["Wv MTase", "PROTEIN", 37, 45], ["CTL", "PROTEIN", 47, 50], ["GpppA", "PROTEIN", 67, 72], ["substrate RNA", "RNA", 91, 104], ["nuclease P1", "PROTEIN", 108, 119], ["radiolabeled GpppA", "TEST", 54, 72], ["nuclease P1", "OBSERVATION", 108, 119], ["position", "OBSERVATION_MODIFIER", 148, 156]]], ["In the presence of Wv MTase (CTL+), almost 55% of GpppA was converted into a new product co-migrating with the N7Me GpppA cap analog, as standardly visualized by UV shad- Two controls were carried out, one without enzyme and one without ATA and the molecular weight markers were visualized by UV shadowing.", [["Wv MTase", "GENE_OR_GENE_PRODUCT", 19, 27], ["GpppA", "GENE_OR_GENE_PRODUCT", 50, 55], ["Wv MTase", "PROTEIN", 19, 27], ["CTL", "PROTEIN", 29, 32], ["GpppA", "PROTEIN", 50, 55], ["GpppA", "PROTEIN", 116, 121], ["enzyme", "PROTEIN", 214, 220], ["the N7Me GpppA cap analog", "TREATMENT", 107, 132], ["enzyme", "TEST", 214, 220], ["ATA", "TREATMENT", 237, 240], ["the molecular weight markers", "TEST", 245, 273], ["shadowing", "OBSERVATION_MODIFIER", 296, 305]]], ["(B) Determination of the IC50 values for ATA on the N7 MTase activity of Wv and Dv MTases.", [["ATA", "CHEMICAL", 41, 44], ["ATA", "SIMPLE_CHEMICAL", 41, 44], ["Wv", "GENE_OR_GENE_PRODUCT", 73, 75], ["Dv MTases", "GENE_OR_GENE_PRODUCT", 80, 89], ["N7 MTase", "PROTEIN", 52, 60], ["Wv and Dv MTases", "PROTEIN", 73, 89], ["the IC50 values", "TEST", 21, 36], ["ATA", "PROBLEM", 41, 44], ["Dv MTases", "TREATMENT", 80, 89]]], ["The percentage of activity was determined after quantification of GpppA and 7Me GpppA.", [["GpppA", "GENE_OR_GENE_PRODUCT", 66, 71], ["7Me GpppA", "GENE_OR_GENE_PRODUCT", 76, 85], ["GpppA", "PROTEIN", 66, 71], ["7Me GpppA", "PROTEIN", 76, 85], ["GpppA", "TEST", 66, 71], ["percentage", "OBSERVATION_MODIFIER", 4, 14]]], ["The IC50 value was determined by fitting of the dose-response curve as in Fig. 3. owing.", [["The IC50 value", "TEST", 0, 14], ["response curve", "TEST", 53, 67]]], ["At longer incubation times part of N7Me GpppA was further methylated into N7Me GpppA 2 OMe (not shown).", [["GpppA", "GENE_OR_GENE_PRODUCT", 40, 45], ["N7Me GpppA", "PROTEIN", 35, 45], ["N7Me GpppA 2 OMe", "DNA", 74, 90]]], ["We conclude that, under these optimized reaction conditions, the RNA corresponding to the first 351 nucleotides of the Dv genome, is a good substrate to specifically follow the N7 MTase activity of Wv MTase.", [["nucleotides", "CHEMICAL", 100, 111], ["Dv", "GENE_OR_GENE_PRODUCT", 119, 121], ["Wv MTase", "GENE_OR_GENE_PRODUCT", 198, 206], ["Dv genome", "DNA", 119, 128], ["N7 MTase", "PROTEIN", 177, 185], ["Wv MTase", "PROTEIN", 198, 206]]], ["We next determined the IC 50 values of ATA inhibition on both MTases, by quantifying the GpppA conversion into N7Me GpppA in the presence of increasing ATA concentrations after 20 min, during the linear phase of the N7 MTase reaction.", [["ATA", "CHEMICAL", 39, 42], ["ATA", "CHEMICAL", 152, 155], ["ATA", "CHEMICAL", 152, 155], ["N7", "CHEMICAL", 216, 218], ["ATA", "SIMPLE_CHEMICAL", 39, 42], ["GpppA", "SIMPLE_CHEMICAL", 89, 94], ["N7Me GpppA", "SIMPLE_CHEMICAL", 111, 121], ["ATA", "SIMPLE_CHEMICAL", 152, 155], ["GpppA", "PROTEIN", 89, 94], ["N7Me GpppA", "PROTEIN", 111, 121], ["ATA inhibition", "TREATMENT", 39, 53], ["the GpppA conversion", "TREATMENT", 85, 105], ["increasing ATA concentrations", "PROBLEM", 141, 170], ["the N7 MTase reaction", "TREATMENT", 212, 233], ["increasing", "OBSERVATION_MODIFIER", 141, 151]]], ["ATA inhibits the N7 Wv MTase activity at higher concentrations than those observed in the 2 O MTase assay, the IC 50 value being 38 M (\u00b12 M) compared to 4.2 M, respectively.", [["ATA", "CHEMICAL", 0, 3], ["ATA", "SIMPLE_CHEMICAL", 0, 3], ["MTase", "PROTEIN", 23, 28], ["MTase assay", "TEST", 94, 105]]], ["As shown in Fig. 4B , ATA moderately inhibits the N7 Dv MTase activity, with an IC 50 value of 127 M (\u00b16 M), compared to IC 50 of 2.3 M, for the inhibition of the 2 O Dv MTase activity.", [["ATA", "CHEMICAL", 22, 25], ["ATA", "CHEMICAL", 22, 25], ["ATA", "SIMPLE_CHEMICAL", 22, 25], ["MTase", "PROTEIN", 56, 61], ["MTase", "PROTEIN", 170, 175], ["an IC", "TEST", 77, 82], ["IC", "TEST", 121, 123]]], ["Thus, our results indicate that ATA inhibits the N7 MTase activity of Dv and Wv to a minor extent compared to the 2 O MTase activity.Analysis of Wv MTase/ATA complex docking modelAnalysis of complex models obtained by docking ATA to Wv MTase shows the inhibitor molecule facing the AdoMet binding site (Fig. 2B ).", [["ATA", "CHEMICAL", 32, 35], ["AdoMet", "CHEMICAL", 282, 288], ["ATA", "CHEMICAL", 32, 35], ["AdoMet", "CHEMICAL", 282, 288], ["ATA", "SIMPLE_CHEMICAL", 32, 35], ["Dv", "GENE_OR_GENE_PRODUCT", 70, 72], ["Wv", "GENE_OR_GENE_PRODUCT", 77, 79], ["2 O MTase", "GENE_OR_GENE_PRODUCT", 114, 123], ["Wv MTase", "GENE_OR_GENE_PRODUCT", 145, 153], ["ATA", "SIMPLE_CHEMICAL", 226, 229], ["Wv MTase", "GENE_OR_GENE_PRODUCT", 233, 241], ["AdoMet", "SIMPLE_CHEMICAL", 282, 288], ["N7 MTase", "PROTEIN", 49, 57], ["Dv", "PROTEIN", 70, 72], ["Wv", "PROTEIN", 77, 79], ["MTase", "PROTEIN", 118, 123], ["Wv MTase", "PROTEIN", 145, 153], ["ATA complex", "PROTEIN", 154, 165], ["Wv MTase", "PROTEIN", 233, 241], ["AdoMet binding site", "PROTEIN", 282, 301], ["Analysis", "TEST", 133, 141], ["Wv MTase/ATA complex", "TREATMENT", 145, 165], ["Wv MTase", "TREATMENT", 233, 241], ["the inhibitor molecule", "TREATMENT", 248, 270], ["the AdoMet binding site", "PROBLEM", 278, 301]]], ["In particular, ATA interacts with many positively charged amino acids conserved in flavivirus MTases (Arg37, Arg41 (mostly conserved), Arg57, Lys61, Arg84, and Arg213) and establishes a hydrogen bond with the 3 O atom of the AdoMet ribose, contributing to cofactor stabilization in its binding pocket.", [["ATA", "CHEMICAL", 15, 18], ["amino acids", "CHEMICAL", 58, 69], ["AdoMet ribose", "CHEMICAL", 225, 238], ["amino acids", "CHEMICAL", 58, 69], ["Arg57", "CHEMICAL", 135, 140], ["Lys61", "CHEMICAL", 142, 147], ["Arg84", "CHEMICAL", 149, 154], ["Arg", "CHEMICAL", 160, 163], ["hydrogen", "CHEMICAL", 186, 194], ["O", "CHEMICAL", 211, 212], ["AdoMet", "CHEMICAL", 225, 231], ["ribose", "CHEMICAL", 232, 238], ["ATA", "SIMPLE_CHEMICAL", 15, 18], ["amino acids", "AMINO_ACID", 58, 69], ["flavivirus MTases", "ORGANISM", 83, 100], ["Arg37", "GENE_OR_GENE_PRODUCT", 102, 107], ["Arg41", "GENE_OR_GENE_PRODUCT", 109, 114], ["Arg57", "GENE_OR_GENE_PRODUCT", 135, 140], ["Lys61", "GENE_OR_GENE_PRODUCT", 142, 147], ["Arg84", "GENE_OR_GENE_PRODUCT", 149, 154], ["Arg213", "AMINO_ACID", 160, 166], ["AdoMet ribose", "SIMPLE_CHEMICAL", 225, 238], ["ATA", "PROTEIN", 15, 18], ["flavivirus MTases", "PROTEIN", 83, 100], ["Arg37", "PROTEIN", 102, 107], ["Arg41", "PROTEIN", 109, 114], ["Arg57", "PROTEIN", 135, 140], ["many positively charged amino acids", "PROBLEM", 34, 69], ["flavivirus MTases", "PROBLEM", 83, 100], ["a hydrogen bond", "TREATMENT", 184, 199], ["the AdoMet ribose", "TREATMENT", 221, 238], ["cofactor stabilization in its binding pocket", "PROBLEM", 256, 300], ["flavivirus MTases", "OBSERVATION", 83, 100], ["cofactor stabilization", "OBSERVATION", 256, 278], ["binding pocket", "OBSERVATION", 286, 300]]], ["Interestingly, the docked model indicates a hydrogen bond between an ATA hydroxyl group and the side chain of Lys61, part of the conserved catalytic tetrad (K-D-K-E) that supports the 2 O MTase activity.", [["hydroxyl", "CHEMICAL", 73, 81], ["hydrogen", "CHEMICAL", 44, 52], ["hydroxyl", "CHEMICAL", 73, 81], ["Lys61", "CHEMICAL", 110, 115], ["K-D-K-E", "CHEMICAL", 157, 164], ["ATA hydroxyl", "SIMPLE_CHEMICAL", 69, 81], ["Lys61", "SIMPLE_CHEMICAL", 110, 115], ["2 O MTase", "GENE_OR_GENE_PRODUCT", 184, 193], ["Lys61", "PROTEIN", 110, 115], ["catalytic tetrad", "PROTEIN", 139, 155], ["K-D", "PROTEIN", 157, 160], ["K-E", "PROTEIN", 161, 164], ["O MTase", "PROTEIN", 186, 193], ["a hydrogen bond", "TREATMENT", 42, 57], ["an ATA hydroxyl group", "TREATMENT", 66, 87], ["Lys61", "TREATMENT", 110, 115], ["hydrogen bond", "OBSERVATION", 44, 57]]], ["Thus ATA, bound at the site predicted by docking and MD, may impair the correct location of RNA in the catalytic site through steric hindrance and through interaction with residues involved in RNA recognition.DiscussionThe results here reported show that basic hypotheses on the flaviviral MTase mechanism of action (more specifically, deepening our understanding of the role played by the LBS) could efficiently lead to the proposal of a novel binding site for inhibitors.", [["ATA", "CHEMICAL", 5, 8], ["ATA", "SIMPLE_CHEMICAL", 5, 8], ["flaviviral MTase", "GENE_OR_GENE_PRODUCT", 279, 295], ["ATA", "PROTEIN", 5, 8], ["RNA", "RNA", 92, 95], ["catalytic site", "PROTEIN", 103, 117], ["flaviviral MTase", "PROTEIN", 279, 295], ["LBS", "PROTEIN", 390, 393], ["a novel binding site", "TREATMENT", 437, 457], ["inhibitors", "TREATMENT", 462, 472], ["steric hindrance", "OBSERVATION", 126, 142]]], ["Starting from our Wv MTase crystal structure (Bollati et al., 2009) , we proposed a model of the protein/RNA interaction during N7 methylation activity (no crystal structure available so far).", [["N7", "CHEMICAL", 128, 130], ["the protein/RNA interaction", "TREATMENT", 93, 120], ["N7 methylation activity", "TREATMENT", 128, 151]]], ["We then used the proposed (LBS) RNA binding site to select three compounds out of 1280 that were screened by means of a docking analysis in silico.", [["the proposed (LBS)", "TREATMENT", 13, 31], ["RNA binding site", "PROBLEM", 32, 48], ["a docking analysis", "TEST", 118, 136]]], ["Among the three best ligands identified we showed by in vitro inhibitory assays that ATA is a potent inhibitor of flaviviral 2 O MTase activity for both Wv and Dv.", [["ATA", "CHEMICAL", 85, 88], ["ATA", "CHEMICAL", 85, 88], ["ATA", "SIMPLE_CHEMICAL", 85, 88], ["flaviviral 2 O MTase", "GENE_OR_GENE_PRODUCT", 114, 134], ["a potent inhibitor", "TREATMENT", 92, 110], ["flaviviral", "TREATMENT", 114, 124]]], ["ATA also inhibited the Wv and Dv N7 MTase activity on longer RNAs, but to a minor extent.", [["ATA", "CHEMICAL", 0, 3], ["ATA", "CHEMICAL", 0, 3], ["ATA", "SIMPLE_CHEMICAL", 0, 3], ["Wv", "GENE_OR_GENE_PRODUCT", 23, 25], ["Dv N7 MTase", "GENE_OR_GENE_PRODUCT", 30, 41], ["Dv N7 MTase activity", "TREATMENT", 30, 50], ["N7 MTase", "OBSERVATION", 33, 41], ["minor extent", "OBSERVATION_MODIFIER", 76, 88]]], ["The efficient inhibitory action of ATA against 2 O MTase activity is consistent with its specific interaction with residue Lys61, as indicated by docking.", [["ATA", "CHEMICAL", 35, 38], ["ATA", "CHEMICAL", 35, 38], ["Lys61", "CHEMICAL", 123, 128], ["ATA", "SIMPLE_CHEMICAL", 35, 38], ["2 O MTase", "GENE_OR_GENE_PRODUCT", 47, 56], ["Lys61", "AMINO_ACID", 123, 128], ["MTase", "PROTEIN", 51, 56], ["residue Lys61", "TREATMENT", 115, 128], ["consistent with", "UNCERTAINTY", 69, 84]]], ["Indeed, this residue was previously shown to be important for 2 O MTase activity but not for N7 MTase activity (Zhou et al., 2007) .", [["2 O MTase", "GENE_OR_GENE_PRODUCT", 62, 71], ["N7 MTase", "GENE_OR_GENE_PRODUCT", 93, 101], ["MTase", "PROTEIN", 66, 71], ["N7 MTase", "PROTEIN", 93, 101]]], ["Moreover, since N7 MTase and 2 O MTase assays were performed on RNA of different lengths, it is possible that the different IC 50 values found reflect a difference in the affinity for the RNA substrates in the inhibition assays.", [["N7 MTase", "GENE_OR_GENE_PRODUCT", 16, 24], ["2 O MTase", "GENE_OR_GENE_PRODUCT", 29, 38], ["N7 MTase", "PROTEIN", 16, 24], ["N7 MTase", "TREATMENT", 16, 24], ["2 O MTase assays", "TEST", 29, 45], ["a difference in the affinity", "PROBLEM", 151, 179], ["the RNA substrates", "PROBLEM", 184, 202]]], ["Taken together, our results demonstrating the inhibitory capability of ATA (in the micromolar range) support the hypothesis that the LBS (adjacent to the MTasebound AdoMet) which is targeted here as a new inhibitory site may be suitable for drug lead development.DiscussionInterestingly ATA has been reported to inhibit the replication of different kinds of viruses including human immunodeficiency virus (HIV) (Schols et al., 1989) , influenza virus (Hung et al., 2009) and vaccinia virus (Myskiw et al., 2007) .", [["ATA", "CHEMICAL", 71, 74], ["LBS", "CHEMICAL", 133, 136], ["AdoMet", "CHEMICAL", 165, 171], ["ATA", "CHEMICAL", 287, 290], ["human immunodeficiency virus (HIV)", "DISEASE", 376, 410], ["influenza virus", "DISEASE", 435, 450], ["vaccinia virus", "DISEASE", 475, 489], ["ATA", "CHEMICAL", 71, 74], ["AdoMet", "CHEMICAL", 165, 171], ["ATA", "SIMPLE_CHEMICAL", 71, 74], ["LBS", "SIMPLE_CHEMICAL", 133, 136], ["AdoMet", "SIMPLE_CHEMICAL", 165, 171], ["ATA", "SIMPLE_CHEMICAL", 287, 290], ["human immunodeficiency virus", "ORGANISM", 376, 404], ["HIV", "ORGANISM", 406, 409], ["influenza virus", "ORGANISM", 435, 450], ["vaccinia virus", "ORGANISM", 475, 489], ["LBS", "PROTEIN", 133, 136], ["ATA", "PROTEIN", 287, 290], ["human immunodeficiency virus (HIV", "SPECIES", 376, 409], ["influenza virus", "SPECIES", 435, 450], ["vaccinia virus", "SPECIES", 475, 489], ["human immunodeficiency virus", "SPECIES", 376, 404], ["HIV", "SPECIES", 406, 409], ["vaccinia virus", "SPECIES", 475, 489], ["the LBS", "PROBLEM", 129, 136], ["a new inhibitory site", "PROBLEM", 199, 220], ["drug lead development", "PROBLEM", 241, 262], ["different kinds of viruses", "PROBLEM", 339, 365], ["human immunodeficiency virus", "PROBLEM", 376, 404], ["influenza virus", "PROBLEM", 435, 450], ["vaccinia virus", "PROBLEM", 475, 489]]], ["Moreover a recent patent (WO/2005/123965) indicates a possible inhibitory role of ATA against SARS corona virus.", [["ATA", "CHEMICAL", 82, 85], ["SARS", "DISEASE", 94, 98], ["ATA", "SIMPLE_CHEMICAL", 82, 85], ["SARS corona virus", "ORGANISM", 94, 111], ["SARS corona virus", "SPECIES", 94, 111], ["SARS corona virus", "PROBLEM", 94, 111], ["patent", "OBSERVATION", 18, 24]]], ["In the same patent, results indicating generic activity of ATA against flaviviruses are also reported.", [["ATA", "CHEMICAL", 59, 62], ["flaviviruses", "DISEASE", 71, 83], ["ATA", "SIMPLE_CHEMICAL", 59, 62], ["flaviviruses", "PROBLEM", 71, 83], ["patent", "OBSERVATION", 12, 18], ["generic activity", "OBSERVATION", 39, 55]]], ["The authors of the patent, however, do not propose a model explaining the reported antiviral efficacy.", [["patent", "OBSERVATION", 19, 25], ["antiviral efficacy", "OBSERVATION", 83, 101]]], ["The results here presented suggest a specific molecular target and a possible mechanism for the inhibitory activity of ATA against flaviviruses.", [["ATA", "CHEMICAL", 119, 122], ["flaviviruses", "DISEASE", 131, 143], ["ATA", "CHEMICAL", 119, 122], ["ATA", "SIMPLE_CHEMICAL", 119, 122], ["a specific molecular target", "PROBLEM", 35, 62], ["flaviviruses", "PROBLEM", 131, 143]]], ["As a cautionary note, it should be recalled that ATA has been generally reported in the literature as a non-specific inhibitor of several different enzymes (Bina-Stein and Tritton, 1976) .", [["ATA", "CHEMICAL", 49, 52], ["ATA", "SIMPLE_CHEMICAL", 49, 52]]], ["In fact, ATA appears to be able to impair different kinds of protein/nucleotide interactions; therefore, it may also play yet unknown roles in the inhibition of other viral replication processes beyond RNA capping.", [["ATA", "CHEMICAL", 9, 12], ["nucleotide", "CHEMICAL", 69, 79], ["nucleotide", "CHEMICAL", 69, 79], ["ATA", "SIMPLE_CHEMICAL", 9, 12], ["ATA", "PROTEIN", 9, 12], ["protein/nucleotide interactions", "PROBLEM", 61, 92], ["other viral replication processes", "TREATMENT", 161, 194], ["RNA capping", "TREATMENT", 202, 213], ["viral replication", "OBSERVATION", 167, 184], ["RNA capping", "OBSERVATION", 202, 213]]], ["Moreover, considering ATA's capability of inhibiting protein/nucleotide interactions, we cannot exclude different/further effects, even on MTase, such as the blockage of the HBS site (key RNA binding site for 2 O methylation), or effects resulting in a decreased protein affinity for AdoMet.", [["nucleotide", "CHEMICAL", 61, 71], ["AdoMet", "CHEMICAL", 284, 290], ["nucleotide", "CHEMICAL", 61, 71], ["AdoMet", "CHEMICAL", 284, 290], ["ATA", "SIMPLE_CHEMICAL", 22, 25], ["MTase", "GENE_OR_GENE_PRODUCT", 139, 144], ["AdoMet", "SIMPLE_CHEMICAL", 284, 290], ["MTase", "PROTEIN", 139, 144], ["HBS site", "DNA", 174, 182], ["RNA binding site", "DNA", 188, 204], ["inhibiting protein/nucleotide interactions", "PROBLEM", 42, 84], ["MTase", "TREATMENT", 139, 144], ["the blockage of the HBS site", "PROBLEM", 154, 182], ["a decreased protein affinity", "PROBLEM", 251, 279], ["blockage", "OBSERVATION", 158, 166]]]], "a52566f6d96ec5a9a371582766a992a4ac38bd64": [["Because encounters between males can be aggressive [27] we predict that the movement behaviour after a possible encounter would indicate avoidance behaviour (moving away from the encounter location, moving away from one another, increased distance travelled and decreased path tortuosity).Study areaThe study was conducted in the Maasai Mara, in the southwest of Kenya (centred at 1\u02daS and 35\u02daE), which is part of the larger Serengeti-Mara ecosystem.", [["decreased path tortuosity", "PROBLEM", 262, 287], ["Study area", "TEST", 289, 299], ["The study", "TEST", 299, 308], ["tortuosity", "OBSERVATION", 277, 287], ["larger", "OBSERVATION_MODIFIER", 417, 423], ["Serengeti", "OBSERVATION", 424, 433], ["Mara ecosystem", "OBSERVATION", 434, 448]]], ["The study area (~2,600 km 2 ) included the Maasai Mara National Reserve and the surrounding wildlife conservancies.", [["The study area", "TEST", 0, 14]]], ["After the wet season, the long grass attracts large numbers of migratory ungulates, including the white-bearded wildebeest (Connochaetes taurinus) and the common zebra (Equus quagga), from the Serengeti in Tanzania.", [["wildebeest", "ORGANISM", 112, 122], ["Connochaetes taurinus", "ORGANISM", 124, 145], ["zebra", "ORGANISM_SUBDIVISION", 162, 167], ["Equus quagga", "ORGANISM", 169, 181], ["Connochaetes taurinus", "SPECIES", 124, 145], ["Equus quagga", "SPECIES", 169, 181], ["white-bearded wildebeest", "SPECIES", 98, 122], ["Connochaetes taurinus", "SPECIES", 124, 145], ["common zebra", "SPECIES", 155, 167], ["Equus quagga", "SPECIES", 169, 181], ["large", "OBSERVATION_MODIFIER", 46, 51], ["numbers", "OBSERVATION_MODIFIER", 52, 59], ["migratory", "OBSERVATION_MODIFIER", 63, 72], ["ungulates", "OBSERVATION_MODIFIER", 73, 82], ["common zebra", "ANATOMY", 155, 167]]], ["Throughout the year there is an abundance of cheetah prey including resident white-bearded wildebeest, Thomson's gazelle (Eudorcas thomsonii), Grant's gazelle (Nanger granti) and impala (Aepyceros melampus) [31] .", [["Eudorcas thomsonii", "ORGANISM", 122, 140], ["Nanger granti", "ORGANISM", 160, 173], ["Eudorcas thomsonii", "SPECIES", 122, 140], ["Nanger granti", "SPECIES", 160, 173], ["Aepyceros melampus", "SPECIES", 187, 205], ["white-bearded wildebeest", "SPECIES", 77, 101], ["Eudorcas thomsonii", "SPECIES", 122, 140], ["Aepyceros melampus", "SPECIES", 187, 205]]], ["The habitat in the Maasai Mara varies, ranging from open grasslands and shrubland, to riverine forests found along the major rivers and their tributaries [32] .", [["open grasslands", "TREATMENT", 52, 67], ["riverine forests", "TREATMENT", 86, 102], ["habitat", "OBSERVATION_MODIFIER", 4, 11]]], ["The open grassland plains, which are dominated by red oat grass (Themeda triandra), are mostly found toward the south and west of the study area, while the north and north-east consist mostly of Croton thickets (Croton dichogamous) and Vachellia woodlands (Vachellia drepanolobium and V. gerrardii).Cheetah collaringGlobal Positioning System (GPS) satellite collars (African Wildlife Tracking -www.awt.co.za) were fitted on four adult male cheetahs between 19 th October 2016 and 9 th February 2018.", [["oat grass", "ORGANISM", 54, 63], ["Themeda triandra", "ORGANISM", 65, 81], ["Croton", "ORGANISM", 195, 201], ["thickets", "ORGANISM_SUBDIVISION", 202, 210], ["Croton dichogamous", "ORGANISM", 212, 230], ["Vachellia woodlands", "ORGANISM", 236, 255], ["Vachellia drepanolobium", "ORGANISM", 257, 280], ["V. gerrardii", "ORGANISM", 285, 297], ["oat", "SPECIES", 54, 57], ["Themeda triandra", "SPECIES", 65, 81], ["Vachellia drepanolobium", "SPECIES", 257, 280], ["V. gerrardii", "SPECIES", 285, 297], ["red oat grass", "SPECIES", 50, 63], ["Themeda triandra", "SPECIES", 65, 81], ["Croton dichogamous", "SPECIES", 212, 230], ["Vachellia woodlands", "SPECIES", 236, 255], ["Vachellia drepanolobium", "SPECIES", 257, 280], ["V. gerrardii", "SPECIES", 285, 297], ["the study area", "TEST", 130, 144], ["Croton thickets", "TEST", 195, 210], ["Vachellia woodlands", "PROBLEM", 236, 255], ["open", "OBSERVATION_MODIFIER", 4, 8], ["grassland plains", "OBSERVATION", 9, 25]]], ["In compliance with Kenyan law, all immobilizations for deployment/removal of collars were performed by a Kenya Wildlife Service veterinarian.", [["all immobilizations", "TREATMENT", 31, 50], ["deployment/removal of collars", "TREATMENT", 55, 84]]], ["Cheetahs were free-darted and immobilized using a combination of ketamine (2-2.5 mg/kg) and medetomidine (0.07 mg/kg), remotely administered by a Dan-Inject CO 2 rifle (Dan-Inject, Denmark), and reversed with atipamezole (0.3 mg/ml; following [33] ).", [["ketamine", "CHEMICAL", 65, 73], ["medetomidine", "CHEMICAL", 92, 104], ["atipamezole", "CHEMICAL", 209, 220], ["ketamine", "CHEMICAL", 65, 73], ["medetomidine", "CHEMICAL", 92, 104], ["atipamezole", "CHEMICAL", 209, 220], ["ketamine", "SIMPLE_CHEMICAL", 65, 73], ["medetomidine", "SIMPLE_CHEMICAL", 92, 104], ["atipamezole", "SIMPLE_CHEMICAL", 209, 220], ["ketamine", "TREATMENT", 65, 73], ["medetomidine", "TREATMENT", 92, 104], ["atipamezole", "TREATMENT", 209, 220]]], ["Sedation time was kept to a minimum, typically less than 1 hour.", [["Sedation time", "TREATMENT", 0, 13]]], ["After immobilization all cheetahs recovered fully, showing no signs of distress and no apparent side effects were observed in the short-and long-term.", [["immobilization", "TREATMENT", 6, 20], ["distress", "PROBLEM", 71, 79], ["apparent side effects", "PROBLEM", 87, 108], ["no signs of", "UNCERTAINTY", 59, 70], ["distress", "OBSERVATION", 71, 79]]], ["Collars, which were only fitted on adults, weighed 400 grams which is the recommended weight for cheetah collars [34] .", [["Collars", "TREATMENT", 0, 7], ["cheetah collars", "TREATMENT", 97, 112]]], ["All collars were removed if they malfunctioned or if the batteries were low.", [["All collars", "TREATMENT", 0, 11], ["the batteries", "TEST", 53, 66]]], ["The animal handling protocols used conformed to the standards of the American Society of Mammalogists [35] and permissions to deploy collars were provided by the Kenya Wildlife Service (Permit No.: KWS/ BRM/5001) and the National Commission for Science, Technology and Innovation (Permit No.: NACOSTI/P/16/69633/10821).", [["The animal handling protocols", "TREATMENT", 0, 29]]], ["The collared males were all singletons, except for one male (M03), who was part of a fivemale coalition.", [["a fivemale coalition", "TREATMENT", 83, 103], ["collared males", "OBSERVATION", 4, 18]]], ["While this is a relatively small sample size, it is a quarter of the entire population as there are approximately 32 adults within the study area [36] .", [["a relatively small sample size", "PROBLEM", 14, 44], ["relatively", "OBSERVATION_MODIFIER", 16, 26], ["small", "OBSERVATION_MODIFIER", 27, 32], ["sample", "OBSERVATION_MODIFIER", 33, 39], ["size", "OBSERVATION_MODIFIER", 40, 44], ["quarter", "OBSERVATION_MODIFIER", 54, 61], ["entire", "OBSERVATION_MODIFIER", 69, 75], ["population", "OBSERVATION_MODIFIER", 76, 86], ["approximately", "OBSERVATION_MODIFIER", 100, 113], ["32 adults", "OBSERVATION_MODIFIER", 114, 123]]], ["On average, the collars were deployed for 285 days ranging from 115 to 349 days (Table 1) .", [["the collars", "TREATMENT", 12, 23], ["average", "OBSERVATION_MODIFIER", 3, 10]]], ["For each pair of cheetahs (hereafter referred to as a dyad), we only used simultaneously collected data for the analyses.Data processing and analysisStatic interactions.", [["the analyses", "TEST", 108, 120]]], ["Space use for each individual per dyad was based on their utilisation distributions, which is the distribution of an individual's locations over time [37] , using the adehabitat package [38] in R [39] .", [["the adehabitat package", "TREATMENT", 163, 185]]], ["To calculate the utilisation distributions we used a fixed kernel density estimate using a bivariate normal kernel.", [["a fixed kernel density", "TREATMENT", 51, 73]]], ["We used the reference bandwidth parameter (h ref ) as the smoothing factor unless h ref > 1000 then we used 80% of the h ref to minimise over-smoothing of the data.", [["the reference bandwidth parameter", "TREATMENT", 8, 41]]], ["For each dyad we then calculated the amount of overlap of the 99% kernels and the 50% kernels.Data processing and analysisMarking posts are used by male cheetahs to communicate their presence to conspecifics.", [["Data processing", "TEST", 94, 109]]], ["Using the methods described by [29] , we located marking posts based on a cluster analysis using data from the GPS collars and opportunistically when conducting fieldwork.", [["a cluster analysis", "TEST", 72, 90]]], ["We used the recurse package [40] to calculate 1) how many marking posts were visited by each individual and 2) how many marking posts were visited by both individuals in a dyad (hereafter referred to as mutual marking posts).", [["the recurse package", "TREATMENT", 8, 27]]], ["We tested the data for normality using the Shapiro-Wilk test and used a t-test if the data were normally distributed and a Wilcoxon test if they were not.", [["the data", "TEST", 10, 18], ["the Shapiro-Wilk test", "TEST", 39, 60], ["a t-test", "TEST", 70, 78], ["the data", "TEST", 82, 90], ["a Wilcoxon test", "TEST", 121, 136]]], ["If the data were not normally distributed then we provided the median \u00b1 median absolute deviation in addition to the mean \u00b1 standard deviation.Data processing and analysisDynamic interaction.", [["the data", "TEST", 3, 11], ["the median \u00b1 median absolute deviation", "TREATMENT", 59, 97], ["absolute deviation", "OBSERVATION", 79, 97], ["standard deviation", "OBSERVATION", 124, 142]]], ["Then, to determine whether interactions between two individuals in a dyad were likely to occur, we calculated the proximity between simultaneous locations using the wildlifeDI package [42] .", [["the wildlifeDI package", "TREATMENT", 161, 183]]], ["The 3hr resolution of the data is quite coarse so we used different proximity thresholds to group possible encounters based on the average 3-hour step-length which was 1,021m \u00b1 1,487m (mean \u00b1 standard deviation).", [["the data", "TEST", 22, 30], ["quite coarse", "PROBLEM", 34, 46]]], ["The GPS data were examined once every few days.", [["The GPS data", "TEST", 0, 12]]], ["If any unusual behaviour was detected, such as no movement after a possible encounter, the field team would investigate to establish whether any injuries or deaths occurred as a result.", [["injuries", "DISEASE", 145, 153], ["deaths", "DISEASE", 157, 163], ["any unusual behaviour", "PROBLEM", 3, 24], ["any injuries", "PROBLEM", 141, 153], ["deaths", "PROBLEM", 157, 163]]], ["Then, per dyad, we calculated 1) the distance to the encounter location for each individual, 2) the distance travelled per individual and 3) the path tortuosity, or straightness.", [["the path tortuosity", "PROBLEM", 141, 160], ["straightness", "PROBLEM", 165, 177], ["tortuosity", "OBSERVATION", 150, 160]]], ["Path tortuosity was calculated by dividing the net displacement by the total distance travelled.", [["Path tortuosity", "PROBLEM", 0, 15], ["the net displacement", "PROBLEM", 43, 63], ["tortuosity", "OBSERVATION", 5, 15], ["net", "OBSERVATION_MODIFIER", 47, 50], ["displacement", "OBSERVATION_MODIFIER", 51, 63], ["total", "OBSERVATION_MODIFIER", 71, 76]]], ["A value of around 1 would indicate that the individual travelled in a straight line whereas a value <1 would be indicative of a tortuous path.", [["A value", "TEST", 0, 7], ["a straight line", "TREATMENT", 68, 83], ["a tortuous path", "PROBLEM", 126, 141], ["indicative of", "UNCERTAINTY", 112, 125], ["tortuous", "OBSERVATION", 128, 136]]], ["We compared the proximity of the two individuals within a dyad, distance to encounter location, distance travelled and tortuosity before and after a possible encounter.", [["tortuosity", "OBSERVATION", 119, 129]]], ["We tested the data for normality using the Shapiro-Wilk test and used a t-test if the data were normally distributed and a Wilcoxon test if they were not.ResultsIn total, we secured simultaneous data on four male cheetah dyads ranging from 113 to 329 days per dyad.", [["cheetah", "ORGANISM", 213, 220], ["the data", "TEST", 10, 18], ["the Shapiro-Wilk test", "TEST", 39, 60], ["a t-test", "TEST", 70, 78], ["the data", "TEST", 82, 90], ["a Wilcoxon test", "TEST", 121, 136]]], ["For all the dyads, the 99% kernels overlapped but the amount of overlap ranged from 10% to 100% where in Dyad 2 the 99% kernel of individual M01 fell completely within the 99% kernel of individual M03 (Fig 1) .", [["M01", "DNA", 141, 144], ["the 99% kernels", "TREATMENT", 19, 34], ["individual M01", "TEST", 130, 144], ["amount", "OBSERVATION_MODIFIER", 54, 60]]], ["Only the core areas (50% kernel) of Dyad 3 had an extensive area of overlap (28% and 48%), whereas the cores of the other dyads did not overlap or the area of overlap was minimal (< 4%).", [["core", "OBSERVATION_MODIFIER", 9, 13], ["areas", "OBSERVATION_MODIFIER", 14, 19], ["extensive", "OBSERVATION_MODIFIER", 50, 59], ["area", "OBSERVATION_MODIFIER", 60, 64], ["overlap", "OBSERVATION_MODIFIER", 68, 75], ["area", "OBSERVATION_MODIFIER", 151, 155], ["minimal", "OBSERVATION_MODIFIER", 171, 178]]], ["We found 125 marking posts in the study area and the number of mutual marking posts per dyad ranged from 4 to 37 with the average number of visits to these marking posts ranging from 1 to 46.16 (Table 3) .", [["the study area", "TEST", 30, 44], ["125 marking", "OBSERVATION_MODIFIER", 9, 20], ["number", "OBSERVATION_MODIFIER", 53, 59], ["mutual marking", "OBSERVATION", 63, 77]]], ["For the three dyads that had the most extensive spatial overlap and the largest number of mutual marking posts (Dyads 1, 2 and 3) the average time that an individual was within 500m of a mutual marking post did not vary significantly between individuals in the same dyad, ranging from 5.06 \u00b1 4.56 hours to 7.95 \u00b1 5.85 hours (mean \u00b1 standard deviation; Table 3 ).", [["mean", "TEST", 325, 329], ["extensive", "OBSERVATION_MODIFIER", 38, 47], ["spatial", "OBSERVATION_MODIFIER", 48, 55], ["overlap", "OBSERVATION", 56, 63], ["largest", "OBSERVATION_MODIFIER", 72, 79], ["number", "OBSERVATION_MODIFIER", 80, 86], ["mutual marking", "OBSERVATION", 90, 104]]], ["The data were not normally distributed and the median for the same three dyads ranged from 2.52 \u00b1 2.35 hours to 7.02 \u00b1 6.01 hours (median \u00b1 median absolute deviation).", [["The data", "TEST", 0, 8]]], ["In the case of Dyad 1 and 2, individual M01, who we classified as territorial, visited mutual marking posts more frequently compared to individuals M02 and M03, neither of which were strictly territorial ( Table 1) .", [["territorial", "OBSERVATION_MODIFIER", 66, 77]]], ["The time between different individuals visiting the same mutual marking post ranged from 3.11 \u00b1 4.01 days to 13.64 \u00b1 8.51 days and did not differ significantly across the dyads (Table 3) .Dynamic interactionFor three of the four dyads (Dyads 1, 2 and 3) the possibility of individuals within each dyad encountering each other was high as they overlapped extensively in space and had a large number of mutual marking posts.", [["individuals", "PROBLEM", 273, 284], ["large", "OBSERVATION_MODIFIER", 385, 390], ["number", "OBSERVATION_MODIFIER", 391, 397], ["mutual marking", "OBSERVATION", 401, 415]]], ["The minimum distance between individuals in a dyad ranged from 89 m to 196 m but the average proximity between individuals ranged from 17,145 \u00b1 6,865 m to 26,367 \u00b1 11,288 m (Fig 2) .", [["individuals", "TEST", 111, 122], ["minimum", "OBSERVATION_MODIFIER", 4, 11], ["distance", "OBSERVATION_MODIFIER", 12, 20]]], ["Possible encounters were classified according to four different thresholds and we detected four possible encounters with a proximity threshold of <500m, 11 with a proximity threshold of <1000m, 21 with a proximity threshold of <1500m and 25 with a proximity threshold of <2000m (Table 4 ).", [["a proximity threshold", "TEST", 246, 267]]], ["Possible encounters were more likely to occur at night than during the day (\u03c7 = 8, df = 1, p = 0.005) and occurred most frequently at 21hr and midnight.", [["more likely", "UNCERTAINTY", 25, 36]]], ["In other words, rather than moving away from each other, male cheetahs stayed in close proximity to each other for up to 6 hours after a possible encounter.Encounter outcomesFor the distance to the encounter location, distance travelled and tortuosity we wanted to determine whether there was individual variation within each dyad.", [["tortuosity", "PROBLEM", 241, 251], ["individual variation within each dyad", "PROBLEM", 293, 330], ["tortuosity", "OBSERVATION", 241, 251]]], ["However, because of the paucity in the number of possible encounters that were detected per dyad we were only able to carry out the analysis for possible encounters with a proximity threshold <2000m.", [["the analysis", "TEST", 128, 140], ["paucity", "OBSERVATION_MODIFIER", 24, 31]]], ["In general, cheetahs were closer to the encounter location after a possible encounter compared to before for all four time lags, apart from individual M03 in Dyad 3 where the opposite trend was Intraspecific interactions among carnivores: A case study of male cheetahs observed, however none of the results were significant (S1 Table) .", [["A case study", "TEST", 239, 251]]], ["Similarly, cheetahs travelled less after a potential encounter compared to before, apart from individual M03 in Dyad 3 where the opposite trend was observed.", [["M03", "DNA", 105, 108]]], ["Some of the results, especially at the 12hr and 24hr lag were significant for Dyad 1 and 2 (S1 Table) .Encounter outcomesOn the 11 th February 2017 the collar on M04 stopped transmitting but when the team visited the last location sent by the collar, neither cheetah nor collar could be found and the individual has not been seen since.", [["24hr lag", "TEST", 48, 56], ["collar", "ANATOMY", 243, 249]]], ["On the 1 st October 2017 the collar on M01 stopped transmitting data after the collar data showed that individuals M01 and M03 had come within 89m of each other.", [["M01", "DNA", 39, 42], ["the collar", "TREATMENT", 25, 35], ["transmitting data", "TEST", 51, 68], ["the collar data", "TEST", 75, 90], ["individuals M01", "TEST", 103, 118], ["M03", "TEST", 123, 126]]], ["The team went to the last GPS coordinate that was transmitted by the collar and found the remains of M01 70m from the last GPS fix sent by the collar.", [["collar", "ANATOMY", 143, 149]]], ["Upon inspecting the carcass, a puncture wound was found on the left side of the skull.", [["wound", "ANATOMY", 40, 45], ["left", "ANATOMY", 63, 67], ["skull", "ANATOMY", 80, 85], ["wound", "PATHOLOGICAL_FORMATION", 40, 45], ["skull", "ORGAN", 80, 85], ["a puncture wound", "PROBLEM", 29, 45], ["carcass", "ANATOMY", 20, 27], ["puncture", "OBSERVATION_MODIFIER", 31, 39], ["wound", "OBSERVATION", 40, 45], ["left", "ANATOMY_MODIFIER", 63, 67], ["skull", "ANATOMY", 80, 85]]], ["Based on the circumstantial evidence, we believe that the death of M01 was either a direct or an indirect result of an aggressive interaction between him and the 5-male coalition (M03).", [["death", "DISEASE", 58, 63], ["M01", "CANCER", 67, 70], ["M03", "CANCER", 180, 183], ["the death of M01", "PROBLEM", 54, 70], ["an aggressive interaction", "PROBLEM", 116, 141], ["aggressive", "OBSERVATION_MODIFIER", 119, 129]]], ["Interestingly, three months prior to this encounter M03 and his coalition mates started establishing a territory approximately 25km southwest from M01's territory.", [["his coalition mates", "TREATMENT", 60, 79]]], ["Two days before the encounter the coalition travelled 25 km to the encounter location, spent 12 hours within 150 m of M01 and then travelled 19km straight back to the core of their territory.", [["territory", "ANATOMY_MODIFIER", 181, 190]]], ["M03 did not return to the vicinity of the encounter between the 1 st October 2017, when the encounter took place, and 3 rd February 2018, when M03's collar was removed.", [["M03's collar", "TREATMENT", 143, 155]]], ["The closest they came to M01's territory during that time was approximately 10 km (Fig 3 and the animation in S2 Movie).DiscussionUsing GPS collar data we documented static and dynamic interactions between male cheetahs in Kenya's Maasai Mara and investigated the outcomes of these interactions in terms of movement behaviour and mortalities.", [["M01", "DNA", 25, 28]]], ["As we predicted, male cheetahs showed extensive spatial overlap of the 99% kernels.", [["extensive", "OBSERVATION_MODIFIER", 38, 47], ["spatial overlap", "OBSERVATION", 48, 63]]], ["This high degree of overlap observed in the Maasai Mara could be related to the pattern of prey availability [43] , although we do not have the data to test this.", [["high degree", "OBSERVATION_MODIFIER", 5, 16], ["overlap", "OBSERVATION", 20, 27]]], ["However, apart from one dyad, there was little overlap of core areas (50% kernels) and it could be that core areas are defended more intensively than the peripheral areas [29] .", [["little", "OBSERVATION_MODIFIER", 40, 46], ["overlap", "OBSERVATION_MODIFIER", 47, 54], ["core", "OBSERVATION_MODIFIER", 58, 62], ["areas", "OBSERVATION_MODIFIER", 63, 68], ["could be", "UNCERTAINTY", 90, 98], ["core", "OBSERVATION_MODIFIER", 104, 108], ["areas", "OBSERVATION_MODIFIER", 109, 114], ["peripheral", "ANATOMY_MODIFIER", 154, 164]]], ["We also found that, similar to African wild dogs (Lycaon pictus), possible encounters occurred more at night than during the day [17] .", [["dogs", "ORGANISM", 44, 48], ["Lycaon pictus", "ORGANISM", 50, 63], ["dogs", "SPECIES", 44, 48], ["Lycaon pictus", "SPECIES", 50, 63], ["African wild dogs", "SPECIES", 31, 48], ["Lycaon pictus", "SPECIES", 50, 63]]], ["While cheetahs, like African wild dogs, are predominantly diurnal they can be active at [45] and nocturnal activity for males has been found to be considerably higher than for females [46] .", [["African wild dogs", "ORGANISM", 21, 38], ["dogs", "SPECIES", 34, 38], ["nocturnal activity for males", "PROBLEM", 97, 125]]], ["Data from camera traps set at marking posts found that visits occurred more at night than during the day ( [44] ; KK unpublished data) suggesting that male nocturnal activity is partly driven by patrolling behaviour which is probably why encounters predominantly took place at night.", [["camera traps", "TEST", 10, 22], ["KK unpublished data", "TEST", 114, 133]]], ["In some species, including African wild dogs and white-faced capuchins (Cebus capucinus), avoidance behaviours, characterised by an increase in distance and speed travelled postencounter, were observed as a result of interactions between different groups [17, 18] .", [["dogs", "ORGANISM", 40, 44], ["capuchins", "ORGANISM", 61, 70], ["Cebus capucinus", "ORGANISM", 72, 87], ["dogs", "SPECIES", 40, 44], ["Cebus capucinus", "SPECIES", 72, 87], ["Cebus capucinus", "SPECIES", 72, 87], ["African wild dogs", "PROBLEM", 27, 44], ["white-faced capuchins", "PROBLEM", 49, 70], ["species", "OBSERVATION_MODIFIER", 8, 15], ["increase", "OBSERVATION_MODIFIER", 132, 140]]], ["It is possible that males stayed in close proximity to each other, as part of a territorial defense strategy, if a recent scent of a conspecific was detected.", [["possible", "UNCERTAINTY", 6, 14], ["males", "OBSERVATION", 20, 25], ["territorial", "OBSERVATION_MODIFIER", 80, 91], ["defense", "OBSERVATION", 92, 99]]], ["This behaviour has been observed in dwarf mongoose (Helogale parvula) groups, who moved slower and covered shorter distances in the hour following the encounter of rival faeces at a latrine site within their territory [16] and red fox (Vulpes vulpes) males who spent more time in scent-marked areas [47] .", [["dwarf mongoose", "ORGANISM", 36, 50], ["Helogale parvula", "ORGANISM", 52, 68], ["faeces", "ORGANISM_SUBDIVISION", 170, 176], ["red fox", "ORGANISM", 227, 234], ["Vulpes vulpes", "ORGANISM", 236, 249], ["dwarf mongoose", "SPECIES", 36, 50], ["Helogale parvula", "SPECIES", 52, 68], ["Vulpes vulpes", "SPECIES", 236, 249], ["dwarf mongoose", "SPECIES", 36, 50], ["Helogale parvula", "SPECIES", 52, 68], ["red fox", "SPECIES", 227, 234], ["Vulpes vulpes", "SPECIES", 236, 249], ["rival faeces", "PROBLEM", 164, 176], ["marked", "OBSERVATION_MODIFIER", 286, 292]]], ["Cheetahs exhibit a high rate of multiple paternity [49] so it is possible that multiple males stay in the vicinity of a receptive female with the hope of getting a chance to mate.", [["high", "OBSERVATION_MODIFIER", 19, 23], ["multiple", "OBSERVATION_MODIFIER", 79, 87]]], ["These encounters could however result in fatalities if the removal of competition increases future mating opportunities [50] .", [["the removal", "TREATMENT", 55, 66]]], ["If encounters occur as a result of access to a receptive female rather than to a static, long-term resource such as a territory then this could explain why the five-male coalition did not take-over the territory of individual M01 after he died.DiscussionAggressive interactions with fatal consequences are not uncommon in cheetahs.", [["cheetahs", "CANCER", 322, 330]]], ["Similarly, Mills and Mills [27] found that 50% of male-male encounters recorded in the Kgalagadi Transfrontier Park in Botswana/South Africa resulted in death.", [["death", "DISEASE", 153, 158], ["death", "PROBLEM", 153, 158]]], ["For some species, such as voles (Microtus oeconomus), lions and grizzly bear (Ursus arctos), the removal of males, through either displacement or mortality, has a negative effect on population growth as a result of increased infanticide [53] [54] [55] .", [["Microtus oeconomus", "ORGANISM", 33, 51], ["lions", "ORGANISM", 54, 59], ["Ursus arctos", "ORGANISM", 78, 90], ["Microtus oeconomus", "SPECIES", 33, 51], ["Ursus arctos", "SPECIES", 78, 90], ["Microtus oeconomus", "SPECIES", 33, 51], ["Ursus arctos", "SPECIES", 78, 90], ["some species", "PROBLEM", 4, 16], ["the removal of males", "TREATMENT", 93, 113], ["population growth", "PROBLEM", 182, 199], ["increased infanticide", "PROBLEM", 215, 236], ["species", "OBSERVATION", 9, 16]]], ["Infanticide has however not been observed amongst cheetahs [56] possibly because it rarely occurs in predominantly solitary species [57] .", [["Infanticide", "CHEMICAL", 0, 11]]], ["The removal of males could however have other population-level consequences [58] but the impact of male mortality on population dynamics in cheetahs is unclear.DiscussionStatic and dynamic interactions can play a role in disease transmission [3, 4] .", [["cheetahs", "DISEASE", 140, 148], ["The removal of males", "TREATMENT", 0, 20]]], ["In the Mara-Serengeti ecosystem there is a relatively high prevalence of mange [59, 60] and in Southern Africa cheetahs have been positively tested for feline coronavirus (FCoV) and feline panleukopenia virus (FPV), which can be highly contagious and fatal [61, 62] .", [["feline coronavirus", "DISEASE", 152, 170], ["feline panleukopenia", "DISEASE", 182, 202], ["feline coronavirus", "ORGANISM", 152, 170], ["FCoV", "ORGANISM", 172, 176], ["feline panleukopenia virus", "ORGANISM", 182, 208], ["FPV", "ORGANISM", 210, 213], ["feline coronavirus", "SPECIES", 152, 170], ["feline panleukopenia virus", "SPECIES", 182, 208], ["feline coronavirus", "SPECIES", 152, 170], ["FCoV", "SPECIES", 172, 176], ["feline panleukopenia virus", "SPECIES", 182, 208], ["FPV", "SPECIES", 210, 213], ["feline coronavirus", "PROBLEM", 152, 170], ["feline panleukopenia virus", "PROBLEM", 182, 208], ["relatively", "OBSERVATION_MODIFIER", 43, 53], ["high", "OBSERVATION_MODIFIER", 54, 58]]], ["Pathogens such as these can easily spread through faeces and other bodily fluids, which are deposited and investigated by male cheetahs at marking posts.", [["faeces", "ANATOMY", 50, 56], ["bodily fluids", "ANATOMY", 67, 80], ["faeces", "ORGANISM_SUBSTANCE", 50, 56], ["Pathogens", "PROBLEM", 0, 9]]], ["This could explain why in 2015 several males in the Maasai Mara, who overlapped spatially, died of a yet unknown disease within a short space of time [63] .", [["unknown disease", "PROBLEM", 105, 120]]], ["Despite the clear patterns that were observed, there are several caveats that warrant discussion.", [["clear", "OBSERVATION", 12, 17]]], ["It is therefore possible that other uncollared individuals, including the other members of the 5-male coalition, could have influenced the results.", [["other uncollared individuals", "PROBLEM", 30, 58], ["therefore possible", "UNCERTAINTY", 6, 24]]], ["Secondly, because of the resolution of the collar data we might have missed visits to marking posts and we inferred when interactions took place rather than being able to detect actual interaction (apart from one occasion).", [["the collar data", "TREATMENT", 39, 54]]], ["Our results are therefore likely to be on the conservative side and we suggest that future studies use higher resolution data and/ or proximity loggers to investigate actual interactions between individuals (e.g. [17, 65] ).", [["future studies", "TEST", 84, 98]]], ["However, even with a relatively coarse resolution of data and only a small number of individuals we managed to investigate interactions and subsequent outcomes between males giving a first detailed insight into intraspecific interactions in cheetah.", [["small", "OBSERVATION_MODIFIER", 69, 74]]], ["Summaries for each dyad of the distance to the encounter location, distance travelled and tortuosity before and after a possible encounters with proximity threshold of <2000m.", [["tortuosity", "PROBLEM", 90, 100], ["tortuosity", "OBSERVATION", 90, 100]]]], "7f30f43865806aecc48314bed5533236a6dc0d84": [["The On Call series consists of handbooks designed to assist physicians with the initial evaluation and management of patients by using a problem-oriented approach.", [["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125], ["the initial evaluation", "TEST", 76, 98], ["management", "TREATMENT", 103, 113], ["a problem-oriented approach", "TREATMENT", 135, 162]]], ["Emergency Medicine On Call is a notable addition to this series, the goal of its editor being ''to provide the house officer and student with a valuable tool to initiate effective evaluation and care of the emergency patient.''", [["patient", "ORGANISM", 217, 224], ["patient", "SPECIES", 217, 224], ["effective evaluation", "TEST", 170, 190]]], ["One hundred twenty-five presenting complaints spanning pediatrics, adult medicine, geriatrics, trauma, and toxicology are presented in an easy-to-follow format.", [["trauma", "DISEASE", 95, 101], ["trauma", "PROBLEM", 95, 101]]], ["Each chapter starts with a sample case that transitions into immediate questions, differential diagnosis, key physical and laboratory findings, and management plans.", [["laboratory findings", "TEST", 123, 142]]], ["Common International Classification of Diseases, 9th Revision (ICD-9) diagnoses for each problem are also listed.", [["Diseases", "PROBLEM", 39, 47], ["9th Revision (ICD", "TREATMENT", 49, 66], ["each problem", "PROBLEM", 84, 96], ["Diseases", "OBSERVATION", 39, 47]]]], "PMC7457082": [["IntroductionIn December 2019, a series of pneumonia cases of unknown cause emerged in Wuhan, Hubei Province, China.", [["pneumonia", "DISEASE", 42, 51], ["pneumonia cases", "PROBLEM", 42, 57], ["pneumonia", "OBSERVATION", 42, 51]]], ["Subsequently, a novel coronavirus was isolated and is known as the 2019 novel coronavirus (SARS-COV-2), which was designated as coronavirus disease 2019 (COVID-19) (1).", [["coronavirus disease", "DISEASE", 128, 147], ["coronavirus", "ORGANISM", 22, 33], ["coronavirus", "ORGANISM", 78, 89], ["SARS-COV-2", "ORGANISM", 91, 101], ["coronavirus", "SPECIES", 78, 89], ["a novel coronavirus", "PROBLEM", 14, 33], ["SARS-COV", "TEST", 91, 99], ["coronavirus disease", "PROBLEM", 128, 147], ["COVID", "TEST", 154, 159], ["coronavirus disease", "OBSERVATION", 128, 147]]], ["With the worldwide prevalence and outbreak of COVID-19, the pressure regarding the prevention and treatment of this epidemic has intensified, and several local medical resources were seriously insufficient (2).", [["COVID", "TEST", 46, 51], ["the pressure", "TEST", 56, 68], ["treatment", "TREATMENT", 98, 107], ["this epidemic", "PROBLEM", 111, 124]]], ["Thus, understanding the risk stratification could help in the better allocation of the available medical resources as well as ensure appropriate clinical management of high-risk patients to improve the survival rate.IntroductionThe clinical spectrum of COVID-19 infection appears to be wide, encompassing asymptomatic infection, mild upper respiratory tract illness, severe viral pneumonia with respiratory failure, shock, and even death.", [["upper respiratory tract", "ANATOMY", 334, 357], ["respiratory", "ANATOMY", 395, 406], ["COVID-19", "CHEMICAL", 253, 261], ["infection", "DISEASE", 262, 271], ["infection", "DISEASE", 318, 327], ["upper respiratory tract illness", "DISEASE", 334, 365], ["viral pneumonia", "DISEASE", 374, 389], ["respiratory failure", "DISEASE", 395, 414], ["shock", "DISEASE", 416, 421], ["death", "DISEASE", 432, 437], ["patients", "ORGANISM", 178, 186], ["COVID-19", "ORGANISM", 253, 261], ["patients", "SPECIES", 178, 186], ["COVID-19", "SPECIES", 253, 261], ["the survival rate", "TEST", 198, 215], ["COVID", "TEST", 253, 258], ["infection", "PROBLEM", 262, 271], ["asymptomatic infection", "PROBLEM", 305, 327], ["mild upper respiratory tract illness", "PROBLEM", 329, 365], ["severe viral pneumonia", "PROBLEM", 367, 389], ["respiratory failure", "PROBLEM", 395, 414], ["shock", "PROBLEM", 416, 421], ["even death", "PROBLEM", 427, 437], ["asymptomatic", "OBSERVATION_MODIFIER", 305, 317], ["infection", "OBSERVATION", 318, 327], ["mild", "OBSERVATION_MODIFIER", 329, 333], ["upper", "ANATOMY_MODIFIER", 334, 339], ["respiratory tract", "ANATOMY", 340, 357], ["severe", "OBSERVATION_MODIFIER", 367, 373], ["viral", "OBSERVATION_MODIFIER", 374, 379], ["pneumonia", "OBSERVATION", 380, 389], ["respiratory failure", "OBSERVATION", 395, 414], ["shock", "OBSERVATION", 416, 421]]], ["The current reported death rate is about 0.66\u20137.2% (1, 3\u20135).", [["death", "DISEASE", 21, 26], ["death rate", "TEST", 21, 31]]], ["Some studies have published the risk factors that may be associated with poor prognosis, such as age or severe immune response (4\u20137).", [["Some studies", "TEST", 0, 12], ["the risk factors", "PROBLEM", 28, 44], ["severe immune response", "PROBLEM", 104, 126]]], ["However, only a few studies focusing on clinical risk stratification, and the risk factors for in-hospital death or intensive care unit (ICU) care of patients were undefined.IntroductionAn effective and comprehensive model for screening high-risk patients at admission is necessary for patients infected with SARS-COV-2.", [["death", "DISEASE", 107, 112], ["SARS", "DISEASE", 309, 313], ["patients", "ORGANISM", 150, 158], ["patients", "ORGANISM", 247, 255], ["patients", "ORGANISM", 286, 294], ["patients", "SPECIES", 150, 158], ["patients", "SPECIES", 247, 255], ["patients", "SPECIES", 286, 294], ["a few studies", "TEST", 14, 27], ["IntroductionAn effective", "TREATMENT", 174, 198], ["screening", "TEST", 227, 236], ["SARS", "PROBLEM", 309, 313]]], ["Therefore, we aimed to verify the efficacy of the Multi-lobular infiltration, hypo-Lymphocytosis, Bacterial coinfection, Smoking history, hyper-Tension, and Age (MuLBSTA) scale for mortality or ICU risk stratification in patients with COVID-19 and clarify the predictive value of the scale for poor prognosis.Study Design and Data Collection ::: MethodsWe recruited patients from January 1 to March 25, 2020 in this retrospective study.", [["Multi-lobular", "ANATOMY", 50, 63], ["hypo-Lymphocytosis", "DISEASE", 78, 96], ["Bacterial coinfection", "DISEASE", 98, 119], ["patients", "ORGANISM", 221, 229], ["patients", "ORGANISM", 366, 374], ["patients", "SPECIES", 221, 229], ["patients", "SPECIES", 366, 374], ["the Multi-lobular infiltration", "PROBLEM", 46, 76], ["hypo-Lymphocytosis", "PROBLEM", 78, 96], ["Bacterial coinfection", "PROBLEM", 98, 119], ["hyper-Tension", "PROBLEM", 138, 151], ["COVID", "TEST", 235, 240], ["poor prognosis", "PROBLEM", 294, 308], ["this retrospective study", "TEST", 411, 435], ["Multi-", "OBSERVATION_MODIFIER", 50, 56], ["lobular", "OBSERVATION_MODIFIER", 56, 63], ["infiltration", "OBSERVATION", 64, 76], ["hypo-Lymphocytosis", "OBSERVATION", 78, 96], ["Bacterial coinfection", "OBSERVATION", 98, 119]]], ["All patients were diagnosed with COVID-19 pneumonia according to RT-PCR.", [["pneumonia", "DISEASE", 42, 51], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["COVID", "TEST", 33, 38], ["pneumonia", "PROBLEM", 42, 51], ["RT", "TEST", 65, 67], ["PCR", "TEST", 68, 71], ["pneumonia", "OBSERVATION", 42, 51]]], ["All laboratory and imaging reports during the hospitalization were recorded.", [["imaging", "TEST", 19, 26]]], ["The institutional ethic committee of our institutes approved this study (No. 2020.43).Study Design and Data Collection ::: MethodsHistory of exposure, clinical manifestations, laboratory findings, CT characteristics, and epidemiological and outcome data were obtained from the collection forms and electronic medical records from admission to discharge.", [["this study", "TEST", 61, 71], ["laboratory findings", "TEST", 176, 195], ["CT characteristics", "TEST", 197, 215]]], ["All recorded data were independently reviewed by two researchers.CT Image Review ::: MethodsSigns and severity of lung lesions observed in Computed Tomography (CT) scans were evaluated, and lung involvement in each lobe was recorded.", [["lung lesions", "ANATOMY", 114, 126], ["lung", "ANATOMY", 190, 194], ["lobe", "ANATOMY", 215, 219], ["lung lesions", "DISEASE", 114, 126], ["lung lesions", "CANCER", 114, 126], ["lung", "ORGAN", 190, 194], ["lobe", "ORGAN", 215, 219], ["All recorded data", "TEST", 0, 17], ["lung lesions", "PROBLEM", 114, 126], ["Computed Tomography (CT) scans", "TEST", 139, 169], ["lung involvement in each lobe", "PROBLEM", 190, 219], ["severity", "OBSERVATION_MODIFIER", 102, 110], ["lung", "ANATOMY", 114, 118], ["lesions", "OBSERVATION", 119, 126], ["lung", "ANATOMY", 190, 194], ["involvement", "OBSERVATION", 195, 206], ["each lobe", "ANATOMY", 210, 219]]], ["More than three lung lobes involvement were regarded as multi-lobular infiltrates.", [["lung lobes", "ANATOMY", 16, 26], ["lung lobes", "MULTI-TISSUE_STRUCTURE", 16, 26], ["multi-lobular infiltrates", "PROBLEM", 56, 81], ["lung", "ANATOMY", 16, 20], ["lobes", "ANATOMY_MODIFIER", 21, 26], ["multi-lobular", "OBSERVATION_MODIFIER", 56, 69], ["infiltrates", "OBSERVATION", 70, 81]]], ["The \u201ctotal severity score\u201d was calculated by summing the five lobe scores (range: 0\u201325 points), and each of the five lung lobes were visually scored from 0 to 5 (8).", [["lung lobes", "ANATOMY", 117, 127], ["lobe", "MULTI-TISSUE_STRUCTURE", 62, 66], ["lung lobes", "MULTI-TISSUE_STRUCTURE", 117, 127], ["The \u201ctotal severity score", "TEST", 0, 25], ["five", "ANATOMY_MODIFIER", 112, 116], ["lung", "ANATOMY", 117, 121], ["lobes", "ANATOMY_MODIFIER", 122, 127]]], ["All CT images were independently reviewed by two fellowship-trained cardiothoracic radiologists, and final decisions were reached by consensus.MuLBSTA Score and CURB 65 Score ::: MethodsThe MuLBSTA Score were scaled in all patients.", [["patients", "ORGANISM", 223, 231], ["MuLBSTA", "PROTEIN", 143, 150], ["MuLBSTA", "CELL_LINE", 190, 197], ["patients", "SPECIES", 223, 231], ["All CT images", "TEST", 0, 13], ["MuLBSTA Score", "TEST", 143, 156], ["CURB", "TEST", 161, 165], ["Methods", "TREATMENT", 179, 186], ["Score", "TEST", 198, 203]]], ["The score points as follows: Multi-lobular infiltrates (5 points), lymphocyte count \u2264 0.8 \u00d7 109/L (4 points), bacterial coinfection (4 points, presented with bacteria positive by laboratory tests or sputum tests and there were consolidation signs on CT feature), acute smoker (3 points, and the patients who had quit-smoking history were scaled as 2 points), hypertension (2 points), and age \u2265 60 years (2 points).", [["Multi-lobular infiltrates", "ANATOMY", 29, 54], ["lymphocyte", "ANATOMY", 67, 77], ["bacterial coinfection", "DISEASE", 110, 131], ["hypertension", "DISEASE", 359, 371], ["lobular infiltrates", "CANCER", 35, 54], ["lymphocyte", "CELL", 67, 77], ["patients", "ORGANISM", 295, 303], ["patients", "SPECIES", 295, 303], ["The score points", "TEST", 0, 16], ["Multi-lobular infiltrates", "PROBLEM", 29, 54], ["lymphocyte count \u2264", "TEST", 67, 85], ["bacterial coinfection", "PROBLEM", 110, 131], ["bacteria positive", "PROBLEM", 158, 175], ["laboratory tests", "TEST", 179, 195], ["sputum tests", "TEST", 199, 211], ["consolidation signs", "PROBLEM", 227, 246], ["CT feature", "TEST", 250, 260], ["hypertension", "PROBLEM", 359, 371], ["Multi-", "OBSERVATION_MODIFIER", 29, 35], ["lobular", "OBSERVATION_MODIFIER", 35, 42], ["infiltrates", "OBSERVATION", 43, 54], ["bacterial", "OBSERVATION_MODIFIER", 110, 119], ["coinfection", "OBSERVATION", 120, 131], ["consolidation", "OBSERVATION", 227, 240], ["acute", "OBSERVATION_MODIFIER", 263, 268], ["smoker", "OBSERVATION", 269, 275], ["hypertension", "OBSERVATION", 359, 371]]], ["All patients received a total score calculation for MuLBSTA score.", [["patients", "ORGANISM", 4, 12], ["MuLBSTA", "PROTEIN", 52, 59], ["patients", "SPECIES", 4, 12], ["a total score calculation", "TREATMENT", 22, 47], ["MuLBSTA score", "TEST", 52, 65]]], ["A score of 12 points was used as the cutoff value for mortality risk stratification [MuLBSTA 0-11 (low-risk\u201d mortality) and MuLBSTA 12-22 (high-risk mortality)] (9).MuLBSTA Score and CURB 65 Score ::: MethodsConfusion, Urea, Respiratory rate, Blood pressure, Age 65 (CURB65) score were also scaled.", [["Blood", "ANATOMY", 243, 248], ["Urea", "CHEMICAL", 219, 223], ["Blood", "ORGANISM_SUBSTANCE", 243, 248], ["A score", "TEST", 0, 7], ["the cutoff value", "TEST", 33, 49], ["mortality risk stratification", "TEST", 54, 83], ["MuLBSTA", "TEST", 85, 92], ["MuLBSTA", "TEST", 124, 131], ["MuLBSTA Score", "TEST", 165, 178], ["CURB", "TEST", 183, 187], ["MethodsConfusion", "TEST", 201, 217], ["Urea", "TEST", 219, 223], ["Respiratory rate", "TEST", 225, 241], ["Blood pressure", "TEST", 243, 257], ["Age", "TEST", 259, 262]]], ["The CURB65 is recommended for assessing the severity of pneumonia in hospital settings and the score system refer to previous studies (10, 11).Clinical Outcomes ::: MethodsComplications such as electrolyte disturbance, acute myocardial injury (AMI), acute kidney injury (AKI), acute respiratory distress syndrome (ARDS), and shock were recorded.", [["myocardial", "ANATOMY", 225, 235], ["kidney", "ANATOMY", 256, 262], ["respiratory", "ANATOMY", 283, 294], ["pneumonia", "DISEASE", 56, 65], ["electrolyte disturbance", "DISEASE", 194, 217], ["acute myocardial injury", "DISEASE", 219, 242], ["AMI", "DISEASE", 244, 247], ["acute kidney injury", "DISEASE", 250, 269], ["AKI", "DISEASE", 271, 274], ["acute respiratory distress syndrome", "DISEASE", 277, 312], ["ARDS", "DISEASE", 314, 318], ["shock", "DISEASE", 325, 330], ["myocardial", "MULTI-TISSUE_STRUCTURE", 225, 235], ["kidney", "ORGAN", 256, 262], ["CURB65", "DNA", 4, 10], ["pneumonia", "PROBLEM", 56, 65], ["the score system", "TEST", 91, 107], ["previous studies", "TEST", 117, 133], ["electrolyte disturbance", "PROBLEM", 194, 217], ["acute myocardial injury", "PROBLEM", 219, 242], ["AMI", "PROBLEM", 244, 247], ["acute kidney injury", "PROBLEM", 250, 269], ["AKI", "PROBLEM", 271, 274], ["acute respiratory distress syndrome", "PROBLEM", 277, 312], ["ARDS", "PROBLEM", 314, 318], ["shock", "PROBLEM", 325, 330], ["pneumonia", "OBSERVATION", 56, 65], ["acute", "OBSERVATION_MODIFIER", 219, 224], ["myocardial", "ANATOMY", 225, 235], ["injury", "OBSERVATION", 236, 242], ["acute", "OBSERVATION_MODIFIER", 250, 255], ["kidney", "ANATOMY", 256, 262], ["injury", "OBSERVATION", 263, 269], ["AKI", "OBSERVATION", 271, 274], ["acute", "OBSERVATION_MODIFIER", 277, 282], ["respiratory distress", "OBSERVATION", 283, 303], ["ARDS", "OBSERVATION", 314, 318], ["shock", "OBSERVATION", 325, 330]]], ["Clinical outcomes included Death, ICU care, and recovery/discharge.Statistical Analysis ::: MethodsAll tests were two-sided, and P < 0.05 was considered statistically significant.", [["Death", "DISEASE", 27, 32], ["Death", "PROBLEM", 27, 32], ["ICU care", "TREATMENT", 34, 42], ["Methods", "TEST", 92, 99], ["All tests", "TEST", 99, 108]]], ["Categorical variables were described as frequency rates or percentages, and continuous variables were presented as mean (SD) or median (IQR).", [["Categorical variables", "TEST", 0, 21], ["percentages", "TEST", 59, 70]]], ["The mean values for continuous variables were compared using the independent t-tests when the data were normally distributed; otherwise, the Mann\u2013Whitney test was used.", [["The mean values", "TEST", 0, 15], ["the independent t-tests", "TEST", 61, 84], ["the Mann\u2013Whitney test", "TEST", 137, 158]]], ["For laboratory results, we also assessed whether the measurements were outside the normal range.", [["the measurements", "TEST", 49, 65], ["normal range", "OBSERVATION", 83, 95]]], ["The ROC curve was used to examine the efficacy of the MuLBSTA score for death or ICU.", [["death", "DISEASE", 72, 77], ["The ROC curve", "TEST", 0, 13], ["death", "PROBLEM", 72, 77]]], ["The Kaplan\u2013Meier (K\u2013M) survival analysis was performed to estimate the survival probabilities for COVID-19 infection by the log-rank test.", [["infection", "DISEASE", 107, 116], ["COVID-19", "SPECIES", 98, 106], ["survival analysis", "TEST", 23, 40], ["COVID", "TEST", 98, 103], ["19 infection", "PROBLEM", 104, 116], ["the log-rank test", "TEST", 120, 137]]], ["All statistical analyses were performed using 22.2 SPSS software (Statistical Package for the Social Sciences).Presenting Characteristics ::: ResultsThe study population included 117 hospitalized patients with confirmed cases of COVID-19.", [["patients", "ORGANISM", 196, 204], ["patients", "SPECIES", 196, 204], ["All statistical analyses", "TEST", 0, 24], ["The study population", "TEST", 149, 169], ["COVID", "TEST", 229, 234]]], ["The youngest patient was 3 months old.", [["patient", "ORGANISM", 13, 20], ["patient", "SPECIES", 13, 20]]], ["Furthermore, 2 patients were admitted with mild symptoms and classified as common type, but then were classified as critically severe type after admission due to the symptoms rapidly aggravated.", [["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["mild symptoms", "PROBLEM", 43, 56], ["the symptoms", "PROBLEM", 162, 174], ["mild", "OBSERVATION_MODIFIER", 43, 47]]], ["Moreover, there were 35 (29.9%) patients were older than 60 years.", [["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40]]], ["A total of 55 (47.0%) patients were men.", [["patients", "ORGANISM", 22, 30], ["men", "ORGANISM", 36, 39], ["patients", "SPECIES", 22, 30], ["men", "SPECIES", 36, 39], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["The underlying diseases showed in Table 1.", [["The underlying diseases", "PROBLEM", 0, 23], ["diseases", "OBSERVATION", 15, 23]]], ["For the clinical severity type, 81 (69.2%) patients were common type, and 16 (13.7%) and 20 (17.1%) were severe and critically severe types, respectively.", [["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["the clinical severity type", "TEST", 4, 30], ["severe and critically severe types", "PROBLEM", 105, 139], ["severe", "OBSERVATION_MODIFIER", 105, 111], ["critically", "OBSERVATION_MODIFIER", 116, 126], ["severe", "OBSERVATION_MODIFIER", 127, 133], ["types", "OBSERVATION_MODIFIER", 134, 139]]], ["Among all patients, most of them (96, 82.1%) were discharged, 21 (17.9%) were admitted to the ICU, and 5 (4.3%) died.Presenting Characteristics ::: ResultsOf all 117 patients, the symptomatic treatment and invasive treatment were shown in Table 1.", [["patients", "ORGANISM", 10, 18], ["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 10, 18], ["patients", "SPECIES", 166, 174], ["the symptomatic treatment", "TREATMENT", 176, 201], ["invasive treatment", "TREATMENT", 206, 224]]], ["Among of nine patients with continuous renal replacement therapy, three were acute kidney injury, six were electrolyte disturbance or hypercytokinemia (2 patients had concurrent both of two conditions).", [["renal", "ANATOMY", 39, 44], ["kidney", "ANATOMY", 83, 89], ["acute kidney injury", "DISEASE", 77, 96], ["electrolyte disturbance", "DISEASE", 107, 130], ["hypercytokinemia", "DISEASE", 134, 150], ["patients", "ORGANISM", 14, 22], ["renal", "ORGAN", 39, 44], ["kidney", "ORGAN", 83, 89], ["patients", "ORGANISM", 154, 162], ["patients", "SPECIES", 14, 22], ["patients", "SPECIES", 154, 162], ["continuous renal replacement therapy", "TREATMENT", 28, 64], ["acute kidney injury", "PROBLEM", 77, 96], ["electrolyte disturbance", "PROBLEM", 107, 130], ["hypercytokinemia", "PROBLEM", 134, 150], ["renal", "ANATOMY", 39, 44], ["replacement", "OBSERVATION", 45, 56], ["acute", "OBSERVATION_MODIFIER", 77, 82], ["kidney", "ANATOMY", 83, 89], ["injury", "OBSERVATION", 90, 96]]], ["And five patients were chronic kidney injury.", [["kidney", "ANATOMY", 31, 37], ["chronic kidney injury", "DISEASE", 23, 44], ["patients", "ORGANISM", 9, 17], ["kidney", "ORGAN", 31, 37], ["patients", "SPECIES", 9, 17], ["chronic kidney injury", "PROBLEM", 23, 44], ["chronic", "OBSERVATION_MODIFIER", 23, 30], ["kidney", "ANATOMY", 31, 37], ["injury", "OBSERVATION", 38, 44]]], ["One received extracorporeal membrane oxygenation due to the condition continues to deteriorate.", [["extracorporeal membrane", "ANATOMY", 13, 36], ["extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 13, 36], ["extracorporeal membrane oxygenation", "TREATMENT", 13, 48], ["the condition", "PROBLEM", 56, 69], ["extracorporeal membrane oxygenation", "OBSERVATION", 13, 48]]], ["Otherwise, the medicine treatment were also showed in Table 1, there were 8 (6.8%) patients repeatedly tested PCR positive, stayed in the hospital for more than 30 days, and received convalescent plasma (from cared patients).The Clinical Characteristics and CT Feature in Different Patients ::: ResultsIn all patients, there was no statistical difference in body mass index (BMI) between common type and severe type patients.", [["plasma", "ANATOMY", 196, 202], ["body", "ANATOMY", 358, 362], ["patients", "ORGANISM", 83, 91], ["plasma", "ORGANISM_SUBSTANCE", 196, 202], ["patients", "ORGANISM", 215, 223], ["Patients", "ORGANISM", 282, 290], ["patients", "ORGANISM", 309, 317], ["body", "ORGANISM_SUBDIVISION", 358, 362], ["patients", "ORGANISM", 416, 424], ["patients", "SPECIES", 83, 91], ["patients", "SPECIES", 215, 223], ["Patients", "SPECIES", 282, 290], ["patients", "SPECIES", 309, 317], ["patients", "SPECIES", 416, 424], ["the medicine treatment", "TREATMENT", 11, 33], ["PCR", "TEST", 110, 113], ["convalescent plasma", "TREATMENT", 183, 202], ["statistical difference in body mass index", "PROBLEM", 332, 373], ["common type and severe type patients", "PROBLEM", 388, 424], ["no", "UNCERTAINTY", 329, 331], ["mass", "OBSERVATION", 363, 367], ["severe", "OBSERVATION_MODIFIER", 404, 410]]], ["Among all severe type patients, the mean point of CURB65 score was 1.4 \u00b1 1.5.", [["patients", "ORGANISM", 22, 30], ["CURB65", "PROTEIN", 50, 56], ["patients", "SPECIES", 22, 30], ["CURB65 score", "TEST", 50, 62], ["severe", "OBSERVATION_MODIFIER", 10, 16]]], ["And 12 (33.3%) of the patients underwent the prone position management.The Clinical Characteristics and CT Feature in Different Patients ::: ResultsThe lymphocyte count and rate in severe type patient were significantly lower than those in common type patients (P < 0.05).", [["lymphocyte", "ANATOMY", 152, 162], ["patients", "ORGANISM", 22, 30], ["Patients", "ORGANISM", 128, 136], ["lymphocyte", "CELL", 152, 162], ["patient", "ORGANISM", 193, 200], ["patients", "ORGANISM", 252, 260], ["patients", "SPECIES", 22, 30], ["Patients", "SPECIES", 128, 136], ["patient", "SPECIES", 193, 200], ["patients", "SPECIES", 252, 260], ["the prone position management", "TREATMENT", 41, 70], ["The lymphocyte count", "TEST", 148, 168], ["rate", "TEST", 173, 177], ["lymphocyte count", "OBSERVATION", 152, 168], ["severe", "OBSERVATION_MODIFIER", 181, 187], ["type", "OBSERVATION_MODIFIER", 188, 192], ["significantly", "OBSERVATION_MODIFIER", 206, 219], ["lower", "OBSERVATION_MODIFIER", 220, 225]]], ["Among the severe type patients, 21 (58.3%) and 28 (7.8%) presented with decreased lymphocyte count and rate, respectively, of which the percentages were higher than those in common type patients.", [["lymphocyte", "ANATOMY", 82, 92], ["patients", "ORGANISM", 22, 30], ["lymphocyte", "CELL", 82, 92], ["patients", "ORGANISM", 186, 194], ["patients", "SPECIES", 22, 30], ["patients", "SPECIES", 186, 194], ["decreased lymphocyte count", "PROBLEM", 72, 98], ["rate", "TEST", 103, 107], ["severe", "OBSERVATION_MODIFIER", 10, 16], ["decreased lymphocyte count", "OBSERVATION", 72, 98], ["percentages", "OBSERVATION_MODIFIER", 136, 147], ["higher", "OBSERVATION_MODIFIER", 153, 159]]], ["Furthermore, the increased CPR level was higher in severe type patients than in common type patients (33 [91.7%] vs. 34 [42.0%]).The Clinical Characteristics and CT Feature in Different Patients ::: ResultsFor the assessment of CT features, in all of 36 severe type patients, 34 (94.4%) and 35 (97.2%) showed more than 3 lung lobes affected and more than 2 mixture signs, respectively.", [["lung lobes", "ANATOMY", 321, 331], ["patients", "ORGANISM", 63, 71], ["patients", "ORGANISM", 92, 100], ["Patients", "ORGANISM", 186, 194], ["patients", "ORGANISM", 266, 274], ["lung lobes", "MULTI-TISSUE_STRUCTURE", 321, 331], ["CPR", "PROTEIN", 27, 30], ["patients", "SPECIES", 63, 71], ["patients", "SPECIES", 92, 100], ["Patients", "SPECIES", 186, 194], ["patients", "SPECIES", 266, 274], ["the increased CPR level", "TEST", 13, 36], ["the assessment", "TEST", 210, 224], ["CT features", "TEST", 228, 239], ["increased", "OBSERVATION_MODIFIER", 17, 26], ["severe", "OBSERVATION_MODIFIER", 51, 57], ["lung", "ANATOMY", 321, 325], ["lobes", "ANATOMY_MODIFIER", 326, 331]]], ["The lung lobes involvement was shown in Table 2.", [["lung lobes", "ANATOMY", 4, 14], ["lung lobes", "MULTI-TISSUE_STRUCTURE", 4, 14], ["lung", "ANATOMY", 4, 8], ["lobes", "ANATOMY_MODIFIER", 9, 14]]], ["Severe type patients had significantly higher lung severity scores than common type patients (7.8 \u00b1 3.9 vs. 3.3 \u00b1 2.4, P < 0.05).The Scores and Clinical Complications ::: ResultsA total of 18 patients had a MuLBSTA score >12 points and were all of severe type (Table 3).", [["lung", "ANATOMY", 46, 50], ["patients", "ORGANISM", 12, 20], ["lung", "ORGAN", 46, 50], ["patients", "ORGANISM", 84, 92], ["patients", "ORGANISM", 192, 200], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 84, 92], ["patients", "SPECIES", 192, 200], ["Severe type patients", "PROBLEM", 0, 20], ["significantly higher lung severity scores", "PROBLEM", 25, 66], ["P", "TEST", 119, 120], ["a MuLBSTA score", "TEST", 205, 220], ["lung", "ANATOMY", 46, 50], ["severity", "OBSERVATION", 51, 59]]], ["In the severe type patients, 20 (55.6%) were older than 60 years, 14 (38.9%) had hypertension, 7 (19.4%) were smokers, 20 (55.6%) had a lymphocyte count of <0.8*109/L, 30 (83.3%) had multi-lobular infiltrates, and 19 (52.8%) had bacterial coinfection.", [["lymphocyte", "ANATOMY", 136, 146], ["multi-lobular infiltrates", "ANATOMY", 183, 208], ["hypertension", "DISEASE", 81, 93], ["bacterial coinfection", "DISEASE", 229, 250], ["patients", "ORGANISM", 19, 27], ["lymphocyte", "CELL", 136, 146], ["patients", "SPECIES", 19, 27], ["hypertension", "PROBLEM", 81, 93], ["a lymphocyte count", "TEST", 134, 152], ["multi-lobular infiltrates", "PROBLEM", 183, 208], ["bacterial coinfection", "PROBLEM", 229, 250], ["severe", "OBSERVATION_MODIFIER", 7, 13], ["hypertension", "OBSERVATION", 81, 93], ["infiltrates", "OBSERVATION", 197, 208], ["bacterial", "OBSERVATION_MODIFIER", 229, 238], ["coinfection", "OBSERVATION", 239, 250]]], ["The frequency of all the terms in severe type patients was higher than that in the common type patients.The Scores and Clinical Complications ::: ResultsFor CURB65 score, the mean point in severe type patients were significantly higher than common type patients (P < 0.05).", [["patients", "ORGANISM", 46, 54], ["patients", "ORGANISM", 95, 103], ["patients", "ORGANISM", 201, 209], ["patients", "ORGANISM", 253, 261], ["patients", "SPECIES", 46, 54], ["patients", "SPECIES", 95, 103], ["patients", "SPECIES", 201, 209], ["patients", "SPECIES", 253, 261], ["CURB65 score", "TEST", 157, 169], ["severe type patients", "PROBLEM", 189, 209], ["severe", "OBSERVATION_MODIFIER", 34, 40], ["severe", "OBSERVATION_MODIFIER", 189, 195], ["higher", "OBSERVATION_MODIFIER", 229, 235]]], ["Among of 36 severe type patients, there were 16 patients and 10 patients were more than 2 points and 3 points, respectively.", [["patients", "ORGANISM", 24, 32], ["patients", "ORGANISM", 48, 56], ["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 24, 32], ["patients", "SPECIES", 48, 56], ["patients", "SPECIES", 64, 72], ["36 severe", "OBSERVATION_MODIFIER", 9, 18]]], ["In ICU care and death patients, there were 4 (19.0%) patients and 2 (40%) patients had CURB65 score more than 3 points.", [["death", "DISEASE", 16, 21], ["patients", "ORGANISM", 22, 30], ["patients", "ORGANISM", 53, 61], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 22, 30], ["patients", "SPECIES", 53, 61], ["patients", "SPECIES", 74, 82], ["CURB65 score", "TEST", 87, 99]]], ["The proportion of MuLBSTA score more than 12 points was much higher compared with the proportion of CURB65 score more than 3 points in ICU care and deaths (P < 0.05) (Figure 1).The Scores and Clinical Complications ::: ResultsDuring admission, the complications of severe type patients were as follows: 19 (52.8%) patients had with electrolyte disturbance; 11 (30.6%) with AMI; 17 (47.2%) with respiratory failure; 2 (5.5%) with AKI; and 5 (13.9%) with ARDS.", [["respiratory", "ANATOMY", 394, 405], ["deaths", "DISEASE", 148, 154], ["electrolyte disturbance", "DISEASE", 332, 355], ["AMI", "DISEASE", 373, 376], ["respiratory failure", "DISEASE", 394, 413], ["AKI", "DISEASE", 429, 432], ["ARDS", "DISEASE", 453, 457], ["patients", "ORGANISM", 277, 285], ["patients", "ORGANISM", 314, 322], ["patients", "SPECIES", 277, 285], ["patients", "SPECIES", 314, 322], ["MuLBSTA score", "TEST", 18, 31], ["electrolyte disturbance", "PROBLEM", 332, 355], ["AMI", "TEST", 373, 376], ["respiratory failure", "PROBLEM", 394, 413], ["AKI", "TEST", 429, 432], ["ARDS", "PROBLEM", 453, 457], ["severe", "OBSERVATION_MODIFIER", 265, 271], ["respiratory failure", "OBSERVATION", 394, 413], ["AKI", "OBSERVATION", 429, 432], ["ARDS", "OBSERVATION", 453, 457]]], ["Moreover, 4 (11.1%) patients experienced shock and were all of severe type.", [["shock", "DISEASE", 41, 46], ["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["Moreover", "TEST", 0, 8], ["shock", "PROBLEM", 41, 46], ["shock", "OBSERVATION", 41, 46], ["severe", "OBSERVATION_MODIFIER", 63, 69]]], ["The frequency of electrolyte disturbance, AMI and respiratory failure in severe type patients were higher than common type patients.", [["respiratory", "ANATOMY", 50, 61], ["electrolyte disturbance", "DISEASE", 17, 40], ["AMI", "DISEASE", 42, 45], ["respiratory failure", "DISEASE", 50, 69], ["patients", "ORGANISM", 85, 93], ["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 85, 93], ["patients", "SPECIES", 123, 131], ["electrolyte disturbance", "PROBLEM", 17, 40], ["AMI", "PROBLEM", 42, 45], ["respiratory failure", "PROBLEM", 50, 69], ["severe type patients", "PROBLEM", 73, 93], ["electrolyte disturbance", "OBSERVATION", 17, 40], ["respiratory failure", "OBSERVATION", 50, 69], ["severe", "OBSERVATION_MODIFIER", 73, 79]]], ["The hypokalemia and respiratory failure type I were most common (Table 3).Efficacy and Prognosis Value of the MuLBSTA Scale for Death or ICU Care ::: ResultsOf all 21 patients who required ICU care, 13 (61.9%) and 16 (71.9%) had a MuLBSTA score >12 points.", [["respiratory", "ANATOMY", 20, 31], ["hypokalemia", "DISEASE", 4, 15], ["respiratory failure type I", "DISEASE", 20, 46], ["Death", "DISEASE", 128, 133], ["patients", "ORGANISM", 167, 175], ["patients", "SPECIES", 167, 175], ["The hypokalemia", "PROBLEM", 0, 15], ["respiratory failure type I", "PROBLEM", 20, 46], ["ICU care", "TREATMENT", 189, 197], ["a MuLBSTA score", "TEST", 229, 244], ["hypokalemia", "OBSERVATION", 4, 15], ["respiratory failure", "OBSERVATION", 20, 39]]], ["The median point of the MuLBSTA score was 13 (IQR, 9, 15).", [["the MuLBSTA score", "TEST", 20, 37], ["median", "OBSERVATION_MODIFIER", 4, 10]]], ["All (100%) patients who died had a MuLBSTA score \u2265 12 points, and the median point was 17 (IQR, 14, 17).Efficacy and Prognosis Value of the MuLBSTA Scale for Death or ICU Care ::: ResultsThe diagnosis of the MuLBSTA score for death or ICU treatment is shown in Figure 2.", [["Death", "DISEASE", 158, 163], ["death", "DISEASE", 226, 231], ["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["a MuLBSTA score", "TEST", 33, 48], ["the MuLBSTA score", "PROBLEM", 204, 221], ["death", "PROBLEM", 226, 231], ["ICU treatment", "TREATMENT", 235, 248]]], ["The area under the curve (AUC) of death diagnosis was 0.956, the cutoff value was 12 (specificity, 89.5%; sensitivity, 100%).", [["death", "DISEASE", 34, 39], ["the curve", "TEST", 15, 24], ["death diagnosis", "TEST", 34, 49], ["the cutoff value", "TEST", 61, 77], ["specificity", "TEST", 86, 97], ["sensitivity", "TEST", 106, 117]]], ["The AUC of ICU diagnosis was 0.875, and the cutoff value was 11 (specificity, 91.7%; sensitivity, 71.4%).Efficacy and Prognosis Value of the MuLBSTA Scale for Death or ICU Care ::: ResultsThe subgroup analysis of the association between the MuLBSTA score and death or ICU care patients were showed in Figure 3.", [["Death", "DISEASE", 159, 164], ["death", "DISEASE", 259, 264], ["patients", "ORGANISM", 277, 285], ["MuLBSTA", "PROTEIN", 241, 248], ["patients", "SPECIES", 277, 285], ["the cutoff value", "TEST", 40, 56], ["specificity", "TEST", 65, 76], ["sensitivity", "TEST", 85, 96]]], ["Patients with a MuLBSTA score \u2265 12 had a higher ICU care (log-rank, P = 0.001) and higher death (log-rank, P = 0.000) risks.", [["death", "DISEASE", 90, 95], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["a MuLBSTA score", "TEST", 14, 29], ["a higher ICU care", "TREATMENT", 39, 56], ["higher death", "PROBLEM", 83, 95]]], ["The decreasing number of patients at high risk group and the total number of deaths accumulated over time and ICU admissions in the cohort are shown in Figure 3.DiscussionIn this cohort study, we reported the clinical characteristics and available risk stratification scores associated with the clinical outcomes in patients with COVID-19 pneumonia who died or required ICU care after admission.", [["deaths", "DISEASE", 77, 83], ["pneumonia", "DISEASE", 339, 348], ["patients", "ORGANISM", 25, 33], ["patients", "ORGANISM", 316, 324], ["patients", "SPECIES", 25, 33], ["patients", "SPECIES", 316, 324], ["this cohort study", "TEST", 174, 191], ["COVID-19 pneumonia", "PROBLEM", 330, 348], ["ICU care", "TREATMENT", 370, 378], ["decreasing", "OBSERVATION_MODIFIER", 4, 14], ["number", "OBSERVATION_MODIFIER", 15, 21], ["pneumonia", "OBSERVATION", 339, 348]]], ["Patients with a MuLBSTA score \u226512 points were more likely to die or require ICU care.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["a MuLBSTA score", "TEST", 14, 29], ["ICU care", "TREATMENT", 76, 84]]], ["Particularly, severe type patients were more likely to be older, associated with more underlying diseases, severe immune response and lung involvement.", [["lung", "ANATOMY", 134, 138], ["patients", "ORGANISM", 26, 34], ["lung", "ORGAN", 134, 138], ["patients", "SPECIES", 26, 34], ["more underlying diseases", "PROBLEM", 81, 105], ["severe immune response", "PROBLEM", 107, 129], ["lung involvement", "PROBLEM", 134, 150], ["severe", "OBSERVATION_MODIFIER", 14, 20], ["diseases", "OBSERVATION", 97, 105], ["severe", "OBSERVATION_MODIFIER", 107, 113], ["immune response", "OBSERVATION", 114, 129], ["lung", "ANATOMY", 134, 138], ["involvement", "OBSERVATION", 139, 150]]], ["These findings suggest that for patients with COVID-19, the MuLBSTA score at first-time hospital admissions may be necessary for risk stratification in patients who have poor prognosis.DiscussionAs a new type of highly contagious disease in human, this is the first coronavirus to cause a human pandemic (12).", [["coronavirus", "DISEASE", 266, 277], ["pandemic", "DISEASE", 295, 303], ["patients", "ORGANISM", 32, 40], ["patients", "ORGANISM", 152, 160], ["human", "ORGANISM", 241, 246], ["coronavirus", "ORGANISM", 266, 277], ["human", "ORGANISM", 289, 294], ["patients", "SPECIES", 32, 40], ["patients", "SPECIES", 152, 160], ["human", "SPECIES", 241, 246], ["human", "SPECIES", 289, 294], ["human", "SPECIES", 241, 246], ["human", "SPECIES", 289, 294], ["COVID", "TEST", 46, 51], ["the MuLBSTA score", "PROBLEM", 56, 73], ["highly contagious disease in human", "PROBLEM", 212, 246], ["a human pandemic", "PROBLEM", 287, 303], ["highly", "OBSERVATION_MODIFIER", 212, 218], ["contagious", "OBSERVATION_MODIFIER", 219, 229], ["disease", "OBSERVATION", 230, 237]]], ["The pathophysiology and risk factors of unusually high mortality for COVID-19 have not yet been completely understood.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 69, 77], ["COVID", "TEST", 69, 74]]], ["In this study, we validated an effective clinical risk stratification scoring scale-MuLBSTA score for patients infected with SARS-COV-2.", [["SARS", "DISEASE", 125, 129], ["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["this study", "TEST", 3, 13], ["COV", "TEST", 130, 133]]], ["This scale is based on the mortality outcomes of 528 patients infected with respiratory viruses according to Guo et al. (9).", [["respiratory viruses", "DISEASE", 76, 95], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["respiratory viruses", "PROBLEM", 76, 95], ["respiratory viruses", "OBSERVATION", 76, 95]]], ["However, there is no sufficient evidence to verify the efficacy of assessment of poor prognosis in COVID-19 patients (13).", [["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["assessment", "TEST", 67, 77], ["no sufficient evidence", "UNCERTAINTY", 18, 40]]], ["The scale is used as an early warning model in predicting mortality in viral pneumonia (9).", [["viral pneumonia", "DISEASE", 71, 86], ["viral pneumonia", "PROBLEM", 71, 86], ["viral", "OBSERVATION_MODIFIER", 71, 76], ["pneumonia", "OBSERVATION", 77, 86]]], ["This scale synthesizes multiple risk factors of the patient, and finally obtains a total score according to the proportions of different risk factor, which is equivalent to the score of the patient's basic condition.DiscussionOld age and underlying diseases are now well-known as risk factors in COVID-19 patients, and it has been reported that the SARS-COV-2 infection was more like to occur in older men with comorbidities (13\u201315).", [["SARS", "DISEASE", 349, 353], ["infection", "DISEASE", 360, 369], ["patient", "ORGANISM", 52, 59], ["patient", "ORGANISM", 190, 197], ["patients", "ORGANISM", 305, 313], ["SARS-COV-2", "ORGANISM", 349, 359], ["men", "ORGANISM", 402, 405], ["patient", "SPECIES", 52, 59], ["patient", "SPECIES", 190, 197], ["patients", "SPECIES", 305, 313], ["men", "SPECIES", 402, 405], ["a total score", "TEST", 81, 94], ["different risk factor", "PROBLEM", 127, 148], ["underlying diseases", "PROBLEM", 238, 257], ["the SARS-COV-2 infection", "PROBLEM", 345, 369], ["comorbidities", "PROBLEM", 411, 424], ["diseases", "OBSERVATION", 249, 257]]], ["Wu et al. thought that older age was associated with a greater risk of developing ARDS and death, and it may be owing to less rigorous immune response (16).", [["ARDS", "DISEASE", 82, 86], ["death", "DISEASE", 91, 96], ["developing ARDS", "PROBLEM", 71, 86], ["death", "PROBLEM", 91, 96], ["ARDS", "OBSERVATION", 82, 86]]], ["In their cohort, 29.9% of patients were older than 60 years, and 16.2 and 15.4% had associated with hypertension and diabetes.", [["hypertension", "DISEASE", 100, 112], ["diabetes", "DISEASE", 117, 125], ["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["hypertension", "PROBLEM", 100, 112], ["diabetes", "PROBLEM", 117, 125], ["hypertension", "OBSERVATION", 100, 112], ["diabetes", "OBSERVATION", 117, 125]]], ["Hypertension and CVD had higher prevalence in the severe cases than in the mild ones.", [["Hypertension", "DISEASE", 0, 12], ["CVD", "DISEASE", 17, 20], ["Hypertension", "PROBLEM", 0, 12], ["CVD", "PROBLEM", 17, 20], ["the mild ones", "PROBLEM", 71, 84], ["higher", "OBSERVATION_MODIFIER", 25, 31], ["prevalence", "OBSERVATION_MODIFIER", 32, 42], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["cases", "OBSERVATION", 57, 62], ["mild", "OBSERVATION_MODIFIER", 75, 79]]], ["Moreover, no study have demonstrated that a single underlying illness is a risk factor for death or treatment in the ICU at present.", [["illness", "DISEASE", 62, 69], ["death", "DISEASE", 91, 96], ["study", "TEST", 13, 18], ["a single underlying illness", "PROBLEM", 42, 69], ["death", "PROBLEM", 91, 96], ["treatment", "TREATMENT", 100, 109]]], ["Old age or age and underlying disease alone may not be sufficient to determine the risk.", [["underlying disease", "PROBLEM", 19, 37], ["disease", "OBSERVATION", 30, 37]]], ["In earlier reports increased age in the male population has been associated with higher mortality (17).", [["increased", "OBSERVATION_MODIFIER", 19, 28]]], ["Smokers are vulnerable to respiratory viruses, and smoking could upregulate angiotensin-converting enzyme 2 receptor levels (17).", [["respiratory viruses", "DISEASE", 26, 45], ["smoking", "CHEMICAL", 51, 58], ["angiotensin", "CHEMICAL", 76, 87], ["Smokers", "ORGANISM", 0, 7], ["angiotensin-converting enzyme 2 receptor", "GENE_OR_GENE_PRODUCT", 76, 116], ["angiotensin-converting enzyme 2 receptor", "PROTEIN", 76, 116], ["respiratory viruses", "PROBLEM", 26, 45], ["angiotensin", "TEST", 76, 87], ["enzyme 2 receptor levels", "TEST", 99, 123], ["respiratory viruses", "OBSERVATION", 26, 45]]], ["The prevalence of high smoking level in males may partly explain the higher susceptibility and mortality of male patients.DiscussionIn addition, virus-induced direct cytopathic effects and viral evasion of host immune responses are believed to play major roles in the severity of coronavirus infection (18, 19).", [["smoking", "CHEMICAL", 23, 30], ["coronavirus infection", "DISEASE", 280, 301], ["patients", "ORGANISM", 113, 121], ["coronavirus", "ORGANISM", 280, 291], ["patients", "SPECIES", 113, 121], ["virus", "PROBLEM", 145, 150], ["direct cytopathic effects", "PROBLEM", 159, 184], ["coronavirus infection", "PROBLEM", 280, 301], ["high smoking", "OBSERVATION", 18, 30], ["may partly explain", "UNCERTAINTY", 46, 64], ["cytopathic", "OBSERVATION_MODIFIER", 166, 176], ["coronavirus", "OBSERVATION_MODIFIER", 280, 291], ["infection", "OBSERVATION", 292, 301]]], ["The dysregulation of immune response may result in an excessive inflammation, leading to adverse outcomes (20, 21).", [["inflammation", "DISEASE", 64, 76], ["an excessive inflammation", "PROBLEM", 51, 76], ["immune response", "OBSERVATION", 21, 36], ["excessive", "OBSERVATION_MODIFIER", 54, 63], ["inflammation", "OBSERVATION", 64, 76]]], ["Lymphocytopenia was present in 83.2% patients with COVID-19 at admission (22), and severe cases tend to have lower lymphocyte counts (5).", [["lymphocyte", "ANATOMY", 115, 125], ["Lymphocytopenia", "DISEASE", 0, 15], ["patients", "ORGANISM", 37, 45], ["lymphocyte", "CELL", 115, 125], ["patients", "SPECIES", 37, 45], ["Lymphocytopenia", "PROBLEM", 0, 15], ["COVID", "TEST", 51, 56], ["severe cases", "PROBLEM", 83, 95], ["lower lymphocyte counts", "PROBLEM", 109, 132], ["severe", "OBSERVATION_MODIFIER", 83, 89], ["lower lymphocyte counts", "OBSERVATION", 109, 132]]], ["In this study, we had similar findings that lymphocyte counts significantly decreased in severe type patients, and more than half of patients had decreased lymphocyte count.", [["lymphocyte", "ANATOMY", 44, 54], ["lymphocyte", "ANATOMY", 156, 166], ["lymphocyte", "CELL", 44, 54], ["patients", "ORGANISM", 101, 109], ["patients", "ORGANISM", 133, 141], ["lymphocyte", "CELL", 156, 166], ["patients", "SPECIES", 101, 109], ["patients", "SPECIES", 133, 141], ["this study", "TEST", 3, 13], ["lymphocyte counts", "TEST", 44, 61], ["decreased lymphocyte count", "PROBLEM", 146, 172], ["lymphocyte counts", "OBSERVATION", 44, 61], ["significantly", "OBSERVATION_MODIFIER", 62, 75], ["decreased", "OBSERVATION_MODIFIER", 76, 85], ["severe", "OBSERVATION_MODIFIER", 89, 95], ["type patients", "OBSERVATION_MODIFIER", 96, 109], ["decreased lymphocyte count", "OBSERVATION", 146, 172]]], ["Coronaviruses commonly attack the respiratory system and SARS-CoV-2 has been shown to cause lung damage (22, 23).", [["respiratory system", "ANATOMY", 34, 52], ["lung", "ANATOMY", 92, 96], ["SARS", "DISEASE", 57, 61], ["lung damage", "DISEASE", 92, 103], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 57, 67], ["lung", "ORGAN", 92, 96], ["SARS-CoV", "SPECIES", 57, 65], ["Coronaviruses", "PROBLEM", 0, 13], ["the respiratory system", "TEST", 30, 52], ["SARS", "PROBLEM", 57, 61], ["lung damage", "PROBLEM", 92, 103], ["respiratory system", "ANATOMY", 34, 52], ["lung", "ANATOMY", 92, 96], ["damage", "OBSERVATION", 97, 103]]], ["As a significant auxiliary modality, chest CT is a key component of the diagnosis of virus-infected patients (24).", [["chest", "ANATOMY", 37, 42], ["virus-infected", "DISEASE", 85, 99], ["chest", "ORGAN", 37, 42], ["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108], ["chest CT", "TEST", 37, 45], ["virus", "PROBLEM", 85, 90], ["significant", "OBSERVATION_MODIFIER", 5, 16], ["chest", "ANATOMY", 37, 42], ["virus", "OBSERVATION", 85, 90], ["infected", "OBSERVATION_MODIFIER", 91, 99]]], ["It allows the sensitive assessment of lung lesions as well as the degree and location of lung involvement.", [["lung lesions", "ANATOMY", 38, 50], ["lung", "ANATOMY", 89, 93], ["lung lesions", "DISEASE", 38, 50], ["lung lesions", "CANCER", 38, 50], ["lung", "ORGAN", 89, 93], ["lung lesions", "PROBLEM", 38, 50], ["lung involvement", "PROBLEM", 89, 105], ["lung", "ANATOMY", 38, 42], ["lesions", "OBSERVATION", 43, 50], ["lung", "ANATOMY", 89, 93], ["involvement", "OBSERVATION", 94, 105]]], ["In previous studies, ground glass and consolidation opacities have been shown to be the most common imaging signs in patients with COVID-19 (8, 23, 25).", [["opacities", "DISEASE", 52, 61], ["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125], ["previous studies", "TEST", 3, 19], ["ground glass and consolidation opacities", "PROBLEM", 21, 61], ["COVID", "TEST", 131, 136], ["ground glass", "OBSERVATION", 21, 33], ["consolidation opacities", "OBSERVATION", 38, 61]]], ["Although weakened immunity and lung damage are problems in the majority of patients, the effect on death or ICU remains unclear.DiscussionThe MuLBSTA score is a good diagnostic marker for poor prognosis.", [["lung", "ANATOMY", 31, 35], ["lung damage", "DISEASE", 31, 42], ["death", "DISEASE", 99, 104], ["lung", "ORGAN", 31, 35], ["patients", "ORGANISM", 75, 83], ["MuLBSTA", "DNA", 142, 149], ["patients", "SPECIES", 75, 83], ["weakened immunity", "PROBLEM", 9, 26], ["lung damage", "PROBLEM", 31, 42], ["death", "PROBLEM", 99, 104], ["weakened", "OBSERVATION_MODIFIER", 9, 17], ["immunity", "OBSERVATION", 18, 26], ["lung", "ANATOMY", 31, 35], ["damage", "OBSERVATION", 36, 42]]], ["In the present study, a score of 12 points indicates the specificity and sensitivity of death were 89.5 and 100%, and 11 points present the specificity and sensitivity of ICU care were 91.7 and 71.4%, respectively.", [["death", "DISEASE", 88, 93], ["a score", "TEST", 22, 29], ["death", "TEST", 88, 93], ["ICU care", "TEST", 171, 179]]], ["These results strongly suggest that the scale has good efficacy to assess the clinical risk of death and ICU care in patients infected with SARS-COV-2.", [["death", "DISEASE", 95, 100], ["SARS", "DISEASE", 140, 144], ["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125], ["death", "PROBLEM", 95, 100], ["ICU care", "TREATMENT", 105, 113]]], ["The survival analysis showed that the higher is the MuLBSTA score, the higher is the death risk.", [["death", "DISEASE", 85, 90], ["The survival analysis", "TEST", 0, 21], ["the death risk", "PROBLEM", 81, 95], ["higher", "OBSERVATION_MODIFIER", 38, 44], ["higher", "OBSERVATION_MODIFIER", 71, 77]]], ["In our results, 50% of severe type patients had a score of \u226512 points, but no common type patients had more than this score.", [["patients", "ORGANISM", 35, 43], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 35, 43], ["patients", "SPECIES", 90, 98], ["no", "UNCERTAINTY", 75, 77]]], ["The results implied that severe type patients are more likely to die, and it may be owing to severe immune response and lung involvement.DiscussionIn clinical practices, there is no effective treatment available for the infected patients, but screening high-risk patients at first admission and appropriate clinical management may be helpful in reducing the incidence of severe complications, such as ARDS or sepsis as well as mortality.", [["lung", "ANATOMY", 120, 124], ["ARDS", "DISEASE", 401, 405], ["sepsis", "DISEASE", 409, 415], ["patients", "ORGANISM", 37, 45], ["lung", "ORGAN", 120, 124], ["patients", "ORGANISM", 229, 237], ["patients", "ORGANISM", 263, 271], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 229, 237], ["patients", "SPECIES", 263, 271], ["severe immune response", "PROBLEM", 93, 115], ["lung involvement", "PROBLEM", 120, 136], ["effective treatment", "TREATMENT", 182, 201], ["screening", "TEST", 243, 252], ["appropriate clinical management", "TREATMENT", 295, 326], ["severe complications", "PROBLEM", 371, 391], ["ARDS", "PROBLEM", 401, 405], ["sepsis", "PROBLEM", 409, 415], ["severe", "OBSERVATION_MODIFIER", 25, 31], ["more likely", "UNCERTAINTY", 50, 61], ["severe", "OBSERVATION_MODIFIER", 93, 99], ["immune response", "OBSERVATION", 100, 115], ["lung", "ANATOMY", 120, 124], ["involvement", "OBSERVATION", 125, 136], ["no", "UNCERTAINTY", 179, 181], ["severe", "OBSERVATION_MODIFIER", 371, 377], ["complications", "OBSERVATION", 378, 391], ["ARDS", "OBSERVATION", 401, 405], ["sepsis", "OBSERVATION", 409, 415]]], ["Although there are some clinical scales about the severity and risk stratification of pneumonia, such as CURB65 or SOFA score, but in our study, the screening proportion of high-risk patients with MuLBSTA score was higher than that of CURB65 score.", [["pneumonia", "DISEASE", 86, 95], ["patients", "ORGANISM", 183, 191], ["CURB65", "PROTEIN", 235, 241], ["patients", "SPECIES", 183, 191], ["some clinical scales", "PROBLEM", 19, 39], ["pneumonia", "PROBLEM", 86, 95], ["SOFA score", "TEST", 115, 125], ["our study", "TEST", 134, 143], ["the screening", "TEST", 145, 158], ["MuLBSTA score", "TEST", 197, 210], ["pneumonia", "OBSERVATION", 86, 95]]], ["Meanwhile, age, hypertension, and smoking status as part of the MuLBSTA score were readily available in the clinical setting, whereas the lymphocyte count and lobe status were assessed by routine blood examination and X-ray or CT scan.", [["lymphocyte", "ANATOMY", 138, 148], ["lobe", "ANATOMY", 159, 163], ["blood", "ANATOMY", 196, 201], ["hypertension", "DISEASE", 16, 28], ["lymphocyte", "CELL", 138, 148], ["lobe", "MULTI-TISSUE_STRUCTURE", 159, 163], ["blood", "ORGANISM_SUBSTANCE", 196, 201], ["hypertension", "PROBLEM", 16, 28], ["the MuLBSTA score", "TEST", 60, 77], ["the lymphocyte count", "TEST", 134, 154], ["routine blood examination", "TEST", 188, 213], ["X-ray", "TEST", 218, 223], ["CT scan", "TEST", 227, 234], ["hypertension", "OBSERVATION", 16, 28], ["lobe", "ANATOMY", 159, 163]]], ["Therefore, the score may be a rapid and effective risk stratification strategy.DiscussionThis study has several limitations.", [["the score", "TEST", 11, 20], ["a rapid and effective risk stratification strategy", "PROBLEM", 28, 78], ["This study", "TEST", 89, 99]]], ["First, the lack of effective antiviral drugs, and all patients underwent different treatment regimens, which may affect the prognosis of patients.", [["patients", "ORGANISM", 54, 62], ["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 54, 62], ["patients", "SPECIES", 137, 145], ["effective antiviral drugs", "TREATMENT", 19, 44], ["different treatment regimens", "TREATMENT", 73, 101], ["antiviral drugs", "OBSERVATION", 29, 44]]], ["Secondly, there may be other risk factors that also affect the prognosis of patients.", [["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["other risk factors", "PROBLEM", 23, 41], ["may be", "UNCERTAINTY", 16, 22]]], ["We verified the validity of the MuLBSTA scale, but the predictive value of a single factor was not analyzed.", [["the MuLBSTA scale", "TREATMENT", 28, 45]]], ["Finally, because this is the retrospective study, we could only evaluate the short-term prognosis.", [["the retrospective study", "TEST", 25, 48]]], ["The long-term prognosis would be analyzed in further studies.DiscussionTo the best of our knowledge, this is the first retrospective cohort study that focusing on the MuLBSTA score risk stratification of patients with COVID-19 who have experienced a definite outcome.", [["patients", "ORGANISM", 204, 212], ["patients", "SPECIES", 204, 212], ["further studies", "TEST", 45, 60], ["long-term", "OBSERVATION_MODIFIER", 4, 13]]], ["We found that a MuLBSTA score of \u226512 points at admission was a high risk factor for death or ICU care in adult patients with COVID-19.", [["death", "DISEASE", 84, 89], ["patients", "ORGANISM", 111, 119], ["MuLBSTA", "PROTEIN", 16, 23], ["patients", "SPECIES", 111, 119], ["a MuLBSTA score", "TEST", 14, 29], ["death", "PROBLEM", 84, 89], ["ICU care", "TREATMENT", 93, 101], ["COVID", "TEST", 125, 130]]], ["The risk stratification provides the evidence for novel coronavirus clinical interventions in efforts to improve outcomes.ConclusionsA higher MuLBSTA score at admission had higher death or ICU risk in patients with COVID-19.", [["coronavirus", "DISEASE", 56, 67], ["death", "DISEASE", 180, 185], ["coronavirus", "ORGANISM", 56, 67], ["patients", "ORGANISM", 201, 209], ["MuLBSTA", "PROTEIN", 142, 149], ["patients", "SPECIES", 201, 209], ["novel coronavirus clinical interventions", "TREATMENT", 50, 90], ["higher MuLBSTA score", "PROBLEM", 135, 155], ["higher death", "PROBLEM", 173, 185], ["COVID", "TEST", 215, 220]]], ["The MuLBSTA scale is valuable for the risk stratification of COVID-19 patients, especially regarding death or ICU care.Data Availability StatementAll datasets generated for this study are included in the article/supplementary material.Ethics StatementThe study was approved by the hospital ethics committee.", [["death", "DISEASE", 101, 106], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["The MuLBSTA scale", "TREATMENT", 0, 17], ["ICU care", "TREATMENT", 110, 118], ["this study", "TEST", 173, 183]]], ["Written informed consent was waived owing to the rapid emergence of this infectious disease.Author ContributionsMY and YG designed the study and takes responsibility for the integrity and accuracy of the data analysis.", [["infectious disease", "DISEASE", 73, 91], ["this infectious disease", "PROBLEM", 68, 91], ["the study", "TEST", 131, 140], ["the data analysis", "TEST", 200, 217], ["infectious", "OBSERVATION", 73, 83]]], ["RX, KH, and KZ contributions to the acquisition, analysis, interpretation of data for the work, and writing of the manuscript.", [["the acquisition", "TEST", 32, 47], ["analysis", "TEST", 49, 57]]], ["RX, KH, KZ, HX, NZ, HF, LX, RS, LW, HL, and ZY had roles in patient recruitment, data collection, and clinical management.", [["HX", "SIMPLE_CHEMICAL", 12, 14], ["ZY", "SIMPLE_CHEMICAL", 44, 46], ["patient", "ORGANISM", 60, 67], ["patient", "SPECIES", 60, 67], ["HF", "PROBLEM", 20, 22], ["data collection", "TEST", 81, 96], ["clinical management", "TREATMENT", 102, 121]]], ["All authors contributed to data acquisition, data analysis, and all reviewed and approved the final version of the manuscript.Conflict of InterestThe authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", [["data acquisition", "TEST", 27, 43], ["data analysis", "TEST", 45, 58]]]], "PMC7158304": [["The Male Reproductive Tract as a Unique Immunological Environment ::: IntroductionThe male reproductive tract, and the male gamete especially, present a unique challenge to the immune system.", [["reproductive tract", "ANATOMY", 91, 109], ["gamete", "ANATOMY", 124, 130], ["immune system", "ANATOMY", 177, 190], ["reproductive tract", "ORGAN", 91, 109], ["immune system", "ANATOMICAL_SYSTEM", 177, 190], ["reproductive tract", "OBSERVATION", 91, 109]]], ["The human testis continuously produces highly differentiated sperm derived from a pool of spermatogonial stem cells at a level of productivity and complexity matched only by the hematopoietic system.", [["testis", "ANATOMY", 10, 16], ["sperm", "ANATOMY", 61, 66], ["spermatogonial stem cells", "ANATOMY", 90, 115], ["hematopoietic system", "ANATOMY", 178, 198], ["human", "ORGANISM", 4, 9], ["testis", "ORGAN", 10, 16], ["sperm", "CELL", 61, 66], ["spermatogonial stem cells", "CELL", 90, 115], ["sperm", "CELL_TYPE", 61, 66], ["spermatogonial stem cells", "CELL_TYPE", 90, 115], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9], ["spermatogonial stem cells", "PROBLEM", 90, 115], ["human testis", "ANATOMY", 4, 16], ["spermatogonial stem cells", "OBSERVATION", 90, 115], ["hematopoietic system", "OBSERVATION", 178, 198]]], ["In contrast to the hematopoietic tissues, however, differentiated sperm first appear at the time of sexual maturation, long after the maturation of the immune system and the establishment of systemic immune tolerance (Figure 19.1).1 In humans, the period between the editing of the lymphocyte repertoire and the first appearance of significant numbers of the earliest premeiotic germ cell (the spermatocytes) is generally more than 10 years.", [["hematopoietic tissues", "ANATOMY", 19, 40], ["sperm", "ANATOMY", 66, 71], ["immune system", "ANATOMY", 152, 165], ["lymphocyte", "ANATOMY", 282, 292], ["germ cell", "ANATOMY", 379, 388], ["spermatocytes", "ANATOMY", 394, 407], ["hematopoietic tissues", "TISSUE", 19, 40], ["sperm", "CELL", 66, 71], ["humans", "ORGANISM", 236, 242], ["lymphocyte", "CELL", 282, 292], ["germ cell", "CELL", 379, 388], ["spermatocytes", "CELLULAR_COMPONENT", 394, 407], ["differentiated sperm", "CELL_TYPE", 51, 71], ["lymphocyte repertoire", "PROTEIN", 282, 303], ["premeiotic germ cell", "CELL_TYPE", 368, 388], ["humans", "SPECIES", 236, 242], ["humans", "SPECIES", 236, 242], ["sexual maturation", "PROBLEM", 100, 117], ["the immune system", "TREATMENT", 148, 165], ["Figure", "TEST", 218, 224], ["the lymphocyte repertoire", "TREATMENT", 278, 303], ["the earliest premeiotic germ cell", "PROBLEM", 355, 388], ["hematopoietic tissues", "ANATOMY", 19, 40], ["significant", "OBSERVATION_MODIFIER", 332, 343], ["numbers", "OBSERVATION_MODIFIER", 344, 351], ["premeiotic germ cell", "OBSERVATION", 368, 388]]], ["As a consequence, spermatogenic cells express many cell-specific proteins and other molecules that have the potential to be seen as \u201cforeign\u201d or \u201cnonself\u201d by the immune system.The Male Reproductive Tract as a Unique Immunological Environment ::: IntroductionWe know that the immune system tends to view spermatogenic cells as foreign because of the relatively high incidence of autoimmune infertility among human populations.", [["spermatogenic cells", "ANATOMY", 18, 37], ["cell", "ANATOMY", 51, 55], ["immune system", "ANATOMY", 162, 175], ["immune system", "ANATOMY", 275, 288], ["spermatogenic cells", "ANATOMY", 303, 322], ["autoimmune infertility", "DISEASE", 378, 400], ["spermatogenic cells", "CELL", 18, 37], ["cell", "CELL", 51, 55], ["nonself", "GENE_OR_GENE_PRODUCT", 146, 153], ["spermatogenic cells", "CELL", 303, 322], ["human", "ORGANISM", 407, 412], ["spermatogenic cells", "CELL_TYPE", 18, 37], ["spermatogenic cells", "CELL_TYPE", 303, 322], ["human", "SPECIES", 407, 412], ["human", "SPECIES", 407, 412], ["spermatogenic cells", "PROBLEM", 18, 37], ["the immune system", "PROBLEM", 271, 288], ["spermatogenic cells", "PROBLEM", 303, 322], ["autoimmune infertility", "PROBLEM", 378, 400], ["spermatogenic cells", "OBSERVATION", 18, 37], ["autoimmune", "OBSERVATION", 378, 388]]], ["Even in developed countries with modern health care, sperm autoantibodies represent 5\u201310% of all male infertility,2., 3. while testicular biopsies from infertile men frequently display evidence of asymptomatic inflammatory reactions.4., 5.", [["sperm", "ANATOMY", 53, 58], ["testicular biopsies", "ANATOMY", 127, 146], ["infertility", "DISEASE", 102, 113], ["testicular biopsies", "MULTI-TISSUE_STRUCTURE", 127, 146], ["men", "ORGANISM", 162, 165], ["sperm autoantibodies", "PROTEIN", 53, 73], ["men", "SPECIES", 162, 165], ["modern health care", "TREATMENT", 33, 51], ["sperm autoantibodies", "PROBLEM", 53, 73], ["testicular biopsies", "TEST", 127, 146], ["asymptomatic inflammatory reactions", "PROBLEM", 197, 232], ["infertility", "OBSERVATION", 102, 113], ["testicular", "ANATOMY", 127, 137], ["biopsies", "OBSERVATION", 138, 146], ["evidence of", "UNCERTAINTY", 185, 196], ["asymptomatic", "OBSERVATION_MODIFIER", 197, 209], ["inflammatory", "OBSERVATION", 210, 222]]], ["In other forms of autoimmune disease, such as type 1 diabetes or gastritis, the development of autoimmunity is due to disruption of the normal regulatory controls of the immune system, leading to reactions against antigens that normally are ignored.", [["immune system", "ANATOMY", 170, 183], ["autoimmune disease", "DISEASE", 18, 36], ["type 1 diabetes", "DISEASE", 46, 61], ["gastritis", "DISEASE", 65, 74], ["autoimmunity", "DISEASE", 95, 107], ["gastritis", "PATHOLOGICAL_FORMATION", 65, 74], ["antigens", "PROTEIN", 214, 222], ["autoimmune disease", "PROBLEM", 18, 36], ["type 1 diabetes", "PROBLEM", 46, 61], ["gastritis", "PROBLEM", 65, 74], ["autoimmunity", "PROBLEM", 95, 107], ["antigens", "PROBLEM", 214, 222], ["autoimmune", "OBSERVATION", 18, 28], ["diabetes", "OBSERVATION", 53, 61], ["gastritis", "OBSERVATION", 65, 74], ["autoimmunity", "OBSERVATION", 95, 107], ["normal", "OBSERVATION", 136, 142], ["regulatory controls", "OBSERVATION", 143, 162]]], ["Only a limited number of antigens are involved and a specific dominant autoantigen usually has been identified.6 In the case of the male reproductive tract, by contrast, autoimmunity generally involves antigens that would not be edited out of the self-reactive repertoire in the first place.", [["reproductive tract", "ANATOMY", 137, 155], ["autoimmunity", "DISEASE", 170, 182], ["reproductive tract", "ORGANISM_SUBDIVISION", 137, 155], ["antigens", "PROTEIN", 25, 33], ["dominant autoantigen", "PROTEIN", 62, 82], ["antigens", "PROTEIN", 202, 210], ["a specific dominant autoantigen", "PROBLEM", 51, 82]]], ["Hence, autoimmune infertility generally involves multiple antigens as well as different antigens from one individual to another.7., 8., 9.", [["autoimmune infertility", "DISEASE", 7, 29], ["antigens", "PROTEIN", 58, 66], ["antigens", "PROTEIN", 88, 96], ["autoimmune infertility", "PROBLEM", 7, 29], ["multiple antigens", "PROBLEM", 49, 66], ["autoimmune infertility", "OBSERVATION", 7, 29]]], ["Moreover, infertility is not the only urological problem with an immunological basis.", [["infertility", "DISEASE", 10, 21], ["infertility", "PROBLEM", 10, 21], ["infertility", "OBSERVATION", 10, 21]]], ["Chronic pelvic inflammatory disease in men, which may be accompanied by recurrent and even debilitating perineal or scrotal pain, is a serious and frequently intractable condition.10., 11., 12.", [["pelvic", "ANATOMY", 8, 14], ["perineal", "ANATOMY", 104, 112], ["scrotal", "ANATOMY", 116, 123], ["Chronic pelvic inflammatory disease", "DISEASE", 0, 35], ["scrotal pain", "DISEASE", 116, 128], ["men", "ORGANISM", 39, 42], ["men", "SPECIES", 39, 42], ["Chronic pelvic inflammatory disease", "PROBLEM", 0, 35], ["recurrent and even debilitating perineal or scrotal pain", "PROBLEM", 72, 128], ["a serious and frequently intractable condition", "PROBLEM", 133, 179], ["pelvic", "ANATOMY", 8, 14], ["inflammatory", "OBSERVATION", 15, 27], ["may be", "UNCERTAINTY", 50, 56], ["debilitating", "OBSERVATION_MODIFIER", 91, 103], ["perineal", "ANATOMY", 104, 112], ["scrotal", "ANATOMY", 116, 123], ["pain", "OBSERVATION", 124, 128]]], ["Infections may represent the initial cause of the majority of such cases, but the underlying mechanisms almost certainly involve an autoimmune component.10", [["Infections", "DISEASE", 0, 10], ["Infections", "PROBLEM", 0, 10], ["the underlying mechanisms", "PROBLEM", 78, 103], ["an autoimmune component", "PROBLEM", 129, 152], ["autoimmune", "OBSERVATION", 132, 142]]]]}